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ABSTRACT
Adozelesin (formerly U73-975, The Upjohn Co.) is a covalent, m inor-groove binding 
analogue o f  the antitumour antibiotic (+)CC-1065. Adozelesin consists o f  a cyclopropa- 
pyrroloindole alkylating sub-unit identical to (+)CC-1065, plus indole and benzofuran sub-units 
which replace the m ore complex pyiroloindole B and C sub-units, respectively, o f  (+)CC-1065. 
Adozelesin is a clinically important drug candidate, since it does not contain the ethylene bridge 
m oieties on the B and C sub-units which are thought to be responsible for the unusual delayed 
hepatotoxicity exhibited by (+)CC-1065. Sequencing techniques identified two consensus 
sequences for adozelesin binding as p(dA) and 5'(T/A)(T/A)T-A*(C/G)G. This suggests that 
adozelesin spans a total o f  five base-pairs and shows a preference for A=T base-pair rich 
sequences, thus avoiding steric crowding around the exocyclic NH 2 o f  guanine and a  w ide 
m inor groove. In this project, the covalent m odification o f  two DNA sequences, i.e. 5'- 
d(CGTAAGCGCTTA*CG ) 2  and 5'-d(CGAAAAA*CGG> 5 '-d(CCGTTTTTCG), by adozelesin 
w as examined by high-field NM R and restrained m olecular m echanics and dynamics. Previous 
studies o f  m inor groove binding drugs, using techniques as diverse as NM R, X-ray 
crystallography and molecular modelling, indicate that the incorporation o f  a guanine into the 
consensus sequence sterically hinders binding and, m ore importantly, produces a w ider m inor 
groove which is a ‘slack’ fit for the ligand.
The aim o f  this investigation was to provide an insight into the sequence selective 
binding o f  adozelesin to 5 '-AAAAA*CG and 5'-GCTTA*CG. The !H  NM R data revealed that, 
in both cases, (3-helical structure and W atson-Crick base-pairing was maintained on adduct 
formation. The 5'-GCTTA*CG adduct displayed significant distortion o f  the guanine base on 
the non-covalently m odified strand. This distortion resulted from  an amalgamation o f  two 
factors. Firstly, the presence o f  a  strong hydrogen-bond between the amide linker o f  the indole 
and benzofuran sub-units and the carbonyl o f  a central thymine base plus a second, weaker, 
hydrogen-bond to the exocyclic NH2 o f  the guanine. Secondly, covalent m odification o f  an 
adenine by adozelesin yields a distortional wave w hich terminates 6 base-pairs upstream  in the 
5 '-direction. NM R data and the resulting m olecular model show that adozelesin lies closer to 
the m odified strand as a consequence o f  this strong hydrogen-bond and perhaps also o f  the 
distorted guanine pushing adozelesin to the opposite side o f  the groove. No distortion o f  this 
kind was noted in the ‘A ’ tract model; however, the *H NM R data shows that the adenine bases 
rem ain propellor twisted, which is characteristic o f  m acroscopically bent DNA. This m olecular 
model showed that, within this m ost preferred sequence, adozelesin lay centrally w ithin this 
straighter ‘A ’ tract, yielding an improved complementary fit o f  the drug within the D N A  m inor 
groove. No hydrogen-bonds were detected. This study indicates the possible role o f  the ureylene 
linker in the selective binding o f  adozelesin to the unpredicted GC-containing consensus
sequence. Various other m inor groove binders (cyanomorpholinoadriamycin, DSB-120 and 
sibiromycin) also had their sequence-selectivity properties probed with lim ited success, owing 
to their inability to yield a single drug-DNA adduct for high-field N M R study.
The adozelesin-DNA self-complementary adduct in this study has provided a  new  and 
exciting starting point for rational drug design o f  an adozelesin dimer, a  proposed antineoplastic 
agent with enchanced sequence-selectivity. These adozelesin-DNA adducts have proved to be 
an excellent model system to investigate the m olecular basis for DNA recognition and binding.
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CHAPTER 1: INTRODUCTION
Half a century has passed since the first tentative uses o f the nitrogen mustards in the 
treatment of cancer. Today, even in the era o f modem high technology, after billions o f pounds 
have been spent and a truly colossal effort into research and development has been made, there 
is still no ‘wonder drag’ to cure cancer. Compounds such as adriamycin and cisplatin are 
clinically effective against a broad spectrum of tumours but some neoplasias still exhibit little 
response. All anticancer agents have the disadvantage of unpleasant side effects, though it is 
hoped in most cases that these will be more than compensated for in quality and quantity of life.
Drug design can be defined as, ‘the approaches and steps which are involved in the 
production of new chemical entities o f pharmacological importance’. From a 
pharmacodynamics standpoint, the ideal cancer drug should be: receptor selective, with
extremely high potency and largely free of side effects. Whilst these factors are fundamental to 
new drug development, from a commercial stance also, the reality is that anticancer treatments 
address a sizeable clinical need and the state o f medical knowledge is such that it justifies the 
funding risk.
There are four major sources of new drugs. Some old drugs may evolve to have a new 
use, possibly originating from their side-effects. Natural products which are not found in 
humans may have activity as a drug, for example; plant compounds, antibiotics from bacteria or 
fungi, or products from marine animals e.g. bryostatin. Chemicals which are found in humans 
that exhibit activity as a drug, like hormones e.g. insulin, vitamins and peptides e.g. 
enkephalins. Lastly there are novel chemical syntheses, which can proceed either randomly, 
accidentally or rationally when the receptor, agonist or antagonist structure is known. New 
anticancer agent development which focuses mainly on the synthesis of analogues, by 
modification o f functional groups to enhance potency, pharmacokinetics and selectivity, has 
been employed extensively. The prodrug carzelesin, which is an analogue o f the natural product 
(+)CC-1065, is an example of this approach (Li et a I., 1992).
Today, it is becoming more popular to examine the target, for example topoisomerases 
I and II, or look for a new one. Techniques such as high-field NMR, X-ray crystallography, 
computer molecular modelling and the use of molecular biology for DNA sequencing and gene 
cloning are readily available. They provide a wealth of information on receptor-substrate 
topology, mechanism of interaction and the resulting modulation o f effects, both at the 
molecular and whole system level. Other novel approaches to improve the selectivity o f these 
cytotoxic drugs include the use o f immunoconjugates or polymer conjugates (Verweij, 1996).
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The cytotoxic drug {e.g. adriamycin) is attached to a tumour-specific antibody {e.g. BR96) 
which will then be readily taken up by the cancer cell, carrying the drug directly to the site of 
action (Onetto et a l, 1995). Polymers may act in a similar manner (Duncan, 1992), making use 
of a unique cancer cell enzyme to cleave for example, a peptide linkage which bridges the 
ligand and the polymer, releasing the ligand in its active form. Ideas such as these could be of 
key importance for drug targeting.
DNA is known to be the intracellular target o f many cancer chemotherapy agents. 
Their mode o f action is via blockage of DNA or RNA synthesis, perhaps by prevention of an 
enzyme binding at a specific sequence or progressing along DNA. The enormity o f the 
sequence selectivity problem arises with the need to target only a tiny consensus sequence, a 
few base pairs long, within the 2-9xl09 base human genome. This is comprised o f only adenine, 
guanine, thymine and cytosine in a large number of permutations. Identification o f longer 
consensus sequences, which would probably occur less frequently within cellular DNA, could 
be a solution to the problem of lack o f specificity. The design o f chemotherapeutic agents 
which could span larger numbers o f bases would then be required. However, as becomes clear 
in the following review of DNA-binding drugs, characterization o f smaller segments o f DNA 
and elucidation o f the mechanisms by which naturally occurring antitumour antibiotics interact 
with them, constitutes a myriad o f problems in itself. This is prior to attempts to design and 
synthesize superior analogues, which sometimes seems to be akin to molecular roulette!
There are three possible sites on DNA to which a molecule can bind: the major 
groove, the minor groove or between the bases. The major groove is characteristically deep but 
very wide. It is lined with the potential hydrogen-bond acceptor atoms; N-7 of guanine and 
adenine (n), 0-4  of thymine {o) and 0-6 of guanine (o), while the amino group at the C-6 of 
adenine and C-4 o f cytosine act as hydrogen bond donors (h) (Stryer, 1988). Therefore the 
patterns of donor and acceptor atoms are as follows: (AT) nho, (TA) ohn, (GC) noh and (CG) 
hon. It is this mixture of a large number of hydrogen-bond interactions and width induced 
accessibility, which renders the major groove the site o f choice to where large proteins {e.g. 
transcription factors and enzymes) can interact sequence-selectively with DNA. The depth is 
conducive to small drug molecules binding; however, the width makes this site unfavourable to 
many small ligands, especially if  they are hydrophobic in nature. Sequence selectivity is 
difficult to achieve in an environment where the drug (key) is a slack fit in the major groove 
receptor (lock), in effect allowing a molecule o f any shape to bind at any position. Intercalation 
of drug betwen the bases provides another binding mode e.g. adriamycin (Capranico et al., 
1986). The problem with intercalation is that the sequence specificity only extends to the pair 
of base pairs which encase the drug e.g. d(CG) or d(GC) for adriamycin (Chaires et al., 1987). 
There will be a large number o f CG or GC base sequences, leading to a relatively non-specific
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binding mode. Non-specificity is very undesirable because it results not only in a 
chemotherapeutic action at the target sequence but also in reaction at many other sites giving 
rise to mutations or side-effects.
The minor groove, however, has many qualities which promote it as the intracellular 
drug target of DNA. It is deep and narrow in p-helical DNA, so that a drug binding within it 
will be able to fit tightly within the hydrophobic environment o f the minor groove. The large 
surface area of the groove provides opportunities not only for stabilizing hydrogen-bonds, but 
also for strong forces o f attraction generated from many van der Waals forces. Bases within the 
DNA can be alkylated to form a covalent adduct. The N-3 o f adenine and guanine, and 0-2 of 
thymine and cytosine constitute hydrogen-bond acceptor atoms of the minor groove, whilst the 
amino group o f guanine is the sole hydrogen donor. Hence, the minor groove has less 
hydrogen-bonding possibilities than the major groove i.e. (AT) no, (TA) on, (GC) nho and (CG) 
ohn. It would therefore follow that minor groove binding would be less sequence specific, due 
to the lack of distinction between AT or TA base-pairs (both are hydrogen-bond acceptor, 
acceptor) and CG or GC base-pairs (acceptor, donor, acceptor). This equivalence of base- 
pairing is not observed within the major groove, explaining the high fidelity by which proteins 
can read the DNA sequence. However, it is the topology o f the minor groove which is the most 
important contributing factor to the achievement of sequence selectivity within the minor 
groove: ‘A’ tracts give rise to extremely narrow grooves for a close complementary fit with the 
ligand; GC regions can accommodate bulkier molecules. The most important reason for 
designing drugs which target DNA is because it is at the core o f every cell’s ability to sustain 
life. Therefore, targeting the minor groove as a drug receptor could lead to modulation o f 
processes such as DNA replication to achieve a therapeutic effect.
Intercalator with
Minor groove binding moiety (covalent or non-covalent)
Covalent minor groove binding
—  Non covalent minor groove binding
Figure 1 Schematic diagram of how the various families of ligands bind to DNA.
There are three possible modes by which ligands interact with the minor groove of 
DNA (Fig. 1). These are;
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1) Noncovalent minor groove binding
2) Covalent minor groove binding
3) Minor groove binding with intercalation
1.1 N o n co v a len t m in o r  g ro o v e  b in d e rs
There are four major classes of non-covaient minor groove binders: the oligopeptide 
antibiotics, the bis-benzimidazoles, the bisamidines and the bis(quatemary ammonium) 
heterocycles. Their modes o f binding and specificity will now be reviewed in detail.
1.1.1 Oligopeptide antibiotics
Netropsin and distamycin A are both naturally occurring peptide antibiotics. The 
former was isolated from Streptomyces netropsis (Finlay et al., 1951) and displays a range of 
antiviral, antitumour and antibacterial activity against both gram-positive and gram-negative 
bacteria (Hahn, 1975; Zimmer, 1975). Distamycin A similarly exhibits these types o f biological 
activities and inhibitory effects. Neither are in general clinical use, except as topical 
applications. Distamycin A was discovered by Arcamone et al., in 1964, produced by 
Streptomyces distallicus. Both netropsin and distamycin A belong to a class o f compounds 
known as pyrrole-amidine antibiotics and are di- and tri- peptides respectively. The structure of 
netropsin (Fig. 2) consists of two N-methylpyrrole rings with an amide linkage between them, 
and either side o f them. A guanidium group is at the amino terminus and a propylamidinium 
tail is attached to the carboxyl terminus. Distamycin differs only in having three N- 
methylpyrrole carboxamide subunits and a formamide instead o f the guanidium head unit (Fig.
2) (Kopka& Larsen, 1992).
Netropsin Distamycin
Figure 2 The molecular structures of netropsin and distamycin.
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The biological activities and sequence selectivities of these agents on binding to DNA 
have been investigated in great detail. X-ray crystal structures of netropsin and distamycin 
(Berman et a l, 1979; Gurskaya et al, 1979) indicate that the rings and, hence, the backbone of 
these drugs are crescent-shaped, with the concave side containing the amide groups. This 
structural feature makes these ligands perfect complementary fits for insertion into the minor 
groove o f (3-DNA.
Zimmer et a l , (1975, 1980) and Wartell et a l , (1974) have shown that netropsin has a 
high preference for binding to the DNA minor groove, when it is rich in adenine and thymine 
base pairs. Wartell et a l , (1974) proposed that the positively charged ends o f netropsin, interact 
with the 5 -phosphate anionic oxygens either side of an AT base pair, so the ligand spanned the 
width o f the minor groove. A later binding model (Berman et al., 1979) placed netropsin 
lengthwise across four base pairs within the groove. Hydrogen-bond details were included 
between amide nitrogen atoms and thymine 02  (T02) or adenine N3 (AN3) for stabilization of 
the complex. The structures of netropsin-DNA complexes from later studies are similar to this 
proposed model.
Patel (1982) used NMR techniques to probe the binding o f netropsin to 5 - 
d(C1G2C3G4A5A6T7T8C9G10C11G12)2 in solution. DNA oligomers are numbered sequentially 
from 1 to n in the direction of 5'- to 3'-. The complementary strand is numbered in the same 
manner beginning at n+1 if  the sequence is non-self-complementary, or if  the sequence is self- 
complementary the numbering is identical to the first strand i.e. 1 to n. Intermolecular nuclear 
Overhauser effect (NOE) measurements were used to constrain a model o f the complex, with 
the pyrrole H3 protons positioned adjacent to A6H2 and the guanidino methylene protons next 
to A5H2. Netropsin spans four base pairs in total. Hydrogen-bonds, as Berman et a l, (1979) 
also described, occur between AN3 and T02 of DNA and the three amide peptide groups of 
netropsin. Patel (1982) used the spatial confinements of an AT rich minor groove to explain the 
sequence selectivity of this ligand. Owing to guanine having a bulky amino group which 
protrudes into the minor groove, netropsin would be obstructed from binding and forming the 
above described stabilizing interactions.
This non-intercalative DNA-binding drug has also been studied by Zakrzewska et a l, 
(1983) using a computational approach. This comparative study looked at the interaction of 
SN18071, a bisquatemary heterocycle and netropsin with a poly(dA) poly(dT) DNA sequence. 
It was concluded that hydrogen-bonds increase sequence-specificity but are not a prerequisite 
for binding to the oligomer, due to the ability o f SN18071 to conform to the spatial restrictions 
of the AT minor groove, even though it has no hydrogen-bonding capacity. The minimum 
energy for the netropsin-poly(dA) poly(dT) complex was lower than that generated with 
SN 18071. This demonstrated the preference of netropsin for an AT site, which has a low
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electrostatic potential and, hence, attracts the positively charged drug. As a consequence, the fit 
of netropsin into the minor groove is far superior to that of SN18071.
X-ray diffraction data were collected on the netropsin-5'-d(CGCGATATCGCG) 
complex (Coll et al., 1989) to examine why the binding affinity of netropsin was greater for 
poly(A)-poly(T) sites rather than poly(AT). Binding took place at the AT-rich segment of the 
minor groove, with netropsin lying in both orientations. Instead o f the usual three-centred 
bifurcating hydrogen-bonding as described by Berman et a l , (1979), only single H-bonds were 
present due to alternating AT bases, giving rise to short and long H-bond distances from T02 or 
AN3 to netropsin NH groups. Netropsin bound to the 5'-ATAT groove, which is slightly wider 
than a homologous A strand duplex, owing to the lack of resulting base-pair propellor twist. 
The sugar-phosphate backbone was pulled towards netropsin inwards via van der Waals forces 
to create a narrower groove which is a snugger fit for netropsin. This conformational 
rearrangement, in effect, creates the same environment as the poly(A)-poly(T) duplex, which is 
the preferred binding site of netropsin, probably due to this extra incurred energy penalty on 
poly(AT) oligomers.
Distamycin-DNA interactions bear a close resemblance to those of netropsin. 'H 
NMR (nuclear magnetic resonance) has been used to investigate the interaction o f distamycin A 
with 5'-d(CGCGAATTCGCG)2 (Klevit et al., 1986), which also binds within the minor groove. 
Very intense NOEs were noted between the pyrrole H3s o f rings one, two and three and the 
adenine H2s of A5, A6 and A18, respectively. This work also demonstrated that the 5'- 
d(AATT)3' base pair sequence was large enough to bind distamycin, without requiring another 
AT in the binding site as Kopka et al., 1985, and Coll et al., 1987 suggested. The latter reported 
that, when distamycin binds to 5 '-d(CGCAAATTTGCG)23', the ligand covered five o f the six 
bases. Klevit et al., (1986) stated that there was little difference in the binding affinity of 
distamycin to four or five successive AT base pairs. This indicated that while only four AT 
base pairs may be required for selectivity, the extra length (due to the third pyrrole) required 
that this ligand extend into a fifth base pair region. The orientation of the drug is dependent on 
the DNA flanking sequences around the binding site (Dervan et al., 1986).
Pelton et al., (1988) tried to probe further the important factors for the interaction of 
distamycin A with 5'-d(C1G2C3G4A5A6T7T8C9G10C,1G12)2 using 2D NMR techniques and 
molecular modelling. By analogy with netropsin, distamycin formed three-centred, or 
‘bifurcating’ hydrogen-bonds between the amide group o f distamycin and the adenine N3, 
thymine 02 atoms within the minor groove (Fig. 3). Van der Waals contacts relating to 
sequence-selectivity were also seen as previously described, from adenine H2 to pyrrole H3 
protons. It is thought that a mixture of hydrogen-bonds and electrostatic forces are responsible
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for the strong binding o f distamycin. DNA O 'l atoms were stacked over each pyrrole ring, the 
third ring rotating out of plane slightly, in order to follow the same pitch as the minor groove.
Pelton et al., (1989; 1990), titrated distamycin A with oligomers of expanding AT 
target sequences and examined them by NMR. At low drug concentrations i.e. less than a 1:1 
drug:DNA stoichiometry, two species of distamycin A bound to DNA complex existed. A 
mixture of these oligomers bound to one and two distamycin A molecules simultaneously, head 
to tail alongside each other (so that the +ve charges were not adjacent to each other) were 
encountered. Higher drug:DNA concentration ratios resulted in only the 2:1 complex being 
present. The fact that only one antiparallel complex was accounted for means distamycin 
exhibits the ability to read the minor groove sequence selectively, which is why it is known as a 
‘lexitropsin’. Binding is similar to that described previously, minus the bifurcating H-bonds. 
This is due to the spatial confinements o f having two distamycin molecules in the groove, each 
having to lie alongside a wall instead of within the centre o f the minor groove. Because one 
ligand is a good fit in the narrow ‘A’ tract o f DNA, for two to squeeze in, the groove has to 
nearly double in width, from 3*2-4A ‘A’ tract groove width to 6-8A, equivalent to the combined 
drug widths. In the 5 -d(CGCGA5A6T7T8T9CGCG)-3' sequence (Pelton et al., 1989), the 
pyrrole rings of distamycin spanned A5, A6 and T7, with the formyl proton pointing in the 5 
direction of the A rich strand (T8), whilst the second distamycin lies across 5 '-A6T7T8T9-3 ' o f 
the ‘T’ rich strand, indicating that the specificity o f sequence and orientation in this 2:1 complex 
is very high. Blasko et al., (1993) observed a 2:1 and a 4:1 binding mode of distamycin with 5 
d(CGCAAATTTGCG)2, using NMR and molecular modelling. In this case the minor groove 
opened ~ 16A to allow these four ligands to bind in their usual antiparallel fashion.
C21 ~
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Figure 3 Bifurcating bonds in the distamycin-DNA complex (Pelton et al., 1988).
Garbesi et al., (1996) performed a similar piece of research, with an alternative 
oligomer 5'-d(CGTACGTACG)2, via NMR. The original DNA helical structure was, once
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again, preserved on the co-operative binding o f two distamycin A molecules. Interestingly, this 
oligomer does not contain four successive AT base pairs, suggesting that distamycin will 
interact with mixed sequences. As a consequence o f this, the guanine NH2 moiety may not be 
responsible for sterically inhibiting the binding o f distamycin. It maybe the increase in minor 
groove width associated with these guanine and cytosine rich GC sequences that yields a ‘slack’ 
fit for this ligand, resulting in distamycin’s preference for the spatial confinements o f the narrow 
A tracts o f DNA. These wider GC grooves are, however, well suited for binding o f two 
distamycin molecules. A large dipole-dipole interaction between the pyrrole and carboxamide 
groups o f adjacent distamycins or netropsins, was detected using X-ray crystallography (Chen et 
al., 1997). It is this force that is most likely to be responsible for these ligands tolerance for 
lying next to one another and aiding co-operative binding. This is unlike anything seen in other 
families o f minor groove binding agents.
Following the work o f Pelton et al., (1989; 1990), Blasko et al., (1993) and Garbesi et 
al., (1986) which described the anti-parrallel side-by-side binding o f two distamycin molecules, 
Chen and Lown, (1994) manipulated this unique feature to produce cross-linked lexitropsins. 
Poly(methylene) chains were used to link two tripyrrolocarboxamide strands via their central 
pyrrole nitrogen so as not to interfere with the phasing of binding, or encounter the problem of 
the formation o f a U-tum in the end-to-end bound molecules. Covalent attachment of 
monomers prevents competition between separate ligands for binding sites. The optimal 
binding strength K  o f the dimer is also likely to be greater than the product o f stepwise binding 
(ka and kf,), suppressing the 1:1 drug: DNA binding mode. CD studies showed that binding to 
poly(AT)-poly(AT) DNA increased by up to 1000 times in comparison to the monomer, as the 
length of the methylene linkage increased from four to seven units.
This idea o f joining lexitropsin molecules has undergone further development to yield 
the ‘hairpin polyamides’ (Fig. 4) (Mrksich et al., 1994) which have been so successful, that they 
may now be considered as the fifth class of minor groove binders rather than solely an 
oligopeptide analogue. Modification o f the amino acid components allows specific base-pairs 
to be recognized for example, a selection o f eight ring hairpin polyamides were synthesized 
which differed in the arrangement of pyrrole (Py) and imidazole (Im) amino acids allowing 
binding to GC bp containing sequences (Swalley et al., 1997). The polyamides ImlmPyPy- 
gamma-ImlmPyPy-beta-Dp, ImPylmPy-gamma-ImPylmPy-beta-Dp and Imlmlmlm-gamma- 
PyPyPyPy-beta-Dp bound to 5'-TGGCCA, 5'-TCGGCA and 5'-TGGGGA respectively with 
very high specificity (>250 fold) compared to mismatch sites. The hairpin polyamides were 
shown to discriminate 5'-GGGG, 5'-GCGC and 5'-GGCC. This recognition o f GC base-pairs 
by hairpin polyamides expands the sequence repertoire by which DNA can be targetted. Parks 
et al., (1996) also observed lower binding affinities at sites containing single base-pair
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mismatches. It was also noted that varying the position of the gamma linker i.e. AcImlmPy- 
gamma-PyPyPyPy-beta-Dp and AcPyPyPyPy-gamma-ImlmPy-beta-Dp was not found to 
markedly affect binding affinity and specificity. Surovaya et al., (1997) determined via CD 
studies that the hairpin polyamide bis-netropsin has different structural motifs, depending on 
whether the oligopeptides are linked tail-to-tail for parrallel side-by-side binding, or head-to-tail 
for anti-parrallel side-by-side binding. Pt-bis-netropsin was found to traverse 4-5 AT bp of the 
minor groove in its hairpin form. The chiral properties of these compounds have also been 
investigated, specifically by chiral substitution o f the gamma-aminobutyric acid (gamma) chain, 
which links the three-ring polyamides consisting o f pyrrole and imidazole amino acids, to form 
a six-ring hairpin (Herman et al., 1998). Footprinting studies demonstrated that the (R)-2,4- 
diaminobutyric acid linker enhanced the binding affinity by up to 170x relative to the (S) 
enantiomer, while sequence specificity was affected to a lesser degree increasing only 5-fold at 
5'-TGTCA and 5'-AC ATT sites. The sequence specificity of the gamma-tum and beta-tail 
amino acids has also been probed by Swalley et al., (1999), with footprinting studies using the 
DNA restriction fragments 5'-ATGGCNA and 5'-ANGGCTA. Both gamma-tum and beta-tail 
amino acids were found to prefer AT/TA base-pairs to GC by 200-400 fold. GC base-pairs 
were preferred over AT to encase the the 5 bp binding site. This demonstrated that the tail and 
turn amino acid moieties play an important role in sequence-specificity.
Tallimustine
Figure 4 The molecular structures of the hairpin polyamide ImPy-3-ImPy-y-ImPy-{3-ImPy-|3-Dp (bottom) 
and tallimustine (above).
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Modification o f the individual ring systems using 3-hydroxypyrrole (Hp), N- 
methylpyrrole (Py) and N-methylimidazole (Im) units in 9- and 11- ring hairpin polyamides 
allows discrimination between CG (Py/Im), GC (Im/Py), TA (Hp/Py) and AT (Py/Hp) base- 
pairs (White et al, 1997,1998; Keilkopf et al., 1998). Increasing the length of polyamides so 
that they recognize 6 or 7 bp sites which is favourable in view o f enhanced sequence selectivity, 
encounters many problems in practise. Spacers between lexitropsins have to be introduced to 
rephase the hairpin polyamide to achieve sequence recognition, while the subunit 3- 
hydroxypyrrole achieves selectivity in a negative manner i.e. through aversion rather than 
affinity towards specific sites, which is not an attractive property for drug design (Thurston, 
1999). Hairpin polyamides have recently been used to target the HIV-1 transcription element in 
order to block HIV replication. These ligands prevent host cell transcription factors from 
binding to the HTV enhancer element (Dickerson et al., 1998). Hairpin polyamides were most 
effective when a variety of these ligands were combined to competitively inhibit a number of 
minor groove DNA binding proteins simultaneously.
Tallimustine is an aniline mustard derivative of distamycin (Fig. 4) which is presently 
in Phase II clinical trials as a broad spectrum antitumour agent. Alkylation is thought to take 
place in the minor groove at a purine (Pu) N3 in the consensus sequence T^GPu, where Pu is 
preferably A (Wyatt et al., 1995) according to modified DNA sequencing techniques. The 
minor groove comprised of this sequence progressively expands in the 5'- to 3'- direction as it 
comes out of the narrow propellor-twisted T tract, causing unwinding of the helix. This is an 
important factor in stablization o f the tallimustine adduct, because the widening groove at the 
guanine base harbours the phenyl ring more comfortably (Ragg et al., 1998). The charged 
amidinium group lies at the beginning o f the 5 -T tract.
Various analogues o f distamycin and netropsin have been synthesized (Krowicki et 
a l, 1988; Dwyer et a l, 1992; Animati et a l, 1995) and their interactions with DNA have been 
evaluated. Krowicki et a l,  (1988) replaced the guanidinium group with alkylating moieties 
such as cyclopropyl, chloro or fluoroacetyl and compared their biological activities with those 
of unmodified distamycin and netropsin. Cytostatic activity o f some of these compounds, 
notably the chloroacetyl derivative, increased by up to 45 times over netropsin and 18 times that 
of distamycin. Dwyer et a l, (1992) synthesized an imidazole derivative o f distamycin which is 
capable o f binding to the consensus sequence 5'-d(AAGTT). The problem of the positive 
imidazole being adjacent to AN3 was erradicated by substituting the site with a guanine, whose 
C2 amino protons add a sequence selectivity aspect to the binding, because o f their hydrogen- 
bonding capabilities. Animati et a l,  (1995) studied the effect o f varying the number o f pyrrole 
rings in distamycin. As previously described with distamycin, drug to DNA complexes in a 
ratio of 2:1 were formed. The tetrapyrrole derivative showed increased specificity at the A3T3 
binding site, recognizing five base-pairs and exhibiting no sliding from the 5 - A A ATT site.
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Distamycin and netropsin have great potential as leads in the development o f new lexitropsins 
with enhanced biological activity by logical structural modifications.
1.1.2 The bis-benzimidazoles
Hoechst 33258 was first synthesized by Loewe and Urbanietz (1968). It has 
subsequently found a diverse number of uses: as a fluorescent histochemical stain, clinically as 
an anthelmintic agent for treatment of intestinal worms (Raether and Lammler, 1971), and has 
displayed some activity against intraperitoneally implanted L1210 and P388 leukemias in mice 
(screening data on Pibenzimol, NCI, Bethesada, USA). Hoechst 33258 consists o f three 
aromatic ring systems; a phenol, two benzimidazole rings and a piperazine ring. These are 
arranged in a crescent shape (Fig. 5) similar to distamycin and netropsin, perfect for binding 
into the minor groove o f right-handed helical DNA. There are two possible binding modes for 
Hoechst 33258 to (3-form DNA, which are dependent on its concentration (Bontemps et al., 
1975). At low ligand concentrations, Hoechst 33258 binds tightly (binding constant ~106-107M‘
l) to the outside o f the double helix, with its axis at 45° to that o f the oligomer, which 
characterizes association within the minor groove. Higher drug:DNA ratios lead to lower 
affinity interactions (binding constant 104-105M"‘) with the external surface of DNA. The high 
affinity binding which occurs in A-T rich regions o f the minor groove (Ridler and Jennings,
1980), is comparable to that o f the oligopeptide antibiotics. The NH moieties with the 
hydrogen-bonding capabilities in both families are situated on the concave face, with a cationic 
group available for favourable electrostatic interactions with the negative potential o f the AT 
groove. The high selectivity of Hoechst 33258 binding has been researched extensively, using a 
variety of spectroscopic methods and oligomer sequences o f the ilk 5 d(CGCXXXXXXGCG)2, 
where the Xs represent a string o f purine base pairs. It is hoped that these will lead to an 
understanding in the chemistry of DNA recognition by base perturbations in the binding site.
OH
Hoechst 33258
Figure 5 Hoechst 33258 at neutral pH (one positive charge).
Searle and Embrey (1990) investigated the interaction o f Hoechst 33258 within the 
minor groove of 5 -d(C T i l l  GC A A AAG)2, by NMR spectroscopy. A single species resulted 
from the reaction consisting o f two Hoechst 33258 molecules binding symmetrically within the
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A and T tracts. Both N-methylpiperazine groups were orientated towards the central GC of the 
complex, illustrating the high level o f competence this ligand shows in its ability to ‘read’ the 
minor groove. As with distamycin and netropsin, there is evidence of bifurcating bonds 
between the NHs o f the benzimidazole rings and adenine N3 or thymine 02, resulting from 
characteristic A tract base propellor twisting and a narrower groove. Hoechst 33258 sits within 
the limits o f the AT base pair region, where the electrostatic attraction between them is greatest, 
contributing to the strength o f its binding. Evidence o f many van der Waals interactions 
between the concave face of the drug and DNA was noted. These were thought to be a product 
of the close complementarity of Hoechst 33258 with the minor groove.
Parkinson et a l, (1990) also used spectroscopic methods to look at Hoechst 33258-5'- 
d(CGCGAATTCGCG)2 interactions. The greatest chemical shift changes belonging to the 
sugar H I' protons were used to locate the ligand position, followed by NOE analysis to produce 
a three-dimensional model. This structure was in agreement with the findings of Searle & 
Embrey (1990) and an earlier X-ray crystal structure, produced by Teng et a l, (1988). Other 
studies have also targetted the 5'-AATT with varying flanking sequences. Fede et al., (1991) 
decribed the positioning of the Hoechst 33258 subunits in detail within the 5'- 
d(GTGGAATTCCAC)2 duplex. The piperazine moiety in this unsymmetrical complex was 
located at A5T6 and t 19T20 by intermolecular NOE data generated between this group and the 
AH2 and sugar HI' protons. Hydrogen-bond donors and acceptors lock the ligand into 
juxtaposition with the binding site, contributing to the stability o f the complex. The NH of  
benzimidazole adjacent to the phenol head is bonded with T702, while the neighbouring 
benzimidazole interacts with 1^07. Embrey et a l, (1993) used a sophisticated DNA duplex 5'- 
d(GCTAATTACC)2, consisting of five consecutive binding sites, containing the minimum 
3xAT base pairs, to react with Hoechst 33258. Once again binding only occurred at the 5'- 
AATT site, phenyl ring protons being situated closely to A4H2. The NOE data suggest that the 
final tightly bound structure is analogous to those described previously. Hoechst 33258 
displays no partiality for GC flanking sequences which could have possibly accommodated the 
bulky piperazine ring within the wider groove with greater ease. Intramolecular NOEs indicated 
no perturbation in (3-helical DNA structure, so the flanking 5 '-AT bases are able to harbour a 
piperazine bby some subtle change in minor groove width.
The analogue meta-hydroxy Hoechst 33258 was allowed to react with 5'- 
d(C1G2C3G4A5A6T7T8C9G10C11G12)2 to assess the effect o f the hydroxyl group on selectivity and 
binding, by investigating any new hydrogen bond-formations (Parkinson et a l, 1994). In 
agreement with earlier results, the piperazine ring was situated at T8 o f the 5'-d(AATT8) binding 
site (from H4' NOE data). Embrey et al., (1993) noted that the phenol ring flips in the minor 
groove even at low temperatures, although this activity ceases on relocation o f the hydroxyl
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group to the meta position. This led Parkinson et a l, (1994) to predict from their model that 
hydrogen-bonds between the meta-hydroxyl and C=0 of C9 or the exocyclic NH2 of G4 were in 
place and were substantial enough to prevent ring movement. Additional hydrogen-bonds 
would undoubtably increase the stability o f the complex, plus enhancing toleration and possibly 
recognition of a GC base pair at the 5'- end o f the AATT target sequence. However, as 
previously discussed, hydrogen-bonds are not directly responsible for the specificity with which 
these ligands can target a sequence. Both pyrimidine and purine bases having equal numbers of 
hydrogen-bond acceptor atoms; 02  and N3 respectively.
An X-ray crystal structure o f the meta-hydroxy analogue o f Hoechst 33258, was 
determined with the same 5'-d(CGCGAATTCGCG)2 sequence (Clark et al., 1996). This 
compound has its benzimidazole group replaced by pyridoimidazole. This meta-hydroxy 
analogue was found to span 5-AATTC. The intermolecular hydrogen-bonding influenced the 
conformation of the whole structure. The phenol adjacent to A5 within the minor groove, was 
present as ‘in’ and ‘out’ conformations relative to the minor groove. Hydrogen-bonds were 
formed in each conformation, although the latter case required extended water networks to 
achieve this. The customary bifurcating H-bonds along the concave surface of the ligand were 
present, but the pyridyl nitrogen N7 did not take part in this, so the overall result was very 
similar to that of binding o f Hoechst 33258 itself. For these subunits to align for H-bonding 
simultaneously within the minor groove, the ring systems have to twist relative to each other 
away from co-planarity. This results in widening o f the groove and, hence, a different overall 
structure to that of Hoechst 33258.
Wood et a l, (1995) examined the crystal structure of another analogue of Hoechst 
33258, where an imidazole ring replaces piperazine. The main difference between this model 
and that o f Clark et a l, (1996) is the narrowing o f the minor groove at the 3'-end of the binding 
site, relative to the substitution with the less spatially consuming imidazole group. This is 
thought to be the main reason for the increase in the binding affinity o f this analogue compared 
to Hoechst 33258, because both molecules form the same hydrogen-bonds in the groove. Clark 
et a l, (1997) replaced the piperazine and phenyl groups of Hoechst 33258 with an amidinium 
and phenylamidinium moiety, respectively. This demonstrated that, where no other interactions 
were available, five hydrogen-bonds were sufficient for high affinity binding.
Clearly, narrowing of the minor groove width (associated with a close complementary 
fit around the drug), and hydrogen-bonding, are both necessary for high affinity binding of 
Hoechst 33258. In all stuctures, regardless o f the sequence, there is one bifurcating hydrogen- 
bond from one benzimidazole NH, with either a single or bifurcating H-bond from the second 
benzimidazole ring. Abu-Daya et a l, (1995) conducted a study using DNase I footprinting
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techniques to probe the binding of Hoechst 33258 to oligomers o f varying A T target sequences. 
These results suggested that future novel compounds should be based on the benzimidazole 
structure, due to its significantly higher affinity for AATT sites than other arrangements o f A 
and T by berenil or the oligopeptide ligands.
1.1.3 Bisamidines
Berenil is a member o f a large group of compounds, called the bisamidines, which 
have a common terminal amidine moiety. First synthesized in the 1950s, it was found to 
possess a variety o f useful activities including antimicrobial, antiviral and antiparasitic 
properties (Newton, 1975). It is still used as a trypanocide in Africa today as a treatment for 
bovine trypanosomiasis, although its effectiveness has decreased over the years due to 
resistance (Kopka & Larsen, 1992). Berenil is also capable of inhibition of mammalian 
topoisomerase II activity and binding to the DNA-containing kinetoplasts in mitrochondria 
(Portugal, 1994). The molecular structure o f berenil (Fig. 6), consists o f two diamidine benzyl 
rings joined by a triazene bridge. Braithwaite and Baguley (1980) demonstrated that berenil 
bound to the minor groove of DNA duplex, selectively at dA dT base pairs. This was also 
proved via displacement o f ethidium bromide from its intercalation site in DNA, by a 5-fold 






Figure 6 The molecular structure of berenil.
As for many other DNA-drug complexes, the binding of berenil to a selection of 
p(dA)„-p(dT)n, p(dAT)„ p(dAT)n and p(dTA)„ p(dTA)n DNA duplexes, has been investigated by 
X-ray crystallography (Pearl et al., 1987). Analogously to the oligopeptides and bis- 
benzimidoles discussed previously, berenil binds isohelically within the A-T minor groove. The 
concave surface o f berenil is complementary to the base o f the minor groove. The presence of a 
guanine base, with an amino moiety protruding into the binding region, would sterically hinder 
berenil from binding in a G-C rich locality. Both positively charged terminal amidine groups of 
berenil are able to rotate. This enables them to come into close hydrogen-bonding contact with 
the oxygen atoms of the phosphate backbone, although this is at the expense o f the hydrogen- 
bonding within the base pair. The ring systems in the molecular model are slightly twisted 
relative to one another by approximately 9-6°. Two strong hydrogen-bonds were formed in the
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d(AT)4*d(AT)4-berenil complex, between the ligands terminal amidine groups and 02  of 
thymine. In constrast, the reverse occurred with the d(TA)4*d(TA)4 duplex, the hydrogen-bonds 
being directed towards the N3 of adenine acceptors instead. Adenine H2 obstructs this latter 
interaction, providing a possible explanation as to why berenil has a higher affinity for 5'-AT 
rather than 5'-TA sequences.
Yoshida et a l , (1990) generated a molecular model from NOE data collected on the 
berenil-5 '-d(GCAATTGC)2 complex, which conflicts with the favoured binding model 
proposed by Pearl et a l, (1987). This solution structure agreed with the proposition that berenil 
bound spanning the central 5 -AT base-pair. However, Yoshida et a l, (1990) placed the ligand 
effectively in a mirror image orientation. This allowed hydrogen-bonding to occur between the 
internal adenine N3s and the amidine protons. Unfortunately, this model does not take into 
account the length of the berenil molecule and the fact that it is too long to span comfortably the 
width of the minor groove across an AT base pair without undergoing some structural 
deformation (Kopka and Larsen, 1992). Brown et a l, (1990) examined the crystal structure of 
5 '-d(C1G2C3G4A5A6T7T8C9G10C11G12)2-berenil complex. The binding sequence was found to 
consist o f a 5 '-AAT section, where the amidinium tail was hydrogen-bonded to A5N3 and 
A604' via a water molecule, whilst the head group formed a bifurcating bond to A18N3 and 
T802. This model accomodates the size of berenil correctly. Lane et a l, (1991) studied the 
same complex by NMR and established that the binding site was 5'-ATT, which is an 
equivalent site on the opposite strand to that previously described (Brown et al., 1990). 
Molecular mechanics calculations produced a structure in which the berenil was planar and 
isohelical with the minor groove floor, allowing for hydrophobic interactions between phenyl 
rings and the walls of the groove. The charged amidinium groups formed hydrogen-bonds with 
the N3 o f A6 and A17, when the triazene moiety aligned itself NH-N=N across 5'-A6T7T8, to 
minimize deformation o f the DNA helix.
Hu et a l, (1992) have studied berenil binding by NMR, using a 5'-TA-containing 
sequence 5'-d(GCTTAAGC)2 According to Pearl et a l, (1987) and Abu-Daya et a l, (1995), 
this 5 '-TA step was less favourable in comparison with the 5'-AT step for ligand binding. The 
greatest chemical shift was observed for thymidine protons, whilst, in contrast, it was the 
adenosine protons in the 5'-AATT complex that experienced a large chemical shift. This 
suggested that berenil was in the same orientation in both sequences. From the NOE data the 
binding site of 5 -d(GCTTAAGC) was deduced as 5'-TAA. Smaller chemical shift differences 
between this complex and free duplex, compared to those seen with the 5 '-AATT sequence 
were indicative o f weaker interactions. Hence, this sequence displays a lower affinity for 
berenil than 5 -d(GCAATTGC)2, in agreement with both Portugal and Waring (1987), and Pearl
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et al., (1987). Interestingly, berenil binding to 5 '-d(CGCAAATTTGCG)2 also occurs via 
hydrogen-bonds to the 02  of thymine, around the central four base-pairs (Brown et al., 1992).
More recent research by Pilch et al., (1995) has probed the ability of berenil to 
intercalate with DNA as it simultaneously binds to the minor groove. Viscometry o f the 
berenil-poly(A-T)2 complex indicated that some intercalation was taking place, because an 
increase in relative viscosity is proportional to an increase in molecular length, a consequence of 
intercalation. Unwinding of the negative supercoils of the pBR322 plasmid was observed, 
which is only achievable by insertion o f berenil between the bases of the helix. Two inflection 
points were visible on the CD spectra which correlated with more than one optically detectable 
ligand binding event. It was also observed in UV melting studies that berenil binding to p(A- 
T)n was less exothermic and hence less favourable than netropsin (minor groove binder) or 
ethidium bromide (intercalator), suggesting that the binding mechanism could be a mixture of 
both modes. Pilch et a l, (1995) suggested that berenil does not bind to DNA solely via the 
minor groove binding mode, as all previous paths o f research have indicated. It maybe that 
there is a mixed binding mode; intercalation versus minor groove binding in competition with 
one another, or possibly a single binding mode with dual characteristics. Correlations between 
mixed binding modes and anticancer activity by topoisomerase 1 inhibition (Chen and Liu, 
1994), mean that berenil could be a lead for future drug design if  it is capable o f both 
intercalation and minor groove binding.
DAPI (4',6-diamidino-2-phenylindole) is another diarylamidine compound 
synthesized in the 1970s, as the result o f a comprehensive search for more effective 
trypanocides. This novel unfused aromatic compound now has the reputation o f being a classic 
minor groove binder. Like berenil, DAPI has head and tail diamidino moieties which are 
available for hydrogen-bonding. The centre o f the molecule consists o f a benzene ring 
connected to an indole ring system (Fig. 7). DAPI is an inhibitor o f a selection o f DNA 
processing enzymes such as RNA polymerase II, DNA ligase, exonuclease III and DNA 
polymerase I (Parolin et al., 1990). Chiang et al., (1994) found DAPI to be responsible for 
inhibition of the TATA binding protein TBP, from binding to the TATA box consensus 
sequence, which is a prerequisite for RNA polymerase II binding and hence gene transcription. 
DAPI is fluorescent, which has led to its use clinically as a chromosomal stain in screening 
cancer cells for chromosomal abnormalities.
Larsen et a l, (1989) analysed the X-ray crystal structure o f DAPI bound to 5'- 
d(C1G2C3G4A5A6T7T8C9G10CllG12)-5'-d(C13G14C15G16A17A18T19T20C21G22C23G24) This ligand 
was found to bind in a single orientation across the central AATT segment. A bifurcating 
hydrogen-bond from the N3 of amidinium adjacent to the indole was formed with T200 2  and
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A6N3, whilst N4 of the amidinium tail hydrogen-bonded with the sugar oxygen o f A18. The 
nitrogen o f the indole ring forms a bifurcated hydrogen-bond with Tl902  and T702. Therefore, 
DAPI adheres tightly to the 5 -ATT binding site within the minor groove.
DAPI
Figure 7 Molecular structure of DAPI.
It has also been demonstrated that DAPI is, in fact, a mixed mode binder. Wilson et 
al., (1989; 1990) provided evidence o f intercalative binding within d(G-C) and mixed 
d(G-A-C-T) sequences. Changes in base sequence composition are responsible for geometric 
changes to the minor groove, namely the width and depth, by becoming wider and shallower. 
As a consequence of this, the ligand binds to the minor groove with low affinity and the 
intercalative binding mode becomes more energetically favourable.
Trotta et al., (1996) discovered that the d(AT)n base pairing was not the only factor to 
determine whether DAPI bound to the minor groove o f DNA. The ligand:nucleotide binding 
ratio also has an important effect. NMR data on the DAPI-5-d(CGATCG ) 2  complex, which 
existed at a high 2:1 drug:duplex binding ratio, provided evidence for two simultaneous modes 
o f binding. Firstly, there is binding within the minor groove across 5 -ATC, and secondly, there 
is 7X-TC stacking of the aromatic ring systems o f DAPI onto the terminal base pairs. This mode of 
external stacking is novel but not so useful biochemically. This is because genes are surrounded 
by nonsense codons, which are DNA sequences void of information for protein transcription. It 
is at the end of one of these regions where DAPI would stack.
Propamidine and pentamidine are probably the most comprehensively researched aromatic 
diamidines after berenil. X-ray crystallography and NMR spectoscopy have been used to try to 
find the key, to these ligands binding modes and sequence specificities. A large databank has 
been compiled on their complexes with various oligonucleotide sequences. The structure of 
pentamidine or l,5-bis(4'-amidinophenoxy)pentane is given in (Fig. 8). Propamidine or 1,3- 
bis(4'-amidinophenoxy)propane (Fig. 8) is the short chain homologue o f pentamidine. Clinical 
interest in these bisamidines has revived due to pentamidines application in the treatment of 
Pneumocystic carinii pneumonia, an opportunistic infection occurring in greater than 70% o f 
patients with AIDs, which is a major cause of their death (Tanious et al., 1997). Design o f new 
ligand analogues is important because of toxicity. Like the other members in this family, 
pentamidine and propamidine are also antitrypanosomal and antiviral agents.
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Figure 8 Molecular structures of propamidine and pentamidine.
Jenkins et al., (1993) and Greenidge et al., (1993) used NMR and molecular 
modelling studies to probe the binding of pentamidine to 5'-d(CGCAAATTTGCG)2 and 5 - 
d(CGCGAATTCGCG)2 , respectively. Three possible binding sites were available in the 5'- 
AAATTT sequence, taking into account pentamidines requirement for a 4-5 base-pair segment 
for binding (Zimmer and Wahnert, 1986). Preferential binding took place across the 
asymmetric 5-ATTT site, where van der Waals forces and hydrogen-bonds from pentamidine 
terminal amidine NH2 to A6 and A16N3, are more abundant. The molecule retains its planarity 
and is a good isohelical fit within the minor groove, so that binding energy penalties are not 
incurred by DNA distortion. Molecular models generated by Greenidge et al., (1993) agree 
with these conclusions; in that pentamidine is more elongated than in the crystal structure, 
spanning over four bases. Analysis of some pentamidine analogues demonstrated that varying 
the number of (methylene units),,, where ‘n ’ is an odd number in para-substituted analogues or 
even in metasubstituted ones, increased the ability o f these molecules to fit isohelically within 
the minor groove.
Conte et al., (1995) used the asymmetric sequence 5 -d(GCAATGAGCG) to bind 
propamidine. 5 -AAT was found to be the major binding site although some binding also 
occurred across 5 -TGA indicating that a GC base pair can be tolerated in an AT rich target 
sequence. Propamidines binding site is 3-4bp in length, lbp shorter than the 4-5bp which 
pentamidine spans, reflecting propamidines shorter linker. Nunn and Neidle, (1995) compared 
the crystal structure o f propamidine binding to 5 '-d(CGCGAATTCGCG)2 with 5'- 
d(CGCAAATTTGCG)2. The binding differed by a 2A displacement o f the ligand toward the 
3 -end o f the A3T3 strand, relative to the position in the A2T2 sequence. This is enough to 
redefine hydrogen bonding patterns as a consequence o f the modified minor groove geometry 
i.e. increased length o f the AT sequence (A2T2-»A3T3), leads to a narrower groove. This results 
in more van der Waals interactions and hence, a more ‘comfortable’ fit for propamidine in the 
groove.
Jenkins and Lane, (1997) stated that the binding affinity o f 
berenil>propamidine>pentamidine. This is probably a reflection of the entropic cost endured on 
binding, in a bid to procure the ‘best fit’ conformer for the minor groove. This suggests future
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rational design should move in the direction o f ligands possessing less internal rotation for 
increased binding affinity.
1.1.4 Bisfqua ternary ammoniumlheterocvcles
The bis(quatemary ammonium) heterocycles (BQAH) are a family consisting o f a 
synthetic series o f molecules which bind to the minor groove o f DNA. They are related to 
polyamidines, but have quaternary ammonium heterocycles as the charged centres. Perhaps the 
most well known analogue is SN-6999 i.e. 4-[4-[4-(4- 
quinolylamino)benzamido]anilino]pyridine, which consists of four aromatic rings: a
quinolinium (Q), benzamido (BQ), anilino (BP) and a pyridinium (P) (Fig.9). Other members 
are SN-4094, SN-6136 and SN-18071 (Fig.9). BQAHs exhibit potent antitumour and antiviral 
activies (Cain et al., 1969) in vivo and in vitro, mainly as a result o f their effects on DNA 
metabolism and inhibition of DNA gyrase (Storl et al., 1993). The lipophilicity of these drugs 
is thought to have a positive correlation with anticancer potency. While p(dAdT)n-p(dAdT)n 
rich DNA sequences, are preferred over p(dGdC)n*p(dGdC)n (Denny et al. 1979; Baguley 1982). 
Some of the early analogues, e.g. SN-4094, showed chronic toxicity in vivo. There are little 
mutagenicity data available on BQAHs as genotoxins; however, due to its ability to bind to 





Figure 9 Molecular structures of some bis(quatemary ammonium)heterocycles.
It was established by Braithwaite and Baguley (1980), through viscosity 
measurements that SN-6999 bound to the exterior of DNA in the minor groove. This agreed 
with data showing SN-6999 was unable to unwind closed superhelical DNA, the classic test for 
intercalation. Leupin et al., (1986) investigated the binding o f SN-6999 to the DNA duplex 5'- 
d(GCATTAATGC) 2  by NMR. From analysis of the NOEs, it was concluded that the ligand 
bound in the AT rich region with little pertubation o f the (3-DNA helix, as all proton walks 
remained intact. SN-6999 bound to the minor groove in an extended manner, spanning 
approximately five base pairs. However, because the lifetime o f the complex was quite short,
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the asymmetric ligand binding did not result in loss of magnetic equivalence between the 
complementary strands as expected. Temperature-dependent changes were noted for the 
lineshape of a thymine methyl. Alongside NOE data, this led to the conclusion that SN-6999 
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Figure 10 Diagram to show how SN-6999 binds to equivalent sites in the DNA duplex.
Figure 10 shows that these two species are not distinguishable and, hence, the NOEs for each 
strand are degenerate. Leupin et al., (1986) proposed that this binding mode was a result o f a 
‘flip-flop’ process o f intermolecular rearrangement, without dissociation of the drug from the 
complex. This was because only a slow exchange o f imino protons was observed, suggesting 
that SN-6999 was obstructing solvent from accessing this area of base-pairing in the DNA 
minor groove.
Gao et al., (1993) presented a crystal structure o f SN-6999-5 - 
d(C1G2C3[e6G4]A5A6T7T8C9G10C11G12), in which SN-6999 did not exhibit such a pronounced 
quarter-moon shape, as compared to other minor groove binders. The P and Q rings were not in 
plane with the BQ and BP rings, which were orientated ‘edge on’ within the minor groove 5 - 
AA sequence. This provided the opportunity for abundant van der Waals interactions. The P 
ring was situated at e6G4 C23 and C^G22, whilst Q was adjacent to the centre o f the sequence. 
The positive charges of both moieties contributed to the ligands affinity for the DNA. SN-6999 
binding also results in a tilted and stiffened DNA helix. By analogy with other minor groove 
binders, initial specificity was attributed to H-bonding ability (Baguley, 1982). However, SN- 
18071 defies this proposal because it is unable to form any hydrogen-bonds, yet has a binding 
affinity only slightly lower than SN-6999.
Chen et al., (1992) extended the work o f Leupin et al., (1986) to a piece o f DNA with 
a shorter AT sequence in an attempt to produce a 1:1 complex with SN-6999 bound in only one 
orientation. Guanine amino groups were placed on each side o f the target sequence (5'- 
d(GGTTAATGCGGT)-5'-d(ACCGCATTAACC)) to impede sterically any ligand sliding. The
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NMR chemical shifts were greatest for bases T3—>G8 on one strand and from Aig->C23 on the 
other opposite strand, indicating the position o f the bound SN-6999. Although no multiple sets 
of signals were visible, the methyl resonances were broad, implying that two orientations o f the 
drug were present, exchanging at an intermediate rate. The proportionate NOE intensities o f the 
quinolinum 3H-»A18 and C23, at opposite ends o f the binding site, demonstrated that these two 
drug-DNA species existed in equal quantities.
Rydzewski et al., (1996) hypothesized that a homogenous ‘A’ tract binding site 5'- 
d(G1G2G3A4A5A6A7A8C9Gl0G11) could hold the key to trapping SN-6999 in one orientation, due 
to the imposed spatial confinements. In fact, the binding ratio was only 7:3 in favour o f the 
pyridinium ring being situated near 5'-A5. This preferential binding mode optimized shape 
complementarity and the various types o f interactions between DNA and SN-6999, resulting in 
this observed 7:3 major:minor orientational ratio. SN-6999 associated more closely with the 3 '- 
ends o f both the p(A)s and the p(T)5 sequences, in effect lying obliquely between both strands as 
would a covalent cross-linker. A high resolution structure o f a BQAH-DNA complex is still 
required to elucidate the molecular basis, kinetics and affinities o f the binding of these ligands 
before rational design of new, related therapeutic compounds is really possible.
1.2 The covalent minor groove binders
There are two major classes o f covalent minor groove binders: the pyrrolo[2,l-c][l, 
4]benzodiazepines and the cyclopropapyrroloindoles. Their modes of binding and specificity 
will now be reviewed in detail.
1.2.1 Pvrrolof2.1-cl 11.41 benzodiazepines
The pyrrolo[2,1 -c] [ 1,4]benzodiazepine (PBD) family is composed of natural products 
from various thermophilic Actinomycetes. They are sometimes known as ‘antitumour 
antibiotics’ owing to their capacity to inhibit strongly the multiplication of e.g. mice reticulo­
endothelial sarcoma cells at low drug (e.g. sibiromycin) concentrations. At high drug 
concentrations, the growth o f various bacteria, such as Bacillus mycoides, is also inhibited 
(Gause et al., 1969). Anthramycin was isolated from Streptomyces refuineus (Tendler and 
Korman, 1963) and the name reflects the anthranilic acid component o f the molecule. 
Sibiromycin was discovered in 1969 in Siberia (Gause et al., 1969), from Streptosporangium 
sibiricum. Tomaymycin was derived from Streptomyces tomaymyceticus, in the Tomei region 
between Tokyo and Nagoya (Arima et al., 1972). Lastly, the neothramycins A and B were
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isolated from Streptomyces N° MC916-C4 (Takeuchi et al., 1976), also in Japan. All these 
compounds have a common structural feature the pyrrolo[2,l-c][l,4]benzodiazepine nucleus. 
However, they differ in the degree o f pyrrole ring saturation, the side chain at C2, the pattern o f 
substitution and the substituents on the aromatic ring (Fig. 11). For example, anthramycin and 
sibiromycin are both 8-methoxy-9-hydroxy substituted, whilst tomaymycin is 7-methoxy-8- 
hydroxy. Sibiromycin has a large sugar ‘7-sibirosaminide’ side-chain. The carbinolamine at 
N10-C11 is the functional group capable o f reaction with DNA. In the case o f the 
neothramycins where a 10,11 enamine is present, hydration in solution results in the required 
carbinolamine.
All pyrrolo[2,1 -c] [ 1,4]benzodiazepines are potent inhibitors of RNA and DNA 
synthesis, whereas the synthesis o f proteins is not affected (Horwitz and Grollman, 1968; 
Maruuama et al., 1978; Gause and Dudnik, 1971). On anthramycin binding to DNA, some cells 
try to remove the ligand by an excision process, resulting in induction o f unscheduled DNA 
synthesis (Hurley et al., 1979). Human skin fibroblasts use this process and can remove 
approximately 86% of bound anthramycin in 72 hours. It is this inhibition o f nucleic acid 
synthesis which is responsible for the very potent antitumour activity o f the PBDs, as 
demonstrated in vivo (Hurley, 1977). However, their clinical application has been prevented by 
dose limiting toxicities, such as cardiotoxicity in the case o f anthramycin and sibiromycin 
(Cargill et al., 1974), and tissue necrosis at the site o f injection. The ability o f this family o f 
compounds to cause mutation has also been investigated using strains o f Salmonella 
typhimurium and Saccharomyces cerevisiae (Hannan et al., 1978). Anthramycin does not alter 
the mutation rate of these cells, but excision and recombinational repair processes were
Neothramycin A (Rj=H , R^OH) 
Neothramycin B (Rj=OH, R.2=H)
pyrrolo[2,1 -c][ 1,4]benzodiazepine nucleus 
Anthramycin
Tomaymycin
H 3C H N
Sibiromycin
O
Figure 11 Molecular structures of the pyrrolo[2,l-c][l,4]benzodiazepines
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necessary for elimination of PBD adducts from their genetic material. For a review, see Turner 
and Denny, (1996).
Hurley et a l, (1977) utilized radiolabelled pyrrolo[2,l-c][l,4]benzodiazepines, in 
order to probe the structure of the resulting adduct and the mechanism of action which leads to 
it. Anthramycin, sibiromycin and tomaymycin were used to elucidate how their structural 
differences affected their reactivity. Each of these compounds was incubated with calf thymus 
DNA. Sibiromycin reached saturation within 20 minutes, whereas in comparison, tomaymycin 
and anthramycin were slower to bind, taking three times as long. Competition experiments 
were performed to ascertain whether all compounds bound to the same DNA sequence. In 
conclusion, it was found that sibiromycin was in complete competition with the binding of 
tomaymycin and anthramycin. Incomplete competition between anthramycin and tomaymycin, 
meant that anthramycin-saturated DNA was still able to bind 30% of the tomaymycin required 
to saturate DNA alone. Therefore, at least three possible binding sites exist;
1) selective for anthramycin and sibiromycin
2) selective for tomaymycin and sibiromycin
3) anthramycin, tomaymycin or sibiromycin can bind
Adjusting the pH to an acidic value resulted in destabilization o f the PBD-DNA complexes. 
Sibiromycin was able to withstand the most acid conditons. At the point where the complex 
became unstable, dissociation occurred and the ligand was released in its original state. At 
physiological pH, this could effectively lead to drug walking along the DNA, due to repeated 
cycles o f binding, excision and dissociation. The hierarchy for acid stability, 
sibiromycin>anthramycin>tomaymycin, correlates with the rate o f reaction. This suggests that 
sibiromycin binds very tightly to the DNA preventing denaturation via acid hydrolysis. 
Radiolabelling of non-exchangeable hydrogens in the pyrrole ring and side chains established 
that none o f these were involved in the mechanism of binding these ligands to DNA. This led 
Hurley et a l, (1977) to propose a mechanism o f reaction where the electrophilic C ll of the 
N10-C11 imine undergoes nucleophilic attack by the N2 of a guanine base to form an aminal 
(Fig. 12).
Corey, Pauling and Koltun (CPK) space-filling models of sibiromycin, tomaymycin 
and neothramycins A and B DNA adducts were constructed by Hurley et a l, (1980). As with 
the minor groove binders previously discussed, the concave surface of the PBD, carrying 
protons 9,10,11,1 la and 1, fit in a manner complementary to the base o f the minor groove. The 
models demonstrated that these drugs positioned themselves in the groove, without giving rise 
to helical pertubations. They probably stablize themselves through hydrogen-bonding from the 
phenolic protons to the 2-keto group of cytosine or thymine. This could be to the same base- 
pair to which anthramycin is bound, or in the case o f sibiromycin to the adjacent base-pair,
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which could also be an adenine or guanine N-l of the modified strand. It is this adjacent base 
pair 2-keto group which can also accept hydrogen-bonds from the N 10 proton o f anthramycin 
and tomaymycin. The N10-H of sibiromycin H-bonds to the cytosine of the modified base pair 
because o f the altered 7-membered ring conformation, resulting from C l la  being sp2 instead o f 
sp3 hybridized. Sibiromycin is the only PBD not to have an asymmetric carbon at Cl la, which 
is responsible for an advantageous right-hand twist o f the molecule. This allows the PBD to 
form a perfect complementary fit within the minor groove of p-helical DNA (Mostad et al., 
1978). It is this ‘S’ configuration which is the naturally occurring form of the PBDs. However, 
the sibirosamine sugar does have a stabilizing influence via its interaction with the DNA 
backbone, increasing the strength o f attachment as it protrudes out of the minor groove. 
Interestingly, adriamycin and daunomycin require an amino sugar moiety for their biological 
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Figure 12 Mechanism of reaction between PBD nucleus and guanine NH2 of DNA to form a covalent 
adduct.
Petrusek et al., (1981) also used CPK models to investigate the molecular structure o f 
PBD-DN A adducts. Saturation binding of these ligands produced a rigid helix, with the drug 
molecules lying end-to-end within the minor groove, like a third DNA strand. Binding o f 
anthramycin was also revealed as a two-phase process, composed o f a fast (20-50min) and a 
slow (~24h) reaction. The fast reaction occurred with p(dG) sequences, 5-G G  being a 
preferred binding site. Anthramycin exhaustively bound to these sites prior to resorting to 5 '- 
GX sequences, where X was A, C or T. These small ligands span two to three base-pairs. The 
stereochemistry at Cl 1 was determined to be ‘S’. Neothramycin A and B analogues were used 
to investigate the steric limitations imposed by the substituents of these drugs on binding to the 
minor groove. Neothramycin A was found to bind with higher affinity than the B isomer, and
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the B isomer C-3-methoxy or C-3-butoxy derivatives. However, these analogues of 
neothramycin A did not bind. This indicates that C-2 or C-3 substituents facing inside the 
minor groove, as in the A isomer, can only be tolerated if  they are small, unlike in the B isomer 
where larger groups pointing outwards from the groove can be accommodated. Limiting the 
size of substituents and consequently of the resulting ligand, is likely to be advantaegous in the 
design o f PBDs. This is because the more they are concealed within the minor groove, the less 
detectable they are to excision repair complexes.
Further molecular modelling studies used AMBER to evaluate the directional binding 
preferences, in the minor groove for non-sugar containing PBDs (Remers et a l, 1986). The 
ligands were covalently bound to G3N2 of 5 '-d used AMBER to evaluate directional binding 
preferences within the minor groove, for non-sugar (AIT2G3C4A5T6)2, and proved to be an 
excellent fit when positioned in either orientation. Energy analysis suggests that the favoured 
conformation o f the adduct, has the side-chain from C-2 extending alongside the modified 
strand in the 5 '-direction.
The pyrrolo[2,l-c][l,4]benzodiazepines are selective for guanine-rich DNA 
sequences, unlike the AT selective agents previously discussed which prefer the narrow 
confinements o f p(dA) tract DNA. Hertzberg et al., (1986) hypothesized that the PBDs were 
sensitive to sequence-dependent variations in helical structure, resulting in their sequence 
specificity. The observation of Hurley et al., (1977) of incomplete competition between 
anthramycin and tomaymycin, the perceived fast reaction with p(dG) sequences (Petrusek et al.,
1981) and the increased inhibition of restriction enzymes on ligand binding to p(dG) (Kaplan,
1982) all testify to this conviction. Hertzberg et al., (1986) used MPE -  Fe(II) footprinting 
techniques to identify the exact PBD binding locations. Cleavage o f the DNA took place 2 - 3  
bases either side of the guanine, where the ligand was bound and spanned a total o f 3 bases. 
Enhanced cleavage was noted in some sequences where PBD binding had resulted in 
conformational changes in the nature o f the DNA helix. The preferred binding sequence was 
5 -PuGPu and the most disliked was 5 '-PyGPy. Each PBD has a different twist angle across its 
nucleus, measured from the aromatic ring to the 5-membered ring e.g. anthramycin is 35° and 
tomaymycin is 9°. They also differ in their degrees o f pyrrole ring pucker (Arora, 1981). 
Anthramycin (larger dihedral angle) binding, was proposed to open up regions o f DNA close to 
the binding sequence, possibly resulting in increased enzymatic cleavage of DNA.
Hurley et al., (1988b) synthesized analogues o f the PBDs to investigate the effect of 
the substituents at C-8 on drug reactivity. These were evaluated using exonuclease III stop 
assays. Electron-withdrawing substituents, such as chlorine, reduced the availability of the 
electrons in the lone pair o f N10 and protonation o f N10 did not take place, rendering the imine
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stable to nucleophilic attack. Electron-donating substituents, e.g. -OH, -CH3, -OCH3, had the 
reverse effect, increasing the availability of the lone pair at N10 and consequently the rate of 
nucleophilic attack on the protonated imine. The extent of DNA alkylation by these drugs 
correlated with their in vivo potency.
The anthramycin-5 '-d(ATGCAT)2 adduct has been analysed using 13C and *H NMR 
spectroscopy by Graves et a l, (1984). On ligand binding to this palindromic sequence, the 
DNA strands lose their equivalence, as expected. The resonance of Cl 1 experienced an upfield 
shift of 16ppm, which is consistent with the formation o f the covalent aminal linkage at that 
position. Guanine N2 was identified as the site of anthramycin binding by default, as a large 
change in chemical shift would have been expected for GH8 if  the aminal linkage had been 
formed at N7.
However, 2D NMR data gave a more detailed insight into this adduct (Krugh et al., 
1989). The duplex 5,-d(ATamGCAT)-5'-d(ATGCAT) was used with one guanine sterically 
blocked, so that a single adduct was formed. Because anthramycin methyl ether undergoes 
rapid interconversion between 11(R) and 11(S) stereoisomers, it would be feasible that the 
exocyclic amino group during nucleophilic attack could attack either face, leading to two 
separate adducts. The fact that the side chain o f anthramycin chain could extend in either 
direction along the duplex adds a further two elements to the equation. Interestingly, only one 
adduct out o f the four variations is present. This is supported by strong NOE connectivities 
between Hla/Hlb->AUH2, indicating that the side chain is pointing in the 5'-direction of the 
modified strand. A weak NOE HI 1->H1 la suggests that these neighbouring protons are trans 
to one another, while strong NOEs from HI 1—>C4H1' and HI la-»AuH l' demonstrate that HI 1 
and HI la are each orientated towards a different strand. All these NOEs are consistent with the 
11(S) configuration of anthramycin.
Pierce et al., (1993) employed UvrABC nuclease to identify anthramycin and 
tomaymycin binding sites on modified DNA, which may have been overlooked by Hertzberg et 
a l, (1986) in their low sensitivity experiment. UvrABC nuclease digests in both directions 
along DNA, only stalling when it encounters a modified base. The 5 '-AGA sequence was the 
preferred binding site o f both ligands. However, the 5'- and 3'- flanking bases both influenced 
the affinities of these ligands for DNA. Anthramycin prefers 5'-A>G>T>C and 3 -A>G>T/C, 
whilst tomaymycin favours 5'-A>G/T>C and 3'-A/G>C/T. The preferred binding sites of  
anthramycin are therefore; 5'AGA, 5'AGG>5'GGA, 5'GGG, while tomaymycin favoured 
5'AGA>5 'GGC, 5'TGC, 5'AGC.
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The origins o f this observed specificity were explained by an X-ray crystal structure o f  
the anthramycin-5'-d(CCAACGTTGG) adduct (Kopka et a l, 1994). The twist angle between 
purine-purine steps (A-A, A-G or G-G) was found to be smaller than average (24-37°), whilst in 
a G-A step it was slightly larger (31-42°). This twist enhances purine-purine ring stacking, 
which is advantageous energetically, even when their pyridine partners are destacked. 
Anthramycin and other PBDs recognize this twist in the base-pair sequence, which creates the 
perfect minor groove configuration for these ligands to fit into the 5 -TGG binding site. In the 
studied duplex, the twist angle at the T-G step is 51° but in the adduct this is lowered to 34°, 
demonstrating how anthramycin induces the fit of DNA around itself. The 5 '-AT base pair 
creates an unobstructed, deep narrow minor groove in which the side chain can effortlessly lie.
Barkley et al., (1986) looked at the tomaymycin-5'-d(ATGCAT)2 adduct using 
various techniques. Evidence was presented for the existence o f diastereomers i.e. 1 IS, llaS  
and 11R, llaS. This is in contrast to the findings o f Graves et al., (1985), where anthramycin 
adduct existed only as 11(S), 1 la(S). To examine further whether tomaymycin would only bind 
as one diastereomer, a duplex with a single binding site 5 '-d(CICGAATTCICG)2 was used 
(Boyd et ah, 1990). Binding was found to take place at 5'-CGA, with C ll displaying ‘S’ 
stereochemistry and the side chain projecting in the 3'-direction. The production of >90% of a 
single tomaymycin species is therefore shown to be dependent on the flanking sequences. 5'- 
PyGPu led to one diastereomer whereas 5 -PyGPy resulted in two diastereomers, when equal 
proportions of 11(S)5' existed. This is attributable to the lower affinity o f tomaymycin for 
pyrimidines in the binding site (Pierce et ah, 1993). The most significant difference between 
these ligands, is that tomaymycin (unlike anthramycin) is unable to form stabilizing hydrogen- 
bonds (as demonstrated by NMR). These are likely to be an important factor in deciding the 
orientation o f anthramycin orientation within the minor groove.
DSB-120 is a synthetic analogue o f the naturally occurring PBDs (Fig. 15). The 
design exploits the knowledge gained by Boyd et a l, (1990), on the solely 11(S)3' bis- 
tomaymycin adduct, where the side chain ‘tails’ effectively bind to DNA in a symmetric ‘tail- 
to-tail’ orientation. These PBD nuclei were attached together through a trimethylene bridge via 
08  (Bose et ah, 1992). No phenolic hydroxy group is present at C-9 because anthramycin and 
sibiromycin (which both contain this functional group) are cardiotoxic, whilst neither 
tomaymycin or neothramycin are. Hurley and Thurston (1984) suggested that the cardiotoxicity 
maybe a result o f oxidation or tautomerization of the C90H to an orthoquinone imine. Each 
PBD nucleus is able alkylate the DNA from within the minor groove, the outcome o f this 
reaction being an interstrand cross-link. Sequence-selectivity studies (Bose et ah, 1992), 
demonstrated that DSB-120 preferred a central AT base pair in the binding site between the GC 
bases, where the aminal linkages anchor the ligand in position. The DNA decamer 5'-
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d(C1I2C3G4A5T6C7I8C9G10) was chosen for an NMR study (Mountzouris et al., 1994), because it 
contained a single target sequence in which DSB-120 could bind. A single interstrand cross­
perturbation in the helical structure existed at I8, owing to its very weak intemucleotide 
connectivities to C7. This could occur if the bridge between the two alkylating moieties of 
DSB-120 was slightly too short, resulting in small positional rearrangements o f the bases to 
accommodate the ligand more comfortably. The data also suggested that DSB-120 does not 
substantially sink itself into the minor groove. Secondary interactions were described by 
Jenkins et al., (1994), which were in the form of two hydrogen-bonds originating from the 
aminal proton o f DSB-120 to the adjacent 3 -A-N3 o f the covalently modified G. In all, the 
ligand spanned 6bp pairs with the interstrand cross-link forming between four of these at 5 '- 
GATC (Fig. 13).
Figure 13 The interstrand cross-link formed by DSB-120.
Following the great improvement in cytotoxicity observed in the interstrand cross­
linker DSB-120 compared to the monoalkylating parent compound, a CUCTexo methylene 
unsaturated analogue ‘SJG-136’ was synthesized (Gregson et al., 1999), in an attempt to span a 
greater number o f base-pairs and increase affinity. The unsaturated PBD structure was found to 
increase the melting temperature o f calf thymus DNA by 33.6°C, whereas DSB-120 only 
produced a 15.1°C rise, illustrating the stabilizing effect o f the C2/C2'-unsaturation. This ligand 
was found to be 9000x more potent than DSB-120 in human ovarian tumour cell lines.
The design and development o f new cross-linkers could enhance sequence selectivity, 
adduct stability and binding affinity, whilst limiting unwanted side-effects seen in their 
monofunctional predecessors.
link was observed between G4-N2 and G14-N2. NOE data also suggested that a small





(+)CC-1065 is an antitumour antibiotic which was first unearthed during routine 
screening of soil cultures by The Upjohn Company, Michigan (Hanka et al., 1978). Produced 
by Streptomyces zelenis, (+)CC-1065 exhibits broad spectrum antimicrobial activity. However, 
it is its extreme potency as an antineoplastic agent against a wide variety of murine tumours 
which made it such a worthy pharmacological canditate for further research and development. 
This compound has also been isolated from Streptomyces canulus. Due to the therapeutic 
activity o f (+)CC-1065 against experimental tumours in mice such as; P388 leukaemia, B16 
melanoma and L1210 leukaemia (Martin et al., 1978; Neil et al., 1981), as well as promising 
results against human tumours in vitro, for example; breast, colorectal, ovarian and pancreatic 
carcinomas, neuroblastoma, adenocarcinoma o f the lung and melanoma (Bhuyan et al., 1981), 
(+)CC-1065 was accepted by the National Cancer Institute for clinical development as an 
antitumour agent. As an example o f its potency, this drug produced 90% inhibition o f L1210 
cell growth in vitro while only at a concentration o f 0 05ng ml'1. Its nearest contender is 
Actinomycin D at 4-0ng ml’1.
(+)CC-1065 is the parent compound in the cyclopropapyrroloindole family, so named 
after their common reactive moiety, which is responsible for alkylating DNA. The structure 
consists of three subunits; two identical pyrroloindole units (B and C) and the 






Figure 14 The molecular structure of (+)CC-1065 and its absolute stereochemistry at C3b and C4a.
In analogy with the DNA minor groove binders netropsin and distamycin, (+)CC-1065 has a 
right-handed twist along its axis relative to the out-of-plane bending o f the amide linkers 
(Chidester et al., 1981). The hydrophobic groups align perfectly along the concave edge of the 
molecule for complementary interactions with the minor groove, while the hydrophilic 
components protrude from the convex surface.
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An abundance of research has taken place utilizing a vast range o f techniques, to try to 
characterize the sequence-specificity and the mechanism of action of (+)CC-1065, in an effort 
to deduce why (+)CC-1065 exhibits such extreme biological potency. Early work looked at the 
effect of this ligand on L1210 leukaemia cells at the biochemical level (Li et al., 1982). 50% 
inhibition o f RNA synthesis required xlO the concentration o f (+)CC-1065 to that needed to 
inhibit DNA synthesis. Protein synthesis was able to continue unaffected. Difference CD 
spectra showed (+)CC-1065 selectively bound to double stranded DNA. Lastly, only lpg ml'1 
of this ligand was required to inhibit the DNA polymerase activity by 70%, leading to the 
conclusion that (+)CC-1065 mediates its cytotoxic effects via DNA synthesis.
Further CD studies (Swenson et al., 1982) established (+)CC-1065 had a preference 
for binding to p(dAT) rich oligomers, where p(dA)-p(dT) was favoured over p(dAT)-p(dAT). 
This interaction was very stable with no visible changes in the spectrum after one week’s 
incubation, representing complex decomposition. Pre-incubation with netropsin severely 
inhibited (+)CC-1065 binding, whist (+)CC-1065 binding inhibited methylation and ethylation 
of G-N3, A-N3 and C-02. It was concluded that (+)CC-1065 covalently binds to DNA within 
the minor groove.
(+)CC-1065 is at least lOOx more potent than adriamycin, as revealed by a human 
tumour cloning assay in which (+)CC-1065 caused >50% lethality at 0-lng ml'1 within lh 
against a variety o f tumours (Bhuyan et al., 1982). This great pharmacological profile was 
marred by a second observation that maximum inhibition o f DNA synthesis did not occur until 
after 20 hours of exposure to (+)CC-1065. This was not due to cell death and hence loss o f 
metabolic activity because RNA and protein synthesis continued. Instead, it suggested delayed 
expression of drug toxicity, correlating with the delayed death observed in (+)CC-1065-treated 
mice (Neil et a l , 1981). Non-tumour bearing mice and rabbits were given (+)CC-1065 by iv. 
and ip. administration (McGovren at al., 1984), which produced delayed hepatotoxicity with 
some bone marrow depression at doses which were life-enhancing although not curative in 
tumour-bearing mice. Doses which did not result in delayed death were only borderline 
antineoplastic. Attempts to impede the hepatotoxicity by the administration o f cytochrome 
P450 enzyme activators were to no avail, the toxicity being implemented by some other 
mechanism. These results precluded the development o f (+)CC-1065 as a clinical antitumour 
agent by the National Cancer Institute but research has continued in the hope o f producing an 
analogue with equal cytotoxic potency minus the hepatotoxicity.
To define precisely to which DNA base (+)CC-1065 binds, oligonucleotides 
containing [3H]dA, [3H]dG, [3H]dC or [3H]dT were treated with (+)CC-1065 to produce a drug- 
DNA adduct (Hurley et al., 1984). This was heated, followed by butanol extraction of a
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molecule containing the (+)CC-1065 chromophore, which proved to be covalently bound 
[3H]dA-(+)CC-1065. NMR analysis established that the 13C and NMR chemical shifts in this 
complex correlated well with those o f 3-methyl adenine. The 13C downfield shift o f C4 was 
consistent with the cyclopropane ring opening and forming a covalent attachment to the N-3 of 
adenine. Further chemical shift changes o f C-3b, C-7, C-8 and C-9 in the adduct were 
associated with the irreversible conversion o f the cyclohexadienone to a phenol (Fig. 15). This 













Figure 15 Mechanism of nucleophilic attack by the N3 of adenine upon the methylene (C4), electrophilic
carbon of (+)CC-1065 cyclopropyl ring to form a (+)CC-1065-(N3-Adenine)DNA adduct
Hurley et al., (1984) used (+)CC-1065 modified simian sarcoma virus (SVHO) 
restriction fragments, which were 5 '-32P end labelled, to probe the loss o f this adduct from the 
DNA on heating. The (+)CC-1065-modified adenine is removed from the DNA strand via 13- 
elimination, which involves cleavage of the glycosidic bond on heating, leaving this sugar 
without a base i.e. apurinic. Maxam-Gilbert sequencing, following piperidine cleavage o f the 
DNA backbone, yielded two preferred binding sequences for (+)CC-1065; 5-AAAAA* and 5 - 
PuNTTA*, where N is any base and * indicates the alkylated adenine. This sequence specificity 
is projected from the covalently modified adenine at the 3 '-end, traversing five bases in the 5 '- 
direction. Reynolds et al., (1985) performed similar experiments using the SV40 early promoter 
element, which contained the AT rich TATA box. It was hoped (+)CC-1065 would bind 
preferentially here, explaining inhibition of DNA synthesis and thus the biological potency. In 
fact, the favoured binding site was 5 -AGTTA and not the TATA box. CPK models were also 
proposed for this adduct. Taking into account the polarity o f drug binding, which indicates that 
the *C* subunit projects in the 5 -direction from the covalently modified adenine, the DNA was 
used as a chiral reagent to detect the stereochemistry o f C3b and C4a. (+)CC-1065 fits 
comfortably in the minor groove only when the stereochemistry at C4 is ‘R \ The absolute
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stereochemistry is therefore, C3b(R) C4a(S). Analysis o f the stereo drawings also reveals a 
correlation between the subunits of (+)CC-1065 and the bases of the binding sequence. The 
cyclopropapyrroloindole moiety alkylates the 3 -A, the second benzodipyrrole subunit lies 
across a pair o f highly conserved AA or TT bases (where 5-T T  is preferred over 5 -AA), and 
the third pyrroloindole ‘C’ group is adjacent to a less well conserved pair o f bases 5'-PuN.
Additional confirmational data on the absolute stereochemistry at C3b and C4a in the 
(+)CC-1065-DNA adduct was acquired using the optical antipodes, U71-184 and U71-185, 
(Fig. 16) of a simple (+)CC-1065 analogue (Lee and Hurley, 1986). Only the biologically 
active U71-184 bound to DNA, with the absolute stereochemistry equivalent to the natural (+) 
enantiomer o f (+)CC-1065. The cyclopropyl methylene carbon was then in close proximity to 







Figure 16 Molecular stmcture of the optical antipodes U71-184 and U71-185
Jacobsen et al., (1986) examined detection and repair o f this (+)CC-1065-DNA adduct 
within normal and Xeroderma pigmentosum (cells deficient in DNA lesion repair) human 
fibroblasts. It was found that this adduct was the source o f a defect between the excision and 
ligation processes. Recognition, possibly due to the positive charge on adenine, and excision of 
covalent (+)CC-1065-modified DNA, are the first steps in DNA repair. Strand breaks are 
induced by the excision enzyme and the adduct is removed. The presence of a strand break 
activates the chromatin-associated enzyme, p(ADP-ribose) polymerase, which utilizes NAD as 
its substrate for this repair. However, when the incidence o f strand breaks is high, the rate of 
poly(ADP-ribose) synthesis exceeds that o f NAD synthesis, leading to a depletion in the cellular 
NAD pool. This in turn leads to incomplete repair by the enzyme, and the inability of the cell to 
maintain normal energy metabolism resulting in apoptotic cell death.
Hurley and Needham-VanDevanter (1986) analysed the binding of (+)CC-1065 to the 
minor groove. The covalent event is only initiated after noncovalent binding interactions have 
optimized sequence specificity and positioning of the ligand within the minor groove,
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postulating that adduct formation is biphasic. These noncovalent interactions include stabilizing 
electrostatic forces, hydrophobic interactions between the concave surface of (+)CC-1065 and 
particularly adenine H-2 protons, which strengthen the binding affinity, plus many van der 
Waals contacts between (+)CC-1065 and the floor o f the narrow minor groove. Van der Waals 
forces drive the steric manoeuvrings to maximize the affinity for the ligand. As previously 
discussed with other minor groove binders, hydrogen-bonding does not have a role in sequence 
specificity. Its premier function is stabilization o f the drug-DNA complex.
DNase I footprinting was utilized by Hurley et a l , (1987) to examine what effect 
(+)CC-1065 alkylation of DNA had on local helical structure. Mild inhibition o f restriction 
enzyme cleavage projects as far as eleven base-pairs to the 5 '-side o f die covalently modified 
adenine. More pronounced enzyme inhibition occurs on the non-alkylated strand (-), over a 12 
base-pair region, which is particularly notable opposite the ‘A’ subunit and for at least 5 bases 
to the 5'-side along this (-) strand. This reflects the (+)CC-1065 induced helical conformation 
changes specifically adjacent to the ‘B’ and *C* subunits, and to the 5'-side o f this on the 
opposite modified (+) strand. (+)CC-1065 produces an asymmetric effect on DNA 
conformation.
Warpehoski et a l , (1988) synthesized a series o f (+)CC-1065 analogues to explore 
structure-activity relationships. Some important stuctural attributes became apparent during this 
investigation. Firstly, an acyl group substituted on the CPI pyrrolidine N enhanced electrophilic 
reactivity of the CPI unit and consequendy acid-catalyzed nucleophic attack, which was thought 
to be important for alkylation. Secondly, DNA binding increased when the amide-linked indole 
chain o f the central and right hand segments increased in length. This resulted in intensified 
hydrophobic interactions which promoted van der Waals forces and, hence, drug-DNA adduct 
formation. Thirdly, the ring size of the ‘B’ subunit can limit the conformations o f the ligand 
within the minor groove. A five-membered ring permits binding to the helix. O-catechol 
substituents are required for the tight complexation o f (+)CC-1065 within the minor groove 
(Warpehoski and Bradford, 1988). The ethylene bridge moieties o f the B and C subunits, are 
thought to be responsible for the unusual delayed hepatotoxicity exhibited by (+)CC-1065 
(McGovren et a l , 1984; Warpehoski and Bradford, 1988).
Continuing their review (Hurley and Needham-VanDevanter, 1986) o f non-covalent 
binding interactions, Hurley et a l , (1988a) prepared four analogues of (+)CC-1065 (Fig. 17). 
Their non-covalent versus covalent interactions were evaluated relative to sequence-specificity 
and biological potency, in comparison with (+)CC-1065.
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(+) A (+) AB (+) ABC
Figure 17 Structures of the (+)CC-1065 synthetic analogues.
Their findings stated that biological potency was linked to alkylation o f DNA. This was 
established using an analogue identical to (+)ABC minus the cyclopropyl ring, which resulted in 
no binding to DNA. Unlike distamycin and netropsin, the non-covalent interactions involved in 
binding were not strong enough to form a drug-DNA complex detectable by footprinting. The 
B and C subunits were found to increase the rate o f alkylation at specific adenines. However, 
(+)A, (+)AB and (+)ABC demonstrated equivalent sequence-specificity in adduct formation, 
implying that it was the DNA sequence which was responsible for the reactivity o f particular 
adenines towards the CPI subunit o f (+)CC-1065. The B and C subunits were thought to take 
part in stabilizing non-covalent bonding, as well as fine-tuning sequence selectivity prior to 
alkylation. It is possible that the 5 -flanking sequence shows some conformational flexibility, 
which allows the target adenine in a particular locale to approach the electrophilic centre and 
form a covalent bond via nucleophilic attack. This results in a sequence-dependent, Lewis acid- 
catalyzed DNA alkylation, requiring autocatalytic activation o f the alkylation step. This is 
achieved through carbonyl complexation or protonation via a strategically located phosphate in 
the DNA backbone, 2bp removed from the alkylation site in the 5 '-direction. Hurley et al., 
(1990) suggested a kinetic binding scheme to support this theory:
Kb Kr
drug + DNA ^  (drug-DNA)noncov-> (drug-DNA)C0V
A high binding affinity (Kb) indicates high sequence-specificity o f the drug or that the activation 
energy for reaction is very favourable for the sequence. If Kr was not sequence-dependent, 
covalent reaction would take place at sites where drug dissociation was the slowest, or where Kb 
was highest if Kr was slow. (+)CC-1065 has a very high Kb, indicating a high degree of 
noncovalent binding, but adduct formation is constrained by the sequence dependent Kr.
Lin et al., (1991) analysed (+)CC-1065-5'-d(CGCGGAGTTA*GG) by NMR using 
170-labelled water and phosphate. This led to the incorporation of two water molecules into the 
alkylation reaction pathway. One bridges the 8-phenolic proton o f the (+)CC-1065 CPI subunit 
to the anionic oxygen o f the phosphate, two bases to the 3 -side o f T constituting the covalently 
modified base pair. A second ordered water molecule was hydrogen-bonded to the alkylated 
adenine. Due to prolonged dwelling times o f these water molecules, it was proposed that they 
were involved in the mechanism o f covalent bond formation, their role possibly being acid 
catalytic activation o f the CPI in its reaction with N3 o f adenine.
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In sharp contrast to Upjohn and Hurley’s suggestion that (+)CC-1065 alkylation o f 
DNA was a sequence-dependent event, in which the non-covalent binding abilities o f the drug 
bore minimal importance to its sequence-selectivity, Boger and co-workers have presented 
insuperable evidence from a variety o f experiments that this is not the case. Many (+)CC-1065 
analogues were synthesized, one o f which substituted a benzindole group for the pyrroloindole 
in the CPI head unit, to form (+)CBI-CDPI2 (Fig. 18) (Boger and Ishizaki, 1990). This 
compound exhibited greater cytotoxic potency than either (+)CC-1065 or (+)CPI-CDPI2 (Fig.
18), proving that biological activity is not dependent on electrophilic reactivity. Examination of 
the rates o f solvolysis demonstrated the relationship between electrophile reactivity and rate of 
DNA alkylation was in fact inverse and not a direct one. A further set o f (+)CC-1065 
analogues, CPI-CDPI,, CPI-CDPI2, CPI-CDPT, and (+)N-BOC-CPI (Fig. 18) in both their (+) 
and (-) enantiomeric forms were used in a structure-cytotoxicity study (Boger et al., 1990) to 
elucidate the role of the central and right-hand subunit o f (+)CC-1065. (+)CPI-CDPI2 and 
(+)CC-1065 displayed an indistinguishable alkylation profile. This demonstrated that removal 
of hydroxy and methoxy substituents had only a small impact on the binding affinity and no 
impact on the AT-rich binding selectivity. (+)CPI-CDPIi and (+)CPI-CDPI3 were marginally 
weaker alkylators than was (+)CC-1065, whilst (+)N-BOC-CPI required a concentration xlO7 
greater to produce alkylation comparable to (+)CC-1065. The unnatural (-) enantiomers 
required all three subunits for effective alkylation, which, at low concentration, was at different 
sites to those occupied by (+)CC-1065. This evidence clearly supports a binding model where 
subunits B and C play a large functional role in sequence-selectivity, through non-covalent 




n = 2  (+)CPI-CDH2




n“ l Q C Pl-CD H j
n <  (-)CH-CDPI2
n=3 (-)CPI-CDPl3
(+)CI-CDPI2 r = c d p i2 
(+)N-BOC-CI R=OlBu raceamic reagent
Figure 18 Structures of the various (+)CC-1065 analogues Boger et al., have used in their studies.
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(±)N-BOC-CI (Fig. 18) is an authentic version of the CPI alkylation subunit which 
binds to DNA indiscriminately at any adenine (Boger et al., 1991a). Addition of a CDPI2 
subunit yields CI-CDPI2, which has the ability to alkylate specific adenines as a consequence of 
selective noncovalent interactions (Boger et al., 1991b). Removal o f the cyclopropane ring 
results in a racemic reagent (Fig. 18) which can still alkylate adenine. This suggests the 
cyclopropyl ring may not be a fundamental requirement for covalent binding although if  R2 = 
OH, the cyclopropane could still form as an intermediate. The solvolytic reactivity versus 
cytotoxic potency was compared for the compounds (+)CPI-CDPI2, (+)CI-CDPI2 and (+)CBI- 
CDPI2. Using their intensity o f alkylation as a measure, this experiment showed that an inverse 
relationship existed between electrophilic reactivity and cytotoxic potency: (+)CB1-CDPI2 > 
(+)CPI-CDPI2 > (+)CI-CDPI2. (+)CBI-CDPI2, the most stable and least electrophilicly reactive 
agent produced the most DNA alkylation, where the sequence preference followed the order: 5 - 
d(AAA)>d(TTA)>d(TAA)>d(ATA)-3The fourth base in the 5 -direction was also A or T.
Despite the large modification of the alkylating subunit which the substitution o f a 
benzene for a pyrrole ring incurs, it is proven to be well-tolerated with a potency and stability x4 
to that o f corresponding CPI analogues (Boger et al., 1995). Boger and Mesini (1995) noted 
that nucleophilic addition was dictated by stereoelectronic preferences. A-N3 alkylation took 
place at the least substituted cyclopropane carbon. Boger and Johnson (1995) presented a last 
piece o f evidence to prove beyond doubt that non-covalent binding of the B and C subunits was 
responsible for the sequence-specificity observed on (+)CC-1065 adduct formation. A 
comparison was made o f the observed binding directions o f some natural and unnatural 
enantiomers. Analogues were synthesized o f the duocarmycins (DSA), which contain the same 
pharmacophore as (+)CC-1065. The ester of duocarmycin allows substitution of non-covalently 
binding subunits on either side o f the alkylating moiety (Fig. 19). Like (+)CC-1065, (+)DSA- 
CDPI2 alkylated the most 3 ' adenine of the sequence 5'AAAAA*. (-)DSA-CDPI2 alkylated the 
same position as (-)CC-1065 in the sequence 5'AA*AAA (where * denotes covalent 
modification).
(+ )C D PI2-DSA (-) DSA-CDPI2
Figure 19 The molecular structures of (+)CDPI2-DSA and (-)DSA-CDPI2.
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Due to the reversed nature o f (+)CDPI2-DSA, although binding takes place within the same 
adenine sequence, alkylation now occurs at the same site as (-)CC-1065 because it now extends 
along the groove in the opposite direction. The B & C subunits of (+)CDPI2-DSA extend along 
the groove in the opposite direction to (+)CC-1065. The reversal o f enantiomeric alkylation 
selectivity resulting from the reversal in ligand orientation confirms that the same underlying 
recognition features, i.e. non-covalent interactions, are in action for both natural(+) and 
unnatural(-) enantiomers.
Lin and Hurley (1990) used NMR as a tool to elucidate the tautomeric form of the 
covalently modified adenine. A large downfield shift o f a resonance in the 15N NMR spectrum 
of the adduct was attributed to the formation o f a positive charge and partial double bond 
character between N6 and C6 in the alkylated adenine. To ascertain whether the positive charge 
was situated at N3, N6 or N9, quantum mechanical calculations were performed on 3, 9- 
dimethyladenine. This concluded the charge was delocalized over the entire adenine molecule 
(Fig. 20). Due to N6 being predominantly doubly protonated as the 6-amino form, the bond 









Figure 20 Tautomers of adenine in its amino form, resulting from covalent (+)CC-1065-DNA adduct 
formation.
Powers and Gorenstein (1990) studied the (+)CPI-CDPI2-5 -  
d(C1G2C3T4T5A6A7G8C9GI0)2 adduct by 2D NMR. Only one major adduct resulted from the 
CPI-CDPI2 (analogous structure to (+)CC-1065, minus -OCH3 and -OH on the B and C 
subunits) reaction with DNA. A17 was the alkylation site with the C subunit being orientated 
towards the 5 -terminus o f the modified strand. NOESY-generated distance restraints were 
used to produce a refmed molecular model. CPI-CDPI2 binding within the minor groove was 
found to distort the (3-helical structure of DNA. A deviation o f 60° from the helix axis at A 17 
produced a bent DNA structure with a wider minor groove.
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Scahill et al., (1990) studied the (+)CC-1065-5'-d(C1G2A3T4T5A6G7C8) adduct by 
NMR. The COSY spectrum displays large downfield shifts o f the cyclopropyl protons into the 
methylene region, signalling that the ligand is covalently bound. Intermolecular NOEs with 
minor goove H2 and H I' protons verified that (+)CC-1065 was alkylating A6. 13C NMR data 
also revealed that C4a had a chemical shift o f 8 40- lppm. This is indicative of a methine group, 
resulting from cyclopropane ring opening, which is adjacent to two methylene C (C4 and C5) 
and an aromatic ring. This concluded that the nucleophilic addition progressed as in Figure 21a. 
If the mechanism of reaction had been as in Figure 21b, then the neighbouring N-3 would have 









Figure 21 Diagram showing the two possible reaction pathways which could result from adenine-N3 
nucleophilic attack on (+)CC-1065 (Scahill et al., 1990).
(+)CC-1065 is responsible for the blockage o f  a number o f enzymes involved in DNA 
synthesis. The progression of Klenow fragment E.coli DNA polymerase and T4 polymerase 
along DNA is obstructed on encountering the (+)CC-1065-DNA adduct (Sun and Hurley, 
1992a). This blockage may result in the arrest o f DNA synthesis, although some evidence 
exists that the presence o f (+)CC-1065 may lead to the misincorporation o f dG and dA bases, 
indicating that this ligand has mutagenic properties. (+)CC-1065 also inhibits T4 ligase and 
helicase II, which are responsible for unwinding DNA prior to DNA synthesis and repair. It 
achieves this by stiffening and bending the DNA by approximately 17° in the direction o f the 
minor groove, resulting in a winding effect within the adduct site. The reduction o f a helix turn 
by one base pair changes the topology of the binding site. Winding effects maybe related to 
prevention o f adduct excision and the expression o f delayed lethality.
38
McHugh et al., (1994) compared the reaction o f (+)CC-1065 with purified and cellular 
DNA. The structures o f the resulting adducts were essentially the same, except that higher 
concentrations o f drug were required for cellular DNA to produce the same effect as with naked 
DNA. Using spectroscopic techniques to measure the rate of covalent additon of (+)CC-1065 to 
DNA, Warpehoski and Harper (1995) established that the speed o f alkylation was equivalent to 
that catalysed by an enzyme. Gunz and Naegeli (1996) developed a translocation assay to 
analyse the contribution o f non-covalent interactions to binding site recognition in DNA. 
Addition of (+)CC-1065 to DNA at saturation concentration produced a complex in which only 
30% of the bound (+)CC-1065 was attached covalently. However, the non-covalently bound 
(+)CC-1065 was resistant to removal by dialysis and precipitation techniques. On incubation 
with DNA fragments containing a preferred binding site, these noncovalently bound (+)CC- 
1065 molecules dissociated and translocated to the alkylation site. This molecular translocation 
or ‘hopping’ mechanism along DNA in search o f a specific binding sequence, illustrates the 
concept o f ‘biphasic binding’.
Adozelesin (U73-975) is a second-generation synthetic analogue of (+)CC-1065. Like 
the parent compound, adozelesin consists o f three subunits; a cyclopropapyrroloindole (A), an 
indole (B) and a benzofuran (C), all linked together via amide bridges (Fig. 22). Closely 
resembling the structure o f (+)CC-1065, adozelesin can mimic the pitch of (3-helical DNA helix 
minor groove perfectly, forming a covalent DNA adduct via N3 o f adenine. Tayeb et al., (1996) 
established, using CD spectroscopy, that adozelesin exhibits a left-handed conformation at low 







Figure 22 Structure of adozelesin
Lee and Gibson (1991) noted that adozelesin at concentrations between 20-60pM, 
could produce a 1 log cell kill in 6 human tumour cell lines. This makes it more potent than 
(+)CC-1065, with very broad spectrum activity. Adozelesin has displayed a greater potency 
than cisplatin, 5-fluorouracil and doxorubicin in human gynaecological cell lines (Ngugen et al.,
1992). Sequencing techniques were used to probe the consensus sequence of adozelesin 
(Weiland and Dooley, 1991). Blockage of the progression of bacteriophage DNA polymerases
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along the template strand occurred on encountering the adozelesin adduct, specifically at the 
nucleotide alongside the covalently modified base. Two preferred binding sequences were 
identified, p(dA) and 5'-(T/A)(T/A)T-A*(C/G)G. Yoon and Lee (1998) used thermally induced 
strand cleavage assays to elucidate the consensus sequences for adozelesin binding. Their 
findings largely agreed with these of Weiland and Dooley (1991). The preferred binding 
sequences were 5 '-(A/T)(A/T)A*, 5'-(A/T)(G/C)(A/T)A* and another more rare sequence 5'- 
(A/T)(A/T)CA*, which has a cytosine adjacent to the modified adenine in the 5'-direction. 
Tritium-labelled adozelesin was detected at high concentration on cellular nuclear DNA at 5 '- 
TTAGGG.
Bhuyan et al., (1992) compared the cytotoxicity o f adozelesin in human and rodent 
cells. The ligand was shown to be xlO more cytotoxic against the human ovarian carcinoma 
than against hamster ovarian carcinoma and lung or mice melanomas, demonstrating a lack of 
correlation between cytotoxicity and the extent o f DNA alkylation. This could be interpreted as 
either the sites o f alkylation varying in proportion between species influencing the degree of 
cytotoxicity or a difference in the capacity o f the cell type to repair covalently modified DNA. 
Inhibition o f cell growth occurrred at doses which only marginally inhibited DNA synthesis. 
Bhuyan et a l , (1992) examined the effect o f adozelesin on the mitotic cell cycle. Initially, 
progress through S phase (DNA synthesis and replication) was slowed, followed by block of G2 
phase (cell metabolism and where performs functions as an organism prior to cell division, i.e. 
mitosis). This was superceded by lysis and cell death some hours later. The precise mechanism 
by which adozelesin inhibits DNA replication was investigated using SV40-infected African 
green monkey kidney cells (Cobuzzi et al., 1996). Low adozelesin concentrations were found 
to inhibit the initiation o f SV40 replication, while at higher doses elongation o f nascent DNA 
chains was also inhibited.
Baraldi et al., (1997) synthesized analogues o f adozelesin and U71-184, which 
incorporated a pyrazole into the CPI headunit (Fig. 22). These compounds demonstrated AT 
selectivity on binding upstream of the human oestrogen receptor, rather than the Ha-ras 
oncogene which is GC rich. This analogue (Fig. 23), was found to be considerably less potent 
in vitro than in vivo, where it exceded the potency o f adozelesin. This data agrees with Boger’s 
statement that modification of the alkylating motif was well tolerated, even increasing cytotoxic 
potency.
On the grounds of the greater cytotoxic potency, solubility and stability in aqueous 
formulations of adozelesin in comparison to (+)CC-1065, plus its freedom in animal models not 
only from hepatotoxicity but also to prolong life and inhibit tumour growth, adozelesin was
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chosen as a candidate for clinical trial. A phase I clinical trial was conducted by Shamadas et 









Figure 23 Structure of the adozelesin analogue which incorporates the CPzI subunit (Baraldi etal., 1997)
Adozelesin proved to be generally well tolerated over a range o f doses. Drug limiting toxicities 
were quite serious, however, myelosuppression being the main one with thrombocytopenia 
(very low platelet count) being more pronounced than leukopenia. A similar trial by Burris et 
al., (1997) on patients with solid tumours reached the same conclusion that, although no 
objective antitumour activity was apparent, the toxicity and in vitro activity profile justified its 
progression to Phase II clinical trial. Cristofanilli et al., (1998) clinically evaluated the 
therapeutic efficacy o f adozelesin against incurable metastic breast cancer. With the dosage and 
schedule described, adozelesin showed only marginal efficacy with some patients actually 
showing progression in their disease. This trial was aborted in favour of more effective drugs. 
It is not known why adozelesin, which is extremely potent in vitro appears not to be in vivo; 
possibly its biological half-life is too short. However, this drug seems to exhibit the opposite 
toxicity profile in vitro and in vivo to the CPzI analogue described by Baraldi et al., (1997).
Carzelesin (U-80244) is also a second generation analogue o f (+)CC-1065. It exists as 
an inactive prodrug, requiring chemical or enzymatic activation o f the relatively unreactive 
chloromethyl precursor to form the cyclopropyl moiety. Activation o f carzelesin proceeds by 
hydrolysis of the phenylurethane substituent to a chloromethyl phenol, followed by a ring- 
closing step to produce a cyclopropal keto compound ready to alkylate DNA. The synthesis of 
a CPI prodrug was part o f an investigation to ascertain whether the rate of alkylation could be 
regulated and, hence, to see if this in turn increased antitumour efficacy. Examination o f the 
structure of carzelesin shows the usual CPI keto moiety now exists as a phenolic one, which in 
the prodrug form is derivatized with a carbamate. The resulting compound has marginally 
lower potency but equivalent efficacy in vivo to the ordinary cyclopropyl derivatives. The 




Figure 24 Chemical structure of carzelesin.
Li et a l ,  (1992) assessed the performance o f carzelesin as a prodrug. The data from 
cell culture experiments suggested that carzelesin had enough time to circulate throughout the 
medium before being transformed to the active compound U-76074 containing the 
cyclopropane. Incubation of carzelesin with L1210 leukaemia cells showed that this compound 
was approximately xl500 less cytotoxic than U-76074 after lh. After 24h, this difference had 
shrunk to x2-10, relative to the conversion o f carzelesin into its biologically active form i.e. U- 
76074. Carzelesin induces only a small change in the CD difference spectrum when in the 
presence o f DNA, unlike U-76074. This suggests carzelesin has not formed a stable covalent 
DNA adduct but the ligand containing the active cyclopropyl group has, in an analogous manner 
to (+)CC-1065. The prodrug carzelesin demonstrated a broad spectrum of antitumor activity, 
with more survivors which had longer or complete remissions than adozelesin. This is probably 
linked to the improved pharmacokinetic and distribution properties available with the prodrug. 
The successful pharmacological profle of carzelesin secured its position in clinical trials. Phase 
I trials concluded that myelosuppression, i.e. neutropenia and thrombocytopenia, were the dose 
limiting toxicities of carzelesin, occurring after only one exposure (Wolft et al., 1996). The 
origin o f this toxicity has been investigated in mice (Filippini et al., 1997). After an initial drop 
in mature bone marrow cells post carzelesin administration, cell proliferation began again 
within 24h and, within 14 days, the bone marrow was repopulated with all cell lineages. This 
suggested that, with an improved dosing regimen which allowed replenishment o f bone marrow 
cell stocks after drug administration, more cycles o f drug therapy would be possible without 
cumulative myelotoxicity.
Phase II clinical studies (Sorio et al., 1998) on patients with non-Hodgkin’s lymphoma 
demonstrated the same significant haematological toxicity profile as seen with Phase I trials. At 
these doses of carzelesin prescribed, only one partial response in seventeen patients was noted. 
This seems to mimic the problem of lack o f clinical effectiveness, as already seen with 
adozelesin in humans. Indeed, in a comparative study o f carzelesin administration to rats, mice 
and humans, van Tellingen et al., (1998) showed that carzelesin was tolerated by approximately
5 and 66x more in rats and mice respectively than humans, possibly compromising its success 
as an antineoplastic agent.
Bizelesin (U77-779) is another second generation (+)CC-1065 analogue. It is unique 
in having two CPI headunits, one at each end o f the molecule, which confer bifunctional 
alkylation activity, resulting in the production o f DNA interstrand cross-links. These CPI 
subunits are each attached to an indole, which are subsequently joined tail to tail via a ureylene 
linkage (Mitchell et al., 1991) (Fig 25). Intramolecular rearrangement within bizelesin results in 
conversion of the chloromethyl moieties, into the cyclopropane reactive species (U77-809) 
which alkylate DNA in a mode analogous to (+)CC-1065.
Bizelesin
Figure 25 Structure of bizelesin.
The length o f the bizelesin molecule means that the interstrand cross-link formed within the 
minor groove spans 6 or 7 nucleotides, depending on the composition o f the intervening base 
sequence (see later explanation). 5'-*T A ATT A* (where * denotes covalent modification of the 
adenine on this strand and * denotes covalent modification o f the adenine to which this thymine 
is base-paired to on the complementary strand) is the bizelesin cross-link consensus sequence 
(Mitchell et al., 1991). Bizelesin has demonstrated good antitumour efficacy both in vitro and 
in vivo, even against drug-resistant murine tumours such as pancreatic 02  carcinoma and colon 
38 carcinoma. At pM concentrations it is 2-30x more potent than adozelesin (Lee and Gibson, 
1991), without the hepatotoxicity of (+)CC-1065.
Sequence-specificity o f bizelesin was found to be susceptible to the pH conditions of 
the experiment (Lee and Gibson, 1993). At the highly alkaline concentrations used to extract 
and examine damaged DNA, the bizelesin interstrand cross-link was unstable with adduct 
reversal taking place. This effect was not noted when bizelesin monoalkylated DNA. However, 
at low pH and high temperature, depurination (to which the interstrand cross-link was resistant) 
took place probably after the DNA melted to single stranded. Interstrand cross-links occur at 
5'-*TAATTA*, which contains the classic (+)CC-1065 consensus sequence, but they also arise 
less frequently at 5'-*TCCGCG* and 5 -TTCCGC (Sun and Hurley, 1993). This alkylation o f 
GN3 most probably occurs after the covalent binding o f a bizelesin (+)CPI headunit to an 
adenine, which leads to the remaining (+)CPI subunit being placed in the close vicinity o f the
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GN3 6 base-pairs away where the second alkylation takes place. The ultimate formation of the 
interstrand cross-linked product results primarily from the trapping out of a thermodynamically 
more stable product, which maybe favoured by minimal distortion o f the helix resulting in a low 
binding energy penalty or from a kinetically favourable reaction at the first site. Cross-Unking 
involving a guanine was also demonstrated (Lee et al., 1996) in an experiment using the 
consensus sequence 5 '-TAATTN, in which N was G, C or T. Bizelesin did not form interstrand 
cross-links when N was a pyrimidine base. Lee et a l, (1994) compared bizelesin binding to 
genomic and naked DNA. In both cases, binding was sequence-specific but there was a 
difference in the consensus sequences, probably due to the presence of histones and other 
nuclear proteins in genomic DNA. Monoalkylation occurred at the (+)CC-1065 consensus 
sequence 5'-(A/T)(A/T)A*, whilst the preferred cross-link sites were 5'-*T*TTTTTA* (which is 
intrinsically bent), 5'-*T*TTATCA* and 5'-G*TACTAA*, where one GC base-pair was tolerated 
within the binding site.
NMR studies o f bizelesin binding to 5'-*TAATTA* (Seaman and Hurley, 1993), 
noted that the central base-pairs within the cross-link were trapped in two different 
conformations. In 40% of the species the central base-pairs were open, whilst in 60% of species 
they were Hoogstein base paired. They also observed a loss of ‘A’ tract character such as 
propeUor twisting on bizelesin binding to 5'-*TTTTTA*.
Thompson et a l, (1995) examined the role o f the central GC base-pair within the 7 
base-pair cross-link of 5'-CG*TTAGTTA*CG, via 2D NMR and molecular modelling. 
Bizelesin is too short to form a cross-link spanning 7 base-pairs without distortion o f the duplex. 
NOE connectivities revealed that this adduct existed as a single species, retaining Watson-Crick 
base-pairing, and was orientated edge on in the minor groove, alkylating A9 and A20. This 
particular interstrand cross-link occurs even though there is an adenine available for binding at 
the sixth base in the sequence, suggesting there is a structural feature responsible for the 7 base- 
pair preference. Distortion o f this sequence mainly takes place around each alkylated adenine, 
which are pulled down towards each other by bizelesin to decrease the distance it has to 
transverse by half a base-pair, creating an adduct with a high degree of propellor twisting 
throughout the binding site. The role of the G was unveiled by contrasting this adduct with the 
one formed in the presence of an inosine, in which bizelesin only traversed 6 base-pairs. It was 
concluded from these data that G-NH2 hydrogen-bonded with the C=0 of the ureylene linker, 
facilitating distortion o f the helix so bizelesin could form a stable interstrand cross-link.
Thompson and Hurley (1995) have also investigated the nature of the bizelesin 
interstrand cross-link within the ‘A’ tract sequence 5'-CG«TTTTTA*CG, using the same 
techniques. A single adduct was formed which crossed 6 base-pairs. The previously described
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base-pair open conformation within the centre of the duplex, was not observed due to the long 
half-lives of AT base-pairs. The ureylene linkage o f bizelesin oscillated freely between two 
conformations, with no hydrogen-bonding taking place in either. NOE data demonstrated that 
the helix had lost its ‘A’ tract character i.e. propellor twisting and junction sites at either end of 
the ‘A’ tract and, instead, the adduct features were representative o f straight P-form DNA. On 
formation of the interstrand cross-link, bizelesin trapped each covalently modified adenine in its 
p-form. This inhibited the propellor twist of the flanking bases and, reduced the length of the 
‘A* tract from five bases to two, which is not enough to induce propellor twisting, so bizelesin 
binding produced straight DNA.
A quantitative evaluation o f bizelesin adducts formed in genomic and SV40 DNA, 
showed that in contrast to cisplatin which produced 1*2 x 106 lesions per cell, and (+)CC-1065 
which yielded ~104 lesions per cell, bizelesin required only 102 lesions per cell to reduce cell 
growth by 90%, demonstrating its extreme potency (Woynarowski et al., 1995). Bizelesin 
interstrand cross-links, however, do take three times longer to form than ones resulting from 
monofunctional alkylation. Even though bizelesin produces fewer lesions, they appear to be 
more specific, as one would expect for an agent requiring a longer consensus sequence for 
bifunctional alkylation. Drug-induced damage occurred frequently at the origin of replication 
and topoisomerase II cleavage sites, hinting at the mode of antineoplastic activity o f bizelesin.
Seaman et a l,  (1996) looked at the binding of bizelesin to 5'-TAATTA, when the 
ligand was separated into two components by removal of the ureylene linker. It was expected 
that they would bind to the consensus sequence in the same manner as bizelesin, rendering a 
symmetrical adduct. In fact, the disconnected CPI-I subunits alkylated 5'-TAA2TTA1 (numbers 
l’ 2 denote order of alkylation) on the same strand, with retention o f p-helical structure. Gel 
electrophoresis and molecular dynamics studies o f the CPI-I 5 '-TAA2TTA1 and 5'-TAA2AAA1 
bisadducts suggested that the first alkylation produced a distortion in the binding sequence at the 
5'-TA junction site, making it unfavourable for symmetrical bisalkylation. Helical deformation 
was retained on the second CPI-I binding. To test whether the ‘head to tail’ binding mode was a 
result of 5'-TAA2TTA displaying increased reactivity by co-operative bending induced by the 
first alkylation, or whether the 5-TAATTA1 was made less reactive by distortion o f the minor 
groove on monoalkylation, a 5'-TAAAAA consensus sequence underwent bisalkylation. The 
resulting bisadduct 5'-TAA2AAA1 and 5'-TAAAA!A monoadduct, demonstrated that AT did 
not confer increased reactivity, as the ‘head to tail’ bisadduct was still produced. Instead, 
monoalkylation resulted in a distortion 4 to 5 base-pairs in the 5'-direction, at the 5'-TA step 
junction. Therefore the bisalkylation reaction occurs at the least warped adenine furthest away 
form the junction site.
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As demonstrated above, unlike the 5'-*T A ATT A* sequence which yields an 
interstrand cross-link (11-47%), ‘A’ tracts instead accumulate more monoalkylated product e.g. 
5'-TTTTTA\ 5-TTTAAA* and 5'-TTAAAA* (14-27%), than cross-linked (2-10%) (Seaman 
and Hurley, 1996). This is a consequence o f  the intermolecular rearrangement of DNA within 
the 5'-TAATTA sequence, where the base pairs either open or rotate into a Hoogstein 
conformation to stabilize the DNA in an unbent conformation. The second arm of bizelesin can 
then complete the formation o f the interstrand cross-link.
The superior pharmacological efficacy and cytotoxic potency of bizelesin, in 
comparison to the monofunctional alkylators (+)CC-1065 and adozelesin, have made it an 
important chemotherapeutic agent for clinical trial.
1.3 Minor groove binding with intercalation
The last major family o f minor groove binders to be discussed in this mini-review 
incorporate an intercalating binding moiety into their mode of action. The binding and 
sequence selectivity o f the anthracyclines towards DNA will now be discussed in some detail.
1.3.1 Anthracvclines
The anthracycline family consists of some of the best known and most 
chemotherapeutically useful antitumour antibotics. Their clinical activity manifests itself in 
vivo by three mechanisms: DNA intercalation and topoisomerase inhibition via the minor 
groove, aerobic and anaerobic redox activation and membrane association (Fisher and Aristoff, 
1988). Each of these may also contribute to the cytotoxic side effects which occur upon clinical 
application of these drugs, aerobic redox cycling is thought to be the greatest culprit of host 
induced cardiotoxicity. The main structural feature o f these intercalators is the large 
tetrahydrotetracenequinone chromophore which consists o f three flat coplanar, six-membered 
rings (Fig. 26) (Wang et al., 1995). The fourth ring is the minor groove binding moiety. It is a 
puckered cyclohexene ring which has various sugars attached to it, which are specific to the 
individual anthracycline. Collectively, these four rings (A-D) compose the aglycone. This 
chromophore intercalates between adjacent base-pairs during a transient disruption within their 
stacking arrangement, allowing the ring system to infiltrate the DNA whilst the sugar moiety 
binds into the minor groove. Other substituents on the ‘A’ ring are for stabilization of the 
complex by hydrogen-bonding.
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R -  H Daunomycin 
R = OH Adriamycin
daunosamine (amino sugar)
Figure 26 Structures of the major anthracyclines.
Daunomycin (daunorubicin) was first isolated from cultures o f Streptomyces peucetius 
(Di Marco et al., 1964). It was found to display weak antibiotic activity against some bacteria 
but was extremely cytotoxic against tumour cell lines, specifically leukaemia, which has been 
its greatest clinical application. Adriamycin (doxorubicin) is nearly structurally identical to 
daunomycin, the extra hydroxyl substituent suggesting that it is a daunomycin metabolite from 
Streptomyces peucetius var. caesius (Arcamone et al., 1969). Compared to daunomycin, 
adriamycin has a broader spectrum of activity and increased cytotoxic potency, which is 
reciprocated in its widespread clinical use in cancer chemotherapy against solid tumours and 
particularly in the treatment of breast cancer. The development of cross-resistance within cells 
between daunomycin, actinomycin D and Vinca alkaloids (Dano, 1971) is an additional problem 
to the cardiotoxicity experienced on anthracycline administration. Cross-resistance to 
adriamycin in daunomycin-resistant L1210 tumour cells suggested that both compounds had a 
shared mode of action.
The high cytotoxic potency of adriamycin corresponds to the high binding affinity it 
exhibits for DNA on intercalation, making it one o f the anthracyclines most securely fixed to 
DNA (Capranico et al., 1986). Binding is more stable than that produced by daunomycin, due 
to the presence o f the hydroxyl which is capable o f  forming a hydrogen-bond via a water 
molecule to the phosphate backbone o f DNA (Wang et al., 1987). Footprinting data 
demonstrated that intercalation occurs between adjacent guanine and cytosine (d(CG) or d(GC)) 
base pairs preferably flanked by an AT base-pair with the sequence 5 '-(A/T)CG favoured over 
5 -GCG (Chaires et al., 1987). These consensus sequences are often found in promoter and 
enhancer regions, where modification o f DNA could severely affect transcription. Experiments 
with daunomycin have shown there is little effect on RNA synthesis. The main autitumour 
effect is exerted through inhibition of DNA synthesis. This is because anthracylines have the 
ability to competitively inhibit DNA polymerases attachment to the DNA receptor site, as well 








Wang et al., (1987) examined the structure of the daunomycin-5 '-d(CGTACG) 
adduct. The anthracycline occupied the CG base pairs, with the aglycone moiety intercalated 
such that its long axis was approximately perpendicular to that of the DNA helix. The methoxy 
‘D’ ring protruded into the major goove, whilst the cyclohexene ‘A’ ring projected into the 
minor groove. By itself, the aglycone is not an anticancer agent, suggesting the importance of 
the charged amino sugar which seems to stabilize the initial complex, allowing the aglycone to 
thread between the base-pairs. The configuration of the attachment site where the amino sugar 
is bonded to the ‘A’ ring is important for conferring right hand chirality in the molecule, making 
its conformation complementary to the P-helix. This glycosidic linkage is quite rigid. Unlike 
adriamycin, daunomycin forms no hydrogen-bonds with the minor groove. However, some 
stabilizing effects are apparent from the ‘A’ ring anchor at C9. The acetyl group is within 
hydrogen-bonding distance o f G-N2 and the hydroxyl forms a water-bridged hydrogen-bond to 
cytosine C=0. These interactions result in a long residence time of the drug and hence high 
cytotoxic potency. Wang et a l , (1995) explained the preference for the 5 '-(A/T)CG consensus 
sequence in terms of a possible clash between the N o f the amino sugar and the NH2 of G, if the 
guanine was on the 5 -side o f the intercalation site. This would result in a less stable adduct. 
The possibility o f this collision was, nevertheless, exploited to form a methylene cross-link by 
nucleophilic attack o f formaldehyde on the daunomycin 5 '-d(CGCGCG) adduct. It was 
hypothesised that this entire complex could be used as an anticancer agent, the DNA acting as a 
carrier for the drug which would be released slowly in vivo on the cleavage of the aminal 
linkage, perhaps prolonging the cytotoxicity o f the drug. Interestingly, administration o f the 
daunomycin-DNA-HCHO complex and free daunomycin, yielded different results relative to 
the dosage (Wang et al., 1995). The free daunomycin killed the L1210 cells within 3 days. 
Low concentrations of the complex produced larger cells which subsisted until day 5, whilst 
high concentrations o f daunomycin-DNA-HCHO caused cell shrinkage and cell death within 48 
hours, suggesting increased antineoplastic activity. Because DNA is non-immunogenic, this 
complex could hold the key to a new line o f cancer chemotherapy.
Topoisomerase II inhibition is as important as DNA polymerase inhibition, as a 
mechanism through which anthracyclines can exert their cytotoxic efects. Anthracyclines 
possibly alter the structure or population of topoisomerase II in a manner which results in the 
loss o f the topoisomerase-mediated protein-DNA linkage. N-Trifluoroacylation of the sugar 
amino moiety removes the positive charge from the ligand and, therefore, its ability to 
intercalate, but the antitumour activity remains in the cell by topoisomerase II inhibition (Fisher 
and Aristoff, 1988). This mode of action is not clearly understood.
The amino sugar o f anthracyclines is the moiety o f choice to modify, when attempting 
to vary pharmocokinetic properties or introducing alkylating groups. This is because alteration
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of the anthraquinone to reduce its redox potential not only results in the desirable curtailment of 
cardiotoxic side effects but also loss of cytotoxic potency. The quinone is a functional group in 
many antitumour agents. Cullinane et al., (1994) tried to elucidate the role of the bioreductive 
activation process in the formation of adriamycin-DNA adducts. Previous studies in vitro 
demonstrated that anthracycline covalent binding to DNA was via C l  o f a reductively activated 
quinone methide. Xanthine oxidase and cellular flavoproteins such as NADH dehydrogenase 
are enzymatic reducers in vivo. However, Cullinane et al., (1994) was able to use a DTT/Fe 
reducing system in which addition of le’ produced a semiquinone, another e' yields the 
hydroquinone which leads to the quinone methide (tautomeric with C l  carbocation). It is this 
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Figure 27 Reductive activation of adriamycin.
The C9 position could be modified extensively, as in other anthracyclines, and the reaction 
would still proceed to form an adduct. No adduct has yet been isolated to verify this theory, due 
to their heat and alkali instability. Van Rosmalen et al., (1995) examined the stabilities of this 
adduct in vitro and deduced its half-life to be approximately 40h at 37°C. The covalent 
attachment of adriamycin to DNA has a half-life o f ~5h, although this does not lead to the 
immediate release o f the ligand from the DNA. The four rings o f the chromophore remain 
strongly intercalated, which results in the long half-life o f this adduct.
3 '-Deamino-3'-(3-cyano-4-morpholinyl)adriamycin (CMA) is a synthetic analogue o f 
adriamycin (Acton et al., 1984). A cyano group is attached to the morpholinyl ring which also
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incorporates the sugar amine (Fig. 28). This yields a compound with antitumour activity which 
far exceeds that o f its parent. CMA is between xl00-»xl000 more cytotoxic than adriamycin 
against P388 leukaemia in mice and from xl00-»x500 more potent against HT-29 human colon 
carcinoma. The fact that these cancers and human ovarian sarcoma are not resistant to CMA 
suggest that it may have a different mechanism o f action to adriamycin. CMA is of significant 
clinical importance not only because of its extreme cytotoxicity but due to its lack o f 
cardiotoxicity. Begleiter and Johnson (1985) studied the interaction o f CMA with HT-29 cells 
using an alkaline elution assay. DNA cross-linking was observed which increased with drag 
concentration. Equally cytotoxic concentrations of adriamycin however, produced no cross­





Figure 28 The structure of CMA.
CMA, the 5-imino derivative of CMA (ICMA) and chlorambucil were compared on 
their reaction with DNA, to try to elucidate the roles o f the different functional groups in CMA 
on binding (Jesson et al., 1989). CMA was more potent and produced a higher level o f cross- 
linking than ICMA, suggesting that the quinone is employed in forming cross-links. 
Chlorambucil was unable to intercalate into DNA, unlike CMA and ICMA, but chlorambucil 
was still able to perform cross-linking in the presence of ethidium bromide when CMA was 
inhibited from so doing. Intercalation is therefore important for CMA activity. This was also 
confirmed by diminished intercalation on reduction o f the quinone, possibly due to the lack of 
stabilizing hydrogen-bonds which form on complexation with DNA. Westendorf et al., (1989) 
detected the loss o f CN from [,4C]N-morpholinoadriamycin during cross-link formation with 
DNA, as Acton et a l, (1984) had predicted yielding the reactive iminium ion, which would 
react well with nucleophilic centres o f G-N2 and G-N7. Other modifications to the N*-position 
on the morpholinyl ring also blocked cross-linking, leading to the conclusion that an intact 
morpholino ring was required for adduct formation.
In vitro transcription assays on the CMA-DNA adduct showed transcriptional 
blockages at 5 -C C  and 5 -G G  sites (Cullinane and Phillips, 1991; 1992; 1994). Because G-N2
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or G-N7 are susceptible to alkylation by other ligands it was assumed that CMA did likewise, 
the 5'-CC blockage arising from being opposite the binding site. This consensus sequence 
results in intrastrand cross-links, although some interstrand cross-links were noted at 5'-GC 
sites in vivo. More sensitive assays were required to detect interstrand cross-links in vitro from 
HeLa cells, due to their low population. Intercalation of CMA at these interstrand cross-linking 
sites was examined by NMR (Odefey et al., 1992), using the sequence 5'-d(CGTACG). CMA 
inserted itself between the CG base-pairs at either end of the oligomer, with the sugar- 
morpholine side-chain extending further into the groove than seen with the parent 
anthracyclines, nearer to an AT base-pair. The stabilizing hydrogen-bond previously seen with 
adriamycin was also present here, between 0 9  hydroxyl and the N2 o f guanine. Further NMR 
studies have been performed on this sequence and 5'-d(C1G2A3T4C5G6) to review the binding of 
(2S)-2-methoxymorpholinodoxorubicin and morpholinodoxorubicin (Mazzini et al., 1998). 
NOE data showed intercalation o f the aglycone between the terminal CG bases. HI and H3 of 
the aglycone ‘D’ ring showed NOEs with C1 and CUH5 within the major groove. The 11-OH 
and 6-OH interacted with C1 and G12 respectively. As with adriamycin, the 9-OH is in 
hydrogen-bonding distance o f both G-N2 and G-N3. Meanwhile, the daunosamine ring is 
situated in the minor groove from the NOE coordinates o f A3/!0 and G12, depending on whether 
the adduct formed is with the ‘TA’ or ‘AT’ containing sequence. Daunosamine is closer to G2 
and T3 in the ‘TA’ sequence, whilst it migrates towards the other strand, i.e. C11 and T10, in the 
‘AT’ oligomer. The morpholinyl ring showed NOEs to T4 or A4 in a similar manner, which 
could be indicative of a water-mediated H-bond from the hemiacetal proton (N(3) to the 
deoxyribose 04  ', enhancing the residence time of this drug and consequently the potency.
Ettore et al., (1998) studied the X-ray crystal o f CMA and the DNA hexamer 5'- 
d(CGATCG). As reported by Odefey et al., (1992) and Mazzini et al., (1998), CMA 
intercalated between the terminal 5'-CG base-pairs, forming a hydrogen-bond to guanine. 
However, the structure o f the morpholino moiety was observed not only to have lost the cyanide 
group but also to have opened its ring to form N-(2-hydroxyethyl) adriamycin. No alkylation 
took place perhaps because the morpholino group was adjacent to an AT base pair rather than 
one containing a guanine NH2.
Both inter- and intrastrand cross-links o f DNA are heat labile (Cullinane and Phillips, 
1993), which correlates well with the idea that the cross-link is composed o f an aminal linkage 
N-C-N, from 3-position o f the morpholino ring and the N2 of guanine. The N2 of guanine is 
implicated over N7 because X exonuclease detects only minor groove blockages, unless these is 
a large deformation of the helix originating from the major goove which is unlikely. The true 
mechanism of cyanomoipholinoadriamycin cross-linking has still to be elucidated.
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Nogalamycin was first isolated from Streptomyces nogalator by Bhugund and Dietz 
(1965). Some antibiotic activity is exhibited against gram positive bacteria, however, it is its 
potency against a number o f tumours, including L1210 leukaemia cell lines, which is most 
significant. Renal and pulmonary toxicity precluded its clinical development. Nogalamycin is a 
large anthracycline with substituents protruding from both ends of the aglycone chromophore. 
An uncharged nogalose sugar is attached to the ‘A’ ring, whilst a positively charged bicyclic 
aminoglucose sugar is joined to the ‘D’ ring (Fig. 29). The mode of action o f nogalamycin is 
through selective inhibition o f DNA-directed RNA synthesis (Li et al., 1979). Nogalose is 
thought to be closely connected with an enhanced inhibition of the transcription process or RNA 
synthesis, which leads to retardation o f cell growth followed by cell death. Cytotoxicity occurs 
in all phases of the cell cycle but is most pronounced in ‘S’ phase.
Nogalose Sugar
Figure 29 Structure of nogalamycin
An NMR study of the nogalamycin-5 '-d(G1C2A3T4G5C6)2 , complex indicated that two 
ligands bound per oligomer between the d(CA) sites. The nogalose sugar lays in the minor 
groove while the charged bicyclic aminoglucose sugar is situated in the major groove, both 
pointing towards the terminals o f the duplex (Searle et al., 1988). Rearrangement of the base 
sequence o f DNA to 5'-d(C1G2T3A4C5G6) resulted in the intercalation occuring at d(CG) 
instead. The sugar groups now face the centre, which is likely to be energetically more 
favourable than the aglycone arms flailing freely in solution (Robinson et al., 1990). 
Theoretically, because of this drugs preference for 5 -NpG or 5 -CpN steps, with the aglycone 
intercalating on the 3 -side o f C or the 5 '-side o f G and the sugars facing GC, nogalamycin 
should be able to bind to these sequences in either direction. However, oligomer size 
constraints are the controlling factor. Alternate pyrimidine-purine (3 -5') steps are thus required 
for the intercalation o f the aglycone of nogalamycin. A distortion o f the DNA helix was noted 
at C5-G6 (and Gu -C12) from an enhancement o f NOEs between them. This suggests that C5 
buckles towards G6 on nogalamycin binding, encasing the aglycone to form a wedge shaped 
binding site (Robinson et al., 1994). Gao et al., (1990) noted from X-ray diffraction analyses 
that bound nogalamycin spanned three base pairs, with the seemingly planar aglycone flexing so
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as to increase the quality of the complementary fit with DNA. This maximizes hydrogen- 
bonding o f 0 7  and the carbonyl (of CIO) with the minor groove. There are also van der Waals 
forces available in the major groove for additional stabilization o f the complex.
One of the most surprising facts of the mode of antitumour activity of nogalamycin is 
how it manages to intercalate into DNA with such large sugar moieties projecting from both 
ends o f the aglycone, which result in a dumb-bell shaped molecule. The diameter o f methyl 
ester to nogalose is 12A, and the width of the aminoglucose sugar is 6A, while the distance 
between adjacent base-pairs is only 3-4A (Smith et a l,  1996). This makes it impossible for 
either end to thread through DNA without some form of base-pair opening. Although DNA 
could flex or unwind, the most likely event is transient melting of the helix, where an arm of 
nogalamycin can slip through and the helix effectively then zips itself up around the aglycone. 
A mechanism such as this is compatible with the comparatively slow rate o f binding compared 
with other anthracyclines. However, these sugars are also efficient molecular anchors, 
increasing the residence time of the drug and consequently the cytotoxic potency. Nogalamycin 
is one o f the few naturally occuring antibiotics which exerts its action by binding in both the 
minor and the major groove simultaneously.
Successful analogues o f nogalamycin have been synthesized, such as menogaril, 
which is active against a wide spectrum of tumours and has proceeded to Phase II clinical trials. 
Menogaril lacks the acetyl and nogalose sugar functionalities, which were perhaps responsible 
for the toxic side effects seen with nogalamycin. This ligand intercalates with DNA from the 
direction of the major groove.
1.4 Summary
It is clear, from this review, that the binding o f ligands to DNA is an exceedingly 
complex process. Binding strategies not only display enormous diversity between molecular 
families but also within them, depending on the presence o f different functional groups. There 
are, o f course, many other antitumour antibiotics which incorporate themselves into the minor 
groove such as: the aureolic acids (e.g. chromomycin and mithramycin), the quinoxalines (e.g. 
triostin A and echinomycin), the duocarmycins, the microgonotropens, acridine base 
compounds (e.g. AAC and DACA), short peptide chromosomal fragments, ecteinascidins, 
mitomycins, enediynes (e.g. calcheamicin and esperamicin), glycopeptides (e.g. bleomycin) 
and, lastly, pluramycin antitumour antibiotics such as pluramycin, hedamycin and altromycin 
(Fig. 30). The characteristics o f their binding have not been described here to limit the length of  
this review.
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Figure 30 Structures of some common minor groove binders.
In summary, ligand binding to the DNA minor groove is controlled by a host o f
contributing factors:
• Minor groove geometry, narrow ‘A’ tracts or wider GC rich regions.
•  Hydrogen-bonding, electrostatic or hydrophobic interactions, van der Waals forces,
bifurcating bonds.
• Presence o f G-N2 adds a steric obstacle to some ligands binding.
• (3-helix right hand twist is complementary to that o f many naturally occuring binding
agents.
• Does the ligand require intercalation o f a chromophore to form an anchor, 7t-7t stacking of 
aromatic drug-DNA rings?
• Recognition o f an unusual DNA feature; increased helical twist, melted DNA, bent DNA, 
5 -TA junction site.
• Presence o f nucleophiles or electrophiles for covalent bond formation.
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• Flanking base pairs of the binding site.
There appears to be no simple general recognition code to explain the binding of small 
molecules to the minor groove of DNA, which is why DNA-targetted drug design is 
exceptionally problematic.
This introduction has only considered ligands which interact with DNA via the minor 
groove. There are however, many drugs which target the major groove o f DNA. Nitrogen 
mustards e.g. cyclophosphamide and chlorambucil, form a cross-link by alkylating the N7 of 
guanine in adjacent base pairs. Nitrosoureas e.g. carmustine, and busulphan also alkylate the 
major groove of DNA. Cisplatin is perhaps one o f the most well-known alkylating agents 
which produces intrastrand cross-links between N7and 06  of adjacent guanine molecules within 
the major groove, resulting in the breakage o f the hydrogen-bonds between GC bases and thus 
denaturation of the local DNA chain. Not only small ligands interact within the major groove, 
oligonucleotides o f up to 25 base-pairs in length can insert themselves into this site, adhering 
through hydrogen-bonding. The resulting triple helix structure is particularly interesting 
because it leads to the possibility o f using oligonucleotides, to target specific gene sequences in 
a therapeutic manner.
1.5 Aim of this project
The aim of this project was to investigate the binding of various antitumour agents to 
DNA at the molecular level. As reviewed in the previous sections of this chapter, a large 
volume o f information is already available on the affinity, efficacy and sequence-selectivity of 
various families o f drugs towards their intercellular target DNA. However, the picture is far 
from complete, with only a few drugs from each family having their mode of binding examined 
at the molecular level by high field NMR or X-ray crystallography. These studies often only 
investigate the information of a drug-DNA complex at a few DNA target sequences. This 
makes it difficult to establish a trend of requirements for the sequence-selective binding mode, 
either from the perspective o f the drug by itself or more usefully the entire drug family.
Studies using techniques such as gel electrophoresis have already established an 
answer to the question: what DNA consensus sequence does a particular drug prefer? This 
includes the proposed site o f alkylation or intercalation, plus the 5'- or 3'- flanking sequence to 
this site, for example; adozelesin prefers 5 '-(A/T)(A/T)A*(C/G)G or p(A) (Weiland and Dooley, 
1991). The question this project tries to answer is: why does the drug, e.g. adozelesin, prefer 
this sequence? Only a close investigation o f the molecular structure o f the adozelesin-DNA
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adduct by high-field NMR and restrained molecular modelling, can provide an insight into why 
adozelesin favours these sequences over all other combinations of nucleotides. It was hoped 
that scrutinization of the refined molecular model o f this drug-DNA adduct, which represented 
the NMR data, would reveal a number of key points relevant to the similarities and differences 
between adozelesin and other members o f the cyclopropapyrroloindole family, or at a more 
general level compared to all other minor groove binders. This description o f the binding mode 
would constitute; the alkylation site, the flanking sequence and its length, the possibility of 
selective noncovalent interactions or stabilizing hydrogen-bonds within the oligomer sequence, 
or if  the DNA has some unusual feature which is conducive to drug binding i.e. the 
conformation could be straight or bent, wide or narrow.
Characterization o f drug-DNA interactions was only possible after a long sequential 
preparatory procedure, which included:
1) The synthesis and purification of a DNA oligomer, using HPLC and hydroxylapatite 
chromatography. This was followed by collection of a ID *H NMR spectrum to check if  
the correct oligomer was present in a pure form. If the oligomer was non-self- 
complementary, a complementary strand was prepared in the same manner and they were 
then annealed to yield DNA duplex. This DNA sample was then analysed by two- 
dimensional NMR.
2) The production of a single pure drug-DNA adduct, from the reaction o f the ligand with a 
previously synthesized and purified DNA oligomer. Purification o f the drug-DNA adduct 
was achieved using C18 Sep Paks and hydroxylapatite chromatography. This was followed 
by ID !H NMR analysis to verify the drug-DNA reaction had proceeded to completion, 
yielding a single drug-DNA adduct.
3) Collection and analysis of two-dimensional *H NMR data, implementing mainly DQF- 
COSY and NOESY experiments, with some input from ROESY and TOCSY data. Once 
the assignment of all non-exchangeable drug and DNA protons within the adduct had been 
completed, distance-range constraints were generated and listed within a peak-pick 
spreadsheet.
4) A computer molecular model o f the hypothesized structure o f the drug-DNA adduct was 
built, by docking a minimized adozelesin molecule into the minor groove of canonical 
DNA. The distance-range constrants were applied to the structure, which was then refined 
by molecular mechanics and dynamics calculations
A number of antitumour antibiotics were used, owing to the different degrees o f success 
experienced in the second stage of this project. The ligands for which the structures of their 
corresponding DNA adducts were being scrutinized were; cyanomorpholinoadriamycin,
56
sibiromycin, DSB-120 and adozelesin. Information on the precise conformation o f these 
adducts could provide improved information for more fruitful drug design.
1.6 Why choose NMR techniques for structure analysis?
Over the last fifteen years, especially, huge strides have been taken in the development 
of NMR technology which is powerful enough to allow the elucidation of three-dimensional 
biomolecular structures in solution. These technological advances include: the availability of  
superconducting high-field NMR spectrometers with their modem computer systems and field 
strengths o f 9 to 14 Tesla (400 and 600MHz resonance frequency for the proton nucleus) and 
the invention o f multi-dimensional NMR which utilizes various pulse sequences to collect data 
on nuclear spin connectivities. The introduction of increasingly high fields corresponds with 
enhanced sensitivity, which is perfect for the analysis o f complex biological macromolecules, 
that are typically only available at low concentration. Multi-dimensional NMR data provides 
conformational information via through-bond and through-space connectivities. NMR has a 
wide variety o f applications not only in refining molecular conformations but also in 
characterizing binding and dissociation rates, plus intermolecular interactions between a ligand 
and a receptor. Measurement of 2D NOE cross-peak intensities was performed in this 
investigation to generate interauclear distance constraints. These were subsequently used in a 
molecular modelling study to elucidate the 3D conformational structure o f the DNA adduct in 
question.
Much discussion has occurred about the relevance of X-ray crystal structures, such as 
those o f oligonucleotides, to molecular conformation in the solution state (Westhof et al., 1995). 
Crystal packing interactions between the ends of DNA duplexes are thought to produce 
perturbations in the helix terminal structure, so that only the central 8 base-pairs o f a 12-mer are 
structurally accurate. However, this could also produce an environment more like that 
experienced naturally in the long DNA strands within a chromosome. In solution, these bases 
have a propensity to fray, as can be detected by NMR. Generally, there is good correlation 
between both sets o f data although some differences are apparent e.g. hydrogen-bonding. The 
premier advantage o f NMR structural analysis is that, the sample is in solution state, where 
parameters such as pH, temperature and ionic strength can be varied. This is especially 
important for examination o f biological molecules such as DNA, protein, RNA and 
carbohydrates, which for true structural definition require conditions mimicking those they are 
subjected to in vivo.
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1.7 The Nuclear Overhauser effect
The nuclear Overhauser effect (NOE) can be defined as the transfer of magnetization 
between two spins A and B, which are in close spatial proximity (<5 A) by way o f through-space 
cross-relaxation. The irradiation o f one nucleus at its resonance frequency leads to weakening 
or strengthening of the signal due to the second nucleus. This interaction is known as nuclear 
Overhauser enhancement and corresponds to the relaxation o f the observed nucleus by the 
irradiated nucleus, as they tumble about each other at a frequency close to that associated with 
relaxation. There is no requirement for scalar coupling Jab between the nuclei. The nuclear 
Overhauser effect therefore, produces a further increase in the signal to noise ratio.
The nuclear Overhauser effect can be easily illustrated using the two spin system o f an 
AB spectrum e.g. C-H where A and B are relaxing with one another resulting in four populated 
energy levels (Abraham et al., 1988; Evans, 1995; Williams and Flemming, 1987) (Fig. 31a). 
Only spin V2 nuclei are used, where both A and B can exist in either +V2 or -V2 orientations i.e. 
indicating the alignment o f the nucleus enforcing or opposing the applied field. W denotes the 
probability of a single quantum transition, the subscript e.g. W\ gives the change in quantum 
number, and A or B refers to the nucleus. There are six possible transitions in Figure 31a, of 
which WiA and WiB are allowed and give rise to the observed NMR lines, whilst zero (Wo) and 
double (W2) quantum transitions are ‘forbidden’ in the selection rules so cannot be seen. The 
probability of the WiA transition is proportional to the difference in population between the 
connected energy levels, i.e.
E4 -  E3 = (NU +n) -  (n/4) = n or E2 -  = (N/4) -  (N/4 -  n) = n
This also applies to W\B.
Irradiation at the resonance frequency ( 8 b )  of nucleus B (Fig. 31b), during a time 
period t  causes saturation o f this resonance. The irradiation is followed by a nonselective 
irradiation pulse and acquisition o f the free induction decay (FID). At saturation the energy 
levels connected by the transitions have their populations equalized i.e.
E3 = E1 = n/4 -n  and E2 = E4 = N/4 + n 
where the population levels o f El and E2 grow at the expense of E3 and E4. At this point the 
intensity of the A signal remains unaffected as it is a result o f the transitions from El to E2 and 
E3 to E4. The intensity o f A is controlled by the difference in populations between El and E3 
and o f E2 and E4 which remain the same. Relaxation can occur along the reverse of the 
transition pathways, but more effective is the emission o f radiation which arises via zero (W0) 
and double quantum transitions (W2). W2 occurs between the most well separated energy levels 
and is favoured by the high frequency tumbling of molecules with a low molecular weight. The
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population o f  E4 increases at the expense o f  E l hence, the populations o f energy levels E l and 
E3 are less than that o f  E2 and E4, resulting in enhancement o f the signal from the A nucleus.
a) Spin states and transition probabilities W 'j A, of a
two spin system prior to saturation.
Population=N/4 - n -1/2 -1/2
Highest energy 
arrangement (slightly 
lower population) both 
orientations 
El opposed to applied field
E2
+ 1/2 - 1/2
w \ p ,  /  N T 1®J y - 1/2 + 1/2 E3
Population=N/4











lowest energy arrangement 
(slightly
higher population)
b) populations o f  the energy levels immediately following saturation o f B
- 1/2 - 1/2Population=N/4 - n
Population=N/4 +  n 
Irradiation o f  B transition
+ 1/2  - 1/2
Irradiation o f  B transition
- 1/2 + 1/2
 E3
Population=N/4 - n
+1/2 +1/2 P0 pulation=N/4 + n
fewest energy arrangement (slightly 
higher population)
Figure 31 Energy level populations before and after irradiation in an AB system.
Zero quantum transitions ( W0) are common in larger molecules with slower tumbling rates. The 
population o f  E2 is increased at the expense o f E3 (an energy level o f  similar energy) leading to 
an increase in the populations o f  E2 and E l relative to E3 and E4. A reduction in the intensity 
o f  the A nucleus signal results from radiation emission via WQ. This brings the molecule back to 
the ground state, maintaining the Boltzman distribution between the - V 2 - V 2 and +V2 + V2 spin 
states. It is these double and zero quantum transitions after irradiation o f  nucleus B, which 
result in a change in the population distribution o f  spins in nucleus A, hence giving rise to the 
observable NOE. The difference in the populations o f fVlA after these transitions, is denoted as;
(E2 -  EO = (N/4 + n ) -  (n/4 -  n) = 2n or (E4 -  E3) = (N/4 + n) -  (N/4 -  n) = 2n 
leading to an increase in NOE intensity by a factor o f  2.
59
Nuclear magnetic dipole-dipole coupling between nuclei which results in an NOE, is a 
consequence o f the local field at one nucleus due to the presence of a field at another, as 
molecules move around in solution. Homonuclear decoupling is described using the equation:
Where:
/ = intensity of the A transitions 
/_= 1'0 + Yb decoupled B nucleus in an AB spectrum when B
i yA <— observed A nucleus is decoupled
i = intensity without coupling
When y A = Yb, the maximum observed NOE is 0-5 (50% enchancement). In the case of 
heteronuelear decoupling e.g.
13C -H : l  = 1-0 + 0-5
i y13C <—  V* of the *11 magnetogyric ratio
a three-fold enhancement maybe possible in the signal to noise ratio. Molecules moving in 
solution encounter different dipolar interactions, depending on molecular orientation and 
intemuclear distance which may stimulate cross relaxation and hence an NOE.
NOE intensity is proportional to the distance (r) between the irradiated nucleus B and 
the observed nucleus A, which is a function o f correlation time xc (takes into account the 
motional averaging process on the observed NOE). This gives rise to the following equation:
NOEct l_*/(xc) 
r6
The NOE intensity is not always a true reflection o f distance. Problems with low sensitivity for 
observation (low signal-to-noise ratio), make it more difficult to calculate integrals. Large 
molecules encounter further problems because they do not rotate as fast in solution (xc 
(rotational correlation time) » W0_1(Larmor frequency)), so spin diffusion pathways may 





Relaxation NOE intensity here is no longer
propotional to distance o f spin 
1,3.
Figure 32 Three spin system exhibiting cross-relaxation and spin diffusion (Wiithrich, 1986)
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The magnetization transfer between the nuclei ® and ® complicates the interpretation of 
distances from NOE intensities. Increasing the mixing time makes longer range NOEs more 
observable but spin diffusion is then more prominent in short-range contacts.
1.8 Two-dimensional NMR experiments
All two-dimensional experiments incorporate an incremental delay, known as the 
evolution time (ti), into their pulse sequences (Frenkiel, 1993). This incremental delay has a 
range of values from 0 to timax, and occurs between an initial 7 2 pulse and an identical second 
one. At each ti, an FID (free induction decay) is subsequently recorded in the detection period, 
which is defined as t2. The complete data set is then Fourier transformed with respect to ti and 
t2 to the frequency domains Fi and F2, which are linked to the proton chemical shifts in the 2D 
spectrum. Each dimension exhibits absorption mode lineshape. COSY, TOCSY and NOESY 
experiments are the most important tools for macromolecular structure characterization.
The double quantum filtered correlation spectroscopy (DQF-COSY) experimental 
pulse sequence is shown below (Fig. 33):
t  has to be long enough to allow 
switching of rf phases between the 




Figure 33 DQF-COSY pulse sequence.
The COSY experiment (minus the second 90° pulse in the above diagram) provides information 
on protons in a molecule which are scalar coupled. The components of the cross-peak in the 
spectrum are antiphase which means that, unless the interaction between protons is very strong, 
the cross-peak will be difficult to detect in the spectrum. Cross-peaks in the spectrum 
correspond to the nuclei which are coupled to each other and they also contain coupling 
constant information.
The DQF-COSY experiment uses double quantum filters to improve phase-sensitive 
COSY spectra. In COSY spectra, diagonal peaks are in dispersion when the phase is adjusted 
to provide absorption lines o f cross-peaks, this leads to the edges of the diagonal dispersion 
lines tailing off to the baseline slowly. Any peaks such as methyls, which reside close to the
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diagonal could therefore be obscured by the wide diagonal fringes (Wiithrich, 1986). Double 
quantum filtering uses a four-phase cycle to provide axial peak suppression, resulting in 
antiphase absorption modes o f diagonal and cross-peaks. The fine structure o f the scalar 
coupling in the macromolecule is then revealed fully by the cross-peaks.
The fundamental basis, i.e. the nuclear Overhauser effect, o f the NOESY experiment 
has already been explained, as has its purpose to identify pairs o f protons which are close 
enough in space to undergo cross-relaxation. The pulse sequence is as follows (Fig. 34):
Evolution Mixing Detection
-  increasing_
(t j) time delay mixing time (fixed)
relaxation delay FID
Figure 34 The NOESY pulse sequence
The length of the delay (t) is chosen according to the rate o f the transfer process, NOEs need 
time to build up, which in turn is dependent on the size and shape o f the molecule. Small 
molecules have long ti’s as they move quickly around solution, taking a long time to relax, so x 
is long (e.g. 1—>5s) to allow NOE build up. The reverse occurs for large molecules which 
tumble slowly in solution so t  = ~50 -» 300ms. After Fourier transformation of the FID, a 
spectrum is produced with cross-peaks the same sign as the diagonal, which can be +ve or -ve 
depending on whether relaxation favours W2 or W0 routes. No mixing time is required in the 
COSY experiment because scalar coupling information is already available.
Extensions of the COSY and NOESY techniques are the so called rotating frame 
experiments; TOCSY (HOHAHA) and ROESY (CAMELSPIN). Cross-peak information as 
with the previous experiments, is in the form of scalar couplings (TOCSY), and through space 
interactions (ROESY). However, data build up is now dependent on how these nuclear spins 




Figure 35 The TOCSY pulse sequence.
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TOCSY relies on the exchange o f magnetization between coupled spins, by applying a 
pulse train which eliminates the effect of the chemical shift but retains scalar coupling (Frenkiel,
1993). This is known as ‘isotropic mixing’ and is illustrated in the above diagram (Fig. 35). 
DIPSI and WALTZ are the isotropic mixing sequences, that allow continuous irradiation of the 
spins. In an AB system the transfer of magnetization is optimal at VtJab, but in macromolecules 
where there is a large variety of spin systems leading to multistep transfer, there is no general 
maximum mixing time, so it is approximated instead to 25-50msec for large couplings (single 
step transfer) and 50-100msec for the contrary. The TOCSY experiment is more sensitive than 
COSY.
The most significant feature of the ROESY spectrum is that cross-peaks arising from 
spin diffusion are weaker but are also easier to identify, which is useful when elucidating the 
structure o f macromolecules. Cross-peaks are opposite in phase to those constituting the 




Figure 36 The ROESY pulse sequence.
During the mixing time (x) a low level radio frequency field (e.g. 1-2 KHz) is applied to 
the nuclear spins, selecting the component of magnetization which is aligned along the 
irradiation axis, which is otherwise known as spin-locking. The applied radio frequency field is 
much weaker than the initial pulse. The cross-peaks evolve during the mixing time, the length 
of which is chosen relative to the rate o f cross-relaxation.
1.9 Structure refinement by molecular modelling
Molecular modelling provides a three-dimensional graphical interpretation of the 
biological macromolecule, on which experimental NMR data has been collected. Computer 
simulations allow an insight into molecular motion, thermodynamic properties, solvated 
systems and how ligands and receptors interact, such as a drug with DNA. Knowledge of all 
these factors, especially within families of drugs, can lead to more successful rational drug 
design.
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The first step to visualizing the macromolecular structure described by the NMR data, 
is generation of distance constraints using a distance geometry algorithm. These restraints are 
responsible for ‘pulling’ and ‘pushing’ atoms of a starting structure into position during 
molecular mechanics and dynamics energy refinement. Distance geometry is quite an unbiased 
method o f determining molecular conformation, because constraint application to a variety of 
starting structures should yield the same result.
Energy minimization is employed to find the local potential energy minima for the
macromolecule in question (Evans, 1995). A molecule is in effect a collection of atoms held 
together by harmonic and elastic forces, which can be described by potential energy functions of 
structural features such as bond length, bond angle, non-bonded interactions etc. (Boyd and 
Lipkowitz, 1982). These functions are collectively known as the force-field, which is how the 
potential energy surface for all internal degrees o f freedom in a molecule is described 
mathematically:
E = Es + Eb + Eco + E„b + e.g. constraints 
E = the difference in energy between the real molecule and the molecule when 
all forces are at their ideal values.
Es = energy o f bond stretch/compression from the ideal value 
Eb = energy o f bond angle bend from the ideal value 
Ea = energy o f torsional twist from ideal value along bonds 
Enb= energy o f non-bonded interactions
There are three standard energy minimization algorithms: steepest descent, conjugate gradient 
(or Powell) and Newton-Raphson. Steepest descent gradients are especially useful for systems 
known to have deviated far from the lowest energy state, so they can cope with a rapid reduction 
in energy via large energy steps. This method is often used in conjunction with conjugate 
gradients, which have much gentler energy slopes, but have the overriding advantage of being 
able to converge at an energy minima, whilst the former procedure can only oscillate around it. 
The potential energy surface in all methods is harmonic, so adjustments o f atomic positions in 
Cartesian space leading to a reduction in energy, result in further descent into the well towards 
the convergence minima.
Steepest descent minimization is defined by the following equation:
X k -  X k-i + XkSk
3N + (cartesian) 
dimensional 
vector
where: K = the Kth iteration 
k = eigen value 
S = unit length
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The molecular co-ordinates are given by the 3N-dimensional vector. Each iteration the 
molecule is subjected to, involves three steps:
1) Choice of directional descent (using the vector)
2) The size o f the descent (controlled by XK)
3) The descent itself as described in the above equation
The direction o f displacement (S) is straight downhill, parallel to the negative energy gradient, 
as shown by route A (bold line) when the step size is infmitesimally small (Fig. 37).
Contours of potential energy
Energy Minimum Side of 4 6  potential energy surface 
Energy
Very short distances atoms repel one another 
constant = atoms separated
Minima
Intemuclear distance R
Figure 37 Diagram to show the descent via steepest descent (A) and conjugate gradient minimization
The conjugate gradient can also be easily illustrated using this Figure 37. From 
starting point A, minimization progresses along the negative gradient towards B and D. If it 
stops at B, the most negative point in this direction, the second step of the conjugate gradient is 
a combination o f the gradient and the previous search direction, as defined by:
Sk = -gK + 1>kSk-i
Where bK = weighting factor o f the squares o f the current and previous gradient 
-g = negative gradient
This means the minimization will proceed towards the convergence minima during ‘n ’ 
iterations. If the first step had arrived straight to D, the second step would be towards F, which 
would still be closer to the minima than the point arrived at by steepest descent. Steepest 
descent continues its search in the direction o f its previous greatest energy step i.e. B-»C or 
D-*E for larger step sizes. Hence, conjugate gradient minimization is more intelligent in 
finding energy minima than steepest descent. However, this latter method speeds up the initial 
minimization process greatly and the results can then be polished by the former.
Molecular dynamics is another classical ‘potential energy’-based technique, used in 
computer simulation and modelling of macromolecules. This method simulates the vibratory 
motion of the molecule based on its physical properties, yielding what should be a realistic 
result. Using the NMR restrained structure which has been minimized, molecular dynamics 
follows the history from this initial arrangement, by calculating the trajectories of all the atoms
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under the influence of intermolecular potentials. Unlike minimization, molecular conformations 
do not get stuck in local energy minima. So after a period of time ranging from ps to seconds, 
large areas of conformational space will have been sampled to provide a selection of low energy 
structures. Higher temperatures mean more conformations are energetically accessible. These 
structure ‘snapshots’, are generated from tens of thousands of iterations of calculations which 
utilize Newtons laws of motion, to predict the location of an atom after a short time period (e.g. 
10'15s equivalent to a high frequency bond stretch). Large time steps would allow undesirable 
large movements of atoms. This iterative procedure relieves local stresses corresponding to 
bond length distortions or non-bonded atom overlaps.
The molecular dynamics simulation tries to solve the equation mathematically (Evans,
1995);
Fj = m,a; Fj = force on atom i
m* = mass of atom i 
a, = acceleration o f atom i
The force on atom / can be expressed in a differential equation, as a derivative of potential 
energy V with respect to co-ordinates r<. For a known mass this can be solved for various 
positions in time (t/);
dV = m, cPr, 
dr/ dt/2
Because the potential energy is a complex function of the co-ordinates o f all atoms in the 
system, this equation can only be solved generally. The total potential energy Vtotaj is defined 
as:
Vtotal Vbond Vangle^ ” Vditiedr VvdW Vcoulomb VnMR
Where the first three parameters Vbond, V ^ e and Vdihedr restrict bond lengths, angles and 
dihedral angles to their equilibrium values. Vvdw and Vcouiomb describe van der Waals and 
electrostatic interactions within the molecule. While V n m r  is the potential energy pulling atoms 
into their correct spatial positions relative to each other, as defined by the NMR generated 
restraints. Where NOE distances have been sorted into collective ‘bins’ e.g. strong, medium or 
weak, to produce distance-range constraints, the potential energy function V n o e  can be 
described as;
K n o e  (xy -  Ti/)2 i f  Ty > t /  where: r,-, = calculated interproton distance
VN0E = 0 i f  r v  <  T y  < r /  r /  = upper boundary limit
Knoe Or -  r ,1)2 i f  t ,  <  r/-1 = lower boundary limit of target distance
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KNoe is the force constant which has to be high enough to make sure that the distance-range 
constraints between atoms within the molecule, are complied with, in the simulation, otherwise 
an energy penalty is incurred. A value too great could lead to unreasonable demands on 
molecular conformation, yielding high energies and the molecule ‘blowing up’. Convergence at 
a potential energy minima (there maybe more than one for a large macromolecule, especially in a 
long simulation where large structural changes may only occur in motions of ps or seconds 
timescale), demands that NMR restraint violations are at a minimum value.
Molecular dynamics is computationally very expensive in terms of time, which 
increases linearly with the number o f atoms in the system. However, the resulting 
macromolecular structures are generally in good agreement with the experimental data.
1.10 The DNA-drag complexes discussed in this thesis
Two adozelesin-DNA adducts are discussed in detail in this thesis (chapters 3 and 4). 
Adozelesin binding to the self-complementary DNA duplex 5 '-d(CGTAAGCGCTTA*CG)2, is 
the first adduct which is characterized in chapter 3. The second drug-DNA adduct investigated 
was, adozelesin modification o f the non-palindromic ‘A’ tract sequence 5'- 
d(CGAAAAA*CGG)-5 -d(CCGTTTTTCG). The reaction of CMA, sibiromycin and DSB-120 
with various DNA sequences, were also studied and the results are reviewed in chapter 5.
67
CHAPTER 2: EXPERIMENTAL PROCEDURE
2.1 Laboratory reagents -  Sources
(3-Cyanoethyl phosphoramidites (deoxy: adenine, thymine, guanine, cytosine and inosine, i.e.
dA, dT, dG, dC and dl) -  Cruachem
Acetonitrile -  Cruachem
Iodine (oxidising agent) -  Cruachem
Trichloroacetic acid (TCA), (deblock) -  Cruachem
Acetic anhydride (Cap A) -  Cruachem
4-(Dimethylamino) pyridine (DMAP), (Cap B) -  Cruachem
Tetrazole (Activator) -  Cruachem
Aqueous ammonia (NH4OH) -  Sigma 29-5% NH3
Ammonium acetate (NH4 OAc) -  Fisons anal, grade, 99%
Acetic acid (CH3COOH) -  Fisons HPLC grade 
Acetonitrile (CH3CN) -  Fisons HPLC grade 
Controlled pore glass (CPG) support, 15 pi dC, dG -  Cruachem 
DNA -  Grade Bio Gel hydroxylapatite -  Biorad 
Deuterium oxide (D20 )  -  Sigma
Disodium hydrogen orthophosphate (Na2HP0 42H20 ) -  Fisons anal, grade, 98-100%
Sodium dihydrogen orthophosphate (NaH2P042H20 ) -  Fisons anal. Grade, 99-101%
Sodium chloride (NaCl) -  BDH Chemicals AnalaR®, 99-9% 
methanol (CH3OH) -  Fisons HPLC grade 
Dimethylformamide-d7 -  Sigma
Adozelesin -  A gift from The Upjohn Company, Kalamazoo, Michigan 49001, USA 
Cyanomorpholinoadriamycin -  A gift from E. M. Acton, SRI INT, Bioorg Chemlab, Menlo Pk. 
Ca. 94025 USA
Sibiromycin -  A gift from Prof. David E. Thurston, Department o f Pharmacy, University of 
Portsmouth, Portsmouth, Hants, U.K.
DSB-120 -  A gift from Prof. David E. Thurston, Department of Pharmacy, University of 
Portsmouth, Portsmouth, Hants, U.K.
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2.2 Oligonucleotide synthesis
An Applied Biosystems Model 381A DNA Synthesizer was used for the initial 15pi 
synthesis o f the various oligonucleotide sequences; 5 '-d(GTTCCATGGAAC)-3',
5 - d ( C I C G A A T T C I C G ) - 3 5 d(GC A G A A T T C T I C ) - 3 5 d(GTGATGAG)-3 
5 'd(GCTAGCTAIC)-3', 5 ' d ( G T T G C A T G C A A C ) - 3 5 (GAGATCTC)-3' and
5 rd-(CGAAAAACGG)-3
The CPG silica support was derivatized with a nucleoside corresponding to the base at 
the 3 '-hydroxyl end of the required DNA strand. This provided the starting material to which 
the dA, dT, dG, dC and dl P-cyanoethyl phosphoramidites were sequentially added via a 62 step 
synthetic cycle, as proposed by Perkin Elmer (Appendix I). The P-cyanoethyl phosphoramidites 
(1 g each o f dA, dT, dG, dC or 0-5 g o f dl) were made up to 01M  by adding the corresponding 
volumes o f phosphoramidite diluent i.e. dry acetonitrile.






Table 1 The volumes o f dry acetonitrile required to solvate the P-cyanoethyl phosphoramidites.
An explanation of the four stages of oligonucleotide synthesis performed by the DNA 
synthesizer can be found in Appendix II. The addition of each deoxynucleotide was monitored 
by separate collection of the trityl cation which is bright orange in solution. Failure o f the 
production of this ion signalled that the synthesis was unsuccessful.
2.3 Post-synthetic treatment of DNA
This encompasses the cleavage of the DNA from the column, deprotection o f the P- 
cyanoethyl phosphoramidites, benzoyl and isobutyryl groups, followed by detritylation and 
separation o f the desired strand from the failed syntheses (Applied Biosystems Manual; 
Thompson and Hurley (1995)).
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1) Cleavage from the silica support
This was achieved by a 20-25min treatment with 5ml aqueous ammonia (NH 4 OH), 
during which time the aqueous ammonia was repeatedly flushed through the column between 
two syringes. The NH 4 OH cleaves the ester linkage between the CPG support and the 3 '- 
hydroxyl o f the initial nucleoside (base and sugar, no phosphate group), revealing the free 3'- 
OH group of the DNA strand (Fig. 38).
2) Deprotection o f the phosphates
These (3-cyanoethyl protecting groups are removed at the same time as the DNA is 
cleaved from the support, in the above reaction (Fig. 38).
3) Deprotection o f the bases
This step was achieved via ammoniolysis and resulted in the removal of the benzoyl 
group (Bz) from the exocyclic amines of adenosine (ABz) and cytosine (CBz) and the isobutyryl 
group (lb) from the guanosine (GIb). Thymidine, already being unreactive, did not require a 
protecting group. Ammoniolysis was performed by incubating a vial (which could withstand 
positive pressure), containing the DNA product plus failed syntheses at 40°C for approximately 
15 hours (Fig. 38).
Figure 38 Cleavage from the CPG support and deprotection of phosphates and bases.
At this point, the DNA product and failed syntheses are completely deprotected except for the 
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2*4 High Pressure Liquid Chromatography (HPLC)
The HPLC analysis was carrried out using a Millipore Waters 600E system controller 
and 490E programmable wavelength detector. Purification o f the single stranded DNA was 
achieved using the reversed phase method with a Dynamax-300A, Ci» (20mm x 200pm) 
preparative HPLC column. The DNA was injected onto the column in lOOmM ammonium 
acetate (aq), pH 7, and then eluted (flow rate lOml/min), using a programmed elution gradient to 
achieve a linear change to 30% HPLC grade acetonitrile over a period of 40 minutes (Thompson 
and Hurley, 1995). Each fraction correlating to the various peaks was collected independently. 
After this initial slow increase, a more rapid change to 100% acetonitrile was required to flush 
the column of any residual compounds. Polarity and molecular size form the basis of separation 
with small, highly polar analytes being eluted first (e.g. failed syntheses) and large, non-polar 
molecules being retained the longest.
Figure 39 HPLC trace for ‘trityl on’ DNA
HPLC of the tritylated DNA sample produced a trace (Fig. 39), with a typical pattern, 
independent of the base make-up of the DNA sequence. The first set o f peaks represent the 
‘failed syntheses’ and the second large, off-scale peak corresponds to the DNA with the trityl 
protecting group in place. The first set of peaks corresponding to ‘failed syntheses’, related to 
the small number of DNA strands which were capped at each stage, when they did not succeed 
in reacting with the incoming (3-cyanoethyl phosphoramidite base. The smallest molecular 
weight single strands were eluted first which related to just one or two bases. Longer strands o f
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up to n-1 nucleotides (where n = number of nucleotides in the oligomer), were consecutively 
eluted showing a succession of peaks. The large, separate, off-scale absorbance peak is eluted 
last, and corresponds to the desired synthetic product, the single stranded DNA ‘n-mer’. There 
is a large space between the ‘failed syntheses’ and the product peak, which would not occur if  
the separation was motivated by molecular size alone. This gap is connected to the polarity of 
the molecules. Capping during synthesis to terminate any unreacted chains results in an 
acetylated 5 -OH as opposed to the dimethoxytrityl group, which occupies this position in the 
completed DNA strand. It is the polarity of these two groups which is responsible for their peak 
separation, the smaller acetyl group being more polar than the dimethoxytrityl group. Thus 
acetylated strands are partitioned into the acetonitrile mobile phase at a lower percentage 
concentration than those with the dimethoxytrityl group. Therefore, this polarity difference 
combined with molecular size accounts for the early elution of the ‘failed syntheses’ from the 
column, relative to the larger, less polar dimethoxytritylated DNA n-mer.
HPLC yielded a clear liquid containing the tritylated product. This sample was 
evaporated to approximately 5ml volume, followed by dialysis at 5°C using Spectra/PorCE 
membrane (MWCO:1000) against 3 x 1000ml of MilliQ water, to remove the ammonium 
acetate. The contents of the tubing were then concentrated by rotary evaporation, before 
deprotection o f the 5'-OH by treating with 60ml of 50% (v/v) glacial acetic acid for 20mins at 
room temperature. The acid was then removed by evaporation.
The DNA sample was then ready for further purification by HPLC which was 
performed in the same manner as before, except an acetonitrile gradient o f 0-15% over 40mins 
was used. This ‘trityl o ff  fraction was collected at ca. 12% acetonitrile before concentration 
and dialysis as previously described.
For each oligonucleotide strand, NMR buffer (0*6ml) was required to add to the 
sample. This was prepared by mixing 0-01M NaH2P0 4 and 0-01M Na2HP04 (each made up 
using 0TM NaCl) till they reached pH 6-85 (Thompson et a l, 1995). The DNA sample was 
evaporated to dryness, before being dissolved in 1ml D20 , freeze-dried to dryness once again, 
and then taken up in 0-6ml D20 . This DNA sample was placed in an NMR tube and examined 
by one-dimensional *H NMR.
Salt concentration has a significant effect on spectral resolution and so its addition 
prior to NMR is essential in order to obtain maximal information about the sample. Phosphate 
buffer maintains the pH but its own protons are likely to give rise to *H NMR signals larger than 
those of the macromolecule of interest, possibly obscuring a region o f the spectrum. However, 
they can be exchanged by redissolution in D20 . The phosphate buffer is important for
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sustaining the three-dimensional duplex structure of the DNA, to avoid the formation of hairpins 
at very low ionic strengths (Primrose, 1993).
2.5 One-dimensional *H NMR spectrum
One-dimensional !H NMR data were collected on each purified oligomer, in 
deuterated water, using a Jeol EX400 (400 MHz) spectrometer. There were four basic 
procedures to be observed (Frenkiel, 1993) in setting up the instrument, before the ID ‘H NMR 
spectrum could be acquired. These are listed as follows;
1) To tune the probe.
2) To establish the field and frequency lock.
3) Optimize the magnetic field homogeneity.
4) Calibrate the radiofrequency pulse lengths.
An explanation o f these processes and how they were achieved is given below.
2.5.1 E stablish ing the field an d  frequency lock
Since electromagnets do not produce inherently stable magnetic fields, there needs to 
be a control mechanism to produce high resolution data. This is accomplished by regulating the 
magnetic field so that the deuterium resonance of the solvent is resonant with the radio 
frequency o f the spectrometer. After this lock has been achieved, its phase is altered to give the 
highest signal, which is important for shimming and ensuring the signal is in pure dispersion. 
The lock transmitter is not run at very high power, because this could lead to detrimental effects 
on field stabilization and hence shimming.
Flat Flat
Figure 40 The Free Induction Decay (FID)
The experimental procedure to attain this field and frequency lock on the Jeol EX400 
spectrometer began by reading in the *H menu (data collection between -1-5 and 15ppm) and
73
loading the solvent (D2O). The lock signal was located and the FID sine wave observed to see 
if  it was phased correctly (Fig. 40).
2.5.2 Tuning the probe
Factors such as volume, position, solvent and ionic strength o f the sample can strongly 
affect tuning o f the observation coils within the probe. Whereas the lock channel tuning is 
sample-independent, the probe is not and so requires tuning to increase sensitivity and produce 
the strongest possible radio frequency, by utilizing the transmitter to produce a low level signal 
at the observation frequency to which it tunes. At this point, all of the radio frequency power 
will be absorbed by the probe; the meter gives a measure o f the reflected power which should be 
minimal after tuning. The probe was tuned whilst the sample was not spinning, because tuning 
the probe is difficult if  the signal is oscillating.
2.5.3 Optimizing the magnetic field homogeneity
This is also known as ‘shimming’. By varying the currents in a set o f correction coils 
which are each designed to counteract a particular type o f field gradient, the homogeneity of the 
magnetic field to which the sample is exposed can be improved. The lineshape is important 
dining shimming, because if  the solvent peak base ends up particularly wide, solute peaks in the 
vicinity may be eclipsed by it. The height o f the lock signal was used as an indicator of 
magnetic field homogeneity during shimming. Where just a straightforward one-dimensional 
NMR spectrum was required, the experiment was performed with the sample spinning, so 
shimming also took place whilst the sample was spinning. The sample was spun to increase the 
resolution because the sample tube is not homologous throughout, so spinning averaged the 
magnetic field experienced by the sample.
2.5.4 Calibrating the radiofreauencv pulse lengths
This procedure is most significant for multiple pulse experiments where the sample 
would be subjected to 90° or 180° pulses. For the simple ID accumulation this was not 
performed.
Following the set-up process o f the DNA sample in the spectrometer, and regulation 
o f all the instrument parameters required to produce data of good resolution, is the adjustment of 
the acquistion parameters. All NMR experiments were run at room temperature (21°C) because
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at low temperatures (<10°C), a reduction in molecular tumbling resulting from an increase in
viscosity o f solution or aggregation o f duplexes, may cause line broadening (Feigon et a l ,
1983a).
2.5.5 Adjustment of acQuistion parameters
a) The filter was calculated make it easier to phase the spectrum.
b) The spectral width was chosen (FR 8000 although 3500 would incorporate all of the 
spectrum) A frequency range more than twice the width o f the spectrum was used, as 
smaller ranges can have adverse effects on the baseline. The acquisition time and signal-to- 
noise ratio are independent of spectral width, so remain constant at larger frequencies.
c) Reciever gain. This was usually set to the highest possible value that can be achieved 
without causing the receiver front end or the analogue to digital converter to overload, 
which could result in distortion of the lineshape.
d) Accumulation. The acquisition time is the period over which a signal is accumulated. The 
spectrum is produced by subjecting the sample to a range of frequencies (AHz), and 
analysing the output before storing in a digital form. The signal is sampled twice every 
cycle or 2A times every second, where A = spectral width, which is also equivalent to the 
highest frequency component.
Data was accumulated generally over 64 scans or 128 scans if  the sample was slightly less 
concentrated.
e) Free induction decay (FID). This build up of the FID can be observed after each scan on 
screen. Because the FID is a measurement of intensity as a function of time, it is known as 
the time domain signal, which corresponds to an exponential decay curve o f a sine wave. 
This signal is generated from the application o f a pulse, at the Laimor frequency. For 
extremely complex macromolecules with many spectral lines, the FID is also complicated.
2.5.6 Transformation into a real spectrum
a) The interconversion o f data between the time and frequency domain is a mathematical 
process, known as Fourier Transformation. The FID is Fourier transformed to the ‘real’ 
spectrum. Fourier transformation contains real and imaginery components, but only the 




Figure 41 Fourier Transformation of the FID to a real spectrum
b) Phasing. Phasing is required to produce symmetrical peak lineshapes in the spectrum, with
phasing first taking place around the largest peak i.e. D20  and then at a distance from it,
maximizing the area under a peak to a flat baseline. The gain along the Y axis (YG) may 
also be turned up at this point to increase the signal (and the noise) size.
c) Referencing. The spectrum is referenced to its largest peak, which is the solvent D20  at
4.71ppm.
d) Data correction. Lastly, it is possible to flatten the base line to eliminate spurious noise 
signals and baseline roll.
This protocol produces ID 'H  NMR spectra for the various DNA samples and also provides the 
initial set up procedure for multipulse experiments, such as NOESY and DQF-COSY, which 
will be discussed later.
2-6 Analysis of the ID *H NMR spectrum.
One-dimensional JH NMR spectra were used as a tool to probe the concentration, 
purity and the ratio of oligomers in duplex formation from titration o f non-complementary 
sequences, as well as the progress o f reactions between the drugs and DNA. The information 
acquired from the spectra determined the next course o f action. Line broadening (resulting from 
paramagnetics impurities), and the presence of organic solvent peaks indicated further 
purification was necessary via hydroxylapatite chromatography, solid phase extraction or forced 
dialysis to improve the appearance o f the spectra. The protocols o f these techniques will now 
be described in detail.
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2.7 Annealing
For non-palindromic sequences such as 5 d(GTGATGAG)3' and 
5'd(CGAAAAACGG)3', and their complementary oligomer strands 5 'd(CTCATCAC)3' and 
5'd(CCGTTTTTCG)3', respectively (which do not form a duplex as readily as the self- 
complementary sequences), annealing was necessary. This procedure also ensured removal of 
any intrastrand hairpin loops which may have formed, due to the end of one strand being 
complementary to another region and binding in the incorrect postion. This latter problem 
occurs in both palindromic and non-palindromic sequences. Difficulties in duplex formation 
lead to line broadening and poorly resolved NMR spectra.
Reannealing is not only a simple solution to this problem but is also a very simple 
technique. An NMR tube containing the DNA sample in question, is placed vertically in a 
vacuum flask with enough water to submerge the sample at a temperature o f 75°C. The DNA 
melts (midpoint melting temperature is ca.69°C (Stryer, 1988)) and then begins to cool slowly 
back to room temperature. Annealing between two strands occurs at a higher temperature than 
within a strand, so all the DNA should have been incorporated into duplexes before it is cool 
enough to form hairpins.
2.8 Hvdroxvlapatite Chromatography
Hydroxylapatite chromatography was the purification technique of choice, when the 
DNA sample container impurities observable in the NMR spectrum. It is also an effective way 
o f separating excess single stranded DNA from duplex DNA after the titration of two oligomers, 
to produce a non-complementary duplex. Hydroxylapatite has a positively charged Ca2+ centre, 
and a negatively charged phosphate centres. The principles o f ion-exchange chromatography 
are therefore applicable; however, only some ions can elute adsorbed macromolecules. What 
would normally be seen as a single peak in ion-exchange chromatography or HPLC, may be 
separated by hydroxylapatite chromatography. Charge density, molecular weight or size, and 
isoelectric point are all significant factors in the separation. The underlying mechanism of this 
technique is not well understood. However, for a given pH, the adsorption-desorption process 
does seem to depend on ionic strength, with retention o f DNA on the column occurring at low 
eluent molarity (Gorbunoff, 1984). It is important that pH 6-8 is sustained because deviation 
results in decreased elution o f single and double stranded DNA and, therefore, decreased total 
recovery o f DNA.
This technique was performed as follows: 100ml of dry DNA grade HTP 
hydroxylapatite powder (Biorad) (HA) = [Ca5(P04)3 0 H]2 was added to six parts o f starting
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buffer prepared from O-OIM Na2HPC>4 and 0 0 1M NaH2P0 4 mixed to pH 6*8, and then swirled 
gently. The slurry was allowed to settle for 15 minutes before decanting the fine particles from 
above the settled bed (Bio-Rad hydroxylapatite instruction manual). This process was repeated 
twice. After resuspension, the hydroxylapatite was poured into a Pharmacia XK26 glass 
chromatography column and was allowed to settle under gravity. This preceded washing with 
two column volumes o f the starting buffer. The column was connected to a Gilson Minipulse 2 
peristaltic pump flow rate 10ml/min, and a detector; Pharmacia Biotech monitor UV-1, set at 
wavelength 254nm, with a chart recorder and sample collection utility.
lml of DNA solution was loaded onto the column in 0-01M phosphate buffer. Care 
was taken not to disturb the crystalline surface o f the hydroxylapatite column which could have 
led to uneven adsorption o f DNA onto the column. Elution took place over a gradient of 
0-01M—>0T5M phosphate buffer (pH 6 -8), formed by the gradual mixing of 300ml portions of  
each buffer solution. The sample was eluted from the column in two consecutive broad bands, 
if  separation o f single and double stranded DNA was being performed. The first peak related to 
the small amount o f single stranded DNA, whilst the second much larger peak correlated to the 
duplex DNA. Purification o f duplex DNA only, resulted in the observation o f only the second 
peak. Collection o f this fraction gave the pure DNA duplex. Other impurities were also 
removed, some o f which flowed straight through the column, showing a series of small peaks 
near the beginning o f the trace being probably small and non-polar in character. The collected 
eluent was then concentrated by rotary evaporation and dialysed to remove the salt, before being 
prepared for NMR as previously described.
2.9 Solid phase extraction
Solid phase extraction is a particularly effective method of removing relatively non­
polar compounds from the sample, and was used to successfully separate unreacted drug from 
drug-DNA adducts. This technique requires a 6ml Supelclean LC-18 (phase is octadecyl 
bonded silica) Sep-Pak tube, which is connected to both a reservoir and a Supelco vacuum 
manifold. Prior to commencing the extraction procedure, the column was conditioned with 2ml 
HPLC grade methanol (MeOH) to activate the packing. 10ml of 30% HPLC grade acetonitrile 
(MeCN) was then passed through the column in order to remove any particles originally present 
on the Cig Sep-Pak, which would be soluble at this concentration. 10ml of milliQ water was 
used to wash the activated column, so that organic solvents would not contaminate the DNA 
sample, which was then loaded. 50ml o f 30% HPLC grade acetonitrile was then placed in the 
reservoir and allowed to drip extremely slowly through the column (vacuum did not exceed 
5psi) over a period o f six hours. This ensured all of the DNA was eluted from the Cjg Sep-Pak
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within the acetonitrile mobile phase. Collecting the eluent in small sample volumes and 
analysing the UV signature at 254nm, referenced to 30% MeCN, made it possible to discern 
when all die DNA had been removed from the column
The eluent containing the DNA sample was then reduced to dryness and prepared for NMR, 
using NMR buffer and D20  as previously described.
2.10 Other purification techniques
HPLC, using an acetonitrile gradient o f up to 15%, was also used as a mode of further 
purification. However hydroxylapatite chromatography and solid phase extraction produced 
results o f far superior quality on examination o f the NMR spectrum.
Freeze-drying was also a method o f removing volatile materials such as methanol. 
Contaminants such as triethylamine were removed by forced dialysis. This involved saturating 
the sample solution in the dialysis tubing with NaCl to discharge the DNA, effectively allowing 
the charged triethylamine to be dialysed away. Contaminant paramagnetic ions were 
sequestered by the chelating agent EDTA, which was added (0-01M) to the 0-1M NaCl(aq) 
solution, used to make up the phosphate NMR buffer.
2.11 DNA adduct formation
On production of a pure DNA duplex (verified by NMR), the DNA was ready to be 
treated with a drug to produce a covalently bound drug-DNA adduct, or a non-covalently bound 
complex in the case o f sibiromycin. Each DNA duplex was freeze-dried in a small vial, 
followed by resuspension in 500jj1 D20. The drugs were added to their corresponding binding 
sequences as follows:









Into a vial containing 50mg of adozelesin, 250pl DMF-d? was added to dissolve the drug. 5 pi 
(5mg) adozelesin (yellow) was allowed to react with:
5 d(CGTAAGCGCTTACG)2-3'
5 d(CGAAAAACGG)-3 -5 'd(CCGTTTTTCG)-3'
Into a vial containing 12mg of DSB120, 60pl of DMF-d? was added to take up the drug into 
solution. 20pi DSB-120 (brownish) was allowed to react with:
5 'd(GTGATGAG)-3 '-5 'd(CTCATCAC)-3'
All solutions were then stirred in the dark at room temperature for 48 hours. The excess drug 
was removed from solution by vortexing and the drug-DNA adduct supematent was decanted, 
taking care not to disturb the free drug pellet. The supematent was freeze-dried to remove the 
solvent before further rounds o f freeze-drying. After addition o f NMR buffer and D20. The 
drug-DNA complex was analysed by ID NMR as previously described. Low resolution 
spectra required further sample purification by either Cig Sep-Pak solid phase extraction or 
hydroxylapatite chromatography. The production of a clean, pure sample in high yield allowed 
the commencement o f 2D NMR experimental analysis.
2.12 2D ‘H NMR NOESY protocol
The set-up o f a NOESY experiment proceeds primarily in the same manner as the ID 
experiment i.e. tuning the probe (which in this case is a HX probe), and obtaining a ID 
reference spectrum. However, water suppression techniques employed to eradicate the residual 
water proton signals in the solvent D20  peak. Solvent suppression increases the signal-to-noise 
ratio in the low sensitivity NOESY experiment. Presaturation is the most straightforward 
suppression technique and can be used on a solvent which resonates within a 20-30Hz band 
width. A value greater than this could result in suppression o f solute peaks. Irradiation 
proceeds by the application of a continuous unmodulated period of low level irradiation which 
is applied directly at the solvent frequency (Frenkiel, 1993), prior to the NOESY pulse 
sequence. This results in the water z component of magnetization being reduced to zero.
The water suppression procedure was executed as follows:
1) On the processed one-dimensional spectrum, the water peak was identified and the 
spectrum zoomed to 250Hz width.
2) The water peak height was set to 80% of the screen and the apex was pin-pointed.
3) IRR, this changes the irradiation frequency (IRF). The observation frequency (OBF) value 
needs to be equivalent to IRF (OBF/ERF). This brings the water peak into the centre o f the 
observation window.
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4) The experiment is changed to homeogated (EX HMG SE).
5) The irratin (IRA) is set. The lower the value to which the IRA is set, the greater is the 
suppression o f the water peak. There are 512 settings (IRA=200).
6) Once the identity o f the peak to suppress and strength o f suppression has been chosen, the 
length o f time (pulse delay = PD) for which to suppress it (PD = 4), has to be elected.
7) The receiver gain is now amplified to a value o f 21.
8) A spectrum is then accumulated over 4 scans and Fourier-transformed. Scrutinisation o f the 
spectrum shows whether; the suppression has been too great (next try IRA 220) and the 
peaks have begun to go out o f phase, the suppression was not great enough leaving some 
residual water (next try IRA 190), or if the water peak is now fully suppressed.
9) Zooming around the spectrum (XE 3600) exhibits the frequency around the sample (with a 
little space on either side). Spectral width is equivalent to 10 002ppm. The frequency is 
made equivalent to this value (FR 3600).
10) The filter was calculated (@FLT), to improve the phasing of the spectrum.
11) RESOL = 0 *22, BF has to be half of this value i. e. 0* 11.
12) A reference spectrum, over 16 scans is then accumulated, with phasing this time achieved 
using the methyl peak (next largest peak). After water supression, the FID signal appeared 
shorter.
13) After completion o f solvent suppression, the 2D NOESY experiment was set up, using the 
2D experiment menus (2DEXP @SETP).
14) The current processed ID data were held in the memory for use in the 2D phase-sensitive 
NOESY experiment (0 2 VPHNOEH).
15) The mixing time was set, the smaller the molecule the larger the mixing time (e.g. 200, 250 
or 300ms.
16) The spinner was switched to OFF, so that the sample was not spinning during the 
experiment.
17) The conditions were set for higher resolution (CLP 512 and TOD 512).
18) The lock signal was turned down to just below 500 (LGAIN = 16, LKLEV = 160 i.e. 
multiple o f  10 between them).
19) The data were accumulated over 64 scans at each o f 1024 T1 values.
The Varian 600MHz NOESY data were acquired at a mixing time 250ms with 32 scans at each 
of 1024 T1 values, also with a spectral width o f 10-002ppm and a relaxation delay of 2s 
between scans, NOE spectra in 90% H20  at 150ms mixing time were also recorded using a 1-1 
echo read pulse sequence (Sklenar and Bax, 1987; Blake and Summers, 1990) with a 2s pulse 
repetitition delay and a sweep width of 25-025ppm.
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2.13 DQF-COSY
The phase-sensitive DQF-COSY experiment is performed in a similar manner. 
However, the reference spectrum is not Fourier transformed, so that the FID is used. There is 
no mixing time and the DQF-COSY experiment VPHDQFH was selected instead of  
VPHNOEH.
2.14 Processing of a 2D NOESY spectrum using TRIAD
The data collected from the Jeol EX400 2D NOESY experiment was processed using 
TRIAD, a component o f the SYBYL software suite(SYBYL 6-2 manual), on SGI R4000 and 
SGI R3000 Indy workstations. The first step converted the time domain raw data (.gxd and 
.gxp) to the FID format (.fid), via ‘ex2nmri’. Because all the commands are initially applied to 
the displayed first row o f the data, a method of collecting these orders is required so they can be 
applied simultaneously to all rows within the data set, or to another data set. The mode of data 
collection is a ‘recipe builder’. The FID for this file was displayed half-way down the screen 
and on scrutinization, it was noted, that while the most decayed end o f the FID was central to 
the mid-line, the tail end was not oscillating around zero. To resolve this problem, an average 
value was calculated for the last 5% of the signal and consequently subtracted from every point 
in the FID. This procedure is known as removing the DC offset. An apodization function i.e. 
exponential multiply was then applied and a new FID displayed on screen.
This FID time domain data was then Fourier transformed into the frequency domain, 
revealing an unphased ID spectrum of negative and positive peaks. Interactive phasing 
produced a typical ID spectrum o f DNA or drug/DNA adduct, consisting of only positive peaks. 
This required adjustment o f the zero order (-180-+180) and first order (-360-+360) fine and 
coarse controls. This concluded the processing o f the first row of the first dimension. These 
commands were applied to the remaining rows in this dimension, followed by loading (D1 = 1 
to 1 and D2 = 1 to 1024 (twice the number o f points i.e. 512)) and displaying the subset.
Processing o f the second dimension commenced with a ‘data treatments’ step, so that 
the data was rearranged prior to processing. This consisted o f intermixing the ‘real’ and 
‘imaginary’ elements of the complex FID vector, so that they were in the correct order for 
Fourier transformation. This ‘data treatments’ step shuffled the data sequentially, before the 
recipe was applied to all o f the experiment in the second dimension. ‘Shuffle sequential’ 
organizes data into sequential real and imaginary data blocks. A further subset was then loaded 
(D1 = 1—>512 D2 = 1—+1) and displayed regarding the first dimension.
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Two column subsets of the second dimension then required loading. These were 
selected manually by picking two peaks at either end of the spectrum, which were preferably 
isolated and o f high intensity. A subset was then loaded and displayed for each of the peaks 
picked. Each peak was labelled by a number in points e.g. 242, and the data subset was loaded 
and named as follows; D1 = 242->242, D2 = 1—>512 and the subset name was column 242. 
The subset for the second peaks column points e.g. column 458 was loaded in the same manner, 
before displaying each subset using the same protocol. The views were simultaneously 
displayed on screen using the ‘sash’ display option, and the recipe builder was cleared. 
Processing then proceeds as with the first-dimension; remove dc offset, apodize, FT and phase, 
where phasing adjusts the appearance of both column point peaks at the same time. This 
processing recipe is then applied to the whole of the experiment in the second-dimension. The 
last subset to be loaded and displayed, incorporates all points in each dimension of the 
experiment i.e. D1 = 1—>512 and D2 = 1—>512. This yields the characteristic peak contours of 
two-dimensional spectral data.
To optimize the appearance of the spectrum, the viewing attributes could be altered 
such as; number of peak contours, plotting +/- levels (only positive peaks were selected), or the 
lowest viewing level (this was set to just above the baseline noise). Finally, the spectrum was 
referenced relative to the position of the irradiated solvent D20  peak, at a value o f 8 4-71 ppm.
Some Varian Innova 600 (600 MHz) NOESY data sets were collected (courtesy o f Dr. 
George Gray, at Varian, Palo Alto, CA., U.S.A.) and processed using TRIAD in a similar 
manner. The fundamental differences in the first-dimension were:
1) After removal of DC offset, the NMR calculator was utilized to multiply the first point in 
the vector by a half, for accurate processing in the second-dimension. The NMR calculator 
used the first row as the data source (row 01), was set to multiply using the ‘X’ option, with 
the real value set to 0-5 and the imaginary value set to 0*0.
2) The apodization function substituted ‘exponential multiply’ for ‘sinebell’.
Processing then continued as described previously for the rest o f the first-dimension. There 
were also some changes to the protocol in the second-dimension:
3) The data treatments proceeded via ‘shuttle interleaved’, to recombine the points in the 
vector when the real and imaginary Ti components are interleaved, plus reducing the vector 
length from 512 to 256.
4) This is followed by the NMR calculator step once agaifl, w h efe^  data source is defmed by
one o f the column subsets loaded in the first dimension. In this case both real and 
imaginary values correspond to 0-5.
5) The apodization function was again, the 90° shifted sine-bell.
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6) The FID was then zero-filled to 2X, prior to Fourier transformation to give a 2X x 2X 
spectrum (to return the vector to 512 points).
7) After Fourier transformation the data was reversed to display the data in the usual format, 
with the diagonal running from the bottom left to the top right.
Processing and viewing the spectrum proceeded as before.
Jeol EX400 (400 MHz) DQF-COSY data were also accumulated and then processed 
in TRIAD, with a few alterations to the NOESY processing protocol. Firstly, it is important to 
remember the zero and first order phasing values generated whilst phasing the first-dimension. 
After the data treatments shuffle sequential step the recipe is not applied to the experiment in the 
second-dimension, instead a number of steps are jumped up to; remove DC offset, apodize etc. 
Because the FID only, is visible at the next phasing step, unlike in the NOESY experiment 
where two peaks were present at either end of the spectrum, interactive phasing proceeded using 
the values recorded from processing the first dimension. Hence, DQF-COSY spectral 
processing is much simpler than the protocol used for NOESY.
2.15 Building a computer model of DNA and adozelesin
Both the biological macromolecule DNA and the drug molecule adozelesin were 
constructed within the computer software: SYBYL. Despite the large size and complexity of 
the (3-DNA helix, this macromolecular structure was perhaps the easiest to generate, using the 
in-built biopolymer dictionary facility o f SYBYL. This application contains all the information 
required to build canonical p-DNA, using the A, G, C, T monomer structures, plus their 
conformations and connection rules. Two DNA duplexes were computer generated: 
5 d(CGTAAGCGCTTACG)2-3' and 5 d(CGAAAAACGG)(CCGTTTTTCG)-3
Adozelesin was drawn using the ‘sketch’ utility. Benzofuran and indole ring systems 
served as templates in the construction o f the three sub-units. 100 Steps of steepest descent 
gradient minimization, followed by lOps molecular dynamics simulation (see later protocols), 
were performed to find a lower energy conformation o f adozelesin than the sketched one, where 
all rings were co-planar.
A set o f charges were then generated for each molecule using the Gasteiger-Huckel 
method. This is a combination of the mathematical approaches described by Gasteiger and 
Marsili (1980) and Huckel (see Purcell and Singer, 1967 for a review). The former concentrates 
on the calculation o f the a  component, whilst the latter on the n contribution to charge. The 
resulting Gasteiger-Huckel charge is the sum of these components. Because the atom charges in
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the 7i system are believed to be delocalized over the whole n system, the Htickel charge is 
calculated prior to the Gasteiger-Marsili charge. The electron-distribution over the topology of 
the molecule is an important factor influencing the physical and chemical properties of DNA 
and adozelesin and, hence, the interaction between them.
2.16 Docking
Optimal placement of adozelesin in the minor groove is o f significant importance in 
the production o f a good quality starting structure, for the initiation of a molecular modelling 
study. Docking was used as a tool to identify lower energy ‘ligand’ positions within the 
confined, rigid environment of the minor groove. Adozelesin was the moving ‘ligand’ which 
was manoeuvred into the stationary ‘site’ of the minor groove of DNA.
Before the docking procedure could commence, the centre o f the DNA molecule i.e. 
the axis on which the molecule turns, had to be redefined. The adenines which were about to be 
covalently modified (A12 o f the palindromic sequence and A7 o f the non-complementary 
sequence), defined the new ‘centre’ and hence, the docking energy box encompassed this site. 
In the docking mode, a database was created, so as to save the docked adozelesin DNA complex 
as a single entity. Adozelesin was selected as the ‘ligand to dock’, whilst DNA was defined as 
the ‘site to dock into’ within the interactive docking mode of SYBYL. Manual ligand 
navigation towards the site produces a numerical total energy output as well as visual (red) lines 
of force. These increase in number and strength when the ligand is placed in or very close to the 
site, in a sterically unfavourable or electronically repulsive position. The non-bonded 
interactions between adozelesin and DNA are calculated on a lattice, with the co-ordinates of 
the ligand being converted into an index within the lattice fields. This gives a linear expression 
of interaction energies between the site and a particular ligand atom. When all these energies 
are added together for each ligand atom, the overall site-ligand interaction energy is yielded. 
The Tripos force field calculates steric contributions, whilst there are also electrostatic 
contributions from the atomic charges, both constituting the interaction energy.
The docked adozelesin-DNA complex is taken to be when the energy is lowest with 
few visible lines o f repulsion force, and when the adozelesin appears to be in a suitable position 
for bonding o f the CPI headunit to the adenine base.
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2.17 Covalent adduct formation
Once the adozelesin had been docked into the minor groove o f DNA and existed as a 
single entity in space, a covalent bond was added between adozelesin and N3 of adenine in 
DNA, using the SKETCH utility. Due to problems in locating the exact site of atomic charge 
on the adenine in the cyclopropapyrroloindole family of adducts, the modified adenine used in 
molecular modelling was as shown in Figure 42:
Figure 42 Sketch of the modified adenine base covalently bound to the CPI headunit (Hurley et al., 1984).
On covalent bonding o f adozelesin to adenine in the minor groove, 200 steps of steepest descent 
gradient minimization was applied to a set o f ‘interesting’ atoms; adozelesin (in both 
sequences), A7, C8, T14 and G13 of the ‘A’ tract sequence, or A12, C13, G2 and T3 of the self- 
complementary DNA strand. All other atoms were ignored, allowing the adozelesin to find a 
more energetically favourable position within the minor groove. This minimization was 
proceeded by 5ps of dynamics on adozelesin only, over a temperature gradient of 0 to 300K. 
The average structure from the trajectory yielded the rough starting structure for structural 
refinement.
2.18 The Master Assignment Spreadsheet
The master assignment spreadsheet (MSS) was generated after the adduct structure 
was completed, with the correct atom names and atom types as defined by SYBYL according to 
chemical identity and hybridization. It is used to store the chemical shift (ppm) of each atom 
within the covalent complex, as it is measured on the NOESY spectrum. The MSS is created 
from the molecular spreadsheet menu in the presence o f the docked adozelesin-DNA computer 
model (see section 2-15). This spreadsheet contained two columns; unique atom names and 
shift in ppm. The number o f rows correlated to the number o f atoms within the complex.
NH
Modified adenine base with labelled atom types 
(defined by chemical elements and hybridization).
Adozelesin
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2.19 The peak pick spreadsheet
Once the NOESY spectrum had been completely assigned, the NOE peak attributes 
such as the position in each dimension, width of peak footprint in each dimension, volume of 
peak integral (area under peak) and the intensity o f the peak at the centre, were measured within 
TRIAD. The data were entered into the peak pick spreadsheet (PPSS). Each column 
corresponded to one o f these peak attributes, whilst each row related to a peak in the NOESY 
spectrum. Each peak was manually picked and the peak boundaries defined. The ‘add/define 
peak boundaries’ step utilizes a rubberband tool, which is dragged out to the size of the peak in 
question, with its central cross corresponding to the centre o f the peak. ‘Selecting’ the first peak 
automatically leads to the generation of a peak pick spreadsheet, into which all subsequent data 
is entered. It is extremely important to pick the exact centre of the peak, otherwise the chemical 
shift will be ambiguous in a spectrum where a large number o f proton signals are crowded 
together in a small area.
The threshold level to which all the peak integrals were measured was positioned just 
above the baseline, to eliminate the anomalous peaks o f backgound noise. This leads to a trade­
off between larger volume integrals and a noise-free ‘prettier’ spectrum. However, the change 
in integral values will be proportional across the spectrum. The peak edge for defining the peak 
footprint size was taken to be the one closest to the peak centre (SYBYL 6-2 manual).
After all peaks corresponding to a proton-proton NOE between adozelesin-adozelesin, 
DNA-DNA or adozelesin-DNA had been ‘picked’, each proton had its chemical shift assigned 
(ppm). This value was entered directly into the master spreadsheet. The chemical shift o f the 
peak in each dimension was assigned manually, this was achieved using a cross-hair tool to find 
the centre o f the peak, which correlated with previously picked peak centres in the PPSS. At 
this point, it was important that both dimensions o f the spectrum were referenced exactly to D20  
6 4-71ppm. Otherwise, a proton would not have the same chemical shift value in both 
dimensions and problems would be encountered by TRIAD in correlating the right proton to the 
correct peak. A correction factor was added to the methyl group, since their single signals are 
equivalent to three hydrogens in rapid rotation. TRIAD was unable to generate constraints for 
an NOE in which three protons gave rise to the same NOE peak, leading to ambiguous 
assignment o f each methyl proton. Therefore, the chemical shift of the methyl protons was 
awarded to the methyl carbon instead, and an extra lA  added to the interatomic distance to 
which the NOE corresponded.
The PPSS was then linked to the MSS. All peaks (rows) in the PPSS were assigned 
the two protons which gave rise to the NOE cross-peak by TRIAD. The position of the cross­
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peak (columns for D1 (POS 1) and D2 (POS 2)) value in ppm, was matched to the proton 
defined chemical shift in the MSS with a tolerance of OOlppm. This yielded two peak 
assignment columns (AtomPOS 1 and AtomPOS 2)
2.20 Generation of constraints
Distance constraints were generated in the PPSS in the presence of the adduct 
molecule. A strong(s)/medium(m)/weak(w) methodology was utilized (Hansen et al.y 1995), in 
which the NOE volume integrals were translated into a series of distance-range constraints. The 
peaks and their corresponding intensities were inspected by eye; any peaks which were 
completely engulfed by noise, due to the unfortunate presence o f spectral baseline roll were 
disgarded, whilst peaks on a Tj ridge were multiplied by 0*5, methyls divided by three, and 
overlaid peaks had their intensities divided by the number of protons under the peak. It was 
thought that total deletion o f these NOEs would lead to the loss of important structural data, so 
intensities were weakened such that their contribution to the resulting structure was lower (weak 
contraints) but still present. This was thought to lead to a more accurate emplyment of the 
NMR data.
Generation of the distance range constraints began by selecting the assignment column 
(ATOM POS 1 and ATOM POS 2) in the PPSS. This was followed by setting the distance- 
ranges for the strong, medium and weak constraints, plus the peak intensity threshold;
‘A’ Tract; strong = l-49->3-0A 2-706 x 108
medium = l-49->5-0A 1-413 x 108
weak = 1-49—>7-0 A
Self-complementary; strong = 1.58->3.0A lxlO6
medium = 1.58-»5.0A lxlO5
weak = 1.58->7.0A
The PPSS was updated with the distance range constraints in two columns ‘LOWER’ and 
‘UPPER’ bounds. TRIAD seemed to use the molecular model to define interproton distances, 
so that if  this distance exceeded the range, then no constraint was added. It was expected that 
distances here would exceed those normally seen from an NOE, purely because this was the 
docked adozelesin-DNA structure which had not taken part in energy refinement, and drug 
binding may have distorted the DNA somewhat. This could lead to unusal interproton 
interactions being present which would not be seen in a perfect (3-helix or if  the adozelesin had 
not been docked in the correct conformation. Therefore, each restraint ‘bin’ had its bounds 
widened to encompass the smallest distance (LOWER BOUND) and the largest distances 
(UPPER BOUNDS). After the first 5 Ops o f molecular dymamics, the restraints were tightened 
to their correct values, where the medium UPPER BOUND was 4-5A and the weak UPPER
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BOUND was 6*0A. The cytosine H5-H6 distance of 2-45A (0*25nm), was used as a yardstick 
by which to measure all other proton-proton distances. The thymine H6-CH3 distance of 2 9A 
was used to calibrate all distances regarding a methyl group (Searle and Bicknell, 1992; Metzler 
et al., 1990; Hansen and Hurley, 1995). Both o f these constituted strong NOEs. The peak 
intensity threshold was set by dividing equally the difference between highest and lowest 
experimental NOE intensities.
2.21 Molecular modelling
To reduce the computational time required for the restrained molecular dynamics 
calculations, only the top seven base-pairs o f the self-complementary adozelesin-DNA adduct 
were modelled. The whole o f the ‘A’ tract adduct was modelled as it was non-palindromic, 
containing only one drug-binding site. In both cases, an additional pair o f base-pairs (G-C), 
were added to the top and bottom of the DNA duplex, so that the 7-mer became an 11-mer, and 
the 10-mer ‘A’ tract became a 14-mer. The presence o f these extra bases was to reduce terminal 
base-pair end fray within the calculations, whilst leaving the central 7-mer and 11-mer free from 
artificial restraints e.g. across base-pair hydrogen bonds. Slightly longer DNA duplexes are also 
perceived to behave more authentically like in vivo. However, a large trade-off has to be made 
with the increase in size, due to the computational limits.
In addition to the experimental NOE constraints applied to the molecule, some extra 
constraints were added to help stabilize the adduct during the equilibration protocol. These 
additional constraints consisted of:
1) Two angle constraints (defined by 3 atoms), from adozelesin C (of the H8A, H8B 
methylene bridge), to the N3 of adenine (to which adozelesin is covalently bound), to the 
C2 or C4 (of the modified adenine). Angle = 120° Force constant (fc) = 
1 OOkcal/mol. degree2
This is to pull the covalent bond so that it is planar to the adenine ring system.
2) Fixed distance restraints were applied across all hydrogen bonds between base pairs. The 
distances were set at their original values within the (3-helix. Two constraints were placed 
between an AT base pair and three between a CG base pair. The fc for each base pair is as
follows:
5'- C21 G22 c 1 G2 A3 A4 A5 A6 A7 C8 G9 G10 C23 G23 -3'
fc= 200 200 200 200 100 100 100 100 100 100 200 200 200 200 kcal/mol.A2
3'- G28 c 27 G20 c 19 rjll8 j\7 fj<16 yl5 rpl4 G13 C12 C11 G26 C25 -5'
5'- C15 G16 c 1 G2 rj-i3 A4 A5 G6 c 7 G17 c 18 -3'
fc= 200 200 200 200 100 100 100 200 200 200 200 kcal/mol.A2
3'- C22 c 21 G14 C13 A12 j l l jlO C9 G8 c 20 G19 -5'
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Each constraint was defined by acceptor and donor atoms of the hydrogen bond. This was 
to prevent melting o f the DNA during the intial heating steps of the dynamics run.
3) Torsion angle constraints were added in the same manner as above, each with a fc = 50 
kcal/mol.A2. Four atoms defined each constraint i.e. two either side o f the hydrogen bond.
2.21.1 In vacuo structural refinement
A series o f equilibration steps were performed on both adducts prior to 
commencement o f the molecular dynamics calculations. This was to reduce any unfavourable 
steric clashes and geometric strains within the initial structure, as much as possible. The 
minimization procedure was as discussed below:
1) 100 steps o f steepest descent minimization. (Compute^minimize)
Termination was by a gradient -  the minimization stops when the energy gradient is lower 
than the field value o f 0-05 kcal/mol.A
Initial optimization was via ‘simplex minimization’ to reduce the stress of a high strain 
structure.
Tripos force field and Gasteiger-Huckel charges
2) 10000 iterations o f conjugate gradient minimization.
Convergence criterion of the termination gradient = 0-01 kcal/mol.A
3) Molecular dynamics -  heating up procedure. (Compute-»dynamics)
Use same constraints as for minimization, except for the angle and torsional constraints, 
which were deleted.
Tripos force field
Heating cycle proceeded by 5ps at each o f the listed temperatures: 0, 40, 80,120, 150, 180, 
210, 240, 270 and 300K.
Time step = 2fs
Snapshot = every lOOfs (where structure saved in the trajectory)
Distance dependent dielectric function = 1 
Non-bond cut-off= 8A
NVT canonical ensemble = closed system with fixed size (N i.e. number o f particles and V 
i.e. volume constant) but kept at constant temperature by contact to a heat bath.
The initial velocity at OK was ‘Boltzman’ but at subsequent temperatures it was ‘Previous’.
4) Releasing the distance constraints across the hydrogen bonds between the bases. 
Temperature = 300K
Replay above trajectory to acquire the starting structure for this step,
a) Time length = 5ps
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fc = from 200-»100kcal/mol.A2 for first two base-pairs at either end of the duplex 
(excluding the extra CG base pairs)
from 100—>75 kcal/mol.A2 for the base pairs in the centre of the duplex between the 
terminals
Other parameters = as above Initial velocity = Boltzman
b) Reply above trajectory to acquire the structure for this step.
Time length 5ps
fc = of both 100 and 75—>50 kcal/mol.A2 
Other parameters = as above
c) Replay above trajectory as before.
Time length = 5ps
fc = 50—>25 kcal/mol.A2 
Other parameters = as above
d) Replay trajectory as before.
Time length = 60ps
fc = for;
C1 -G14 and C7-G8 of the self-complementary adduct change the fc from 25—>10kcal/mol.A2 
C -^G20 and G10-Cn of the ‘A’ tract adduct change the fc from 25->10 kcal/mol.A2 
All the remaining base pairs in between change the fc from 25—>0 kcal/mol.A2 
Other parameters = as above
Also reload the distance range constraints from the PPSS, with the newly generated smaller 
range values as discussed previously.
5) The above trajectory was replayed and an average structure calculated from the last 50ps of 
the molecular dynamics run i.e. between lOps and 60ps equal to 501 structures.
Steepest descent minimization -  all other parameters as previously described.
100 steps
Covergence criteria = 001 kcal/mol.A
6) Conjugate gradient minimization 
10,000 steps
Convergence criteria = 0*001 kcal/mol.A 
Other parameters = as before.
This yielded the refined molecular structures for both adozelesin-4A’ tract DNA and 
adozelesin-self-complementary duplex DNA adducts in vacuo.
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2.21.2 In aauo structural refinement
This study began by adding a set of counterions (Na+) to the adduct structure, which 
would mimic the effects o f the NMR buffer in solution. These ions were added across each O- 
P-O bisector along the DNA phosphate backbone, at a distance o f 6A from the phophorus 
(Young et a l 1997). A distance range constraint from 5-»7A was also defined for each ion, 
with a fc value = 25 kcal/mol.A2.
The NMR data were collected on a solvated system. Hence, to calculate a structure 
which accurately reflects the adozelesin-DNA adduct in a biological system, the water 
component must also be included. This is achieved with ‘explicit treatment of the solvent’, 
where the whole system is solvated in a water droplet, allowing the solute to interact with the 
solvent by hydrogen bonding. Unforunately, this method is also very expensive in 
computational time. Molecular Silverware (Blanco, 1991) is the algorithim within SYBYL 
which performs droplet solvation, packing solvent water molecules successively around the 
solute, one shell at a time. Each solvent is added so that its van der Waals surface does not 
overlap with that o f other water molecules. This method is preferable to others, even though it 
is significantly slower, because the resulting solvated system has a lower energy, making the 
molecular modelling equilibration protocol simpler (SYBYL manual).
To the minimized structure yielded from the in vacuo calculation step (2) with added 
Na+ counterions, 6 layers o f water (with Gasteiger-Huckel charges) were computed via 
Molecular Silverware, solvating the DNA adduct. The droplet consisted of approximately 4000 
water molecules.
Equilibration and thermalization of the water molecules and Na+ counterions, has to 
take place in the solvated system prior to equilibration o f the DNA adduct (Westhof et al, 
1995; Young et a l, 1997; Auffinger et al, 1995). This is to reduce strongly unfavourable 
energetic interactions between the solute and the solvent molecules, which could lead to 
collisions between the two and hence, irreversible deformation o f the solute. The resulting 
molecular dynamics simulation would not reflect the system at equilibrium. The equilibration 
and thermalization procedure o f water and Na+ counterions, is discussed below:
A. 100 steps o f steepest descent minimization
Water only i.e. DNA and Na+ are fixed in position (ignored)
Termination is gradient, with a field value of 0 01 kcal/mol.A 
Tripos force field
B. 100 steps steepest descent minimization
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Water and Na+ counterions only, DNA is fixed in position 
Na-*P-DNA fc = 25 kcal/mol.A2
Termination is gradient, with a field value o f 0-01 kcal/mol.A 
Tripos force field
C. 100 steps conjugate gradient minimization
As above except reduce the Na+—>DNA fc to 20 kcal/mol.A2
D. 100 steps conjugate gradient minimization 
Reduce fc to 15 kcal/mol.A2 for Na+->DNA
E. 100 steps conjugate gradient miminization 
Reduce fc to 10 kcal/mol.A2 for Na+-»DNA
F. 100 steps conjugate gradient minimization 
Na+ ->DNA fc = 5 kcal/molA2
G. 100 steps conjugate gradient minimization 
Na+-»DNA fc = 0 kcal/mol.A2
H. Molecular dynamics
Mobile waters only, DNA and Na+ are fixed
Tripos force field
Dielectric function = constant
Initial velocity = Boltzman
5ps and temperature o f 300K
2fs time step and snapshot every lOOfs
NVT ensemble
I. Replay above trajectory and proceed with further molecular dynamics 
Thermalize both water and counterions (DNA fixed) Na+-*»DNA fc = 25 kcal/mol.A2
All parameters same as above except, 2ps spent at each o f the following temperatures; 0, 50, 
100, 150, 200, 250 and 300K
Initial velocity of first step is ‘Boltzman’, ensuing steps are ‘Previous’
J. Replay above trajectory
Thermalize water and counterions (DNA fixed)
Na+-*DNA fc = 20 kcal/mol.A2 
lps at 300K Initial velocity = Boltzman 
K. Replay above trajectory
Thermalize water and counterions (DNA fixed) for lps at 300K 
Na+-*DNA fc = 10 kcal/mol.A2 
Initial velocity = Boltzman 
L. Replay above trajectory
Thermalize water and counterions (DNA fixed) for lps at 300K 
Na+—>DNA fc = 0 kcal/mol.A2. Initial velocity = Boltzman
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M. Replay above trajectory
Thermalization o f the water molecules is now complete, the ‘heating’ procedure on the 
whole system i.e. water, Na+ and DNA now begins. The protocol is generally analogous to 
that described in the in vacuo calculation, commencing at step (3). Only the changes to 
each step will be listed below:
3 )  Distance dependent dielectric function = constant (all dynamics steps in the in aquo 
calculation)
Na+—»DNA fc = 25 kcal/mol.A2 
4a) Na+->DNA fc = 20 kcal/mol.A2 
4b) Na+-*DNA fc = 10 kcal/mol.A2 
4c) Na+ -»DNA fc = 5 kcal/mol.A2 
4d) Na+-»DNA fc = 0 kcal/mol.A2
5 )  For the steepest descent minimization all waters were removed to reduce 
computational time.
6 ) The conjugate gradient minimization was also completed without the presence of 
water.
This yielded the refined molecular structures for both adozelesin - ‘A’ tract DNA and 
adozelesin-self-complementary duplex DNA adduct in aquo.
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CHAPTER 3: RESULTS AND DISCUSSION 
THE 5'-d(CGTAAGCGCTTA*CGV>- ADOZELESIN ADDUCT
Adozelesin is a synthetic analogue o f the cyclopropypyrroloindole (+)CC-1065. 
Sequencing studies have shown that adozelesin, like all the mono-functional (CPI) based 
antitumour antibiotics has a sequence preference for 5'-TTA* (where * indicates the covalently 
modified base) Yoon and Lee, (1998). Hurley et al., (1984) established that (+)CC-1065 
covalently binds to the N3 o f adenine via C8 on the cyclopropane ring opening. NMR and 
molecular modelling studies (Lin et al., see review by Hurley, 1993) have already shown 
(+)CC-1065 binds within the minor groove spanning a total of 5 bp. Adozelesin is structurally 
similar to (+)CC-1065 minus the ethylene bridges o f the non-alkylating sub-units, which maybe 
responsible for the delayed hepatotoxicity o f adozelesin (McGovren et al., 1984, Warpehoski 
and Bradford, 1988).
The ability of the cyclopropapyrroloindole adozelesin to modify covalently the self- 
complementary DNA sequence 5 -d(CGTAAGCGCTTACG)2 has been investigated by high- 
field NMR and restrained molecular modelling. It was hypothesized that adozelesin would 
modify the 5'-TTA* consensus sequence to form a bisadduct. The structure was also expected 
not to display the characteristic winding o f (+)CC-1065, if  the ethylene bridges were in fact 
responsible for this phenomenon. This site contained an unfavourable GC within the flanking 
sequence to the 5'-side o f 5'-TTA*, so  it was hoped that if  adozelesin did bind to this sequence 
it would be possible to assess what effect the GC base-pairs had on the conformation of the 
adduct and more importantly how this sequence selectivity was achieved.
The production of a refined molecular model o f the adozelesin-5 '- 
d(CGTAAGCGCTTACG)2 adduct (Fig. 43) required a long sequential chain of events. Firstly, 
the DNA oligomer had to be synthesized, purified and analysed by 2D !H NMR. Secondly, 
after reaction o f adozelesin with DNA followed by further purification, a second 2D NMR data 
set was collected and analysed. Lastly, distance-range constraints were generated and applied to 
a computerized model o f the structure, by molecular mechanics and dynamics calculations. It 
























Figure 43 Schematic diagram of the adozelesin-DNA adduct.
3.1 Analysis of the ID *H NMR spectrum
In the first instance, prior to the reaction o f the oligomer with adozelesin, all non­
exchangeable protons within the DNA duplex had to be assigned. This was important for later 
comparisons with the proton chemical shifts from the adduct structure, in order to ascertain 
exactly how the binding o f adozelesin influences the conformation o f DNA. Analysis o f this 
spectrum also gave a strong indication on the purity o f the sample. Line broadening, impurities 
and a low signal-to-noise ratio would constitute the main reasons for further sample purification 
or synthesis.
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The proton numbering and distribution within the deoxyribose sugar and around each 
base is given in Figure 44 Although the deoxyribose protons are generally denoted as H2' and 
H 2” , for the purpose o f this study they will be denoted as H2 ' 1 and H2'2, so they are equivalent 
to the SYBYL software naming system. The same applies to H5' and H5", which will be 
designated as H 5 'l and H5 2, respectively.
NHj
c —H
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Figure 44 Molecular stmctures and their spin systems, of the building blocks which comprise DNA
Figure 45 shows the ID JH NMR spectrum o f 5'-d(C 1G2T3 A4 A5G6C7G8C9T 10T 11A 12C 13G 14)2 3'. 
Although only a limited amount o f data can be extracted on the structure o f the DNA duplex, it 
is an important tool for determining whether the correct nucleotide components are in fact 
present, even if their order cannot be deciphered. This is achieved by analysing the base protons 
of each nucleotide. The peaks due to the protons of the 2"-deoxy-P-D-ribose sugar itself, were 
distributed over two-thirds of the spectrum between 8  T 8 - > 6  0ppm. However, the sugar 
protons exhibited extensive overlap, so little could be deduced other than relating each spectral 
region to its respective deoxyribose proton: (Wuthrich, 1986) (Table 2). Due to the self- 
complementary nature o f this duplex sequence, which means that each strand reads the same in 
the 5 '->3 ' direction, both strands are equivalent. This reduces the complexity of the spectrum 
significantly, because, in effect, the spectrum only carries proton resonances synonymous with 
one DNA strand.
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Proton Chemical shift (ppm)
c h 3 1.2 <-> 1.6
H2'l, H2'2 1.8 <-> 3.0




c u m 7.1 <->7.6
A/GH8 7.3 <-> 8.4
AH2 7.3 <-> 8.4
Table 2 The chemical shift vai 
protons.
ues (5 in ppm) o f deoxyribonucleotide base and sugar non-exchangable
From inspection of the above molecular structures, it is clear that the purines adenine 
and guanine give rise to two and one singlet respectively from their non-labile protons. The 
spin systems o f cytosine and thymine are slightly more complicated. Cytosine produces 
doublets at both CH5 and CH6 from the V  scalar coupling, whilst thymine yields a methyl peak 
(integral o f three protons) with a longer range 4J  scalar coupling to CH6, whose proton appears 
as a singlet in the ID spectrum. Counting the number of methyls (unless they are overlaid) 
present between 5 1—>2ppm gave a measure o f whether or not the expected number o f thymines 
were present in the DNA duplex. There are methyl peaks at approximately 5 1-4, 5 1-5 and 5 
l*6ppm, but it is not possible to distinguish which is T3, T10, or T11. In a well-resolved spectrum 
with a high signal-to-noise ratio, it is possible to see cytosine doublets, both in the aromatic 
region, just over 5 7ppm and between 8 5-3—»-6-0ppm for the CH5 protons. In Figure 43, only 
three CH5 doublets appear clearly at about 8 5 0, 8 5-2 and 8 5*25ppm, the fourth cytosine being 
obscured by the surrounding sugar H I' protons. Doublets in the aromatic region, corresponding 
to the CH6 proton, were noted at approximately 8 7-1, 8 7-2 and 8 7*5ppm; the fourth resonance 
was once again overlaid with other aromatic protons within the region. Even in this one- 
dimensional spectrum, a sure identification o f these peaks correlating to the cytosines was 
possible, not only because these were die peaks in the aromatic region generally with the higher 
upfield shifts, consistent with being a pyrimidine, but the /hs-h6 coupling constants for all peaks 
were equivalent (10*8Hz), implying that the H5 and H6 were cis to one another. An estimation 
of the number o f peaks in the aromatic region yielded fifteen peaks, four o f which were cytosine 
H5 doublets, and two peaks which integrated for two and three protons. These data agreed with 
the expected number of aromatic resonances to be generated from the 5 -  
d(CGTAAGCGCTTACG)2 sequence i.e. 4 x GH8, 3 x TH6 , 3 x AH8, 3 x AH2 and 4 x CH6 
(doublets) =17 protons.
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Figure 45 The ID *H NMR spectrum of the 5 '-d(CGTAAGCGCTTACG) 2  DNA duplex.
.................................................... _ _     OP-
2 0  % i  T  T T  5
Figure 46 The ID *H NMR spectrum of the adozelesin-5-d (CGTAAGCGCTTA*CG>2 adduct, where * 
denotes the site of covalent modification.
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3.2 The 2D *H NOESY spectrum
After collection and processing of the Jeol 400MHz NOESY data, the spectrum was 
ready for assignment (Appendix III Fig. 103). The NOE peaks were well resolved, with a high 
signal-to-noise ratio. Each dimension was referenced to the D2O peak at 5 4-71ppm. There 
were a few sharp vertical Ti ridges of spurious noise in the spectrum at the positions of 
particularly strong cross-peaks on the diagonal. These were a result o f systematic errors in the 
discrete FT; however, these did not affect spectral assignment. The NOE-observable 
distances were limited to a maximum distance of about 5 A. This meant that only NOEs 
between protons within a nucleotide (intranucleotide NOE) or between neighbouring 
nucleotides in the same strand (intemucleotide NOE) were close enough to give rise to a 
through-space interaction. Each oligonucleotide strand, hence, gives rise to a cross-connectivity 
network between the ribose and base protons o f the constituent nucleotides.
In this case, because the sequence is self-complementary, these cross-connectivity 
networks are equivalent and so are superimposed on one another, simplifying the spectrum. The 
one-dimensional spectrum previously described crosses the spectrum diagonally from the top 
right (8 Oppm), to the bottom left (8 9ppm). On each side of this diagonal is a symmetrical 
arrangement o f cross-peaks resulting from dipole-dipole induced cross-relaxation. An NOE 
between two protons close in space results in a contoured peak, the x and y co-ordinates of 
which, when they are reverted back to the diagonal, indicate the chemical shifts o f the protons. 
The 2D NOESY assignment procedure has been documented well (Wuthrich, 1986; Wijmenga 
et a l , 1993; Hare et a l, 1983; Chary et a l , 1987; Patel et a l , 1986; Weiss et al., 1984; Feigon 
et al., 1982; 1983a,b; Scheek et a l, 1983; 1984; Chazin et a l, 1986). A combination of these 
protocols was used in assigning the NOESY spectrum.
3.2.1 Cvtosine H5 protons
To begin the sequential assignment of the protons within the DNA duplex, a suitable 
starting point had to be found. Inspection of the ID spectrum had already pinpointed some 
doublets in the region o f 8 5—»6ppm, which appeared to be candidates for being a CH5. So, 
with this information, plus the fact that this proton is very close in space to CH6 to which it is 
scalar coupled in the COSY spectrum, hence probably giving rise to a very intense cross-peak in 
the NOESY, the spectrum was analysed. Four large intense cross-peaks (Fig. 47) were 






Figure 47 The 400 MHz NOESY spectrum of the H6 /H8  to HI' and H5 region.
101
However, these peaks could not be distinguished as being due to C1, C7, C9 or C13 
without some other identification procedure. Each CH5 peak correlated directly into its own 
CHI' and CH6 protons at 4-3 and 2*4A, respectively (Wuthrich, 1986), along the y axis (D2). 
However, it is also close enough to the aromatic base proton on the 5 '-side (3-9A) to produce an 
NOE which it connects to along the x axis (Dl).
The peak at 5 5*78ppm had only one other peak it lined up with in the vertical 
direction, so this was assigned as the terminal because the sugar HI' can only correlate to its 
own aromatic base H6 proton. At the terminal C1, there is no 5'-base with which the C^Hl' can 
interact, so this cross-peak was assigned as C^Hb-frC^Hr and the CH5-»CH6 cross-peak 
directly in line with it was attributed to C!H5. The CH5 peak at 8 5-26ppm correlated with a 
lone peak on the D l axis, which was the furthest downfield peak in the aromatic region and was 
hence most likely to be that o f an adenine. Only C13H5 has an adenine as the flanking 5'- 
nucleotide base, so this CH5 cross-peak was attributed to C13H6—»C13H5 and the adenine H8 
correlated with it was assigned as A12H8 . Assigning the cross-peaks at 8 5-03 and 8 5*20ppm as 
C7H5 or C9H5 proved more difficult, because each was next to a 5'-guanine. Analysis of other 
areas o f the spectrum was therefore required to distinguish these protons.
3.2.2 Thvmine Cth protons
The methyl protons produce a set of very intense cross-peaks in a discrete region 
furthest upfield between 8 1 and 8 2ppm (Fig. 48). Looking down the D2 axis, there are three 
rows o f peaks corresponding to the T3, T10 and T11 methyls, each row consisting o f a pair of 
peaks. One peak is particularly intense and this is consistent with the short intranucleotide 
distance (2-9A) between TCH3->TH6 (Wuthrich, 1986). By analogy to the cytosine H5, the 
second peak is consistent with an NOE to the 5'-flanking, aromatic base proton. This NOE is 
slightly less intense, due to the greater distance between the protons (3-8A). In each pair, the 
TCH3—>TH6 peak was taken to be the most intense one. Beginning with the first row, the 
strong upfield intranucleotide methyl cross-peak (TCH3 8 l*42ppm) correlates into a peak much 
further downfield, in the region where one would expect to find an adenine or a guanine 
aromatic proton. Only one thymine has a guanine to its 5 '-side and this is T3, with the 
neighbouring guanine being G2, yielding an NOE from G2H8->T3CH3. The remaining thymine 
methyls have an associated NOE with the aromatic H6/H8 proton of their neighbouring 5 '-base, 
one o f which (8 l*63ppm) is directly in line from the D l axis (8 7-35ppm) with the methyl at 8 
l-50ppm.
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Figure 48 The 400MHz NOESY spectrum of the aromatics to sugar H2' 1, H2'2 and CH3 NOE region.
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Because T10 is on the 5 '-side of T11, there will be a cross-peak T10H6—»TllCH3 which lines up 
horizontally with the TnCH3-»TnH6 resonance and vertically with the T10CH3-»T10H6 
resonance, forming a small chain of connectivity. This resulted in TUCH3 being assigned a 
chemical shift o f 6 l-63ppm and T10CH3 assigned to 8 l-50ppm. C9 is situated on the 5'-side of 
T10 and the resulting cross-peak C9H6-»T10CH3, with which the T10CH3-»T10H6 peak is directly 
in line, also completes the assignments in the cytosine H5 region. C9H6 has a chemical shift of 
5 7*29ppm and this bisects the cytosine H5 cross-peak at 8 5-20ppm. Hence, the CH5 peak at 8 
5 03ppm is assigned C7H5 by default. Once the resonances o f C7H5 and C9H5 had been 
distinguished, their 5'-flanking guanines were assigned to the connected cross-peaks i.e. 
G6H8—»C7H5 where G6H8 resonates at 8 7*44ppm, and G8H8-»C9H5 where G8H8 resonates at 
8 7-754ppm.
From a complete analysis o f the cytosine H5 and thymine methyl resonances in this 
spectrum, not only have the chemical shifts of these protons in cytosine and thymine been 
deduced but also those o f the connected aromatic base protons. This includes intranucleotide 
NOEs to TH6 and CH6 , as well as intemucleotide NOEs to the neighbouring 5 -GH8 , AH8, 
TH6 or CH6 . Preliminary assignments of the aromatic base protons have therefore been made 
for:
5'-d(C1G2T3___G6C7G8C9T10TuA12C13_ )3'
Only three bases denoted by a blank space in the above sequence have no assignments o f any 
proton. Analysis o f these regions within the spectrum demonstrates the wealth of information 
that can be gained. In this case, a starting point for spectral assignment o f eleven out of fourteen 
nucleotides in the self complementary duplex has been attained in at least one dimension.
3.2.3 The aromatic—>H2 '1. H2'2 ribose proton region
After the regions containing the signals from cytosine H5 and thymine methyl protons, 
the aromadcs to H2'l, H2'2 region o f the spectrum contains the next most intense set o f cross- 
peaks. The intranucleotide distance from H8—>H2'2 is 2-1 A, whilst H6-»H2'2 is 2-2A in (3- 
DNA (Wuthrich, 1986). The H8—»H2'1 intranucleotide distance is 3-8A, whilst H6—»H2'1 is
4-0A. The very short distances to the H2'2 protons account for the high intensity of the cross­
peaks. These deoxyribose protons have chemical shifts between 8 1-8 and 8 3-0ppm. Figure 48 
shows that this is a crowded region of the spectrum with a high number o f NOE cross-peaks 
between the same proton types. The terminal nucleotide was a good point to start the 
assignment because the base aromatic proton (C!H6) chemical shift was already known. 
Moving parallel to the D2 axis, from 8 7*54ppm on D l, two cross-peaks were encountered in
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this region and these were assigned as C1H6->C1H2 '1 and 0 ^ 6 —>C1H2'2. At this point, it is 
not possible to distinguish which cross-peak is a result of the NOE with H2'l or H2'2. From 
each o f these peaks, moving perpendicular to the D2 axis, the next nucleotide in the sequence 
was sought. The G2H8 proton has NOE connectivities with the 5'-flanking deoxyribose H2'l 
and H2'2 protons. These intemucleotide distances are greater than the intranucleotide ones and 
thus these peaks are slightly less intense; however, they line up perfectly with C1H2T and 
C!H2'2. Next, in the same perpendicular direction from D2 intersecting the axis at 8 7-89ppm 
(the chemical shift o f G2H8), two other more intense peaks can be identified which are the 
intranucleotide G2H8—>G2H2' 1 and G2H8—»G2H2'2 NOE connectivities. From aligning the 
base-deoxyribose intemucleotide cross-peaks to find the chemical shift o f G2H8, the preliminary 
assignment from its connectivity with the thymine methyl has been verified, as all the cross­
peaks align yielding an equivalent chemical shift value. In the same manner as the assignment 
procedure progressed from the terminal nucleotide to the guanine sugar protons via the base, 
sequential assignment o f these protons advanced along the duplex DNA strand in the 5'->3' 
direction.
Looking at the assigned H6/H8—»H2'1/H2'2 region o f the NOESY spectrum, it is 
interesting to note that the purine and pyrimidine base type is reflected in the chemical shift. 
Adenine and guanine ribose protons are generally shifted further downfield than those of the 
pyrimidines, while cytosine and thymine H2'l and H2'2 have a greater separation in their 
chemical shifts than the purines. This is most likely to be a result o f the stronger ring current in 
the purines, leading to more effective deshielding o f the H2 'l and H2'2 protons and hence a 
downfield shift (Scheek et al., 1983). As for the greater chemical shift separation of these 
protons in pyrimidines, this is due to the C2 carbonyl bond anisotropy, whose deshielding effect 
is more apparent at H2'2 than H2'l, resulting in an increased downfield shift o f the H2'2 
proton.
3.2.4 The aromatic-»Hl' deoxvribose proton region
This region of the 2D NOESY spectrum (Fig. 47) is often assigned in conjunction 
with the aromatic—>H2' 1/H2 '2 section, either to verify assignments o f aromatic protons or to 
provide an alternative course to the connectivity pathway between nucleotides, when the cross­
peaks become too overlaid in one area. The aromatic->Hr protons are particularly well 
resolved in this spectrum, probably owing to the long mixing time o f 300ms where spin 
diffusion provides a substitute cross-relaxation pathway. This allows the build-up o f NOEs at 
increased distances, for example; H6—»H1' = 3-5A and H8->H1' = 3*6A (Wuthrich, 1986),
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which would normally be closer to the NOE distance limit, yielding weaker NOE cross-peaks in 
the spectrum which are more difficult to assign.
Examination o f the cytosine H5 region which overlaps with the HI' area has already 
given the chemical shift o f the terminal base proton from the CH6-»CH5 cross-peak. 
Examination o f the correlations from the remaining cytosine H5 protons also yielded the H8 
shift o f their 5 '-flanking bases. In the same manner, thymine produced base proton chemical 
shift information which was used in the H6/H8-»H2' 1/H2 '2 assignments, as it will be used in 
the H6/H8->H1' assignments. The more regions that are assigned, the easier it becomes to 
solve another, because the knowledge of chemical shifts in one dimension makes it a less 
difficult task to move sequentially from nucleotide to nucleotide. Beginning at the terminal 
C*H6 (Fig. 45), only one cross-peak (other than CH5) is visible in the vertical plane i.e. to 
C^Hl'. G2H8, the terminal 3 '-base, is close enough to have an NOE to the 5'-flanking sugars 
HI', as well as to its own HI'. Moving horizontally from C^Hb-K^Hl', G2H8—> 0^ 1' is 
reached, then G2H8-»G2H1' is arrived at proceeding vertically. The whole procedure is then 
repeated sequentially until all the HI' ribose protons have been accounted for. It is possible to 
start from any surely assigned proton in the strand, advancing sequentially forwards or 
backwards; however, the terminals in this case were a convenient starting location.
3.2.5 The H6/H8->H3' region
H3' protons have a chemical shift range o f 5 3-2 - 8 5-2ppm. This proton ‘walk’ from 
nucleotide to nucleotide along the DNA strand is assigned using the same approach as with the 
H6/H8-»H1' walk. The aromatic proton chemical shifts are the same through each spectral 
region, so only the deoxyribose H3' protons require identification, beginning at the terminal 
C^Hb-^HS' at 8 4-61ppm (Appendix III Fig. 104). The longer mixing time (300ms) is 
extremely important in the buildup of NOEs between H6/H8->H3', where the interproton 
distance is 4 6 A (Wiithrich, 1986), at the limit of NOE detection. The transfer of magnetization 
from, for example H6—»H3', often occurs via H2'2 because the H6/H8—»H2'2 and H2'2-»H3' 
distances are considerably smaller at 2 -2A; this is, therefore, an efficient spin diffusion pathway. 
The NOE cross-peaks are o f medium intensity which increases with the mixing time. NOESY 
spectra become more peak-rich and hence complex under the effects o f spin diffusion; however, 
NOEs between all protons need to be analysed in order to provide information on the 
conformation o f DNA. Using a longer mixing time than 250 or 300ms for a molecule o f this 
size would produce a problem when measuring the integrals of peaks because they would 
become artificially high, suggesting that the interproton distance is smaller than it actually is. 
At this mixing time, spin diffusion is unlikely to falsify resonance assignments, as cross
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relaxation is most effective around the deoxyribose within each nucleotide and less along the 
assignment pathways.
3.2.6 The H6/H8->H6/H8 region
This region of the spectrum (Appendix III Fig. 105) is typified by the aromatic peaks 
of the ID spectrum, passing through it on the diagonal. There is one small T2 ridge at around 8 
7*3ppm, which coincides with one o f the tallest peaks in the spectrum (apart from the methyl 
groups), where close inspection o f the diagonal at this site also reveals traces o f T2 ridges. 
These ridges run horizontally across the spectrum, have a negative sign and cause distortions in 
the baseline (Wuthrich, 1986). Little can be done to rectify T2 ridging resulting from errors in 
the FT and environmental conditions; fortunately, T2 ridging is minimal in this spectrum. 
Cross-peaks in this area are weaker than in other regions previously described, with interproton 
distances of up to 5 A, spin diffusion being unlikely to progress along this route. At this point, 
the chemical shift o f each base proton in the 5'-d(CGTAAGCGCTTACG)2 DNA duplex is 
already known, so it is possible to jump form one base proton to another along each oligomer o f  
DNA duplex. This results in an NOE cross-peak between C1H6->G2H8, G2H8->T3H6 , 
r t e - ^ A 4 H8 etc. In more complex spectra, this zone is a valuable tool for finding the path 
from one nucleotide to another.
Using this area o f the spectrum simultaneously with the aromatic to HI' region, the 
adenine H2 protons can be assigned. Neighbouring adenine nucleotides i. e. A4 and A5 have an 
NOE connectivity between their AH2 protons, which will yield a cross-peak similar to those 
described above. The interproton distance of adjacent adenines is 3-6A (Wuthrich, 1986), 
leading to a weak/medium intensity NOE at the coordinates A4/A5 8 7*40/6*89ppm. The 
adenine H2 protons also tend to leave a trail down the length of the spectrum, perpendicular to 
D l, making them easier to spot. Using this premise the third AH2 is at 6 7-31ppm, which can 
also join in the A4—»A5 base proton walk. This is because o f the position o f adenine H2 in the 
centre o f the minor groove which allows it to come into close contact, not only with protons 
within its own strand but also to produce interstrand NOE connectivities. A12 is the adjacent 
cross-strand nucleotide to A4 in the self-complementary duplex. An adenine H2 walk can, 
therefore, proceed via a ladder from A12H2->A4H2—>A5H2, cross-peak to cross-peak. Analysis 
of the aromatics to deoxyribose section o f the spectrum was required to verify which AH2 
resonance at the end of the short walk belonged to A12 and which to A5. A4H2 connected both 
protons (8 7-40ppm). Each adenine H2 proton can ‘see’ into its own deoxyribose HI', to the 
thymine HI' to which it is Watson-Crick based paired, and to the HI' proton o f the 3'- 
neighbour of this thymine. In normal base-stacked J3-DNA, the latter NOE connectivity is the
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weakest o f the three, due to the long distance. Examination of the spectrum resulted in the 
assignment o f A4H2 to 5 7-40ppm, A5H2 to 5 6-89ppm and A12H2 to 8 7-3 lppm.
3.2.7 The HI->H2'1/H2'2 region
Once the sugar HI', H2'l and H2'2 resonances have been assigned, it is an easy 
exercise to assign the NOE cross-peaks in the HI'—»H2'1/H2'2 region. Beginning with the 
C1H2'1 and C1H2'2 peaks, the C1H2'1/H2'2->H1' cross peaks are sought by moving from the 
C1H2'1/H2'2->C1H6 peaks parallel to D l until they both perfectly intersect a pair o f cross­
peaks in the H2'l/H2'2—»H1' region. Similarly, from C^Hb-HH', by ‘bouncing’ off the 
diagonal in a perpendicular manner, this C^Hl' resonance will intersect the pair o f newly found 
C'Hl '^ C 1H2'1/H2'2 cross-peaks. In this way, all the other peaks in this area o f the spectrum 
are assigned (Appendix III Fig. 106).
This is not merely an exercise in confirming that these proton chemical shifts have 
been correctly assigned by the presence o f the relevant cross-peak. More importantly, this 
region holds the key to which peak o f the pair corresponds to H2'l or H2'2. The 
intemucleotide distance between HI' and H2'2 in deoxyribose is much shorter than that of 
H1'->H2'1, because they are on the same face o f the sugar. This allows the assignment of the 
most intense cross-peak in each pair to the H2'2 proton. This DNA duplex followed the general 
trend that the H2'2 proton resonated further downfield than the H2'l proton, suggesting the 
H2'2 proton is more deshielded by purine and pyrimidine ring currents than H2'l. Figure 107 
(Appendix III) maps the H2'l to H2'2 connectivities.
3.2.8 The H6/H8->H4'and H6/H8-»H5'1/H5'2 region
This region of the 2D NOESY spectrum (Appendix III Fig. 104), which is in the range 
of 8 3*7 to 8 4 -5ppm, is extremely crowded owing to its occupation by three sets o f cross-peaks, 
between the deoxyribose sugar and base. Visualisation o f this area of the spectrum is, once 
again, a result o f the spin diffusion pathways around the sugar, because the 
H6/H8-»H4'/H5'1/H5'2 interproton distances are in excess o f 5A. Shorter distances
HI 7H3 '-»H47H5' 1/H5'2 often produce more well defined resonances (Appendix III Fig. 108). 
However, peak alignment in more than one area o f the spectrum is required to assign these 
proton chemical shifts accurately, owing to extensive peak overlay.
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Considering the H6/H8—»-H4' resonances first, with close correlation to the HI'—»H4' 
and H3'->H4' regions whose peaks were slightly more intense, a good starting location was 
searched for. In an analogous manner to H6/H8->H1' and H6/H8-»H3', a sequential walk 
should be able to be achieved from one end o f the DNA strand to the other. In practice, due to 
the long intemucleotide, sugar-»base distances, the peaks are weaker or sometimes missing, 
resulting in a fragmented walk. Once again, using 0 ^ 6 ,  C^Hl' and 0 ^ 3 '  as reference points, 
two peaks were noted perpendicular to D2 in these regions, one medium and one which was 
broader and more intense. The medium-sized peak at lower field was assigned as C!H4' 
because it aligned directly with a peak at G2H8, where this aromatic proton would be ‘seeing’ 
the sugar proton o f its 5'-neighbour, as previously described. Downfield of this G2 cross-peak 
is a more intense cross-peak which correlates into a weaker one at T3H6 . Assignment continued 
in this manner until a break in the walk emerged and, if  the H1'->H4' regions could not 
definitively produce an answer to the location o f the H4' for a specific nucleotide, another 
starting point was used. From here it was possible to advance forwards or backwards until all 
assignments were achieved.
The methylene H5'l and H5'2 protons are situated between the deoxyribose ring and 
the phosphate group of the backbone. Looking along the 05'-»C 5' bond in the direction of the 
mainchain, H5'l is pro-S and H5'2 is pro-R. These geminally coupled hydrogens are not 
identical and therefore do not resonate at the same frequency. Their typical coupling constant is 
between 0 and 25Hz (Williams & Fleming, 1987). Because this region is particularly crowded 
with cross-peaks, although the H4' protons have already been provisionally assigned, it is easy 
to confuse H4', H5'l and H5'2. For the nucleotides in which H5'l and H5'2 are more 
separated, it is possible to observe a COSY peak situated just off the diagonal, between 5 3*7-6 
4*5ppm. These peaks are quite intense, owing to the significant amount o f cross-relaxation that 
takes place between them and to the short inter proton distance o f 1-8A. These COSY-style 
peak coordinates can be aligned with the cross-peaks in the H6/H8 , HI', H3', H4'—»H5'1/H5'2 
regions, to assign them to the relevant nucleotide. The H5'l and H5'2 proton resonances were 
distinguished according to Remin and Shugar’s rule (1972); that stated the chemical shift of 
H5'l is greater than that o f H5'2. The data also generally agreed with their observation that the 
coupling constant J4_5'i<J4-5'2.
The presence of the 5'-terminal phosphate group, which can freely rotate, may explain 
why the C^HS'1 and C!H5'2 are shifted upfield in comparison to the other H5'l and H5'2. 
Anisotropic effects result from the circulation o f electrons around the P=0 axis when it is 
parallel to the applied field, leading to an induced magnetic moment which affects neighbouring 
nuclei. Anisotropy around the P=0 of the terminal phosphate, which rotates into more 
energetically favourable positions in solution, produces two deshielding cones extending in
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either direction from the centre o f this P=0 double bond. The methylene protons possibly lie 
perpendicular to the P=0 double bond axis, outside these conical areas, so they are shielded and 
experience a high-field shift. This effect at the terminal must override the usual deshielding 
effect resulting from the negative phosphate group, perhaps due to the terminals free movement 
in solution. The polarizing effect o f the negatively charged terminal phosphate shifts the H2'2 
resonance downfield and H2'l upfield (Chazin et al., 1986). However, each methylene proton 
of C1 is in a similar environment, as demonstrated by their close chemical shifts.
3.3 Sequential resonance assignments summary
These 400MHz 2D *H NMR data clearly show that the 5'- 
d(C1G2T3A4A5G6C7G8C9Tl0T11A12C13G14)2 duplex is (3-form DNA. All sequential cross 
connectivity walks are present between base aromatic and deoxyribose protons, both within the 
nucleotide (intranucleotide) and between nucleotides (intemucleotide) within the same strand, 
proceeding in a 5 '-to-3' direction (Fig. 50). Also contributing to the evidence for right-handed 
helicity is the observation that the cross-peaks relating to the methyls are all o f the same relative 
intensity, suggesting that interproton distances are nearly equal, with the base pairs stacked 
evenly. The pyrimidine H5 and CH3 protons exhibited strong NOEs to H6 or H8 o f the adjacent 
nucleotide in the 5 '-direction, as did the other deoxyribose protons in the strand, in accordance 
with a right handed helix. The quality o f 400MHz data is not good enough to determine the 
exact conformation o f the deoxyribose sugar geometry as endo or exo.
Feigon et al., (1983b), suggested that if  the H2'1-»H8/H6 cross-peak was more 
intense than the H2'2-*H8/H6 cross-peak, then the nucleotide is in anti conformation. The 
glycosidic torsion angle (%) is the angle between the sugar ring and the base (Fig. 49). Where 
(%) (Py) is defined by 04'-Cl'-Nl-N2 and x(Pu) is defined by 04'-Cl'-N9-C4 (Wijmenga et al., 
1993). Examination o f the spectrum can produce no more than an approximation that the 
H 2'l—>H6/H8 peaks o f C1, T3, A4, A5, C7, A12, C13 and G14 appear to be more intense than the 
H2'2-»H6/H8 cross-peaks, thus suggesting the nucleotide is in the anti conformation.
anti = 180° ± 90° (syn =0 ± 90°) 
Typical P-DNA value= -95°














Figure 50 Schematic representation of sequential intranucleotide and intemucleotide NOE connectivities 
(arrows), between neighbouring nucleotides in 3-fom DNA as seen in the NOESY spectrum.
I l l
Table 3 Chemical shifts (ppm) for all DNA protons in the DNA duplex and adozelesin-5'-(CGTAAGCGCTTACG) 
DNA adduct.
H8/H6 H2/H5/CH3 H r H i’ H2'2 H3’ H4' H5’l HS'2 Imino
Cl 7,543 7,512 -0,031 5,784 5,744 -0,04 5,661 5,577 -0,084 1,934 1,803 -0,131 2,334 2,202 -0,132 4,608 4,567 -0,041 3,986 3,934 -0,052 3,65 3,922 0.342 3,623 3,547 -0,076
G2 7,893 7,829 -0,064 5,874 5,716 -0,158 2,584 2,457 -0,127 2,692 2,508 -0,184 4,892 4,833 -0,059 4,264 3,972 -0.292 4,022 3,951 -0,071 3,937 3,791 -0,146 11,45
T3 7,137 7,33 0,193 1,419 1,555 0,136 5,485 5,135 -0.35 1,937 2,192 0.255 2,262 2,367 0,105 4,772 4,798 0,026 4,057 4,149 0,092 4,014 4,022 -0,008 3,924 3,975 -0,051 13.40
A4 8,145 8,223 0,078 7,401 7,809 0.408 5,769 6,067 0.298 2,642 2,574 -0,046 2,791 2,773 -0,018 4,959 4,908 -0,051 4,302 4,284 -0,018 4,116 4,101 -0,015 3,931 4,061 0,13
A5 7,947 7,648 -0.299 6,892 7,858 -0.966 5,833 5,697 -0,136 2,492 2,097 -0.395 2,707 2,484 0,133 4,936 4,449 -0.487 4,317 4,295 -0,022 4,133 3,664 -0.469 4,116 3,023 -1.093
G6 7,439 6,822 -0.557 5,561 4,641 -0.92 2,319 1,601 -0.718 2,482 1,681 -0.801 4,819 4,271 -0.548 4,079 4,013 -0,066 4,254 3,791 -0.463 4,125 3,612 -0.513
C7 7,085 6,737 -0.348 5,026 4,605 -0.422 5,543 5,114 -0.429 1,792 1,201 -0.591 2,249 1,718 -0.531 4,886 4,497 -0.389 4,026 4,099 0,073 4,252 3,796 -0.456 4,011 3,454 -0.557 12,6
G8 7,754 7,583 -0,171 5,789 5,832 0,043 2,561 2,411 -0.451 2,608 2,649 0,041 4,868 4,787 -0,081 4,27 4,084 -0,186 3,945 3,796 -0,149 3,87 3,447 -0.423
C9 7,29 7,194 -0,096 5,202 5,221 0,019 5,821 5,816 -0,005 1,992 1,825 -0,167 2,424 2,175 -0,249 4,637 4,337 -0.32 4,131 4,144 0,013 4,175 4,027 -0,148 4,084 3,808 -0.276 12,55
T10 7,349 7,157 -0,192 1,506 1,365 -0,141 5,909 5,748 -0,161 2,021 1,725 -0.296 2,451 2,265 -0,186 4,766 4,338 -0.428 4,074 2,075 -JJ 2 2 4,036 3,304 -0.732 3,982 2,789 -1.193 14.40
TU 7,314 7,062 -0.252 1,633 1,453 -0,18 5,608 5,095 -0.513 2,026 1,526 -0.51 2,356 1,623 -0.733 4,801 4,392 -0.409 4,043 2,582 -1.461 4,016 3,708 -0.308 3,991 3,555 -0.436 14.02
A12 8,823 8,375 -0.454 7,314 7,956 0.642 6,079 5,749 -0.33 2,624 2,542 -0,082 2,755 2,809 0,054 4,941 4,832 -0,109 4,36 4,271 -0,093 4,107 4,182 0,075 4,033 3,788 -0,245
C13 7,187 7,212 -0,025 5,257 5,538 0.281 5,539 5,241 -0.298 1,756 1,575 -0,181 2,18 2,015 -0,165 4,672 4,493 -0,179 4,059 4,023 -0,036 4,162 3,671 -0.491 4,012 3,353 -0.659 12.32
G14 7,791 7,797 -0,006 6,026 5,993 -0,033 2,257 2,226 -0,031 2,485 2,527 0,042 4,553 4,596 0,043 3,965 4,145 0,18 4,078 4,033 -0,045 3,954 3,759 -0,195
For each deoxynucleotide proton the value in italics, (column 3) represents the shift calculated from subtracting the duplex value (column 1) from the 
adduct value (column 2).
Chemical shift differences (italics) were underlined if  the difference was greater than 0.25ppm.
Table 4 contains both exchangeable and non-exchangeable proton chemical shifts for adozelesin in the resulting 
adozelesin-DNA adduct.
113 H6 CH3 H8A2 H8A H8B H1A H1B H3'l H4'l H6'l H7'l H3’2 H4'2 H52 H6'2 H7*2
7,99 6,98 2,546 4,495 5,063 5,155 3,689 3,812 7,283 7,805 8,243 7,629 7,651 7,932 7,497 7,373 7,736
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However, no estimation could be made for the remaining nucleotides because their peaks 
seemed to be o f nearly the same intensity, probably due to the effects of spin diffusion. This 
concludes the interpretation o f the 2D NOESY spectrum of duplex DNA 5'- 
d(C1G2T3A4A5G6C7G8C9T10T11A12C13G14)2. All non-exchangeable chemical shifts were entered 
into Table 3.
3.4 The Adozelesiii-5'-d(CGTAACGCGTTACGV> adduct
After the NMR analysis o f the DNA duplex had been completed, it was allowed to 
react with adozelesin. The resulting adduct was then subjected to further one- and two- 
dimensional NMR analysis.
3.4.1 The ID !H NMR spectrum
Once the DNA duplex which had reacted with adozelesin had been purified by various 
techniques, a ID NMR spectrum was taken to see if  the drug had bound covalently to the 
DNA. Each spectrum had exactly the same spectral width, allowing them to be superimposed 
over one another, so that the differences between the spectra and, hence, the result o f the drug 
reaction would be easily observed
Analysis o f the spectrum (Appendix IV Fig. 109) can, once again, commence by 
analysis o f the methyl, signals which are generally strong and clear. The DNA has three 
methyls which are attributable to thymines T3, T10 and T11, with chemical shifts ranging from 8 
1*4 to 8 l-65ppm. Adozelesin alone has only one methyl on its cyclopropapyrroloindole 
headunit at C7, with a shift slightly downfield at 8 2-07ppm (Walker et a l, 1997). After the 
first incubation o f the DNA with drug, these peaks decreased to about half the intensity and 
multiplied to at least six peaks in the 8 1-25 to 8 l-75ppm range. These represented the three 
methyls o f both the duplex and the covalently modified DNA. There is approximately a 50:50 
ratio o f each species. A large peak has also appeared at about 8 2*5ppm which is equal in 
intensity to the DNA methyls, so could be attributed to the covalently bound adozelesin. There 
does not appear to be a methyl singlet at 8 2-07ppm unless it is obscured within the sugar H2T, 
H2'2 protons, suggesting all drug that is present is part o f an adduct. The aromatic region 
probably most clearly exhibits the complexity of the spectrum, when two species are present in 
the same solution. Seventeen singlets correspond to the DNA duplex purine and pyrimidine 
H8/H6, plus adenine H2s. This number of resonances again symbolizes the DNA aromatic 
protons o f the drug-DNA adduct.
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Also in this region are the eleven aromatic protons from the three ring systems of adozelesin. In 
all, there are approximately 45 aromatic proton peaks in the space o f l-5ppm.
Further addition o f adozelesin was required to take this reaction to completion and 
yield a single species (Fig. 46). The off scale peak at 5 4-71ppm is due to the solvent HDO. 
Superimposing this spectrum onto Figure 45, showed that the three large methyl groups were 
not from DNA duplex but from the adduct, because the positions of the peaks showed 
movement upfield. A count of the number o f aromatic peaks and their shoulders yields about 
twenty-eight as expected. Because the ID JH NMR spectrum of the adozelesin-DNA adduct is 
so complex, the information gained is limited to this level. Two-dimensional experiments were 
required for a more detailed analysis.
3.4.2 The 2D *H NMR DOF-COSY experiment
The initial step in the 2D NMR proton assignment strategy was to solve the DQF- 
COSY spectrum. COSY peaks result from the coherent transfer o f magnetization (scalar 
coupling) between coupled spins. In analogy with the NOESY spectrum, there is a one­
dimensional spectrum which traverses the COSY spectrum along the diagonal but it only 
contains the proton resonances which are involved in through-bond couplings. The multiplet 
peaks off the diagonal indicate when spin ‘A’ is coupled to spin ‘X’ (Wuthrich, 1986). The 
phase-sensitive data resolve the multiplet structure into positive and negative signals, so each 
cross-peak is split into four components, two positive and two negative, separated by Jax- The 
AX spin-spin coupling therefore produces an ‘antiphase square array’ o f off-diagonal multiplet 
components. The 400MHz DQF-COSY data was not sufficiently well resolved to enable 
coupling constant measurements to be made. However, it does contain all the scalar coupling 
information necessary to yield some definitive starting points for use in the assignment of the 
2D NOESY and will affirm all assignments therein, setting them on solid ground. Only 
homonuclear spin systems were analysed in this 2D !H DQF-COSY spectrum (Appendix V Fig. 
110).
3.4.2.1 The CH5-CH6 region
Analogously to the beginning o f the assignment protocol for the 2D NOESY 
spectrum, the cytosine base H6 to H5, three-bond vicinal coupling, is also a good point at which 
to commence the assignment procedure in the DQF-COSY. This is because this set of 
resonances appears in a separate area of the spectrum, free from the confusion o f any other 
proton cross-peaks. Inspection of Appendix V Figure 111, shows that there are four large
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antiphase square arrays of cross-peaks propagated from cytosines AX spin system, at 8 5-75, 8 
5-54, 8 5*22 and 8 4-60ppm. An upfield shift o f at least 0-4ppm in comparison to the most 
shielded cytosine (C7), in the duplex NOESY spectrum is observed. It is not possible to assign 
the peaks to a particular cytosine but it is important to know their positions for reference in the 
NOESY spectrum of the adduct, because extensive peak overlay or drug induced peak shifting 
into other regions of the spectrum can make them difficult to identify.
Some other peaks o f much weaker intensity than the larger assigned ones are also 
detectable in this region. These are due to another species in solution, which accounts for 
approximately ten to fifteen per cent o f the population. These peaks are not attributable to 
unreacted DNA duplex because they do not have the same chemical shifts. Only the most 
intense peaks of this second species are visible in the DQF-COSY spectrum, which is more 
sensitive than the NOESY. The cross-peaks o f this second species are not only weak in 
intensity but are too few in number to make any attempt at assignments and, hence, give any 
conformational information on the binding o f adozelesin to DNA in this species. However, 
there are five hypotheses to what this adozelesin-5'-d(CGTAAGC)-5'-d(GCTTACG) adduct 
structure could be. One possibility is that only one adozelesin has reacted with the duplex 14- 
mer, instead o f two. Monoalkylation leads to loss of self-complementarity within the adduct, 
resulting in an area equivalent to unmodified duplex and the other end corresponding to drug- 
DNA adduct. The cytosine H5 chemical shifts o f the minor species (Appendix V Fig. 111) are 
approximately 8 4-55, 8 5-09, 8 5-74 and 8 5*87 ppm, which is not in concordance with the 
duplex values o f 8 5 02, 8 5-20, 8 5-26 and 8 5-78ppm. The cytosine H6 chemical shift 
coordinate o f the CH5-CH6 cross-peaks also shows degrees o f up and downfield shifting. This 
evidence implies that a monoalkylated adduct is not responsible for the minor species. A 
second possibility is that one or both of the modified adenine nucleotides in the DNA strand 
may have depurinated. This process forms the basis o f the Maxam-Gilbert sequencing 
technique (Stryer, 1988). The adozelesin modified adenine (A12) is removed from the DNA 
strand via ^-elimination. This involves cleavage o f the glycosidic bond generally on heating, 
leaving the sugar without a base i.e. apurinic (Hurley et al., 1984). Although this phenomenon 
can occur on standing over long periods o f time, this adduct was stored refrigerated in its freeze- 
dried form to discourage this outcome. It is interesting to note that these cross-peaks are more 
visible in the 600MHz than the 400MHz data. This maybe due to the number of months of 
sample storage between times o f data collection allowing additional depurination, or it could be 
their intensity corresponds to the increased sensitivity o f the experiment. However, the facts 
that the 400MHz DQF-COSY experiment was run when this sample was relatively fresh (~ 1 
week old) and that the same sample produced 600MHz data which were not markedly different 
even after five months suggest this sample is quite stable. Depurination, it seems, is not the 
most favourable explanation for the minor species exposed by the 400MHz data. However,
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depurination and monoalkylation could be responsible for the other weak peaks in this region, 
seen only in the 600MHz spectrum.
A more plausible reason for the appearance of the minor species is likely to be the 
alkylation on an alternative adenine. Seaman et al., (1996) described the bisalkylation of 5'- 
d(C1G2T3A4A5*T6T7A8*C9G10) self-complementary duplex by CPI-I, which has an analogous 
structure to adozelesin minus the benzofuran subunit (C). Bisadduct formation resulted from 
the ‘head’ (CPI) to ‘tail’ (I) binding o f CPI-I at A5 and A8. Alkylation first took place at A8, 
causing a distortion in the same strand, five base-pairs upstream in the 5'-direction. 
Modification of the second adenine therefore took place at the position o f least distortion. 
Because this DNA duplex is longer, to accommodate the benzofuran (C) subunit of adozelesin, 
a distortion of this kind would now be situated around C7. Adozelesin would be free to bind at 
both A12 and A5. A12 maybe more available for reaction than A5 to form the major product of 
an adozelesin ‘tail to tail’ bis-adduct. Not only is A12 furthest away from any possible distortion 
in the GC region but alkylation is taking place at the preferred 5 T 10TnA12*C13 consensus 
sequence (Weiland and Dooley, 1991; Yoon and Lee, 1998). The minor species maybe related 
to alkylation o f A5, yielding an analogous ‘head to tail’ bis-adduct to that characterized by 
Seaman et al., (1996). 5'-dfT3A4A5*) still constitutes a consensus sequence (Weiland and 
Dooley, 1991), although any distortion around C7 could discourage binding hence, the 
production o f only a minor species.
Alkylation o f the central adenine A4 would produce a monoadduct. This is because 
the combined length o f the adozelesin subunits A, B and C requires that it span five bases, 
which would protrude into the second binding site, obscuring a second alkylation. A 
monoadduct is a possible candidate for the minor species, although alkylation of A4 could mean 
that the benzofuran ring o f adozelesin protrudes out o f the end o f the duplex, which is not 
energetically favourable. The consensus sequence described by Weiland and Dooley, (1991), 
i.e. 5 '-d(A/T)(G/C)(A/T)A* is similar to 5'-d(C1G2T3A4*) but not identical, suggesting it would 
not bind with such a high affinity. It is not inconceivable that adozelesin could bind non- 
covalently within the minor groove to some other site. Gunz and Naegeli (1996) demonstrated 
that (+)CC-1065 could do this with such affinity that it could not be removed by dialysis or 
precipitation techniques. However, in the presence of high affinity alkylation sites containing 
5'-d(TTA), it is unlikely that the noncovalent binding mode would be able to compete. In the 
‘tail to tail’ bis-adduct (adozelesin modification o f A12*), there would be no space in the 14-mer 
for another adozelesin molecule to non-specifically bind, due to these drugs collectively 
spanning 10 out of 14 bases.
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3.4.2.2 The TH6-TCH, region
None of the expected TH 6 -TCH3 peaks corresponding to thymine A3X spin system 
were present in the 2D DQF-COSY spectrum. These would have been a useful tool for 
separating the TCH3-TH6  cross-peaks from those of the methyl to aromatic proton o f the 5 '- 
flanking nucleotide, in the NOESY spectrum, which can be of similar intensity. Their non­
existence could be related to the insensitivity of the 400MHz data to a four-bond (V) coupling, 
where there is quite a long distance between the protons. If the peaks were of very low intensity 
they would be obscured by the noise.
3.4.2.3 The deoxyribose sugar resonances
The cross-peaks resulting from spin-spin couplings from around the deoxyribose ring, 
exist in abundance throughout the different regions o f the DQF-COSY spectrum (Appendix V 
Fig. 112, 113, 114). Geminal two bond couplings (2J) of H2T—>H2'2 and, especially, 
H 5'l—»H5'2, produce cross-peaks which are extremely close to the diagonal or possibly even 
obscured by it, if  the chemical shift difference between the protons is very small. There are also 
a significant number of three bond couplings (V) around the ring; H1'-»H2'1, H1'->H2'2, 
H2T—»H3', H2'2->H3' and H3'-»H4'. However, the DQF-COSY spectrum can only be 
properly utilized when used in conjunction with the NOESY spectrum, which is lined up 
alongside it. The cross-peaks close up in the DQF-COSY cannot be assigned to a specific 
nucleotide, because there are no sequential connectivities between neighbouring nucleotides. 
However, by aligning this spectrum with the 2D NOESY spectrum, where a starting point such 
as those identified by cytosine CH5-CH6 COSY couplings has already been established, it is 
possible to create a cycle o f NOESY-COSY connectivities. Sequential connectivity ‘walks’ 
between base protons and protons o f the 5'-flanking sugar e.g. H2' 1/H2 '2(n)—»H8/H6(n+1) in the 
NOESY can have their sugar H2'l/H2'2 assignments checked, by moving perpendicularly to 
the D2 axis at the chemical shift o f each preliminarily assigned H2'l and H2'2, straight across 
the COSY spectrum to the diagonal. If there is a cross-peak generated from these co-ordinates, 
then the chemical shifts can be unequivocally assigned. In the same manner, the HI', H3' and 
H4' protons were assigned. Once the H2'l and H2'2 geminal coupling for a sugar was located, 
it was a simple task to find the vicinal HI' sugar resonance to which it was coupled and verify it 
with the NOESY data. From the chemical shift o f HI' the spin-spin coupling to H3' and from 
here to H4' was solved, in agreement with the NOESY spectrum.
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3.4.2.4 The arom atic region
There are no DNA protons that give rise to COSY peaks in Dl = 7-0-»8*5/D2 = 
7-0—>8-5 region. However, four strong peaks were detected (Appendix V Fig. 115) and 
attributed to the aromatic spin-spin couplings within the drug (Fig. 51).
Adenine H
13'2
\ 7  ' l t>
Adozelesin
Figure 51 Spin-Spin couplings and atom labels within adozelesin.
The H6  '1-»H7'1 vicinal coupling of the indole was assigned to the peak which did not align 
with any others because it is an isolated spin system, H6 'l  8  8-24ppm and H 7'l 8  7-629ppm. 
The three remaining peaks are part o f a connectivity network, which represented the vicinal 
couplings around the benzofuran tail. H5'1-»H6'2 was assigned to the central peak in the 
sequence. It was difficult to assign the chemical shift to either proton, without knowing which 
terminal cross-peak corresponded to H4'2 or H7'2. In adozelesin alone, the chemical shift o f  
H4'2 ( 8  7-85ppm) is further downfield than H7'2 ( 8  7-67ppm) (Walker et a l ,  1997). However, 
when the adozelesin has covalently bound to DNA, this new environment may not induce the 
same trends in chemical shift. Therefore, using the NOESY spectrum, the NOE cross-peak 
H3'2->H4'2 was sought and this decisively gave the assignments; H3'2 8  7-65 and H4'2 8  
7-93ppm, because only H4'2 was close enough to have an NOE connectivity to H3'2. This 
assignment led to the deduction o f the others through their sequential COSY connectivities, i. e. 
H5'2 8  7-49, H6'2 8  7-37 and H7'2 8  7-73ppm.
3.4.3 The 2D *H NMR NOESY spectrum
Assignment of the 2D 400MHz *H NMR NOESY spectrum (Appendix VI Fig. 116) 
began with spectrum produced at 250ms mixing time, because this yielded the clearest, most 
well-resolved data. The protocol for assigning the proton ‘walks’ within the DNA o f the
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adozelesin-5 '-d(CGTAAGCGCTTACG)2 adduct is exactly the same as that used for assigning 
the DNA duplex alone. The complexity of the spectrum, however, requires that the utmost care 
be taken when assigning peaks, to ensure that drug-drug or DNA-drug NOE conectivities are 
not incorporated into sequential walks.
3.4.3.1 The cvtosine H5 region
The DQF-COSY spectrum has already identified four cytosine CH6-CH5 spin-spin 
couplings, ranging from 5 4-60 to 5 5’74ppm. The NOESY spectrum (Fig. 52) was then used to 
distinguish between the resonances, one of which had shifted considerably upfield into the H3' 
region. C13 is the only cytosine nucleotide adjacent to an adenine, which is typically found to 
resonate further downfield than C, T or G, as already explained. The ring system of the base 
A12 is covalently modified by the cyclopropapyrroloindole headunit of adozelesin. Therefore, 
the base proton A12H8 will be in close spatial proximity to the aromatic rings o f the CPI subunit 
of adozelesin and, when A12H8 is positioned perpendicularly to the CPI rings, it will feel the 
effects o f the shielding. All of the adenine protons would be expected to participate in some 
upfield shifting due to this effect, although the extent o f it would much depend on how close 
they are to the CPI aromatic rings. However, taking into consideration this effect, adenine H8s 
chemical shift was still expected to be downfield of the other bases. A CH5 peak at 8 5-54ppm 
correlated directly into a cross-peak whose base proton shift was 8 8-375ppm, consistent with 
being an adenine. This was given the preliminary assignment of C13 and the base proton to A12. 
The large cross-peak at 8 5*74ppm had two other peaks aligned with it vertical to D l, one of 
which was slightly more intense than the other HI'—>H6/H8 or H6/H8—>H1' peaks in the 
spectrum, which is consistent with being a terminal. This peak only had an NOE connectivity to 
one other peak in the direction o f D2, so this resulted in the assignment of C*Hr, C!H5 and 
C!H6 . The other resonance along the C]H6 line was thought to correspond to that of a drug 
peak, because there were a horizontal line of points traversing the spectrum here. As before, C7 
and C9 could not be distinguished in this region.
3.4.3.2 The thvmine methyl region
Although some Ti ridging is apparent in this region (Fig. 53), the strong NOE 
connectivities o f the methyls are clearly visible. T3 was assigned as the methyl which was only 
connected to its 5 '-flanking base G2, where T3^  was assigned upfield to G2H8 : this also agreed 
with the sequential assignment of G2H8 relative to C^Hl'. Meanwhile, moving in reverse order, 
the intense NOE at 8 l -43ppm correlated directly with its 5 '-neighbouring H6 , which is in 
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Figure 52 The H6/H8-*H17H5 region at the two-dimensional 400MHz NOESY spectrum of the 
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Figure 53 The H6/H8-»H2'1/H2'2/CH3 region of the two-dimensional 400MHz NOESY spectrum, of 
the 5'd(C1G2 T3 A4 A5G6 C7G8 C9 T,0 T 1 1A,2 ,C 3 G1Vadozelesin adduct
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the 5'-adjoining base o f this second thymine and its methyl, producing a shoulder on the 
methyl-H6 peak. The former methyl was assigned as TnCH3 and the latter as T10CH3. The 
realization o f the C9H6 chemical shift (5-22ppm) from T10CH3 led to the automatic assignment 
of G8H5 and G8H8 . C7H5 was assigned by default but G6H8 could not be assigned from here as 
the peaks including C7H5 were relatively weak. Possibly they are too close in chemical shift to 
the D20  reference point and to the point o f the strong water suppression, yielding a slightly 
negative baseline dip, pulling adjacent peaks into it.
At this point o f the NOESY spectral analysis, preliminary base proton assignments 
have been achieved for 5'-d(C1G2T3—C7G8C9T10TnA12C13—)23 \ Blank spaces represent the 
nucleotides which have not been located. Even though adozelesin has now bound to the DNA, 
one set of NOE connectivities only have been obtained corresponding to one strand of DNA, as 
was the case with the DNA duplex. To retain self-complementarity an adozelesin must be 
bound to A12 of each strand, so that each end of the DNA adduct is identical. This yields a 
drug:DNA binding ratio o f 2:1 for this complex.
3.4.3.3 The H2'1/H2'2->H6/H8 region
The H2'l and H2'2 to C!H6 strong terminal NOEs are easily pinpointed in the 
NOESY spectrum (Fig. 53), providing a good starting location for the sequential walk between 
deoxyribose protons and bases, in the 5'->3' direction. These intense intranucleotide 
connectivities CIH2'1/H2'2->C1H6 display correlations into their 3 '-flanking base G2H8 in the 
horizontal direction towards D2. This intemucleotide connectivity is much weaker, due to the 
longer distance between protons o f adjacent nucleotides. The pattern o f two strong and two 
weak NOEs for each nucleotide only continues as far as A5, where unexpectedly all peaks are of 
equally very strong intensity. Cross-peaks corresponding to A5H2'1/A5H2 2->G6H8 are weaker 
than the intranucleotide NOEs of A5, as anticipated. However, the G6H8-Kj6H2'1/H2'2 NOEs 
are exceptionally weak, the cross-peaks being less than a third o f the size of the intemucleotide 
ones of G6 to A5. The chemical shift of G6H8 is also positioned particularly far upfield for a 
guanine base at 5 6-82ppm, when normally it is somewhere downfield o f 8 7-3ppm. Through 
space connectivities related to C7 are also weak, although its intranucleotide NOEs are its most 
intense peaks, with G6H2'1/H2'2-»C7H6 producing slightly more intense peaks than 
G6H2'1/H2'2-*G6H8. The reversal of inter- and intra-nucleotide peak intensities related to 
G6H8 seems to indicate an inversion o f interproton distances, with G6H8 being closer to its 5 '- 
flanking nucleotides (A5) sugar protons than its own. This may indicate that more than a flip in 
sugar conformation i.e. from 2'C endo to 3'endo ((3 to A-DNA) is taking place. These results 
seem to be more consistent with a distortion o f die nucleotide in the p-helix, because the base-
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sugar ‘walk’ is still present. NOEs proceeding from G8 to C9 show a steady increase in peak 
intensities, with the return of the normal P-form pattern of weaker intranucleotide and stronger 
intemucleotide connectivities, proceeding sequentially along the DNA strand.
3.4.3.4 The Hr~»H6/H8 region
Sequential assignment of the deoxyribose HI' protons (Fig. 52) was carried out as 
previously described for the duplex DNA. The C!H1'—>ClH6 resonance at co-ordinates 8 5*58 
and 8 7-51ppm, respectively, was the starting point. It is interesting to note, that by analogy to 
the description of exceedingly weak NOEs corresponding to G6H8-*H2'1/H2'2, the peaks in 
the HI' ‘walk’ beginning with A5H8->A5H1' through to G8H8—>G8H1' are also exceptionally 
weak, suggesting some perturbation o f the p-helix on adozelesin binding. The sequential ‘walk’ 
then continues uninterrupted through to GI4H8->G14H1'.
3.4.3.5 The H1-»H2 1/H2 '2 region
Inspection of this zone of the spectrum (Appendix VI Fig. 117, 118) verified that each 
assignment was correct when the deoxyribose HI', H2' 1 and H2'2 chemical shifts were mapped 
together, and the resulting intersection was at the centre o f a cross-peak. The most intense NOE 
of each H1'-»H2'1, H I'—»H2'2 pair was assigned to H2'2, due to the much shorter distance 
HI'—>H2'2. All H2'2 resonances were generally downfield o f H2'l, because of the deshielding 
ring currents effects o f the purines and pyrimidines. However, A4, A12 and G14 were an 
exception to this trend, with their H2'2 proton chemical shift upfield o f H2'l. The swapping of 
H2'l and H2'2 resonance positions is easily explained for G14, because this is a common 
occurrence for 3 '-terminal nucleotides which do not have a negatively charged 3'-phosphate. 
This phosphate group normally has a polarizing effect on H2'l and H2'2, sending the former 
upfield and the latter downfield. A4H2'2 and A12H2'2, however, must be experiencing some 
shielding effect by the adozelesin, resulting in the upfield shift o f H2'l.
Referring back to the H6/H8—»H2'1/H2'2 section o f the spectrum after distinguishing 
between H2'l and H2'2, an analysis was made o f whether the intranucleotide cross-peak 
H6/H8—»H2'1 was more or less intense than that to H2'2. In eight out of fourteen nucleotides 
the H2'1-»H6/H8 did appear to be more intense, leading to the crude assumption that their 
glycosidic torsion angles were in the anti conformation (Feigon et a l , 1983b), typical o f P-form 
DNA. No measurements were able to be made as the data was not of good enough quality. Of
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the remaining nucleotides, G2, C9, T1] and C13, it was impossible to tell which was more intense, 
partly due to the presence o f the ti ridging. C7 and A5 however, had H2'2—>H6/H8 NOE 
connectivities which were more intense. By default, this could be taken as an indication o f syn 
conformation of the glycosidic torsion angle. This is generally observed in Z-DNA but the 
evidence so far strongly indicates P-form DNA, as all sequential walks are present along the 
DNA strand, even if  the intensities of some nucleotides are much weaker than expected, 
implying some helical perturbation. It is more likely that the distance between the 
H2'1/H2'2->H6/H8 is a product of both a change in the glycosidic torsion angle and the sugar 
conformation i.e. C3'-endo (A-DNA) or C2'-endo (P-DNA). Accurate measurement of 
distances and J  values from the sugar ring protons to the base aromatic protons is required to 
determine sugar conformation. C2'-endo geometry is denoted by strong NOE cross peaks 
HI '-»H2'1, HI ->H2'2 and H2T->H3', whereas H2'2 may or may not display its NOE to H3' 
because it is so weak (Kintanar et al., 1987; Wijmenga et a l , 1993). An accurate analysis of the 
H3'-»H2'1/H2'2 region was not possible with 400MHz data, because the data was partly 
obscured by Ti ridging and the effects of base-line roll.
3.43.6 The H3'. H4\ HS'l. H5'2 protons
The H3'->H6/H8 (Appendix VI Fig. 119) and fragments o f the H4'—»H6/H8 were 
assigned using previously described procedures. Due to the H4' walk being quite weak in the 
H6/H8 region, assignments were made mainly from H1'-»H4' and H3'-»H4', where the 
interproton distances were shorter and the effects o f spin diffusion were more pronounced. 
Both H5'l and H5'2 resonances were assigned via their intranucleotide connectivities to H3'and 
confirmed by those to H4' (Appendix VI Fig. 120, 121). H5'2 was assigned upfield of H5T in 
accordance with Remin and Shugar’s (1972) rule.
3.43.7 The Adenine H2 protons
A preliminary identification o f the whereabouts of these proton signals was obtained 
by examination o f the ID spectrum (Fig. 46), where three tall, sharp peaks were noted two 
thirds of the way across the aromatic region. Correlation with the 2D NOESY (Appendix VI), 
demonstrated AH2 type peak smears traversing the spectrum at these points. Assigning each 
AH2 to A4, A5 and A12 was achieved by observation of their NOEs to deoxyribose HI' protons.
This concluded the assignment of the non-exchangeable sugar and base protons of 
DNA. All proton chemical shifts are given in Table 3. The chemical shift difference was
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calculated for each deoxyribonucleotide by subtracting the duplex value from the adduct value. 
The change in chemical shift was then represented graphically (Fig. 54) to illustrate which 
protons experienced the greatest shifts on the addition of adozelesin to DNA. The sequential 
connectivity network, with its distinct pattern o f peak intensities along the DNA strand, 




Figure 54 Graphical representation of the chemical shift changes that occur for each proton in DNA, as a 
result of the covalent binding of adozelesin, to form an adduct.
3.4.4 *H NMR assignments of the adozelesin non-exchangable protons
Adozelesin was divided into its three constituent subunits; a cyclopropapyrroloindole 
(CPI) headunit (A), an indole (B) and a benzofuran tail (C), to facilitate assignment of the non­
exchangeable protons, The aromatic protons o f the benzofuran sub-unit (C), have already been 
assigned in the DQF-COSY spectrum, due to the large ortho couplings around the aromatic ring 
systems. The through-space connectivities between these protons H4'2, H5'2, H6'2 and H7'2 
can also be seen in the NOESY, with the additional NOE between H3'2 and H4'2 (Appendix V 
Fig. 115).
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The indole subunit of adozelesin exhibits a three spin system (Walker et al., 1997) 
where H7'l and H6 'l are strongly ortho coupled to each other, as identified previously in the 
DQF-COSY. The weaker coupling to H4'l was only identifiable as an NOE, and similarly 
fromH4'l to H3'l.
Within the CPI subunit which is covalently bound to A12 via N3, a series of cross­
peaks occur in the NOESY data (Appendix VI Fig. 123) between H8A, H8B, H8A2, HI A and 
H1B. It is immediately obvious from analysis of these protons that, in order to bind to the 
adenine, the cyclopropyl ring system has opened. The cyclopropyl H have shifted downfield 
from H8A 8 l-47ppm and H8B 8 2 02ppm (Walker et a l , 1997) to H8A 8 5-06ppm and H8B 8
5-15ppm, into the region o f the NOESY occupied by methylene protons (Scahill et al., 1990). 
The methine proton H8A2 was easily assigned, as the multiplet at 8 4*49ppm, resulting from the 
surrounding ortho coupled protons. The HI A and H1B doublets, with chemical shifts o f 8
3-69ppm and 8 3*81ppm respectively, were both responsible for NOE cross-peaks to the nearby 
H3'l on the indole subunit. The methylene proton HI A is nearer to H3'l and was, hence, 
assigned upfield to H1B, relative to cross-peak size. The H8A and H8B methylene proton 
doublets (at 8 5-06 and 8 5*15 ppm respectively) gave NOEs with greater intensity to A12H2, 
than HI A and H1B which were much weaker. H8B was assigned downfield of H8A because 
the cross-peak to H6 was o f  greater intensity and, hence, nearer to this aromatic proton than 
H8A. Some drug-drug proton NOEs were also noted between H8A/H8B—>H6 , H3 and CH3 
The aromatic H6  proton was identified due to its particularly intense cross-peak with the 
adjacent CH3, in the H2'l/H2'2 region of the spectrum. The last unidentified aromatic signal 
was assigned as H3 based on NOE cross-connectivities to adenine (A12)H2. The complete 
proton assignments for adozelesin are given in Table 4.
3.4.S Assignment of NOE connectivities between DNA and adozelesin
Once complete proton assignments o f DNA and adozelesin had been achieved, the 
two-dimensional NOESY spectrum was scrutinized for NOE connectivities between 
5'd(C1G2T3A4A5G6C7G8C9T10TIIAl2C13Gl4)3' and the CPI(A), indole (B) and benzofuran (C) 
subunits o f adozelesin. This involved searching methodically for all sugar resonances which 
intersected those o f adozelesin. In all, 35 DNA/adozelesin connectivities were found, 
confirming the location of the three adozelesin subunits within the minor groove. These 
connectivities are illustrated in Figure 55. Additionally there were 24 intradrug NOEs from 
proton connectivities within adozelesin, plus 285 NOEs relating to DNA base-base, base- 
deoxyribose and deoxyribose-deoxyribose proton connectivities. This led to a grand total of
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344 NOE cross-peaks for distance-range constraint generation, followed by their application to 
the DNA-adozelesin adduct molecular model.
3.4.6 600MHz DOF-COSY. NOESY. TOCSY and ROESY data
After assignment o f the 400MHz Jeol 2D NOESY and DQF-COSY data had been 
completed and a refined molecular model of the adozelesin-DNA adduct had been attained, 
600MHz Varian 2D lH DQF-COSY, NOESY, TOCSY and ROESY data were made available, 
courtesy o f Dr. George Gray at Varian, Palo Alto. Comparison o f proton assignments made 
from the 400MHz data, where peaks were often somewhat weak, showed a perfect correlation 
with the clear, well-resolved 600MHz spectra, placing all NOE connectivities and proton 
assignments on solid ground.
The 600MHz DQF-COSY and NOESY spectra are displayed in Appendix VII and 
VIII respectively. The enhanced sensitivity o f the 600MHz NMR experiment allowed 
identification o f another 33 adozelesin-DNA cross-peaks. Some o f these NOE connectivities 
were also present in the 400MHz data. However, they were not initially included in distance 
range constraint generation because these cross-peaks were so weak that they could not be 
distinguished with confidence from interference by noise. Only computer printouts were 
available for these 600MHz data sets, so no quantitative information on these NOE 
connectivities was extracted. These extra NOE adozelesin-DNA interproton connectivities 
verified the drug orientation and positioning of each subunit, relative to each nucleotide in the 
DNA strand. The 35 distance range restraints from the 400MHz data pushed and pulled 
adozelesin into position within the minor groove during molecular mechanics and dynamics 
calculations. Measurements of the 33 extra NOE interproton distances on the computer 
generated model, produced distances of generally around 5 A in concordance with weak peaks in 
the 400MHz data being at the distance limits o f NOE detection.
TOCSY data (Appendix IX) provided information on multi-step scalar couplings 
around for example, the aromatic protons o f the benzofuran ring o f adozelesin, or from proton 
to proton around the sugar ring H1'-»H2'1/H2'2—>H3'. ROESY data (Appendix X) only 
displayed the most intense cross peaks, with through space NOEs resulting from spin-diffusion 
being much weaker. ROESY data can provide information on conformational exchange within 
the DNA helix. Seaman and Hurley (1996) examined the covalent modification of 5'- 
d(TAATTA)2 by the interstrand cross-linker bizelesin.
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Figure 55 NOE connectivities between DNA and adozelesin.
The ROESY spectrum exhibited strong and weak negative cross-peaks which corresponded to 
molecular movement between a major and minor isomer. The major isomer contained a central 
AT step in which the adenines were in syn-orientation, leading to unusual Hoogstein instead of 
Watson-Crick base pairing. In the minor isomer, this same AT step was in an open 
conformation, with no hydrogen-bonding between base pairs. The 600MHz ROESY data 
corresponding to the 5 -d(CGTAAGCGCTTA*CG)2-adozelesin adduct did not reveal any 
evidence for molecular movement of this nature. This indicated all base-pairs were Watson- 
Crick style, in concordance with J3-helical DNA.
3.4.7 DNA and Adozelesin Exchangable Proton Assignments
Two-dimensional NOE (H20 ) experiments were conducted (also courtesy of Dr. 
George Gray, at Varian, Palo Alto) and the NH and OH signals were assigned based on their 
connectivity networks into the aromatic region and imino protons of neighbouring bases. All 
exchangable signals were identified within the duplex adduct, except for those associated with 
the terminal bases. The imino signal of the covalently modified adenine (A12) was significantly 
shifted upfield, as previously reported for (+)CC-1065 (Lin and Hurley, 1990), and bizelesin 
(Seaman and Hurley, 1993; Thompson and Hurley, 1995; Thompson et al., 1995), partially 
confirming the site o f attachment. The CPI sub-unit (A) and indole sub-unit (B) NH amine 
protons were identified by connectivities into the neighbouring aromatic protons. The CPI 
phenol proton was identified on the basis o f connectivity into the neighbouring aromatic H3. 
The chemical shift o f the phenolic proton at 8 13*52ppm is consistent with the 8 13*62ppm 
observed within the previously reported (+)CC-1065 adduct (Lin et al., 1991) and 8 13*05 and 8 
13*80ppm within the A-tract bizelesin adduct (Thompson and Hurley, 1995). However, it 
contrasts with 8 11*06 and 8 11-lOppm observed within the bizelesin 7-base-pair cross-linked 
adduct (Thompson et a l, 1995). Studies using !H NMR coupled with 170-labelled water and 
phosphates in the (+)CC-1065 adduct confirmed that the phenolic proton in the (+)CC-1065 
adduct was hydrogen-bonded (via an ordered water molecule) to the phosphate backbone (Lin 
et al, 1991). Based on the similarity of chemical shifts observed, it would appear that a similar 
hydrogen bond is formed within this adduct. Signals for the amide NH proton between the 
indole (B) and benzofuran unit (C) could not be identified in either one or two dimensional *H- 
NMR data. A summary o f the exchangable DNA proton assignments for the DNA-adozelesin 
adduct are given in Tables 3 and 4.
129
3.5 Production of the refined adozelesin-DNA adduct structure by restrained
molecular mechanics and dynamics calculations
Following complete assignment o f all non-exchangable protons within the adozelesin- 
DNA adduct, distance-range constraints were generated from the 400 MHz NOESY spectrum. 
These were applied to a computer molecular model using molecular mechanics and dynamics 
calculations. The result was a visual representation o f the adozelesin-DNA adduct, as defined 
by the data extracted from the NOESY spectrum.
3.5.1 The importance of water in producing a refined adduct structure which accurately 
represents that found in a biological system.
Nucleic acids in vivo first in the aqueous, buffered environment contained within the 
nucleus of the cell. Their macromolecular tertiary structure is maintained by the attractive and 
repulsive forces between charged atoms, o f which they consist. |3-Helical structure of canonical 
DNA is sustained by an equilibrium between (Westhof et al., 1995):
1) Electrostatic forces originating from the negatively charged phosphates.
2) Hydrophobic interactions between the aromatic rings of the bases, promote orderly base- 
pair stacking.
3) Energy of the sugar-phosphate backbone conformation.
Noncovalent bonds within the helix e.g. electrostatic, hydrogen and van der Waals forces, are 
profoundly influenced by the presence of water in biological systems. Water molecules are 
highly polar with a capacity for hydrogen-bonding, making it a perfect solvent for solvating 
charged oligonucleotides. Due to the high degree of organisation within water itself and around 
ions, water can reduce the strength o f electrostatic interactions by a factor o f 80 (dielectric 
constant of water), relative to those experienced by DNA alone in a vacuum (Stryer, 1988). 
Therefore, in an attempt to imitate accurately the structure and movement o f the adozelesin- 
DNA adduct within a biological system, it is mandatory that water be included as an integral 
part o f the structure. The sample itself underwent NMR spectroscopic analysis in aqueous 
buffered conditions. Na+ counterions were directly co-ordinated to the phosphate of the 
backbone, to portray the buffer stabilizing DNA. These were partially hydrated by Molecular 
Silverware systematic packing o f waters around the adduct structure with associated sodiums.
Water contributes to the stability of the three-dimensional conformation o f DNA 
(Westhof et al. , 1995). The phosphates constituting the sugar-phosphate backbone are
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orientated to maximize favourable interactions with the solvent. Water screens the anionic 
charge o f the phosphate oxygens. The esterified oxygens 03 ' and 05' of the backbone are 
hydrated to a lesser extent. All hydrophilic polar atoms, e.g. deoxyribose ring oxygen, are 
orientated to hydrogen-bond with water. Hydrophobic bonding between aromatic rings and 
hydrogen-bonds constituting Watson-Crick base pairing-yield a water-free hydrophobic core. 
Here, the hydrogen-bonding between polar atoms is at maximum strength, holding the two 
oligonucleotide strands together in a {3-helix. The solvent structure is influenced by polar atoms 
for example, DNA phosphate oxygens can result in cones of hydration, water columns, bridges, 
filaments and spines of hydration (Westhof et al., 1995).
There are two methods of simulating the solvent. Implicit treatment o f the solvent, 
describes water as a macroscopic entity, using a distance-dependent dielectric constant (£ ) to 
reflect electrostatic interactions. Although the calculation is much shorter and simpler, implicit 
treatment of the solvent does not truly represent the biological system (Westhof et al., 1995). 
Therefore, the adozelesin-DNA adduct was solvated by 4000 Gasteiger-Huckel charged water 
molecules into a droplet. This microscopic description o f a solvated biological system is known 
as explicit treatment of the solvent. All molecules within the droplet are subjected to molecular 
mechanics and dynamics calculations. Modelling this huge solvated system gives rise to many 
problems. A long thermalization and equilibration protocol is required to minimize solvent- 
solute collision induced conformational changes, which could disturb the natural oscillation 
between the low energy structures of the adducts during dynamics.
In aquo calculations are also computationally expensive in terms o f time (5 days for 
10,000 steps convergence gradient minimization, 5 days for a 5 Ops dynamics run). 
Macromolecular motions can vary greatly in amplitude from hundredths of an angstrom to tens 
of angstroms and over different lengths in time (from femtoseconds to picoseconds, seconds or 
even longer) (Karplus and Petsko, 1990). Molecular dynamics simulations give an important 
insight into molecular structure and motion around a global energy minimum on the potential 
energy surface. A nanosecond is thought to be required for accurate representation o f molecular 
dynamics; however, this was beyond the computational limits of the Silicon Graphics Indy RG 
3000 workstation. The solute-solvent non-bond cut-off value was set to 8A, in an attempt to 
curb and simplify the calculation, although this would not be present in an ideal system.
3.6 SYBYL software suite
Much o f the research cited in the literature uses AMBER or INSIGHT II and 
DISCOVER to structurally refine X-ray crystallographic or NMR data. Other software
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packages are also incorporated, such as MOP AC for charge calculations, MARDIGRAS for 
constraint generation and MIDAS for display purposes. However, the SYBYL software suite 
was utilized during this research project for reasons of availability. It is a general software 
package with interfaces for NMR processing (TRIAD 6-3), a Biopolymer module for protein, 
DNA and RNA macromolecule sketching, and the SYBYL interface for molecular dynamics 
and mechanics calculations. All structure refinement calculations in this study implemented the 
Tripos force field. The SYBYL 6*2 Theory manual (1995) states that the previous version of 
SYBYL 5-4 has validated its force field to provide energy values identical to those computed 
with AMBER version 3*0A.
3.7 The refined molecular models of the adozelesin-5'-d(CGTAAGCV5r- 
d(GCTTA*CG) adduct.
Molecular mechanics and dynamics calculations on the docked adozelesin within the 
5'-d(C1G2T3A4A5G6C7)'5'-d(G8C9Tl0T11A12C13G14) duplex, which incorporated all distance- 
range constraints, were performed in vacuo and in aquo (solvated as a droplet). A complete list 
of the distance-range constraints is given in the peak pick spreadsheet in Appendix XI, which 
was generated in conjunction with the master spreadsheet (Appendix XII). Columns 6 and 7 
represent the lower and upper bounds (in A) for the distance-range constraints, which were 
applied to the adozelesin-DNA model within SYBYL. Nuclear spin-spin coupling, especially 
NOEs and chemical shift are both affected by internal molecular motion. When interconversion 
of local conformations is rapid on the NMR timescale, then average values of these parameters 
are obtained (Karplus and Petsko, 1990). It is therefore justified to calculate the average 
structure from the 50ps dynamics trajectory, where the generated structures correspond to low 
energy conformations around a global minima. Averaging o f the dynamics data produced a 
structurally refined molecular model o f the adozelesin-DNA adduct to best-fit the average 
conformation defined by die NMR data. Average structures from the last 5 Ops of each 
dynamics trajectory for both systems i.e. with and without water, correlated very closely to one 
another, as well as with the two-dimensional COSY and NOESY data.
Analysis o f each trajectory demonstrated how the binding o f adozelesin within the 
minor groove o f  DNA, acted like a third strand encased by each DNA oligomer. Adozelesin 
binding to the minor groove stiffened the DNA helix considerably, limiting its mobility. This 
DNA stiffening effect has been previously noted in two-dimensional gel electrophoresis studies 
on the circularization efficiency o f (+)CC-1065 modified DNA (Sun and Hurley, 1992b). 
(+)CC-1065-DNA adducts exhibited only low levels o f circularization whilst (+)ABC, an 
analogous structure to adozelesin except for the C ring being an indole instead of a benzofuran,
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showed 80 per cent of the population was circularized. (+)ABC has similar topology to 
adozelesin, making it very probable that adozelesin would produce some stiffening o f the DNA 
helix but not to the extent of that observed with (+)CC-1065 which results in winding of the 
helix. Winding of DNA was not observed with the compound (+)ABC (Fig. 17) which implies 
winding is induced by the presence of the ethylene bridge (Lee et al., 1991). It is the ethylene 
bridge (+)CC-1065 which is thought to be responsible for the winding and associated delayed 
hepatotoxicity seen with this drug (McGovren et al., 1984; Warpehoski and Bradford, 1988). 
Adozelesin binding visibly stiffens the helix in the dynamics trajectory, with movement and 
bending of the helix being limited in the area o f the bound drug.
Figure 56 shows the in vacuo computer model of the adozelesin-5'-d(CGTAAGC)-5'- 
d(GCTTA*CG) DNA duplex adduct. Adozelesin is in yellow, the 5 -C1 strand is in magenta 
and the 5 'G 8 modified strand is blue. Watson-Crick base pairing has obviously been 
maintained, in agreement with the information from the NOESY spectrum which indicated (3- 
helical structure has been maintained. Even though this sequence is only seven base-pairs in 
length, which is not a full helical turn of 10-5 ± lbp (Rhodes and Klug, 1981), it is plain that the 
DNA has bent slightly to produce a straighter minor groove in which the adozelesin sits. 
Incorporation o f the whole of adozelesin into the minor groove requires a small local bend of 
the DNA helix axis, so that the third subunit is not protruding out o f the groove into space. 
Powers and Gorenstein, (1990) studied the (+)CPI-CDPI2-5'-d(CGCTTAAGCG)2 adduct by 2D 
NMR and refined molecular modelling. CPI-CDPI2 was also found to distort the helix on 
binding to the minor groove, yielding a bent structure. The C13-G2 base pair is able to 
accommodate the end of the CPI headunit with the AdoCH3 directed towards G2.
Figure 56 The refined molecular model of the adozelesin-5'-d(CGTAAGC)-5'-d(GCTTACG) DNA 
adduct, generated in vacuo.
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A GC base pair may be preferred on the 3 -side of the binding site, because it provides a wider 
environment for the incorporation o f the bulky methyl than the narrower mixed AT tract.
The refined molecular model of this adozelesin-DNA adduct resulting from the in 
aquo calculation is displayed as a 3D stereoview in Figure 57. The colour scheme is identical to 
that described for the in vacuo model. The water molecules which surrounded the adduct in its 
solvated form, are not shown so as to provide a clear view. The features mimic those observed 
in the in vacuo model. It is clear that adozelesin squeezes itself into the minor groove with a 
high degree o f complementarity, with only its hydrophilic surface exposed to the surrounding 
solvent. Analogous to (+)CC-1065 (Chidester et al., 1981) and in common with many other 
classical minor groove binders such as the oligopeptide antibiotics e.g. netropsin and distamycin 
(Berman et a l, 1979; Gurskaya et a l ,  1979), the bis-benzimidazoles e.g. Hoechst 33258 (Searle 
and Embrey, 1990) and the bisamidines e.g. berenil (Pearl et a l, 1987), adozelesin is crescent 
shaped and binds isohelically within the minor groove, following the right handed twist o f the 
P-DNA helix.
Figure 57 Stereoview of the refined molecular model of the adozelesin-5'-d(CGTAAGC)-5- 
d(GCTTA*CG) DNA adduct, generated in aquo.
3.7.1 Adozelesin covalently binds to the minor groove of DNA via the N3 of adenine A12
The presence o f only one complete set o f cross-connectivity walks between 
deoxyribose-deoxyribose and deoxyribose-base protons indicates that there is only one major 
species of adozelesin-DNA adduct formed. This single proton-proton walk also demonstrates 
that the palindromic DNA duplex 5'-d(C1G2T3A4A5G6C7G8C9T10T11A12C 13G14)2 has retained
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self-complementarity on the binding of two adozelesin molecules to form a bisadduct. Each 
adozelesin has to bind to an equivalent adenine (A12), in the same orientation (tail extending in 
the 5 -direction) with the same molecular conformation. Hence, the NOE connectivities 
between adozelesin and DNA are equivalent for each binding site. Taking into account the 
symmetry o f this adduct, both drugs must either bind to A5 or to A12. Covalent modification o f 
A5 would yield a ‘head to head’ style adduct, where the CPI subunit (A) is the head. Whereas 
alkylation o f  A1" would produce an adduct where the ‘tails’ pointed towards the centre of the 
duplex. Alkylation was predicted to take place at A12 because 5'-d(T10T n A12*C13G14) is the 
preferred consensus sequence for adozelesin (Weiland and Dooley, 1991; Yoon and Lee, 1998).
A large body of NMR evidence collected from both 400MHz and 600MHz two- 
dimensional NOESY data sets was available to testify to the covalent modification of the N3 of 
adenine (A12) by adozelesin. The mechanism o f adozelesin binding (Fig. 58) is equivalent to 





Figure 58 The mechanism of the alkylation reaction between the N3 of adenine and adozelesin
Alkylation o f DNA occurs via a concerted reaction in which the cyclopropyl ring opens and the 
indole quinone o f  the (A) subunit is reduced to an indole phenol. Downfield shifts o f the 
protons of the cyclopropyl ring i.e. H8A at 5 l -47ppm and H8B at 8 2 02ppm (Walker et al., 
1997) into the methylene region (8 5 06 and 8 5 15ppm, respectively) demonstrated that 
covalent bond formation with adenine was via the C8 methylene bridge. Boger and Mesini 
(1995) demonstrated that A-N3 alkylation took place at the least substituted cyclopropane 
carbon, which in adozelesin is C8. The adenine A l2H2 proton is positioned in the centre o f the 
base of the minor groove, making it an excellent marker to reference the location o f adozelesin 







bottom of the minor groove. Adozelesin H3 is situated on the opposite side of the ring system 
to the covalent modification site. The fact that there is no NOE from A12H2 to AdoH3 implies 
that the CPI ring system is orientated ‘edge-on’ in the minor groove (Fig. 59 ). In agreement 
with this is the observation that A12H2 shows medium intensity NOE connectivities with H8A2, 
H8A, H8B, H1B and H6 o f adozelesins CPI headunit. Adozelesin CH3 and H1A have slightly 
weaker intensity peaks, indicating that they are more distant from the adenine H2. The H8A2, 
H8A, H8B, H1B and H6 protons align the concave surface o f adozelesin. The NOE data 
provide evidence o f a close spatial relationship between these protons and A12H2 situated at the 
base o f the groove. This supports the proposed ‘edge-on’ binding conformation of the CPI 
headunit, where the convex surface of adozelesin is in close isohelical association with the base 
of the minor groove. If the remaining B and C subunits follow this trend (see later) then 
adozelesin binds analogously to (+)CC-1065, whose stereochemistry was inferred from the 
chirality o f DNA (Reynolds et al., 1985) as C8B(R) and C8a(S).
Other deoxyribose protons of A12, C13 and T3 also showed NOE connectivities with 
the A subunit. The H I' protons are situated deeply within the minor groove so interaction with 
adozelesin is limited to the CH3, which is also embedded deeply in the groove.
3.8 Noncovalent binding of adozelesin
Inspection o f the NOESY spectra (both 400 and 600 MHz data sets ) provided many 
drug-DNA interproton connectivities for defining the location o f the indole (B) and benzofuran 
(C) subunits. NOEs between nucleotides A4, A5 and T11 to the indole (B) subunit, demonstrated 
that B lays across two base-pairs. The benzofuran subunit experiences an abundance o f NOEs 
from T10 and C9, with a few to G6 and C7, suggesting it also traverses two base-pairs. In all, 
adozelesin spans a total o f five base-pairs. This is interpreted firstly from the NOEs occuring 
furthest in the 3 '-direction along the covalently modified strand i.e. across G2 s  C13, where the 
tip o f the CPI headunit is situated. Secondly, NOE connectivities to H5 '2 and H6'2 can be used 
to pinpoint the location o f the benzofuran subunit, which was found to be in between base-pairs 
G6 = C9 and C7 a G8.
3.8.1 The indole subunit
Both A4H2 and A5H2 display many NOEs to the H3' 1 of the indole and the methylene 
HI A, H1B and methine H8A2 protons o f the pyrrole. This implies that A4H2 is situated 
between subunits A and B so that the indole covers part of A4 and the whole o f A5 (Fig.59). 
These base H2 protons at the centre of the floor of the minor groove confirm, via their
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Figure 59 NOE connectivities between select adenine H2 protons and the bound adozelesin geminal H8A2, HI A, H1B, H8 A and H8 B protons. (A) Relative positions of the adenine 
H2 protons. (B) Relative intensities of the adenine H2 connectivities. (Intense peaks are shown in dashed yellow, intermediate peaks in dashed white).
connectivities to adozelesin protons HI A, H1B, H8A2 and H3T, that the hydrophobic protons 
on the concave surface of the drug are situated deeply within the minor groove. Deoxyribose 
HI' and H2'l protons, which are also positioned low down on the wall o f the groove, also 
display NOEs to the H3T and H4'l of the indole. Meanwhile, the H4', H5'l and H5'2 sugar 
protons of T11 are responsible for NOE cross-peaks to H6'l and H7'l, on the convex spine of 
the indole subunit of adozelesin. These sugar protons are located high on the walls of the minor 
groove, along the sugar-phosphate backbone. NOE connectivities from these protons to H6'l 
and H7T but not to H3T or H4'l, suggest that the indole like the CPI subunit is orientated 
‘edge-on’ within the minor groove. The hydrophobic, concave surface is isohelical with the 
floor of the minor groove whilst the hydrophilic, convex side o f adozelesin points out of the 
groove and is exposed to the aqueous solvent. All the deoxyribose protons o f T11 are shielded to 
some degree by the indole ring system. TnH4' is situated over the centre o f the aromatic ring 
so exhibits a large upfield shift. The graph in Figure 52 clearly indicates the positioning o f all 
three adozelesin subunits by the size o f the deviation o f chemical shift (-ve = shielding, +ve = 
deshielding). G2 and C13 experience some shielding by the CPI headunit, whilst A5 and T11 
minima correspond to the indole and, lastly, the large dip at T10 correlates with the close 
proximity o f the benzofuran. There are slightly more NOEs from the deoxyribose protons of die 
modified strand (8) to the indole subunit than the unmodified strand (5). This suggests that the 
indole is positioned parallel to both strands but experiences a marginally closer association with 
the modified, rather than the unmodified DNA strand.
3.8.2 The benzofuran subunit
There is a grand total o f 26 NOE connectivities between the terminal benzofuran 
subunit and T10, C9 and G8 of the covalently modified strand. Meanwhile, there are only 4 weak 
drug-DNA interactions with G6 and C7, producing overwhelming evidence that the benzofuran 
is closely associated with the modified strand. C=G base pairs have no aromatic H2 protons to 
help define the orientation o f the ring system. However, there are a numerous contacts from the 
HT, H2T and H2'2 protons in the base of the minor groove to H3'2, H4'2 and H5'2 but not 
H6'2 or H7'2, which verify the orientation o f the benzofuran as ‘edge-on’. The H4', H5T and 
H5'2 protons of the sugar-phosphate backbone are high on the walls of the minor groove and 
see into H4'2, H5'2 H6'2 and H7'2 of adozelesin. This suggests, although the benzofuran ring 
is ‘edge-on’, it is slightly tilted so that all the protons on the aromatic ring system are close 
enough to result in an NOE. Measurement o f the twist angle between the planes of the 
benzofuran and indole rings and the indole and CPI rings, yielded twist angles o f -7-2° and 
+6-7° respectively (Fig. 61). The twist o f these subunits relative to one another allows
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adozelesin to yield a perfect complementary fit with the minor groove o f P-helical DNA. The 
CPI and benzofuran subunits are nearly in plane, with only -0*5° between them.
Analysis o f Figure 54 clearly shows T10H4' has the greatest upfield shift of 2ppm, 
closely followed by T10H5'2 with 119ppm and T10H5T with 0-73ppm. Medium intensity NOE 
cross-peaks occur between these protons and H4'2, H5'2, H6'2 and H7'2 protons of the 
benzofuran. These large upfield shifts are due to the strong shielding experienced from the six 
membered ring o f the benzofuran, which these sugar protons are situated directly over (-2-5A). 
In an analogous manner C13H5'1/H5'2 are shielded slightly by the CPI headunit. Other protons 
of T10 such as H3' and H2T are shielded only slightly because they are at the NOE distance 
limit for interaction at 5A.
3.8.3 Sequence Selectivity
The indole (B) and benzofuran (C) subunits of adozelesin are responsible for the 
noncovalent binding mode of this drug. Noncovalent binding has been proved in many cases to 
be the source o f sequence selectivity for binding of a drug to DNA, irrespective o f whether 
covalent modification is involved. Adozelesin bound to 5'-
d(C1G2T3A4A5G6C7G8C9T10T11A12*C13G13) at the preferred consensus sequence described by 
Weiland and Dooley, (1991) which is 5'-(T/A)(T/A)T A*(C/G)G. This also incorporates the 5'- 
(A/T)(A/T)A* sequence described by Yoon and Lee (1998). Hurley and Needham-VanDevanter 
(1986) attributed the binding specificity of (+)CC-1065 to the hydrophobic interactions between 
its concave surface and the adenine H2 protons. The van der Waals contacts between (+)CC- 
1065 and the narrow floor of the minor groove are proposed to drive the steric manoeuvreings to 
maximize the affinity o f the ligand. These van der Waals forces hold non-polar molecules 
together, they are weak and of very short range, acting only between surfaces of molecules in 
close contact. Therefore, the van der Waals attractions between the macromolecule DNA (large 
surface area) and adozelesin are likely to be numerous, producing a significant force of 
attraction between these molecules.
Bogesr and Ishizaki (1990) have demonstrated that the biological activity o f (+)CC- 
1065 is not determined by the electrophilic reactivity of the CPI headunit. Adozelesin, 
therefore, must alkylate DNA sequence-selectively by some other method. Boger et al., (1990) 
examined the effect o f removing the hydroxy and methoxy substituents o f (+)CC-1065 (A) and 
(B) subunits. Only a small effect was noted on the binding affinity, while the AT-rich binding 
selectivity remained the same. Adozelesin, which does not have hydroxy and methoxy groups, 
has proved to be very AT-sequence-specific in alkylating 5'-d(CGTAAGCGCTTA*CG)2 with
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only one major product. Boger et al., (1990; 1991a) established, through the synthesis of 
analogues o f (+)CC-1065 with varying numbers o f subunits, that subunits B and C are 
mandatory for achieving sequence-selectivity in the AT minor groove. Noncovalent 
interactions are responsible for the preferential binding to a specific consensus sequence (Boger 
et al., 1991b). These noncovalent interactions are van der Waals forces and hydrophobic 
interactions which occur between adozelesin and the minor groove. Interactions such as these 
will be particularly prevalent in a narrower groove consisting o f AT base pairs, instead o f GC 
base pairs where the groove is wider. The increased width o f a GC-rich groove leads to the 
drug associating more with one strand than the other, instead o f yielding a close complementary 
fit with the drug (Garbesi et al., 1996). Boger et al., (1991b) found that 5'-d(TTA) was the 
second most preferred sequence after 5'-d(AAA) for (+)CBI-CDPI2 alkylation, while 5 - 
d(TAA) was even less favoured. The 5'-d(TTA) consensus sequence must produce an 
environment within the minor groove through its base conformation, which encourages a greater 
number of interactions and hence stronger noncovalent binding than the 5'-d(TAA) sequence. It 
is likely that this is why adozelesin alkylates 5'-d(T10T n A12*) rather than 5 '-d(T3A4A5*).
3.8.4.5 Hydrogen-bonding
Hydrogen-bonding in the case of many minor groove binders has been found to 
contribute only to the stability o f the drug binding within the minor groove o f DNA. Sequence 
selectivity has proved to be unconnected to hydrogen-bonding, for example: in the binding of 
oligopiptide antibiotics (Zakrzewska et al., 1983); minor groove binding by the bis- 
benzimidazoles (Parkinson et al., 1994); the noncovalent binding o f the bis(quatemary 
ammonium) heterocycles (Gao et al., 1993); the cyclopropapyrroloindoles (Hurley and 
Needham-VanDevanter, 1986).
Figure 60 Illustration of the major hydrogen bond formed between the linking moiety and the carbonyl o f 
thymine (T10).
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There are two direct hydrogen-bonds occurring within the adozelesin-5 '- 
d(CGTAAGCGCTTA*CG) adduct. One hydrogen-bond is present from the NH of the linker 
between the indole and benzofuran subunits to the C2=C of T10 (Fig. 60). The short distance of 
1-74 A indicates a strong pull o f adozelesin towards the modified strand, which is verified by the 
large number o f NOEs between 5'-d(C9T10Tn) and adozelesin. The second hydrogen-bond 
arises between the CPI hydroxyl and C1301P, which is a phosphate oxygen. The cresent shape 
of adozelesin results in this -OH being very close (2-02A) to the C13 5 '-phosphate group. Lin et 
al., (1991) also noted a hydrogen-bond from the 8-phenolic proton o f (+)CC-1065, however this 
was to the anionic oxygen o f the phosphate two bases to the 3 '-side o f T, which constitutes the 
covalently modified base pair. The hydrogen-bonds within the adozelesin adduct are at either 
end o f the drug-DNA complex, so stabilization takes place along the whole length o f the 
adozelesin-DNA adduct.
3.8.5.6 Distortion around the G6 base
Examination o f the H2'l/H2'2—»H6/H8 (as previously discussed in section 3.4.3.3) 
showed that there was a change in conformation around G6, owing to the weakness of the NOEs 
connected with this nucleotide. G6H8 is closer to its own 5 '-flanking nucleotides A5 sugar 
protons than its own. This could indicate more than a flip in sugar conformation from C2'endo 
((3-DNA) to C3'endo (A-DNA) is occurring. The presence of the base-sugar walk indicates that 
(3-helical structure still prevails, though the weakness of the NOE connectivities shows that 
these interactions are at the distance limit. The refined molecular model generated from the 
NOE data indicates that there has been a rearrangement in the conformation of the sugar- 
phosphate backbone around G6 (Fig. 61). This deformation would allow the deoxyribose sugar 
of G6 to flip forwards so that this ring system was facing the sugar of A5, giving rise to strong 
NOEs with A5. The NOE data are consistent with a model like this. However, to determine 
whether the deformation is as described, torsion angles would be required from the NMR data 
and longer dynamics trajectories would need to be run (of the order of Ins), to see if  the 
macromolecular motion around this point would change on a longer timescale.
Seaman et al., (1996) established that CPI-I bisalkylation o f 5'-TAA2AAA1 proceeded 
in a ‘head to tail’ fashion. This was attributed to a distortional wave focusing on a junction 
within the 5'-end TA step, on alkylation at A1. This distortion is centred five base-pairs in the 
5'-direction along from the modified base. DNA bending has also been described by Lin et al., 
(see review by Hurley and Draves, 1993) on the covalent modification of 5'- 
d(G1G2C3G4G5A6G7T8T9A10*G11G12)3' by (+)CC-1065. Examination of the H8/H6-»H1' and 
H6/H6—»H2' 1/H2 '2 intra and intemucleotide connectivities demonstrated all nucleotides were
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Figure 61 Section of the noncovalently modified strand of the adozelesin-DNA adduct which highlights the distortion around G6
in the anticonformation except for C18. This cytosine is situated on the noncovalently modified 
strand, with its partner G7 being 3 base-pairs upstream of the alkylation site at A10. G6 in the 
adozelesin-5'-d(CGTAAG6CGCTTA*CG)23' adduct is in an analogous position to this C18 and 
displays the same weakness in NOE connectivities. The distortion at C18 was attributed to the 
sugar assuming C3 '-endo geometry, resulting from deformation of the backbone at A16 and A17 
o f the noncovalently modified strand on (+)CC-1065 binding. Like A16 and A17, A5—»G6 in this 
present study also displayed particularly intense NOEs on adozelesin binding. The observed 
distortion at G6 could therefore be attributed to adozelesin binding locally at A12 on the opposite 
strand, or to a wave of distortion transmitted from covalent modification 6 base pairs 
downstream of G6, on die same DNA strand.
Conformational changes around a C-G base pair have also been detected in 
homeodomain binding specificity studies (Ades and Sauer, 1994). Homeodomains are DNA 
binding motifs which have a preference for TAAT sequences. The wild type engrailed 
(segment polarity gene for Drosophilia development) homeodomain (from the Drosophilia 
transcription factor) is selective for an A:T flanking base pair at position 6 o f the binding site, so 
the sequence TAATTA is more favoured over TAATCC. A CG base pair at positions 5 and/or 
6 was found to cause conformational changes weakening interactions of the homeodomain 
residue. Crystal structures demonstrated that there were no contacts between the AT base pair 
and the homeodomain, so the sequence selectivity was induced on a DNA conformational basis. 
This evidence suggests that agents binding to the minor groove can induce distortive changes in 
DNA conformation between five and 6 base-pairs along the modified strand. It is possible that 
the observed distortion around this base (G6) is the result o f adozelesin alkylating A12, followed 
by a distortional wave which centres around G6 and C7 of the modified strand.
Another hypothesis for the origin o f this conformational change is the possibility of a 
weak, transient, bifurcating hydrogen-bond, from die linker between the B and C subunits of 
adozelesin to the guanine NH2 encouraging distortion o f this base. However, the refined 
molecular structure yields this hydrogen-bond distance as 4-3A, owing to the migration of the 
benzofuran towards the modified strand. The NH of the linker produces a very solid H-bond to 
T10, which will be preferred over the weaker one to G6. No water molecule in this study was 
found to bridge a hydrogen-bond with G6. It is likely that this hydrogen-bond pulls the drug 
ligand towards the modified strand, which stabilizes the benzofuran ‘tail’ so that it is not free to 
move around in the wider minor groove defined by the GC base-pairs. It is possible that the 
adozelesin may avoid steric crowding o f the G-NH2 by migrating towards the modified strand.
144
3.8 In summary
The cyclopropapyrroloindole adozelesin binds to the minor groove o f the DNA 
sequence 5'-(C1G2T3A4A5G6C7G8C^r10T11A12C13G14)3' (Cameron and Thompson, 1999). 
Alkylation took place on cyclopropyl ring opening, to the N3 o f adenine (A12) o f the consensus 
sequence 5'-(T10THA12C13). This also indicated that both adozelesin molecules were bound in a 
‘tail to tail* orientation, yielding a self-complementary DNA adduct. The adenine base H2 
proton was used to define the position of the CPI (A) headunit within the minor groove. 
Adozelesin was found to bind ‘edge-on’. The convex, hydrophilic surface was directed out of 
the minor groove, while the concave, hydrophobic surface lay along the floor of this groove.
The benzofuran and indole subunits o f adozelesin controlled the sequence selectivity 
element o f binding. This sequence selectivity is a result o f noncovalent interactions such as van 
der Waals forces and hydrophobic interactions between adozelesin and DNA. Hydrogen-bonds 
contribute to the stability o f the complex. It is also clear that the interplay o f the conformation 
of the flanking sequence and the topology o f adozelesin is extremely important for adozelesin 
being able to squeeze tightly into the minor groove o f DNA in a sequence-selective manner.
This study has proved that the cyclopropapyrroloindole adozelesin can achieve 
sequence selective binding to a DNA consensus sequence, which contains guanine and cytosine 
bases generally associated with wider DNA minor grooves. Adozelesin appears to only tolerate 
the presence o f the CG base-pairs in the consensus sequence, because it can tether itself to the 
modified strand via a hydrogen-bond between die thymine carbonyl and the amide o f the linker, 
so that the benzofuran is not able to ‘flail’ freely within the minor groove. This suggests an 
important role for the ureylene linker. Thompson et al., (1995) have previously attributed the 
ability o f bizelesin to interstrand cross-link the sequence 5 -TTAGTTA, to the hydrogen-bond 
formed between the ureylene linker C=0 and the guanine-NH2. The hydrogen-bond formed 
within this adozelesin-DNA adduct confirms the importance of the ureylene linker, in allowing 
this ligand to traverse an unpredicted consensus sequence which contains a guanine. Evidence 
o f a distortion around the sixth flanking base-pair has also been provided, which may imply that 
CPI alkylation o f adenine yields a unique distortional wave along the modified strand which 
culminates at G6.
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CHAPTER 4; RESULTS AND DISCUSSION
THE 5 'd (  CGA A AA ACGGV5 rd( CCGTTTTT CGV ADOZELESIN 
ADDUCT
The cyclopropapyrroloindole adozelesin like many other minor groove binders, has 
been shown to display a high sequence preference for poly ‘A’ tract sequences (Weiland and 
Dooley, 1991). Adenine-rich DNA is known to have special conformational character where 
the minor groove is deep and narrow, making it very attractive for molecules to bind within it, 
plus the helix axis is macroscopically bent (Nelson et al., 1987). Although it has been 
established that the parent compound (+)CC-1065 binds covalently within the minor groove at 
the N3 of adenine via C8 (Hurley et al., 1984), and Maxam-Gilbert sequencing has shown the 
preferred binding sequence to be 5 '-AAAAA*, no (+)CC-1065-‘A’ tract DNA adduct has ever 
been published. Therefore, it was hoped that this study would yield an adozelesin ‘A’ tract 
DNA adduct, in order to elucidate the structure and why these monofunctional alkylating 
cyclopropapyrroloindole ligands prefer this binding sequence over all others.
The cyclopropapyrrdoindole adozelesin has also been studied on its ability to 
covalently modify ‘A’ tract DNA. The non-palindromic DNA sequence 
5 'd(CGAAAAACGG)-5 'd(CCGTTTTTCG) was used in contrast to the shorter mixed A-T base 
sequence investigated in Chapter 3. Adozelesin bound to the DNA minor groove with a high 
degree o f sequence selectivity to form a single drug-DNA adduct.
There are many steps to be undertaken sequentially before a refined molecular model 
of the 5 d(CGAAAAACGG)-5 'd(CCGH IT rCG)-adozelesin adduct (Fig. 62) can be achieved. 
These include: obtaining a pure DNA sample, accumulation and analysis o f two-dimensional 
NMR data, production o f a DNA-adozelesin adduct sample, collection and examination o f a 
second 2D NMR data set, construction of a 3D computer molecular model of the adduct 
structure, followed by the application o f NMR generated distance-range constraints to the 
structure via molecular mechanics and dynamics calculations. This process yields the refined 
molecular model of the adozelesin-DNA adduct.
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4,1 Analysis of the ID *H NMR spectrum
The 5 d(CGAAAAACGG)-5 'd(CCGTTTTTCG) DNA duplex is non-self- 
complementary in nature. Therefore, its component strands have to be synthesized and purified 
seperately before they can be annealed together to form the required DNA duplex.
Figure 63 shows the one-dimensional NMR spectrum of the non-exchangeable protons 
within the 5'd(C1G2A3A4A5A6A7C8G9G10) oligonucleotide strand. The spectrum is slightly 
broad, despite the inclusion of EDTA in the NMR buffer to chelate any paramagnetic ion 
contamination which can cause peak broadening. The spectrum was referenced to the D20  peak 
at 5 = 4-71ppm. No methyl singlets were noted between 8 = 1  and 8 = 2ppm, as was expected 
for a DNA strand deficient in thymine nucleotides. The adenine and guanine aromatic H8 
protons, plus the cytosine and thymine aromatic H6 protons, are situated in the aromatic region 
between 5 = 7-0 and 5 = 8-25ppm. There appear to be nine peaks although the resonances at 
approximately 5 = 7-4, 5 = 7-7 and 5 = 7-95ppm appear broad, suggesting overlaid proton 
signals. It is probable that, in an ‘A’ tract sequence consisting o f a homologous adenine five 
base repeat, that the similarity o f the chemical environment for each AH8 proton results in the 
superimposition of resonances. Five adenine H2 proton peaks are also overlaid with the H6/H8 
aromatic protons in this region.
The ID ‘H NMR spectrum of the sequence s ' d ^ ^ V V V ^ ^ V ^ G 20) is 
given in Figure 64. D2O is used as the external reference for this spectrum at 8 = 4-71ppm. 
Inspection o f the methyl region shows that there is a closely packed cluster o f resonances 
correlating with the thymine methyl protons of T14—>T18, at approximately 8 = 1-72, 8 = 1-75, 8 
= 1-77, 5=1-8 and 8 = l-82ppm. The aromatic region has a higher concentration o f peaks at its 
upfield end towards 8 = 7-5ppm in comparison with the spectrum in Figure 63 which 
corresponds to an homologous ‘A’ tract. This reflects the major pyrimidine content of the 
sequence where the base aromatic protons experience greater shielding, owing to weaker ring 
currents than in their purine counterparts (Scheek et al.y 1983). Singlets downfield at 8 = 7-90 
and 8 = 7-95ppm are therefore most likely to be due to of G13 and G20. The remaining set of 
overlapped peaks must therefore correspond to cytosine and thymine H6 protons.
After verification that the correct single strand nucleotide sequences were present in a 
pure form, the samples were mixed together and annealed to form (3-helical duplex DNA. 




Figure 62. Schematic diagram of the adozelesin-DNA adduct.
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The ID NMR spectrum of the non-palindromic 5 ’d(CGAAAAACGG)-5 'd(GCTTTTTGCC) 
duplex is given in Figure 65. The complexity o f the spectrum has increased proportionally with 
the number o f protons which now corresponds to two strands. On formation o f the duplex, one 
thymine methyl has separated from the group shown in Figure 65, moving upfield from the 
cluster at 6 = -1*6 to 6 = 1 -4ppm. This is most likely to be a consequence of the duplex 
assuming straight ‘A’ tract character, with bends at either end on reverting to more general 
sequences of base pairing within the (3-helical structure (Nelson et al., 1987). ‘A’ Tract
character is discussed in greater depth in section 4-4. Peaks in the aromatic region are less 
overlaid in the duplex than when the DNA is separated into its component halves. However, 
two broader peaks are still present at 5 = 7-45 and 6 = 7-85ppm, possibly corresponding to the 
‘T’ and ‘A’ tracts respectively.
4.2 The 2D *H NOESY spectrum
Prior to reaction o f the 5 'd(CGAAAAACGG)-5 'd(CCGTTTTTCG) DNA duplex with 
adozelesin, a 400MHz Jeol NOESY data set was accumulated (Appendix XIII Fig. 148). All 
non-exchangeable protons were then comprehensively assigned. It is very important to locate 
the chemical shifts of all protons in p-helical DNA before formation o f the drug-DNA adduct. 
This allows comparison of their chemical shifts after the drug has reacted with DNA. Large 
chemical shift changes, either upfield or downfield, can indicate local changes in helical 
structure and, more importantly, give precise information on the exact positioning of the drug 
ligand within the minor groove.
This duplex DNA structure was more complicated to assign than was that of 
5'd(CGTAAGCGCTTACG)2, owing to the non-palindromic nature o f the 
5 d(CGAAAAACGG)*5 'd(CCGTiTTTCG) sequence. Lack of self-complementarity meant 
that each oligomer constituting the DNA helix had a separate NOE connectivity walk. Great 
care had to be taken not to jump between proton connectivity walks within a region, which 
could easily lead to misassignment o f the spectrum. This is quite difficult when each region is 
very crowded with peaks. The two-dimensional NOESY assignment strategies described in 
chapter 3 for analysis of the 5'd(CGTAAGCGCTTACG)2 duplex were applied to this ‘A’ tract 
DNA. This utilized the assignment procedures documented by Wuthrich, (1986); Wijmenga et 
al., (1993); Hare et al., (1983); Chary et al., (1987); Patel et al., (1986); Weis et al., (1984); 
Feigon et al., (1983a,b); Scheek et al., (1983;1984); Chazin et al., (1986)
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4.2.1 Cvtosine H5 protons
The DNA duplex 5'd(C‘G2A3A4A5A6A7C8G9G1())-
5'd(C11C12G13T14T15T16T17T18C19G20) contains five cytosine H5 protons. The cytosine H5 
resonances are generally a good starting point for spectral assignment due to their high intensity, 
which makes them easy to identify. Five large cross-peaks were noted at 8 4*94, 8 5-18, 8 5 26, 
8 5-57 and 8 5-65 ppm (Fig. 66). As previously discussed in section 3.2.1, the CH5 peaks can 
be distinguished by their correlations into their own base H6 proton and the base H6/H8 proton 
o f the 5 '-neighbour.
There are two terminal cytosines (C1 and C11) in this duplex which will have no 
correlations with a 5 '-aromatic proton. The cross-peak at 8 5-57ppm is thus preliminarily 
assigned as C1 or C11. C11 is the 5' neighbour o f C12H5. Examination o f other peaks in the 
H6/H8-»H1' region, in the direction o f H6 (8 7-507ppm) from the C1 or C11 cross-peak, yields 
only one other CH6—>CH1' cross-peak (8 5-57ppm) verifying that it is a terminal. This peak 
has a cross-connectivity into a peak close beside it whose aromatic proton shift is 8 7-49lppm. 
This base proton also displays a cross-peak to CH5, which, in turn, shows an NOE to the -H6 o f  
its 5'-neighbour. Two cytosine H5—>H6 cross-peaks have therefore been assigned: CnH5 8 
5*575ppm, CllH6 8 7-507ppm, C12H5 8 5-655ppm and C12H6 8 7-491ppm. The C19H5, C8H5 
and C!H5 remain to be assigned. Both of the highly intense cross-peaks at 8 4-937 and 8 5-258 
have peaks positioned far downfield towards 8ppm with which they align. Only one cytosine 
(C8H5) though has a 5' neighbouring adenine (A7) which would have such a low-field shift. 
C19H5, in contrast, has a 5' thymine (T18) but no cross-peak between CH5 and T18H6, which 
was expected to be located before 8 7-5ppm, was immediately apparent. The remaining cross­
peak at 8 5-183ppm, as for the other peaks corresponding to CH5, seemed to align with peaks to 
5 '-neighbouring base protons as well as with a number of other peaks in the CH6 direction. No 
cross-peak corresponding to ClH5 could therefore be definitively assigned, which corresponded 
to a terminal. To distinguish between 0 ^ 5 ,  C8H5, and C19H5 other regions o f the spectrum i.e. 
H6/H8—»H2' 1/H2 '2 and H6/H8-»H1' needed to be consulted, with specific examination o f 
their cross-connectivity walks.
4.2.2 Thymine CEh protons
Observation o f the methyl region in the ID *11 NMR spectrum (Fig. 67) revealed five 
methyl peaks corresponding to T14—»T18, with chemical shifts around 8 1-4 to 8 l -6ppm. This 




Figure 63. The ID ‘H NMR spectrum of 5'd(CGAAAAACGG) single stranded DNA.
TV
T0<L61C 4
Figure 64The ID *H NMR spectrum of 5'd(CCGTTTTTCG) single stranded DNA.
Figure 65 The ID ‘H NMR spectrum of 5 d(CGAAAAACGG)*5 'd(CCGTTTTTCG) DNA duplex.
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default, it must belong to a sugar H2'l/H2'2 walk. The methyl peak at 8 l ’367ppm was readily 
assigned as T14CH3, since it is the only resonance to have an intense correlation to a proton at 5 
7*872ppm. Only a neighbouring 5 '-guanine would produce such a low-field shift, so Tl4CH3 
was assigned as 5 l*367ppm and G13H8 as 8 7*872ppm. In the same manner, T15CH3 was 
assigned via its correlation to T14H6. The remaining three methyls were in a tight cluster; so, to 
begin their assignment, a hypothesis was made on their positions using peak intensity as a 
guide. The resonance at the co-ordinates 8 7*402/1*54ppm appears to be much broader and is 
taller than the other methyls, possibly symbolizing the overlaying of peaks. If this peak was 
assigned as T16CH3 it would also be in the perfect position for a correlation with T15H6, the 
aromatic proton of its 5'-neighbour. The methyl cross-peak at co-ordinates 8 7*349/1 *575ppm 
seemed to consist of a main peak with a shoulder, which was also aligned with a large peak 
within the methyl cluster. This resulted in the preliminary assignment of T18CH3 at 8 l*593ppm, 
which correlated with T17H6 at 8 7*349ppm. The cross-peak at the co-ordinates 8 
7*349/1 *575ppm was attributed to T17CH3 which showed a correlation with T16H6 back into the 
main thymine methyl cluster. Of course, all o f these hypothetical assignments (T16, T17 and T18) 
had to be duly validated by their NOE connectivities in other regions of the spectrum.
In contrast to the case of the 14-mer of DNA discussed in chapter 3, analysis of 
thymine methyl and cytosine H5 proton resonances did not produce conclusive evidence for 
exact assignment of chemical shifts. However, a number of good starting points for spectral
assignment have been established: 5'd(__________________________________________  ^
where _  denotes no proton assignment within the nucleotide. Little information has been gained 
on ‘A’ tract chemical shifts so far.
4.2,3 The aromatic->H2 '1/H2 '2 deoxvribose proton region
Assignment of the aromatic-»H2'l/H2'2 region (Fig. 67) began by scrutinizing the 
spectrum for NOEs within a cross-connectivity walk, for which the aromatic base proton shifts 
had already been ascertained. The H2'l and H2'2 protons were named using the SYBYL 
software notation for H2' and H2" deoxyribose protons respectively. Beginning at CnH6 (8 
7*507ppm), two NOE cross-peaks were located at 8 2*103 and 8 2*615ppm, corresponding to 
H2'l and H2'2, although it was not possible at this stage to differentiate which peak tallied with 
H2'l and which with H2'2. From these two NOE cross-peaks and knowing the position o f 
C12H6, the weaker intemucleotide connectivities between C11H2' 1/H2 '2—»C12H6 were located. 
The remaining peaks corresponding to C12H6 were the stronger intranucleotide NOEs at 8 2*105 
and 8 2*477ppm, relating to C12H6—>C12H2'1/H2'2. All other protons were assigned in the
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same manner moving sequentially along the strand. The methyl and aromatic proton chemical 
shifts for the thymines as proposed from the NOEs between their H6 and CH3, proved to be 
correct. This also led to the assignment of C19H6 to 8 6*963ppm and consequently to C19H5 (8
4-937ppm) via the NOE between them.
The ‘A’ tract assignment procedure began with examination o f the H6 resonances 
which corresponded to C1 and C8H5. Within this assignment region there are only two peaks 
correlating to the H6 chemical shift of 8 5T83ppm* whilst four NOEs are apparent to the H6 at 
8 5-258ppm. The former must be the terminal C1 nucleotide, while the latter set are the strong 
intranucleotide NOEs from C8H6-»H2' 1/H2 '2 and the weaker intemucleotide NOEs are 
C8H6-»A7H2'1/H2'2. T w o  starting points are now available for beginning the ‘walk’, 
consisting o f intra and intemucleotide NOEs along the ‘A’ tract oligomer. Knowing the 
position o f C8 assisted ‘A’ tract assignment by exposing the direction o f the adenine 
connectivities which are compacted close together.
4.2.4 The aromatic->Hl' deoxvribose proton region
This region was assigned in conjuction with the aromatic-»H2'l/H2'2 region, to 
facilitate assignment when peaks became too overlaid or if  intemucleotide connectivities were 
excessively weak. The aromatic H6/H8—»H1' deoxyribose proton cross-connectivity walk in 
the 2D ]H NMR NOESY spectrum is given in figure 66. The same principles of assignment 
were employed as described in section 3.2.4. After solving which CH5 peak belonged to which 
cytosine nucleotide with the aid of the aromatic H6/H8—>H2' 1/H2 '2 spectrum, the chemical 
shifts o f five CH6 resonances were also known. Analysis o f the TCH3—»H6/H8 connectivities 
had produced three surely assigned aromatic chemical shifts for G13, T14 and T15, plus three 
more speculative ones for T16, T17 and T18. Assignment commenced at any o f these protons, 
depending on where the peaks were most clearly resolved or if  anything was known about the 
location of the previous or next nucleotide in the ‘walk’, in which case aligning their proton 
signals would give the ‘walk’ direction e.g. 5'—>3'. The ‘A’ tract ‘walk’ proved to be easier to 
distinguish than that of the ‘T’ tract, where the clusters of peaks were very difficult to assign 
unambiguously. Here, consultation with the H1'-»H2T/H2'2, H6/H8—»H3' and H1'-»H3' 
regions, especially, to map the NOE cross-connectivities between them, was required to place 
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Figure 66 The H6/H8—>H5/H1' region of the 400MHz NOESY spectrum, of the 
5 d(C1G2A3A4A5A6A7C8C9G10)-5'd(C1 • c 12G13T,4T15Tl6T17T18Cl9G20) DNA duplex
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4.2.5 The H6/H8->H3 region
The H6/H8—>H3' ‘walks’ were located between 5 4-0 and 8 5-0ppm (Apppendix XIII 
Fig. 149). Chemical shifts o f the 5 '-terminal nucleotides of both the ‘A’ and ‘T’ tract strands 
were further upfield (C1 8 4*393 and C11 8 4*461ppm) than those of the remaining nucleotide 
H3' protons (8 4-7—>8 5*0ppm). It is the presence o f the 5' terminal phosphate group with its 
negative charge, which is most likely to explain the upfield shift. Because the 5 '-phosphate can 
rotate freely in solution, anisotropic effects around the carbonyl result in C1 and C11 
experiencing shielding o f some of their protons and hence shifts to higher field (Chazin et al., 
1986). The H3' ‘walk’ was nearly complete, with only a few intemucleotide resonances 
missing. Identification o f C19 resonances was quite difficult due to a ti ridge traversing the 
NOESY spectrum at this point. The H6/H8—»H3' proton ‘walk’ was assigned in the same 
manner as described in 3.2.5. All peaks were cross-referenced to the H6/H8-»H1' and 
H6/H8-»H2'1/H2'2 regions to verify H6/H8 proton assignments, and the HI'—>H3' region to 
confirm H3' assignments.
4.2.6 The H6/H8->H6/H8 region
The aromatic—>aromatic region o f the spectrum (Appendix XIII Fig. 150) maps 
intemucleotide connectivities from base to base along the 
5'd(CGAAAAACGG)*5'd(CCGTTTTTCG) oligomer strands. Referring to the proton chemical 
shifts derived from assignments o f the H6/H8->H1', H2'l, H2'2, H3' regions, it was possible to 
jump from one base proton to another e.g. 0 ^ 6 (8  7*263ppm)-»G2H8(8 7*719ppm)->A3H8(8 
7*703ppm) etc. This area o f the spectrum not only allowed verification assignments already 
made but greatly assisted on finding the route to a neighbouring nucleotide base in other 
complex and locally crowded regions of the NOESY spectrum.
Adenine H2 base proton NOE connectivites were also apparent in this region. Five 
AH2 trails were easy identifiable at 8 6*871, 8 7*172, 8 7*529, 8 7*755 and 8 7*861ppm, 
traversing the spectrum parallel to D2. A ‘walk’ between the AH2 protons was also possible 
from A3 to A5. It is quite difficult to decipher true peaks from the spurious noise o f the AH2 
track, so assignment was performed in conjunction with analysis o f the H6/H8-»H1' region, 
using the procedure outlined in section 3.2.6. For example; A5H2-»A5H1 (w), 
A5H2->T16H1'(w), A5H2-»T17Hl'(m) (where m = medium and w = weak intensity cross-peak). 
All duplex AH2 proton assignments are given in Table 5.
155
Figure 67 The aromatic->H2 1/H2 '2/CH3 region of the 400MHz NOESY spectrum of the 
5 d(CGAAAAACGG)-5 d(CCGTTTTTCG) DNA duplex.
4.2.7 The HI ->H2 1/H2'2 region
Once all the HI', H2'l and H2'2 deoxyribose protons had been assigned using their 
NOE connectivities to aromatic protons, it was possible to check the correlation between them 
in the HI'—»H2'1/H2'2 region (Appendix XIII Fig. 151). The H2'2 proton chemical shift was 
assigned to the most intense NOE of each pair, owing to the shorter interproton distance to HI'. 
Like the 5'(CGTAAGCGCTTACG)2 duplex where the chemical shifts o f most H2'l protons 
were upfield o f H2'2, this trend also predominated in this non-self-complementary duplex, 
however a higher proportion of H2'2 had chemical shifts upfield o f those of the corresponding 
H2'l. This could indicate a slightly different conformation o f p-helical DNA, due to the usual 
tendancy of H2'2 to be more deshielded by proton and pyrimidine ring currents than H2'l, 
hence leading to higher upfield shifting of H2T resonances.
4.2.8 The H6/H8->H4' and H6/H8-»HS'1/H5'2 region
Preliminary inspection o f the H6/H8 aromatic proton to H4', H5'l and H5'2 
deoxyribose proton NOE connectivities (Appendix XIII Fig. 149), indicated that the region 5 
3*9->4*4ppm was very complicated, with many cross-peaks clustered close together in a small 
space making assignment difficult. Correlating cross-peaks in this region with those of 
HI'—»H4', H5'l, H5'2 was the only sure way to assign proton chemical shifts with certainty 
(Appendix XIII Fig. 152).
Only segments o f the aromatic-»H4' ‘walk’, e.g. A3-»A7, were present owing to the 
extensive spin-diffusion required for these intemucleotide NOEs. H1'-»H4' yielded a more 
intense NOE cross-peak than H1'->H5T/H5'2 resulting from the shorter interproton distance. 
This was a method to distinguish H4' resonances from those of the H5'l/H5'2 deoxyribose 
protons. The H5T proton was separated from die H5 2 resonance according to Remin and 
Shugar’s rule (1972), who stated that H5'l resonates downfield of H5'2.
4.3 Summary of sequential resonance assignments
This concluded the assignment of the 400MHz NOESY proton NMR spectrum of the 
non-self-complementary duplex: 5'd(CGAAAAACGG)-5'd(CCGTTTTTCG). All chemical 
shifts o f base and deoxyribose protons are displayed in Table 5. The presence of all sequential 
cross-connectivity walks between base aromatic and deoxyribose protons, both within the 
nucleotide (intranucleotide) and between nucleotides (intemucleotide) within the same strand, 
proceeding in a 5' to 3' direction, verified this duplex was J3-form DNA. The cross-peaks
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relating to die methyls were also of similar intensity suggesting the base pairs were stacked 
evenly, resulting in nearly equal interproton distances, as would be expected for a right-handed 
(3-helix. All pyrimidine H5 and CH3 protons exhibited strong NOEs to the 5' adjacent 
nucleotides H6 or H8, conforming to the requirements of (3-DNA. It was not possible to 
determine whether the conformation of the deoxyribose sugar geometry was endo or exo, 
because this 400MHz data set was not of sufficient quality.
4.4 The unusual characteristics of ‘A’ tract DNA
The 5 d(CGAAAAACGG)-5 d(CCG 1T1TTCG) DNA duplex contains a homologous 
‘A’ tract repeat consisting o f five adenine bases. There have been numerous studies on p(dA) 
DNA using a range o f techniques such as NMR, gel electrophoresis and X-ray crystallography, 
in order to ascertain what special characteristics this sequence bestows on p-helical DNA.
Rhodes and Klug (1981) examined the helical periodicity o f DNA in solution, using 
micrococcal nuclease and DNase I, which slice the oligonucleotide at the most accessible 
phosphodiester bond sites. Helical periodicity or the helical repeat is the number o f base pairs 
required to complete a whole turn o f the DNA helix. Analysis of the length of the resulting 
fragments showed that in DNA sequences with random permutations o f nucleotides, 10-5 ± 0 1  
base pairs (bp) are incorporated into each complete turn of DNA. In contrast poly(A) DNA 
sequences only had 10 ± Olbp constituting their helical repeat, suggesting a slighdy different 
conformation in DNA structure.
Base-pair roll Base-pair propellor twist
Figure 68 Schematic drawing of two base-pairs with roll and propellor twist (Wijmenga et al., 1993)
An X-ray crystal structure o f the DNA duplex sequence 5 'd(CGCAAAAAAGCG) 
was studied by Nelson et al., (1987). The 6bp long ‘A’ tract was found to be straight, with base 
pairs stacked parallel to each other and perpendicular to the axis o f the helix. It is this 
straightness which typifies ‘A’ tract character. It was also established that these base pairs 
exhibit a high degree o f propellor twisting about their longitudinal axis, the adenine often
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rotating by about 20° with respect to its thymine partner (Fig. 68). This maximizes adenine- 
adenine stacking interactions between base pairs, presenting new hydrogen-bonding 
opportunities to stabilize this propellor twisted structure. Each propellor twisted adenine has its 
major groove facing edge, pointing downwards towards the 3 '-terminal o f its own strand. This 
results in the formation o f an extra hydrogen-bond, in addition to Watson-Crick hydrogen- 
bonding, between the N6 amine o f adenine and 04  of the thymine constituting the AT base pair 
to the 3'-side of adenine. Hydrogen-bonding between neighbouring base pairs comprises 
structurally stabilizing bifurcating bonds within the ‘A’ tract. In turn, this leads to a narrowing 
of the minor groove. Junction sites were also described at the 5 '-pyrimidine-purine 3 '-base 
step, where clashes between the propellor twisted bases and normal sequence DNA caused the 
base pairs to curl away from the minor groove. In contrast, the 5 '-purine-pyridine junction site 
causes clashes between purines in the major groove, inducing base pairs to roll (Fig. 68) in the 
opposite direction. One o f the most important findings described by Nelson et al., (1987), was 
that helical twist between two halves o f a helix turn are opposite in sign, so when they are 
adjacent they cancel each other out the helix axis remaining unchanged. However, when one of 
these halves was replaced with a normal sequence with no base pair roll, the ‘A’ tract roll of the 
other half-helical turn is not cancelled, resulting in the change in direction (bend) o f the helical 
axis (Fig. 69).
Goodsell et al., (1994) confirmed that the model Nelson proposed for macroscopic 
curvature of DNA was the correct one, resulting from the additive bending effects o f alternate 
random and ‘A’ tract nucleotide sequences. They verified that tilt-wedge models, which 
attributed DNA bending to the rolling o f base pairs caused by a junction site, were incorrect. 
TA steps were found to have a tendency to roll in a direction that compresses the minor groove. 
However, this was consistent with both wide and narrow minor grooves and not just ‘A’ tracts.
Katahira et al., (1988) used NMR to examine the conformation of the ‘A’ tract 
sequence 5'd(CGCAAAAAAGCG). Two lines of evidence suggested that, although the helix 
was (3-form, the ‘A’ tract bases were propellor twisted. Firstly, deuterium-exchange NOE data 
provided evidence o f NOEs from thymine imino protons, not only to the adenine H2 to which it 
was base paired but also to the H2 o f the 3 '-adenine neighbour. Secondly, NOEs were noted 
between the adenine H2 and its own sugar HI', as well as to the thymine HI' o f the 3'- 
neighbour on the complementary strand. In classical (3-form DNA, the bases are not propellor 
twisted, so an NOE between this AnH2 and Tn+1H1' of the opposite strand would be extremely 
weak if  observable at all. The intensity o f the peaks was found to increase in the 5'->3' 





Half turn alternation 
leads to macroscopic bending 
o f  DNA
Each block represents a half
helical turn o f 5 base pairs
Figure 69 Schematic drawing demonstrating non-A-tract bending (Goodsell et al., 1994, Nelson et al. 
1987)
Examination o f the H6/H8-*H1' region of the 400MHz Jeol NOESY data for the 
sample 5'd(C1G2A3A4A5A6A7C8G9G10)-5'd(C11C 12G13T 14T 15T16T17T18C19G20), also demonstrated 
that this DNA duplex exhibited ‘A’ tract character. For example, the NOEs between 
A6H2-»T16H1', A5H2—»Ti7H1 ' and A4H2-»T18H1' are stronger in intensity than intranucleotide 
NOEs to adenine H I ' or intemucleotide NOEs to the thymine H I' within the same base pair. 
This evidence supports the propellor twisting model o f ‘A’ tract structure, with the adenine H2 
being closer to the 3 -thymine neighbour of the thymine to which adenine is Watson-Crick base 
paired.
4.5 The Adozelesin-5 d(CGAAAAA CGGK5 d(CCGTTTTTCG) adduct
After the NMR analysis of the DNA duplex had been completed, the DNA was 
allowed to react with adozelesin. The resulting adduct was then subjected to further one- and 
two-dimensional NMR analysis. All 600MHz NMR data sets (NOESY, ROESY, TOCSY and 
COSY) were run courtesy o f Dr. George Gray, at Varian, Palo Alto, C.A., U.S.A.
4.5.1 The ID *H NMR spectrum
The one-dimensional proton spectrum in Figure 70 indicates that adozelesin has bound 
to the DNA duplex, to form the adozelesin-5'd(CGAAAAA*CGG)-5'd(CCGTTTTTCG) 
adduct. Superimposing this spectrum over the DNA duplex spectrum (Fig. 65) allowed the 
differences between the spectra to be clearly observed.
Observation o f the methyl region showed that peaks due to the duplex had disappeared 
and, hence, the reaction between adozelesin and DNA had reached completion. Five methyl 
signals were immediately apparent at 5 1-347, 8 1-378, 8 1-466, 8 1-584 and 8 l-617ppm, which
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would correspond to the thymine methyls at T14, T15, T16, T17 and T18. Adozelesin has only one 
methyl group on its CPI headunit at Cl, with a shift slightly downfield at 8 2-07ppm (Walker et 
al., 1997). There is no tall methyl singlet at this point, indicating that all free drug was removed 
during purification using a Cig Sep Pak. On preliminary analysis o f the aromatic region, it 
seems not only very complex but possibly a little broad. However, this region (8 6*8<-»8-3ppm) 
contains 20 x H6/H8 and 5 x AH2 aromatic base protons attributable to the DNA, plus eleven 
adozelesin aromatic protons from its CPI, indole and benzofuran rings. This results in a grand 
total o f 36 aromatic resonances in the small space of l-5ppm and hence, the region would be 
expected to be crowded with peaks.
4.5.2 The 2D *H NMR DOF-COSY experiment
The initial step in the 2D *H NMR assignment strategy was to extract as much 
information as possible on scalar coupling from the 600MHz Varian DQF-COSY spectrum 
(Appendix XTV Fig. 153). Analysis o f the phase-sensitive data for the adozelesin- 
5'd(C1G2A3A4A5A6A7C8G9G10)'5'd(ClC2G3T,T,T6T7T8C, G1<>) adduct, was completed in the 
same manner as previously described for the self-complementary adduct in section 3.4.2.
4.5.2.1 The CH5-CH6 region
Identification o f the cytosine H6-H5 three bond vicinal couplings is always a good 
place to begin the assignment o f non-exchangeable protons in a DNA containing sample. 
Appendix XIV Figure 154 displays the CH5(8 5<->6ppm)-CH6(8 6-8<->8ppm) region o f the 
spectrum. The downfield end o f the spectrum is perhaps a little out o f phase in comparison to 
the upfield half, because there is a smearing effect over the large peaks so that they do not 
appear as an antiphase square array. Adjusting the phasing during processing using TRIAD did 
not irradicate this effect. However, even in this poorer quality spectrum, information about the 
locations o f the CH5-CH6 cross-peaks was still extractable. A large discrete cross-peak was 
noted at CH5 8 5-35, CH6 8 7-03ppm. The signals of the remaining four cytosines are closely 
clustered together. The cytosine H5 cross-peaks at 8 5-51ppm(CH6 8 7-385ppm) and 8 
5 -44ppm (CH6 8 7-35ppm) are o f equal intensity to the lone peak at 8 5-35ppm. This suggests 
that they are all equivalent to a single CH5-H6 correlation. Meanwhile, the CH5 peak at 
approximately 8 5-44ppm (CH6 8 7*22ppm) is much greater in intensity than those previously 
described, indicating that two CH5 resonances are closely overlaid here.
The small cross-peak at 8 4-94ppm is attributable to the C19H5 of unreacted DNA 
duplex. However, there are no similar COSY peaks attributable to C1 and C8H5-H6 resonances,
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implying that the concentration o f this species in solution must be very low, probably less than 
10% of the population. There is also evidence o f a second species in the sample. Three small 
CH5 cross-peaks were noted at approximately 8 5-45ppm (CH6 5 6-9ppm), 5 5-75ppm (CH6 8
PPM
PPM
Figure 70 The ID NMR spectrum of the adozelesin-5'd(CGAAAAA*CGG)- 
5 d(CCGTTTTTCG)adduct.
7-35ppm) and 8 5-90ppm (CH6 8 7-55ppm). This second species could arise as a product of 
depurination or from alkylation o f a second adenine site. Depurination occurs when the 
adozelesin-modified adenine (A7) is removed from the DNA strand via (3-elimination, which 
involves cleavage o f the glycosidic bond, leaving the sugar without a base i.e. apurinic (Hurley 
et al., 1984). Although this phenomenon can occur on standing over a long period o f time, the 
adozelesin-DNA adduct o f the self-complementary sequence was still in tact after 6 months 
suggesting it was stable. Therefore, it would follow that the ‘A’ tract DNA-drug adduct should 
also be stable. These second species cytosine peaks have also experienced quite a large 
chemical shift, more in keeping with an adozelesin bound to the minor groove of DNA, rather 
than a local effect bestowed on the DNA duplex by the loss of a cytosine base.
Alkylation of an adenine alternative to A7 is a more favourable proposition, with A6 
being the most likely candidate for alkylation. A6 would still have the preferred 5' flanking 
sequence for adozelesin binding i.e. 5 'd(A/T)(A/T)A* (Weiland and Dooley, 1991) which in this 
sequence is 5 'd(A3A4A5A6*A7). Seaman et al., (1996) have described the formation o f a
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monoadduct by CPI-I binding to 5 TAAAA*A rather than 5'TAAAAA*, where CPI-I is similar 
in structure to the first two subunits of adozelesin.
4.S.2.2 The TH6-TCH, region
Like the DQF-COSY spectrum of the self-complementary adozelesin-DNA adduct, no 
TH 6-TC H 3 cross-peaks corresonding to a V coupling were detected in this DQF-COSY 
spectrum. If the peaks were extremely weak, it is possible they were obscured by noise.
4.5.23  The deoxyribose sugar resonances
The areas o f the DQF-COSY spectrum which corresponded to the spin-spin couplings 
around the deoxyribose ring were particularly crowded with COSY cross-peaks (Appendix XIV 
Fig. 155, 156, 157). Geminal two bond couplings (2J) e.g. H2'1->H2'2 and H5'1-»H5'2 
yielded peaks close to the diagonal or possibly even obscured by it, when the chemical shift 
difference between these protons was approaching zero. Many V  couplings were also 
represented in the spectrum e.g. H1'->H2'1, HI'—>H2'2, H2'1->H3' and H3'—»H4\ These 
cross-peaks were assigned in conjuction with the NOESY spectrum, verifying that the 
sequential NOESY assignments were correct.
4.5.2.4 The aromatic region
All scalar coupled protons giving rise to COSY cross-peaks within this region 
(Appendix XIV Fig. 154) correspond to the indole and benzofuran aromatic protons of  
adozelesin. These spin-spin couplings have already been described in Figure 49. The 
H 6'l—>H7'1 vicinal coupling was assigned to the cross-peak which showed no correlation to 
the other three, since it is an isolated spin system. Although it was assumed that H6T would be 
downfield of H7'l (Walker et al., 1997), the NOESY spectrum was required to confirm this by 
observation o f the H6'l weaker coupling to H4T. The chemical shifts o f the H6'1-»H7T 
COSY cross-peak were at; 5 7*623 and 6 8*I10ppm. The remaining three COSY peaks 
correlated to H4'2-»H5'2, H5'2-»H6'2 and H6'2->H7'2 of the benzofuran. Once again, the 
NOESY spectrum required consultation to give the direction o f the connectivity network, by 
using the NOE H3'2->H4'2. These protons were found to have chemical shifts of: H3'2 6 
7*903, H4'2 6 7*822, H5'2 8 7*475, H6'2 8 7*308 and H7'2 8 8*000ppm.
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4.5.3 The 2D *H NMR TOCSY spectrum
The 600MHz TOCSY data (Appendix XV) provided information on multi-step scalar 
couplings around the sugar ring e.g. H I»H 2'1/H 2'2->H 3' etc, and around the benzofuran of  
adozelesin. This spectrum included the proton connectivities observed within the DQF-COSY 
spectrum, but this time they were clearly resolved unlike in the previous data set. As well as the 
2J  and 3J  couplings seen in the DQF-COSY spectrum, this TOCSY spectrum displayed COSY 
connectivities on longer range scalar couplings such as V  and 5J  couplings.
Four large COSY peaks were noted at 5 5*43, 8 5-44, 8 5-52 and 8 5-35ppm. The 
intensity of the peak at approximately 8 5*43 suggested there were two proton signals clustered 
around the same point. All CH5 protons are then accounted for in the 
5 d(CGAAAAACGG)-5 d(CCGTTTTTCG)-adozelesin adduct. The remaining low intensity 
peaks visible in this region are attributable to a small proportion o f second species, which has 
already been discussed in section 4.5.2.1.
More peaks were visible in the aromatic region o f the TOCSY spectrum than in the 
DQF-COSY. From the initial positions o f the H4'2, H5'2, H6'2 and H7'2 protons o f the 
benzofuran ring, it is possible to observe a succession of scalar connectivities:
H7'2->H6'2 is a V  coupling, strong COSY peak.
H7'2-----»H5'2 is a 4J  coupling, COSY peak is marginally weaker than the 3J  coupling.
H7'2-------->H4'2 is a Vcoupling, COSY is less intense than the Vcoupling.
These long range scalar couplings can be identified for all protons around the end o f this 
benzofuran ring and also for H3'2—»H4'2 and H 3'l—»H4'1. This is another method of  
confirming that these proton chemical shift assignments are correct. It also helps to simplify the 
NOESY spectral assignments because assignment o f these cross-peaks, means they can be 
eliminated from becoming apart o f the aromatic proton ‘walks’ of DNA which could lead to 
misassignments. Four peaks can be identified in the spectrum which do not correlate with any 
adozelesin proton assigned. These are most likely to be the most intense peaks of the second 
species which are present in the sample i.e. H6'1->H7'1, H4'2-»H5'2, H5'2-»H6'2 and 
H6'2-»H7'2. This is because it is possible to walk between three o f the peaks which are likely 
to correspond with the protons o f the benzofuran ring. It is not possible to assign this second 
species because only a few extremely intense COSY peaks are visible relating to the drug, while 
an even smaller number will be present in the less sensitive NOESY experiment. Examination 
of the remaining regions o f the spectrum provided confirmation o f deoxyribose sugar proton 
assignments acquired from the two-dimensional NOESY spectrum.
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4.5.4 The 2D *H NMR NOESY spectrum
Assignment of the 2D 600MHz *H NOESY spectrum (Appendix XVI Fig. 166) was 
accomplished using the approach, previously described for duplex DNA and the self- 
complementary adduct. Initial inspection o f this spectrum reveals that it is exceedingly 
complicated with an abundance o f DNA-DNA, adozelesin-adozelesin and DNA-adozelesin 
NOE connectivities in every region. Owing to the complexity of this spectrum, the DQF-COSY 
and TOCSY had to be consulted repeatedly to authenticate assignments. All interproton ‘walks’ 
within the adozelesin-5'd(C1G2A3A4A5A6A7C8Q9G10)-5'd(C11C‘2G13T14T15T16T17T18C19G20) 
adduct were complete except for the assignment of the protons o f G , whose position was 
questionable, owing to its ability to correlate with a number of nucleotide resonances across the 
spectrum. However, its omission was not thought to cause a problem for generation of an 
accurate refined molecular model, because it is three base-pairs distant from die binding site. 
G10 is also a terminal nucleotide whose proton chemical shifts and peak intensities are not a true 
reflection of a guanine three base-pairs away from the binding site, because terminal base pairs 
have only one neighbour and often experience terminal end-fray effects.
4.5.4.1 The cvtosine H5 region
The DQF-COSY and TOCSY spectra have already identified the chemical shifts of 
the five H5 cross-peaks at 5 5-35, 8 5*43(x2), 8 5-44 and 8 5*52ppm, which will correspond to 
the cytosines C1, C8, C11, C12 and C19. Examination o f the most downfield CH5 shift at 8 
5*52ppm in the NOESY spectrum (Fig. 71) showed there was a cross-peak directly underneath it 
which correlated with a peak to the right of it, and this peak was also in line with a cytosine 
cross-peak at 8 5*44ppm. This allowed a preliminary assignment o f CnH5 to 8 5*52ppm and 
C12H5 to 8 5*44ppm, when the cross-peak at 8 7*385/5*612ppm corresponds to CUH1 '->CUH6 
and the one to its right is consistent with its 3' neighbour C12H6-»ChH1 After the assignment 
of the C11 and C12H5 cross-peaks, only those due to C1, C8 and C19 remained, two of which are 
nearly overlaid. Further analysis of these overlaid peaks shows that there are two lines o f NOEs 
perpendicular to D2 which intersect these CH5 connectivities. C8 is the 3'-neighbour o f A7; 
therefore, an NOE would be expected between C8H6 and A7H 1\ If C8H6 is taken to have a 
chemical shift o f 8 7*186ppm, then there are a number o f peaks at this chemical shift which 
have NOE connectivities to other protons 8< 7*5ppm but only one with an NOE correlation to a 
peak at 8 8*268ppm. A search for the most downfield NOE correlation to the CH5 at 8 
5*436ppm only resulted in a cross-peak at 8 7*715/5*319ppm. A?H8, being an adenine, is likely 
to be more deshielded than G2H8; therefore, the CH5 at 8 5*436ppm was assigned as C t o ,  with 
ClH6 and G2H8 also now located. The cross-peak at co-ordinates 8 7*183/5 *443ppm was 
assigned as 8 5*443ppm to C8H5, with C8H6 and A7H8 being assigned as 8 7*183 and 8
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8-268ppm, respectively. Hence, by default, the remaining CH5-CH6 NOE was attributed to C19 
at 5 5-356ppm, which is the most upfield shifted cytosine as it was in the duplex DNA.
4.5.4.2 The thvmine methyl region
The methyl connectivities of thymines T14, T15, T16, T17 and T18 were assigned by 
seeking the same NOEs in Figure 72, as discussed in section 4.2 2. From C12H6—»H1', it was 
possible to locate G13H8, via interproton connectivity o f G13H8 to its 5 "-flanking nucleotide 
C12H 1\ Knowing the location of G13H8 was important for ascertaining the whereabouts of 
T14CH3 and the direction of the ‘walk’, between the thymine methyl and its 5'-neighbouring 
nucleotide H6/H8 base proton. A large NOE is visible in the methyl region at G13H8 which 
shows only one correlation into a methyl; therefore, this must be T14CH3 8 l-617ppm and T14H6 
5 7*454ppm. Next, looking for the intemucleotide correlation between T15CH3 and T14H6 will 
provide the chemical shift o f the next methyl in the sequence, i.e. 8 l*466ppm, plus the 
assignment of T15H6 8 7-417ppm. The remaining methyls were assigned in the same manner 
and their shifts are given in Table 5.
4.5.43  The H2'1/H2'2->H6/H8 region
The chemical shifts of the base protons already assigned are: 5 'd(C!G2 A7C8__
)-5'd(CnC12G13T14T15T16T17T18C19_ ), where die _ denotes unassigned nucleotides. Beginning 
at any o f these sites, it is possible to move forwards or backwards along the DNA strand, 
sequentially assigning the strong H6/H8 intranucleotide connectivities to H2'l and H2'2, plus 
weaker intemucleotide NOEs to H2'l and H2'2 of the 5' neighbour. All chemical shifts o f H2'l 
and H2'2 protons from this ‘walk’ (Fig. 72) were entered into Table 5.
4.5.4.4 The HI'. H2'l. H2'2. H3'. H4'. H5'l. H5'2 proton connectivities
Sequential assignment of the deoxyribose protons H I', H3', H4', H5'l and H5'2 were 
made previously described for the duplex DNA (Appendix XVI Fig. 165-171). Owing to the 
complex nature of this spectrum, all areas of the spectrum had to be consulted to confirm the 
chemical shift of each proton. With geminal and vicinally coupled protons, the NOE cross­
peaks were checked to see if  they corresponded to the COSY cross-peaks o f the DQF-COSY 
and TOCSY spectra. H4', H5'l and H5'2 resonances were stronger and clearer on their 
correlation to HI' and H3', where interproton distances were shorter and the effects o f spin 





Figure 71 The H6/H8-»H17H5 region of the 2D 'H NOESY spectrum of the adozelesin- 





in their NOE connectivities to H6/H8. When all protons of each nucleotide had been assigned 
within their own region, resulting in complete proton connectivity ‘walks’ (except for G10) and 
these local assignments then mapped correctly with the assignments in all other areas o f the 
spectrum, the assignment procedure was complete. The cross-referencing o f all proton chemical 
shifts placed their assignment on solid ground. The presence of all proton ‘walks’ confirmed 
this ‘A’ tract had maintained (3-helical structure.
4.5.4.5 The adenine H2 protons
Owing to the complexity of the spectrum resulting from the non-palindromic nature of 
the duplex, plus slight line broadening which had a detrimental effect on the resolution, the AH2 
protons were quite difficult to locate. However, after inspection o f both this spectrum at a lower 
contour slice (closer to the baseline) and the tall, sharp resonance lines in the ID spectrum, the 
adenine H2s were identified. Each produced a faint trail of NOEs which were particularly 
prevalent in the H6/H8-»H1' region. A connectivity ‘walk’ from A3-»A5H2 was located in the 
aromatic region, verifying assignments. Like the adenine H2 protons of the duplex DNA, the 
strongest cross-strand NOEs were to the 3 '-neighbouring thymine to which the adenine was 
base-paired e.g. A5H2—*T17H1' and A4H2-»T18H1' (Fig. 71). This indicated that the ‘A’ tract 
had retained its propellor twisted character (Katahira et al., 1988), even after adozelesin had 
bound to the minor groove of DNA to form an adduct.
This concluded the assignment of the non-exchangeable sugar and base protons of 
DNA. All proton chemical shifts are given in Table 5. The chemical shift difference was 
calculated for each deoxynucleotide by subtracting the duplex value from the adduct value. The 
change in chemical shift was then represented graphically (Fig. 73) to illustrate which protons 
experienced the greatest shifts on the addition o f adozelesin to DNA. These sequential 
connectivity networks, with their distinct patterns o f peak intensities along each DNA strand, 
indicated (3-helical structure with Watson-Crick base-pairing and straight ‘A’ tract character had 
been preserved on drug-DNA adduct formation.
4.5.51H NMR assignments of the adozelesin non-exchangeable protons
The aromatic ring protons of the indole and benzofuran subunits o f adozelesin have 
already been assigned using the DQF-COSY and more comprehensive TOCSY NMR data. 
COSY peaks resulting from the ortho couplings between H4'2, H5'2, H6'2 and H7'2 of the
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Figure 73 Graphical representation of the chemical shift changes that occur for each proton in DNA, as a 
result of the covalent binding of adozelesin to form an adduct.
benzofuran, plus H 6 'l and H 7'l of the indole, were noted in both the DQF-COSY and the 
TOCSY spectra. Longer range 4J  couplings, for example H3'1-»H4 1 and H3'2-»H4'2 were 
only identified from the TOCSY data. All these proton assignments were confirmed by their 
through-space connectivity ‘walks’, present in the aromatic—>• aromatic region o f the NOESY 
spectrum (Appendix XVI Fig. 166). The chemical shifts o f the B and C subunits o f adozelesin 
were entered into Table 5.
This left only the protons of the CPI headunit to be located in the NOESY spectrum. 
Using the same reasoning outlined in section 3.4.4, the H8A, H8B, H8A2, HI A, H1B, H3, CH3 
and H6 protons were assigned and their chemical shifts entered into Table 3B. Strong COSY 
correlations between H8A-»H8A2 (8 3-73/4-30ppm) and H1A-»H8A2 (8 3-71/4-30ppm) were 
clearly visible in the TOCSY spectrum (Appendix XV Fig. 164).
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Chemical shifts for the non-exchangeable protons o f DNA in the DNA duplex and Adozelesin-d(CGAAAAACGG).d(CCGTTTTTCG) 
adduct.
H6/H8 CH3/H2/H5 HI' H21 H2 2 H3' H4' H5'l H5'2
Cl 7,263 7,257 -0,006 5,183 5,436 0.253 6,05 5,319 4 2 1 2,103 1,308 -0.795 2,615 2010 -0.605 4,393 4,392 -0,001 4,159 3,833 -0.326 3,955 3,561 -0,394 3,956 3.481 -0.475
G2 7,719 7,715 -0,004 5,504 5,139 -0.365 2,337 2,504 0,167 2,525 2557 0,032 4,893 4,812 -0,081 4,257 4,128 -0,129 4,024 3,816 -0,208 3,928 3,744 -0,184
A3 7,703 7,945 0,242 6,871 7,551 0.680 5,235 5,744 0.509 2,571 2,520 -0,051 2,517 2727 0,210 4,885 4,905 0,020 4,201 4,306 0,105 3,999 4,119 0,120 3,933 4,055 0,122
A4 8,036 8,001 -0,035 7,529 7,307 -0,222 5,730 5,551 -0,179 2,563 2,435 -0,128 2,718 2451 -0.267 4,961 4,498 -0.463 4,305 3,111 -1.194 4,089 3,729 -0.360 4,001 3,457 -0.544
A5 7,968 7,904 -0,064 7,172 8,111 0.939 5,671 5,672 0,001 2,457 2,538 0,081 2,723 2896 0,173 4,945 4,299 -0.646 4,325 2424 -1.901 4,139 3,718 -0.421 4,112 3,109 -1.003
A6 7,915 7,473 -0.442 7,861 7,679 -0,182 5,741 5,072 -0.669 2,492 1,473 -1.019 2,289 1,816 -0.473 4,943 4,401 -0.542 4,341 3,226 -1.115 4,192 3,723 -0.469 4,132 3,577 -0.555
A7 7,863 8,268 0.405 7,755 8,159 0.404 5,869 5,078 -0.791 2,515 2,562 0,047 2,703 2565 -0,138 4,762 4,304 -0.458 4,343 2,450 -1.893 4,092 4,188 0,096 4,046 4,026 -0,020
C8 7,315 7,183 -0,132 5,258 5,443 0,185 5,595 5,194 -0.401 2,015 2,209 0,194 2,357 2461 0,104 4,801 4,798 -0,003 4,011 4,187 0,176 4,109 3,962 -0,147 4,019 3,550 -0.469
<39 7,860 7,583 -0.277 5,926 5,925 -0,001 2,367 2,387 0,020 2378 2212 -0,166 4,908 4,514 -0.394 4,358 4,110 -0,248 4,212 4,045 -0,167 4,036 3,957 -0,079
G10 7,861 5,823 2,836 2437 4,935 4,371 4,180 4,144
C ll 7,507 7,385 -0,122 5,575 5,515 -0,060 6,141 5,612 -0.329 2,188 1,622 -0.566 2372 2209 -0,163 4,461 4,399 -0,062 4,147 3,908 -0,239 4,081 3,521 -0.560 3,937 3,463 -0.474
C12 7,491 7,346 -0,145 5,655 5,442 -0,213 5,942 5,432 -0.510 2,477 2,198 -0.279 2105 1,996 -0,109 4,767 4,652 -0,115 4,297 3,908 -0.389 4,107 3,840 -0.267 4,085 3,763 -0.322
G13 7,872 7,766 -0,106 5,982 5,724 -0.258 2,615 2,406 -0,209 2788 2549 -0,239 4,797 4,851 0,054 4,335 4,222 -0,113 4,220 3,941 -0.279 4,112 3,248 -0.864
T14 7,191 7,454 0.263 1,367 1,617 0.250 6,069 6,142 0,150 2,085 2,206 0,121 2565 2546 -0,019 4,921 4,827 -0,094 4,220 4,241 0,021 4,212 4,085 -0,127 4,205 4,010 -0,195
T15 7,403 7,417 0,014 1,505 1,466 -0,039 6,122 6,061 0,092 2,580 1,383 -1.197 2620 1,614 -1.006 4,847 4,304 -0.543 4,257 2566 -1.691 4,137 4,249 0,112 4,087 4,016 -0,071
T16 7,402 7,179 -0,223 1,540 1,584 0,044 6,002 5,708 -0.294 2,171 2,190 0,019 2492 1,461 -1.031 4,857 4,389 -0.468 4,290 3,973 -0.317 4,308 3,444 -0.864 4,223 2,908 -1.315
T17 7,349 7,016 -0.333 1,575 1,378 -0,197 6,072 5,066 -1.006 2,108 1,721 -0.387 2598 1,837 -0.761 4,852 4,304 -0.548 4,137 3,119 -1.018 4,114 3,729 -0.385 4,077 3,442 -0.635
T18 7,404 6,947 -0.457 1,593 1,347 -0,246 6,122 5,438 -0.684 2,352 1,801 -0.551 2759 2181 -0.578 4,867 4,404 -0.463 4,254 3,908 -0,246 4,237 3,606 -0.631 4,154 3,235 -0.826
C19 6,963 7,032 0,069 4,937 5,356 0.419 5,502 5,163 -0.339 2,141 1,914 -0,227 1,703 1,489 -0,214 4,905 4,519 -0.386 4,217 2,156 -2.061 4,122 3,306 -0.816 4,044 2,892 -1.152
G20 7,739 7,658 -0,081 5,838 5,887 0,049 2,627 2,432 -0,195 2497 2198 -0.299 4,885 4,516 -0.369 4,272 4,047 -0,225 4,024 3,928 -0,096 3,921 3,894 -0,027
For each deoxynucleotide proton the value in italics (column 3) represents the shift calculated from subtracting the duplex 
value (column 1), from the adduct value (column 2).
Chemical shift differences (italics) were underlined if the difference was greater than 0.25ppm.
Table 5 The chemical shifts for the non-exchangeable protons of adozelesin.
113 H6 CH3 H8A2 H8A H8B H1A H1B H3’l H4’l H6’l H7'l H3'2 H4'2 H5'2 H6'2 H7'2
7,901 7,031 2,896 4,300 3,730 5,153 3,715 4,813 7,450 7,755 8,110 7,623 7,903 7,822 7,475 7,308 8,000
Table 5 The chemical shifts o f all non-exchangeable protons in the DNA duplex and adozelesin-DNA adduct.
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The cross-peak H8B—»H8A2 was slightly less intense, whilst H1B-»H8A2 seemed to be 
obscured by the water suppression in the TOCSY spectrum, although this correlation produced a 
large NOE in the NOESY spectrum.
4.5.6 Assignment of NOE connectivities between DNA and adozelesin
Once the non-exchangeable protons of both adozelesin and DNA had been assigned 
comprehensively, the two-dimensional NOESY spectrum was examined for NOE connectivities 
between protons o f adozelesin and 5'd(C1G2A3A4A5A6A7C8G9G10)- 
5'd(C11C12G13T14T15T16T17T18C19G20) DNA. In all, 71 DNA-*adozelesin connectivities were 
found, confirming the location o f the subunits (A,B,C) o f adozelesin within the minor groove. 
These NOE connectivities are illustrated in Figure 74. Additionally there were 25 intradrug 
NOEs between the protons o f adozelesin, plus 534 NOEs between DNA base-»base, 
base-»sugar, sugar->sugar proton correlations. This led to a grand total o f 630 NOE cross­
peaks for distance-range constraint generation, followed by application to the DNA-adozelesin 
adduct molecular model.
4.5.7 The 600MHz ROESY spectrum
The ROESY spectrum for the adozelesin-
5 'd(CGAAAAA*CGG)-5 'd(CCGTTTTTCG) DNA adduct appears in Appendix XVII. Only the 
most intense cross-peaks seen in the NOESY spectrum can be identified in the ROESY. 
ROESY data can provide information on molecular movement within a complex e.g. Hoogstein 
base-pairing or base-pair opening (Seaman and Hurley, 1996). This data set did not reveal any 
evidence for a conformational change o f this nature. Therefore, after adozelesin has bound to 
the minor groove o f this DNA duplex, the helix retained its P-helical character with Watson- 
Crick base-pairing.
4.6 Refined molecular models of the adozelesin- 
5 'd(CGAAAAA"CGGV5 CCGTTTTTCG) adduct
After the NOESY, DQF-COSY, TOCSY and ROESY data had been completely 
assigned, distance-range contraints were generated and applied to a computer molecular model 
during mechanics and dynamics calculations to yield a refined molecular structure for the 
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Figure 74 NOE connectivities between ‘A’ tract DNA and adozelesin.
The peak-pick spreadsheet (Appendix XVIII) contains a complete list o f  all the DNA- 
DNA, adozelesin-adozelesin, DNA-adozelesin NOE cross-peaks identified in the 600MHz 
NOESY spectrum. This was generated using the master spreadsheet (Appendix XVIV). 
Columns 6 and 7 respresent the lower and upper bounds (in A) for the distance-range 
constraints, which were applied to the adozelesin-DNA adduct molecular model within SYBYL. 
Molecular mechanics and dynamics calculations were performed on this restrained molecular 
model both in vacuo and in aquo (when the system was solvated within a water droplet). The 
NOESY spectrum itself is accumulated as the DNA-adozelesin adduct, rapidly interconverts 
between local conformations on the NMR timescale. This internal molecular motion affects 
nuclear spin-spin coupling, especially NOE intensities and chemical shift. Average values of 
these parameters will therefore be manifested in the NOESY spectrum (Karplus and Petsko, 
1990). An average structure was calculated from the 50ps dynamics trajectory, where the 
generated structures correspond to low energy conformations around a global minimum. 
Taking the mean o f the dynamics data produced a structurally refined molecular model o f the 
adozelesin-DNA adduct to fit the average conformation defined by the NMR data most closely.
4.6.1 The refined molecular model of the adozelesin- 
5'd(CGAAAAA*CGGV5'dfCCGTTTTTCG) adduct generated in vacuo
Figure 75 The refined molecular model of the adozelesin-5'd(CGAAAAACGG)-5'd(CCGTTTTTCG) 
DNA adduct, generated in vacuo.
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Figure 75 shows the in vacuo computer molecular model of the adozelesin- 
5'd(C1G2A3A4A5A6A7*C8G9G10)-5'd(C11C12G13T14T15T16T17T18C19G20) DNA adduct, yielded 
after the refined molecular mechanics and dynamics calculations. This structure correlated 
closely with the two-dimensional NOESY data from which it was generated, with (3-helical 
structure and Watson-Crick base-pairing being maintained. Adozelesin in Figure 75 is 
represented by the space-fill rendering, whilst the DNA is in stick-form. Blue denotes the 5'C1 
strand whilst magenta portrays the 5'C11 DNA oligomer. Examination o f this model makes it 
easy to visualize the close-complementarity of the fit between adozelesin and its binding site in 
the minor groove of DNA. The three subunits o f adozelesin traverse six base pairs between 
C8->A3, yet no distortion of the ‘A’ tract is apparent either from the NMR or modelling data, 
adozelesin being able to fit neatly within the minor groove. The top and bottom edges o f the 
CPI and benzofuran rings are situated at each end o f the drug binding site where the helix can be 
seen to turn the open cavity o f the minor groove to face the back o f the picture. From this point, 
it can be seen that they do not protrude outside the minor groove, the edge o f the CPI perhaps 
filling the entire depth of the minor groove so that it is level with the sugar-phosphate backbone 
which constitutes the wall o f the minor groove.
4.6.2 The refined molecular model of the adozelesin- 
5'd(CGAAAAA*CGGV5'd(CCGTTTTTCGI adduct generated in aauo
In vacuo models are not a true representation of a biological system where for 
example, DNA in a cell would be surrounded by water and ions. Water, as discussed in section 
3.5, is highly polar with a capacity for hydrogen-bonding. It influences greatly the 
macromolecular tertiary structures which it solvates, helping to maintain an equilibrium 
between noncovalent electrostatic, hydrogen- and van der Waals forces within the 
macromolecule e.g. (3-helix o f DNA (Westhof et al., 1995). Therefore, explicit treatment of the 
solvent is necessary to produce an accurately refined molecular model, representing the 
adozelesin-DNA adduct in solution. 4000 Gasteiger-Htickel charged water molecules were used 
to solvate this adduct in a droplet. After equilibration and restrained molecular mechanics and 
dynamics calculations, an average structure was produced from the 501 low energy 
conformations of the molecular dynamics trajectory.
Figure 76 displays a three-dimensional stereoview of the adozelesin- 
5 d(CGAAAAACGG)-5 'd(CCGTTTTTCG) DNA adduct generated in aquo. The water 
molecules are not shown, so that a clear view of the adduct is available. Once again, (3-helical 
structure with Watson-Crick base pairing has been maintained, as indicated by the NMR data. 
This space-filled model correlates closely with the NOESY data. Blue atoms represent
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nucleotides C '-^G 10, whilst magenta portrays the CU->G20 oligomer and yellow depicts 
adozelesin bourd within the minor groove. Examination o f this 3D stereoview demonstrates the 
high level of complementarity achieved by adozelesin on binding to DNA within the minor 
groove. Adoze esin is immersed within the groove, with only its hydrophilic spine exposed to 
the surrounding solvent. The concave hydrophobic edge appears to be following the floor o f the 
minor groove, which will allow the subunits of adozelesin to maximize noncovalent interactions 
with the minor groove. The planes o f the adozelesin subunits also show different degrees of 
twist relative to one another. The CPI headunit and indole are nearly co-planar being only -1T° 
out-of-plane, whilst a much larger twist occurs between the indole and the benzofuran (+21-4°). 
This twist allows the third subunit to follow the curvature o f the helix more comfortably, 
without the drug molecule protruding out of the groove which would be energetically 
unfavourable. Twisting o f the adozelesin molecule increases the complementarity o f the fit 
between the drug and its binding site. Isohelical binding o f drugs within the p-helix has been 
described for many other classic crescent-shaped minor groove binders; the 
cyclopropapyrroloindoles e.g. (+)CC-1065 (Chidester et al., 1981), the oligopeptide antibiotics 
e.g. netropsin and distamycin (Berman et al., 1979; Gurskaya et al., 1979), the bis- 
benzimidazoles e.g. Hoechst 33258 (Searle and Embrey, 1990) and the bisamidines e.g. berenil 
(Pearl et al., 1987).
Analysis o f each dynamics trajectory o f both the in vacuo and in aquo simulations, 
demonstrated how the binding of adozelesin within the minor groove of DNA behaved like a 
third strand encased by each DNA oligomer. This resulted in stiffening the helix, reducing its 
mobility around the binding site. Helix stiffening by adozelesin was also noted in the self- 
complementary adozelesin-DNA adduct (section 3.7) and has been previously described by Sun 
and Hurley, (1992b). Adozelesin did not produce winding o f the ‘A’ tract helix like (+)CC- 
1065 (Lee et al., 1991), with 10 base pairs still constituting a turn of the ‘A’ tract adduct helix.
Figure 76 Stereoview of the refined molecular model of adozelesin- 
5 'd(CGAAAAACGG)-5 'd(CCGTTTTTCG) DNA adduct, generated in aquo
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4.7 Adozelesin covalently binds to the minor groove of DNA via the N3 of adenine
Alkylation of the 5 ,d(C1G2A3A4A5A6A7C8G9G10)-
5'd(CnC12G13T14T15T16T17T18C19G20) DNA duplex by adozelesin, was hypothesized to take 
place at A7*. NOE connectivities from the 600MHz NOESY spectrum were able to confirm the 
covalent modification site as the N3 of adenine (A7). Figure 58 shows the mechanism of 
adozelesin binding to adenine. Downfield shifts o f the protons derived from the cyclopropyl 
ring of adozelesin i.e. H8A at 8 l-47ppm and H8B at 8 2-02ppm (Walker et al., 1997), 
demonstrated that covalent bond formation with adenine was via the C8 methylene bridge.
A7H2 is positioned at the base o f the minor groove and shows NOE correlations to 
those protons on the CPI headunit which are also located at the bottom of this groove i.e. H8A, 
H8B, HI A, H1B, and H8A2. These protons are located on the concave surface of adozelesin. 
No NOE connectivity is observed to the aromatic H3 proton situated on the opposite side o f the 
ring system, signifying this edge of the drug is not directed into the groove. This information 
implies that the CPI ring system is orientated ‘edge on’ within the minor groove, with the 
hydrophobic concave surface of adozelesin binding isohelically with the floor of the groove. 
The A7H2 proton has experienced a significant deshielding effect, moving its chemical shift 
downfield by 0*404ppm on adduct formation. A7H2 is obviously in the same plane as the CPI 
head-unit which is orientated ‘edge-on’ within the groove, resulting in the deshielding o f this 
aromatic H2. Sugar protons of A7 have also been affected by the presence of adozelesin, 
notably A7H1' and A7H4' whose resonances have moved upfield by -0*791ppm and -l-893ppm, 
respectively. The shielding effect on these protons is driven by the fact they are facing directly 
into the aromatic 6-membered ring of the CPI headunit. Meanwhile, C8H lr is shielded (- 
0 -4ppm) because it is adjacent to the top 5-membered aromatic ring o f this headunit.
Electrons circulating within a benzene ring which is subjected to a magnetic field, 
yield diamagnetic effects i.e. they generate a secondary induced magenetic field (Morrison and 
Boyd, 1992; Abraham et al., 1988). The circulation of the tc eclectrons can generate a field 
which either opposes or reinforces the applied field felt by the proton. For benzene protons in 
the same plane as the ring, the induced field reinforces the applied field, so the field felt by this 
proton is increased and the proton is said to be deshielded. Conversely, a proton facing the ring 
system would be aligned so that it is subjected to a field which opposes the applied field, so the 
field this proton feels would be decreased and the proton is said to be shielded. Shielding leads 
to upfield shifts (8) of protons whilst deshielding leads to downfield shifts o f protons. These 
upfield and downfield shifts of DNA and adozelesin protons are apparent in Table 5 (columns in 
italics). The negative value depicts an upfield shift (shielding) of the proton on adduct 
formation, whilst a positive value indicates the proton is deshielded (downfield shift).
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13 8G H I ' and C H I ' show NOE correlations with the methyl group of adozelesin, 
suggesting that it too is located deep in the groove because this is where the H I ' deoxyribose 
protons are situated. The fact that both the cytosine and guanine yielded an NOE to this methyl 
indicates that the CPI ring of adozelesin is lying ‘edge-on’ in the centre of the minor groove. 
The adjacent base pair to the covalent modification site in the 5 -direction, i.e. A6 = T 15, 
displays NOE correlations to the protons of the pyrrolo ring of the CPI headunit. Firstly, cross­
peaks between A6H2 (situated in the centre of the base o f the groove) and HI A, H1B, H8A2 
and H8A, reveal that the pyrrolo ring of the CPI subunit is positioned towards the A6 = T 15 base 
pair. This large CPI ring system therefore spans just over two base pairs with its tip projecting 
towards G9 = C12, whilst the pyrrolo end is directed towards A6 = T15. Secondly, not only are 
the HI A, H1B, H8A2 and H8A protons situated complementary to the base of the minor 
groove, symbolizing ‘edge on’ binding, but these are NOE connectivities from sugar protons 
low on the wall of each side o f the groove to HI A. This agrees with the set o f NOEs from 
C8H1' and G13H1' to the methyl o f adozelesin (-0-4A), which indicated that the ring system 
was lying ‘edge-on’ centrally within the minor groove, equidistant from each oligonucleotide 
strand. Figure 77 shows the cyclopropapyrroloindole headunit covalently bound to the N3 o f 
A7.
Figure 77 The cyclopropapyrroloindole headunit of adozelesin covalently binds to A7N3 in an ‘edge-on’ 
orientation, centrally within the minor groove.
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4.8 Noncovalent binding of adozelesin
An abundance o f adozelesin-5'd(C1G2A3A4A5A6A7*C8G9G10)-
5,d(C11C12G13T14T15T16T17T18CI9G20) interproton connectivities were observed in the 600MHz 
NOESY spectrum for defining the location of the indole (B) and benzofuran (C) subunits. NOEs 
from nucleotides T15, T16 and T17 to the indole subunit suggest that it spans just over two base 
pairs. NOEs from A3, A4 and A5 on one strand plus C19 and T18 on the unmodified strand to the 
benzofuran subunit suggest it is situated quite centrally within the minor groove, traversing just 
over two base-pairs. In contrast to the adozelesin-5'd(CGTAAGCGCTTA*CG)2 DNA adduct 
discussed in chapter 3, which spans approximately five base-pairs, adozelesin in this adduct 
spans nearly to six. Firstly, this is interpreted from the NOEs occurring furthest in the 3'- 
direction along the covalently modified strand i.e. across C8 = G13, where the tip o f the headunit 
is situated. Secondly, NOE connectivities between A3 and C19 to the benzofuran ring proton 
H6 'l, on the tip of this third subunit, place the benzofuran between these two sets o f base pairs 
A3 = T18 and G2 = C19.
4.8.1 The indole subunit
Both A6H2 and A5H2 show NOEs to the indole protons on the second subunit. A6H2 
also displays correlations to the protons on the CPI headunit, suggesting that its position could 
be more adjacent to the linker half way between each ring system. As already described for the 
CPI headunit, the fact that these H2 protons only exhibit correlations with H3'l and H4'l but 
not with H6'l or H7'l indicates that this ring is inserted deeply into the minor groove in an 
‘edge-on’ orientation. The hydrophobic, concave surface o f adozelesin faces the floor of the 
minor groove to maximize the complementary fit o f adozelesin with the P-helix. Weak NOEs 
from both strands, i.e. A6H1', T15H1', T16H1', T17H1' and T15H2'1 which are positioned low on 
the wall o f the groove, to H3' and H4'l imply that the indole like the CPI, is situated centrally 
and ‘edge-on’ within the minor groove.
Other NOE connectivities to the indole subunit originate mainly from the nucleotide 
T17, which shows correlations the six membered ring. Measuring the interproton distances 
between T17H1'-»H6T(2*87A), H7'1(4-22 A) and H4'1(3*39A) supplies the reason for the 
upfield shift o f these sugar protons (-1-Oppm). T17H1' is facing directly into the benzene ring o f 
the indole subunit where it experiences shielding. The T17H2T, T1?H2'2 and T17H3' also feel 
this shielding effect, though to a lesser extent. Similarly, T17H4' displays a large upfield shift 
from the shielding it experiences from the indole. Like H5'l and H5'2, H4' protons are located 
high up on the walls of the minor groove. Hence, strong NOE correlations to H6'1(3-92 A) and 
H7'1(2-4 8 A) are observed, proving that the convex hydrophilic surface o f adozelesin is exposed
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to the solvent environment outside the minor groove. Because no NOEs were detected from e.g. 
A5H4', H5'l, H5'2 to H6'l or H7'l, the data seem to suggest that the convex edge o f the indole 
subunit is tipped towards the noncovalently modified strand. This would be in keeping with the 
co-planarity of the first two subunits, where the end o f the indole ring is unable to follow 
perfectly the curve o f  the groove, so it veers closer to T17. In order to maintain isohelical 
binding the third subunit corrects this deviation by twisting 21-4° as described earlier. This 
results in the central alignment o f the benzofuran and hence, an improved complementary fit of 
adozelesin within the minor groove.
4.8.2 The benzofuran subunit
A grand total o f 41 NOE connectivities between the terminal benzofuran subunit and 
nucleotides A3, A4, A5, T18 and C19 were identified in the NOESY spectrum, o f which 16 NOEs 
were attributable to the noncovalently modified strand and 25 NOEs to the alkylated oligomer. 
On initial inspection, it is easy to assume that this subunit is therefore more closely associated 
with the modified strand. However, some o f these NOEs are to adenine H2s which are located 
in the centre o f the minor groove. Adenines A5H2, A4H2 and A3H2 each show correlations to 
H3'2, H4'2 or H5'2, with no NOE to H7'2, confirming that the benzofuran, like the first two 
subunits, is orientated ‘edge-on’ within the minor groove. A5H2 shows a large downfield shift 
and inspection o f the molecular model (Fig. 78) shows, it is directly in plane with H4' 1(2-3 A) 
and H3 '2(2-7A) although it is adjacent to the linker between the indole and the benzofuran. The 
downfield shift is therefore a result o f the deshielding effects A5H2 experiences from the B and 
C subunits. Owing to the H I', H2'l, H2'2 and H3' protons situation low down on the wall of 
the minor groove, correlations from these protons to H3'2, H4'2 and H5'2 also testify to the 
‘edge-on’ orientation o f the benzofuran.
The H4', H5'l and H5'2 protons are located high on the walls o f the minor groove. 
NOEs from these protons were generally to H6'2 and H7'2, indicating that H6'2 and H7'2 were 
directed outwards from the base of the minor groove. This is in agreement with the convex, 
hydrophilic surface o f the benzofuran being able to interact with the solvent surrounding the 
adduct. C19 shows some huge changes in chemical shift of its H4', H5'l and H5'2 sugar 
protons even though it is five base-pairs away from the alkylation site and on the opposite 
strand. Analysis o f the refined molecular models show that the large shielding effect is due to 
the closeness o f H5'2(3*81 A), H6'2(2-53A) and H7'2(2-32A). A4H4' and A5H4' have also 
experienced upfield shifts, resulting from the shielding o f the 6- and 5-membered rings o f the 
benzofuran respectively. The centralized, ‘edge-on’ orientation of the benzofuran maximizes 
the complementarity observed between drug and DNA, to produce a perfect isohelical fit of  
adozelesin within the ‘A’ tract of (3-helical DNA(Fig. 78).
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Adozelesin
Figure 78 The indole and benzofuran subunits of adozelesin bind noncovalently into the minor groove of 
DNA
4.9 Adozelesin displays sequence selectivity towards an adenine-rich ‘A tract’ DNA 
minor groove
Analysis o f the NOESY, DQF-COSY and TOCSY NMR data sets have shown that 
there is only one fully assignable major adozelesin-DNA species present within this sample. All 
the NOE connectivity ‘walks’ are present and each proton (except those related to G10) is 
accounted for. The DNA duplex 5'd(C‘G2A3A4A5A6A7C8G9G 10)-
5'd(Cn C 12G13T14T15T16T 17T18C19G20) was non-self-complementary and hence, so was the 
adozelesin-DNA adduct, each strand having its own separate set o f sequential cross­
connectivities. Since adozelesin is known to traverse 5bp in the adozelesin-
5'd(CGTAAGCGCTTA*CG)2 DNA adduct (see Chapter 3 and Cameron and Thompson, 1999), 
there is only space in this non-palindromic DNA helix for one adozelesin to bind. Covalent 
binding is most likely to take place at A7 because this is the adenine at the 3 -end o f the ‘A ’ 
tract. Hurley et al., (1984) decribed 5'd(AAAAA*) as a consensus sequence for (+)CC-1065. 
Reynolds et al., (1985) found that the 2nd and 3rd adenines from the 3' end were more well
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conserved than the 4th and 5th adenines in the sequence, which the third benzodipyrrole subunit 
o f (+)CC-1065 interacted with. This evidence suggests a run o f five sequential adenine bases is 
the most preferred binding site for (+)CC-1065 binding and it would follow that adozelesin 
would react in a similar manner. Boger et al., (1991b) noted that the ‘A’ tract sequence was 
preferred over all other binding sites, for a variety o f CPI analogues. This observation was 
confirmed specifically for adozelesin by Weiland and Dooley, (1991). A6 would perhaps be the 
second best candidate for covalent modification and may be the source of the minor species 
detected in the DQF-COSY and TOCSY spectra, as previously discussed.
Figure 79 The DNA duplex 5'd(C1G2A3A4A5A6A7C8G9G10>5'd(C11C12G13T14T15T16T17T18C19G20) retains 
‘A’ tract character on covalent modification by adozelesin.
The indole (B) and benzofuran (C) subunits o f adozelesin are responsible for the 
noncovalent binding mode o f this drug. Noncovalent binding is known to be the source of 
sequence selectivity for a drug binding to DNA, irrespective of whether covalent modification is 
involved. It is this noncovalent binding mode which dictates the flanking sequence around the 
binding site, yielding a specific binding sequence so that adozelesin does not indiscriminately 
alkylate every adenine in DNA. Hurley and Needham-VanDevanter (1983) attributed the
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binding specificity o f (+)CC-1065 to the hydrophobic interactions between its concave surface 
and the adenine H2 protons. The van der Waals contacts between the ligand and the narrow 
groove maximize the affinity o f the ligand, by producing a strong force of attraction at a specific 
binding sequence (Boger et al., 1991b). These noncovalent interactions will be particularly 
prevalent in the narrow ‘A’ tract minor groove. It is likely that adozelesin preferentially 
alkylates A7 over A6 (possible minor species) for this reason, allowing the entire adozelesin 
molecule to be submerged in the very narrow ‘A’ tract minor groove for maximization of 
noncovalent binding.
Inspection o f both the NOESY data and the resulting molecular model demonstrates 
that this DNA sequence has retained its ‘A’ tract character. For example, many protons o f C19 
display NOEs to adozelesin, whereas, in the self-complementary adduct, the equivalent 
nucleotide G8 on the unmodified strand was not involved in any NOE connectivities to the 
benzofuran ‘tail’. The NOEs to the benzofuran from C19 would not be possible without 
propellor twisting o f bases. All adenines displayed propellor twisting and, although Watson- 
Crick base pairing is maintained, bifurcating hydrogen-bonds are clearly present between the 
N6 amino of adenine and 0 4  o f the thymine, constituting the AT base pair to the 3 '-side of 
adenine (Nelson et al., 1987; Katahira et al., 1988). The propellor twisting o f bases narrows the 
minor groove, producing a more compact fit between adozelesin and its binding site within 
DNA. This in turn optimizes the noncovalent binding mode (Fig. 79). ‘A’ tract DNA has only 
lObp per turn (Rhodes and Klug, 1981) and is straight (Nelson et al., 1987). In this 
environment adozelesin binds in the centre o f the minor groove, in an ‘edge-on’ orientation, 
spanning over 6bp. It is the straightness of this groove which perhaps allows adozelesin to bind 
so neatly, without producing tilting of the second and third subunits as observed in the 
adozelesin-5 'd(CGTAAGCGCTTA*CG)2 adduct in Chapter 3. The fact that ca. 6 base pairs are 
traversed by adozelesin instead o f 5 may also reflect the tighter helical turn o f an ‘A’ tract i.e. 
lObp instead o f 10-5bp.
In the self-complementary adozelesin-5'd(C1G2T3A4A5G6C7G8C9T10TllAl2’C13Gl4)2 
adduct, a distortion was noted around the base G6 (section 3.8.5.6). No deformation o f  this kind 
has been detected in the ‘A’ tract adduct, although the sixth flanking base pair in the 5' direction 
along the modified strand happens to be C1, a terminal nucleotide. The HI', H2T and H2'2 all 
display unusually high chemical shifts which there seems to be no reasonable explanation for. 
Terminal nucleotides would be expected to produce very similar chemical shifts in duplex and 
adduct DNA, because they are not part o f the binding site. However, if  adozelesin does cause a 
distortional wave 6bp from the binding site on the modified strand, as indicated by Seaman et 
al. (1996) and Lin et al. (see review by Hurley and Draves, 1993), then this distortion would
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culminate at C1, hence explaining the strange chemical shifts. A longer oligonucleotide would 
be required to investigate this further.
4.10 Hydrogen-bonding
Analysis o f the binding modes of minor groove binding agents, such as the 
oligopeptide antibiotics (Zakrzeqska et al., 1983), the bis-benzimidazoles (Parkinson et ah, 
1994), the bis(quartemary ammonium) heterocycles (Gao et al., 1993) and the 
cyclopropapyrroloindoles (Hurley and Needham-VanDevanter, 1986), has demonstrated that 
hydrogen bonding only contributes to the stability o f a complex.
Unlike the adozelesin-5 'd(CGTAAGCGCTTA*CG) DNA adduct, this ‘A’ tract adduct 
provided no evidence of hydrogen-bonding between C801P phosphate anionic oxygen and the 
CPI hydroxyl. The central location o f the headunit means that the closest moiety with which it 
could hydrogen bond is T1601P, but this is 3-95 A away, nearly twice the length of the H-bond. 
No water molecules were seen to be bridging a bond such as this during the dynamics 
calculations (Lin et al., 1991). The only possible hydrogen-bond is from the NH of the amide 
linker, which is between the indole and benzofuran subunits of adozelesin to the N3 o f adenine 
A5. This distance measured in the refined molecular model is 2-830A, which is rather long for a 
hydrogen-bond (usually ~2A). However, the close complementarity of the fit of adozelesin 
within the narrow ‘A’ tract minor groove is likely to produce an abundance of other noncovalent 
interactions, which will more than compensate for the lack of stabilizing hydrogen-bonds.
4.11 In Summary
The cyclopropapyrroloindole adozelesin binds to the minor groove of the DNA 
sequence 5,d(C1G2A3A4A5A6A7*C8G9G10)-5rd(C11C12G13T14T15T16T17T18C19G20). Alkylation 
took place on cyclopropyl ring-opening, to the N3 of adenine (A7) o f the consensus sequence 
5'd(A3A4A5A6A7*). Adozelesin bound with its benzofuran ‘tail’ orientated towards the 5'- 
terminal of the modified strand. This adduct was non-self-complementary in nature. The 
adenine base H2 protons (A7H2 and A6H2) were used to define the position o f the CPI (A) 
headunit within the minor groove. Adozelesin was found to bind ‘edge-on’, along the centre of 
the minor groove. The convex, hydrophilic surface was directed out of the groove, while the 
concave, hydrophobic surface lay along the floor of this groove. The crescent shape of 
adozelesin resulted in this ligand binding isohelically within the (3-helical DNA.
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The benzofuran and indole subunits of adozelesin controlled the sequence selectivity 
element o f binding. This sequence selectivity is a result of noncovalent interactions such as 
hydrophobic interactions and van der Waals forces between adozelesin and DNA. In all 
adozelesin spanned over 6 base pairs, with the ‘A’ tract retaining its propellor twisting 
conformation on adduct formation. The conformation of the flanking sequence and the 
topology o f adozelesin is extremely important for allowing adozelesin, to wedge itself tightly 
into the ‘A’ tract minor groove o f DNA in a sequence selective manner.
The preference displayed by adozelesin towards these ‘A’ tract sequences is obviously 
a result of the perfect isohelical fit, with which adozelesin is able to bind within the minor 
groove o f macroscopically bent DNA. Although there is no data on a (+)CC-1065-‘A’ tract 
DNA adduct it is likely that through the similarity o f their molecular structures, the resulting 
adduct which displays close complementarity between ligand and binding site, will be very 
similar. Adozelesin however, does not display any of the winding effects observed to be present 
with (+)CC-1065 (Warpehoski et al.., 1988). The narrowness o f the ‘A ’ tract groove is 
conducive to the presence o f noncovalent interactions with the drug. This, in conjunction with, 
the bend o f the DNA sequence which allows adozelesin to lie ‘edge-on’, in a central position 
along the length o f the groove, demonstrates why ‘A’ tract character easily promotes sequence 
selective binding o f adozelesin.
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CHAPTER 5: RESULTS AND DISCUSSION
EVALUATION OF THE MINOR GROOVE BINDERS: 
CYANOMORPHOLINOADRIAMYCIN, DSB-120 AND 
SIBIROM Y CIN
The ability of various other minor groove binding agents to modify DNA has also 
been assessed by ID NMR. Cyanomorpholinoadriamycin (CMA) is an anthracycline which 
displays a mixed binding mode. Both intercalating and covalent minor groove binding moieties 
are incorporated into the structure of CMA. DSB-120 and sibiromycin belong to the 
pyrrolo [2,1-c][1,4]benzodiazepine family, which covalently bind within the minor groove.
5.1 The modification of DNA by cvanomorpholinoadriamvcin
Cyanomorpholinoadriamycin was allowed to react with two duplex DNA sequences; 
5 'd(G1T2T3C4C5A6T7G8C9A10A11C12)23' and 5 'd(G! C V  A4G5C6T7 A8I9C10>23'. Both sequences 
are self-complementary, although only the former was hypothesized to form a self- 
complementary adduct.
5.1.1 The ID *H NMR spectrum of 5 dfGTTCCATGGAACb
A ID NMR spectrum (Fig. 80) was collected on the purified 
5'd(G1T2T3C4C5A6T7G8G9A10A11C12)2 DNA sample. Analysis of the non-exchangeable protons 
within the DNA duplex was performed as previously described in section 3.1. The palindromic 
nature o f this duplex means both strands are equivalent, so the spectrum effectively corresponds 
to one DNA strand.
To begin with, the methyl region o f the spectrum was examined to assess whether 
signals from all the thymines were present. Three methyl peaks were noted at approximately 8 
1-25, 8 1-35, and 8 l-55ppm corresponding to T2, T3, and T7, although not necessarily in this 
order. There are six A/GH8 and six T/CH6 base aromatic protons in this sequence. Thirteen 
resonances are immediately obvious, which included signals from the 12 H6/H8 protons, two of
187
which are doublets at ~8 7*1 and 8 7-45ppm corresponding to cytosine H6. The remaining 
resonance corresponds to an adenine H2 proton, of which their are three in this duplex at A6, A10 
and A11. Therefore, two resonances must be overlaid with two other peaks. The broadness of 
the peak at 8 739ppm suggests that this is the case. Although it is not possible to attribute any 
peak in the aromatic region of the spectrum to a specific nucleotide, the tall and needle like 
appearance of the peaks at ~8 7-26 and 8 7-70ppm suggest they could be due to AH2 protons. 
This spectrum indicated that the DNA sample was pure, so it was allowed to react with CMA.










Figure 81 The ID ‘H NMR spectmm of the CMA-5 '(GTTCCATGGAAC) 2  complex.
188
5.1.1.2 The ID  *H NM R spectrum  o f the CM A-5 dfG T T C C A T G G A A C b complex
Subsequent to purification of the drug-DNA reaction mixture using Ci8 Sep Pak 
cartridges, a one-dimensional proton NMR spectrum was accumulated on the CMA- 
5 d(GTTCCATGGAAC) 2  complex. Inspection o f these data shows that the number o f peaks in 
this spectrum has increased significantly, indicating that a reaction has taken place.
The structure o f cyanomorpholinoadriamycin is given in Figure 82. This drug has 
three aromatic protons corresponding to positions 1,2 and 3 on the D ring o f the aglycone 












Figure 82 The molecular structure o f cyanomorpholinoadriamycin (CMA).
The methyl o f the daunosamine sugar and the methoxy group (which is also situated on the D 
ring of the aglycone), serve as the remaining two clear molecular markers for evidence of 
reaction between CMA and the DNA duplex. The chemical shifts o f the methyl and methoxy 
groups were anticipated to be between 8 l-l-5ppm and 8 3-5-4-0ppm respectively.
Figure 81 shows the NMR spectrum o f the CMA-
5 d(G1T2T3C4C5A6T7G8G9A,0A11C12)2 complex. Analysis of the methyl region should have 
yielded four peaks, if  this palindromic sequence had produced a self-complementary adduct on
2 3 7modification by CMA. These would correspond to T , T , T and the daunosamine 5 -methyl. 
Instead, at least eleven peaks existed in this methyl region. Clearly, the methyl peaks at 8 1 *25, 
8 1 -35 and 8 l-55ppm were equivalent to the T2, T3 and T7 nucleotides of unreacted duplex 
DNA. The intensity of these peaks suggested that only ca. 50% of the DNA had formed a 
complex with CMA, whilst 50% remained as DNA duplex. No methyl peak was expected to 
represent unreacted CMA because all free drug was removed during purification. This left eight
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singlets at approximately 5 1-48, 5 1*30, 8 1-27, 8 1-2 (overlaid), 8 1*17, 8 1-16, 8 1-12 and 8 
l ’lppm. Dividing this number by two results in the correct number of methyls for two CMA- 
5'd(G1T2T3C4C5A6T7G8C9A10A1IC12)2 complexes; 2 x T2, 2 x T3, 2 x T7 and 2 x daunosomine 
CH3. These methyls are not equivalent because CMA binding at each 5'GG intercalation site is 
not in the same orientation and, hence, a self-complementary CMA-DNA adduct is not formed.
Examination o f the aromatic region (Fig. 81) indicated that the number o f peaks far 
exceeded the expected total o f 18 (15 x H6/H8/H2 of DNA and 3 x H1/H2/H3 of the aglycone of  
CMA), which would correspond to a self-complementary adduct. Some areas o f this aromatic 
region between 6-8 and 8-4ppm are quite broad, owing to the peaks being so overlaid.
These data suggest that two CMA-5 'd(GTTCCATGCAAC)2 species are formed on 
mixing the anthracycline CMA with this DNA duplex sequence.
S. 1.1.3 CMA intercalates at the 5'GG site
Jesson et al., (1989) established that intercalation into DNA was important for CMA 
cross-linking activity. The level of cross-linking was also shown to increase as the DNA 
became more G-C rich. Cullinane and Phillips, (1991) utilised in vitro transcription assays to 
probe the sequence specificity of CMA complexes within DNA. Transcriptional blockages 
were noted prior to 5'-CC and 5-GG which were thought to be consistent with intrastrand 
cross-links, whilst low level blockages at 5 '-GC and 5 'CG sequences were thought to reflect 
interstrand cross-links. Intrastrand cross-linking at the 5 'GG site o f the non-template strand, 
was found to predominate over 5 -CC, 5-GC and 5'-CG base combinations (Cullinane and 
Phillips, 1992). The sequence specificity of CMA in vivo was found to be equivalent to that 
found with in vitro testing (Cullinane and Phillips, 1994). From this evidence, it was reasonable 
to expect the aglycone moiety of cyanomorpholinoadriamycin to intercalate preferentially 
between the 5'G8G9 base pairs in the 5,d(G1T2T3C4C5A6T7G8G9AI0A11C12)2.
Without being able to map chemical shift differences between duplex and modified 
DNA to detect the exact positioning o f CMA within the complex, it is apparent that the only 
preferred sequence available for reaction is at 5'-G8G9. This allows two CMA molecules to 
react with this (3-helical dodecamer, each strand coding for one reaction site. It is obvious that 
some complex formation has taken place, as indicated by the complexity of the spectrum.
Formation o f a self-complementary adduct would require each CMA to intercalate 
into the 5 '-G8G9 sequences on each strand, in the same orientation. The daunosamine sugar and
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morpholino moieties would therefore be projected towards the same terminal o f the modified 
strand. For self-complementarity, both CMA molecules should be orientated so that their 
aglycone ‘heads’ are intercalated between 5 -GG. Their morpholino tails are then directed 
either outwards towards the terminals of the duplex, in the 3 -direction o f the 5 -GG template 
strand, yielding a ‘head to head’ complex (Fig. 83). Conversely a ‘tail to tail’ complex is 
formed where the morpholino ‘tails’ are orientated towards the centre of the DNA, in the 5' 









Projection of morpholino 
‘tail’ in 3' direction of 
5 GG templete strand.
Figure 83 Schematic representation of the ‘head to head’ self-complementary complex formed on the 
reaction of CMA with DNA.
5 ' G1 T2 T3 C4 C5 A6 T7 G8 G9 A 10 A" C12
C12 A 11 A'° - 5 ^4 T2 G1 -5
Intercalation of Projection of morpholino
aglycone head. ‘tail’ in 5' direction of
5 'GG templete strand.
Figure 84 Schematic representation of the ‘tail to tail’ self-complementary complex formed on the 
reaction of CMA with DNA.
The ‘head to head’ self-complementary adduct is a probable candidate for one of the 
species present in the reaction mixture. T2, T3 and T7 are in equivalent environments in both 
oligonucleotide strands, contributing three methyl resonances to the spectrum. Wang et al., 
(1987) found that the A ring of the aglycone moiety o f daunomycin projected into the minor 
groove. The hydroxyl group at C9 o f this chromophore formed a hydrogen-bond with G2N2 of 
the 5'd(C1G2T3A4C5G6)2 duplex, where daunomycin intercalated between the terminal 5'CG 
base pairs. This hydrogen-bond was actually part o f a bifurcating hydrogen-bond, between the 
same G2N2 and 0 7  of the glycosyl ether linkage. The binding o f the adriamycin analogue 3 
(2-methoxy-4-morpholinyl)adriamycin to 5'd(CGTACG) was investigated by Odefey et al., 
(1992). Hydrogen-bond detail was also described here between the aglycone 0 9  hydroxyl and
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the N2 o f guanine (G2). Examination o f Figure 83, demonstrates that hydrogen-bonding 
between the 09  hydroxyl of the aglycone and G9N2 is also possible in this self-complementary 
CMA-DNA complex. G9 is the 3' guanine in the intercalation site on the template strand. The 
hydroxyl and aceto group lie on the same surface o f the aglycone as the daunosamine sugar. 
However, the conformation of the cyclohexene ring dictates that C9 in not in the same plane as 
the aglycone, instead it is directed downwards in the same direction as the daunosamine sugar. 
This allows the aceto group which is on the opposite surface o f the ring system, to be below the 
plane o f the aglycone, like the hydroxyl and daunosamine. Hydrogen-bonding between the 
aglycone 0 9  hydroxyl and G9 will anchor this edge of the chromophore into the minor groove.
Intercalation o f the aglycone ‘head’ in the opposite orientation (Fig. 84) appears to be 
less favourable. Firstly, when the lower surface of the aglycone, from which the hydroxyl, 
aceto and daunosamine moieties project, faces in the opposite direction, the hydroxyl 0 9  is now 
closest to C5. C5 is in the equivalent position to G9 (of the ‘head to head’ adduct) for hydrogen- 
bonding. The lack o f a nucleophilic centre, such as the N2 of G9, at C5 means there will be no 
hydrogen-bonding to stabilize aglycone intercalation. The length of the combined daunosamine 
and morpholino moiety presents a second problem. For two CMA molecules to bind to 
5 'd(GTTCCATGGAAC)2 via intercalation between adjacent guanines, it is very unlikely that 
their will be enough space to allow both ‘tail’ groups to fit within the minor groove. There are 
only two base pairs A6 and T7 between these intercalation sites. Odefey et al., (1992) observed 
an NOE from the methoxy group attached to the morpholino ring, to A4H1' of 
5'd(C1G2T3A4C5G6), when intercalation took place between C1 and G2. This suggests that CMA 
spans 3-4 base pairs in total. Both morpholino tails would extend in the 5' direction towards A6 
(on the same strand as the G8G9 intercalation site). However, the first CMA to bind to the minor 
groove is likely to obstruct the daunosamine sugar and morpholino group of the second drug 
molecule from binding in the same position. It is probable that the binding of CMA in this ‘tail 
to tail’ orientation would be energetically unfavourable for this reason. However, formation of 
a monoadduct, with the morpholino substituent of CMA projecting towards the centre of the 
duplex, is quite feasible. In a drug-DNA complex of this nature, all thymine methyls of the 
DNA would be in a different environment, resulting in six different methyl peaks in the 
spectrum.
The fourth species which could be present in this reaction mixture, is a ‘head to tail’ 
CMA-DNA complex (Fig. 85). Owing to the palindromic nature of the DNA, this is equivalent 
to a ‘tail to head’ description of drug binding. All thymine methyls in this CMA-modified DNA 
duplex will be in a different chemical environment, as will the daunosamine sugar methyls of 
each CMA. A total of eight separate methyl resonances would be observable from this ‘head to 
tail’ CMA-DNA complex. Although this could well represent the species seen in the one­
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dimensional *H NMR spectrum, only 400 MHz two-dimensional NMR data could be 
accumulated on this sample.
5 '  G 1 T 2 T3 C4 C5 A6 T 7 G8 G9 A 10 A 11 C 12
Daunosamine and morpholinoHydrogen Intercalation of
bond aglycone head tail’ binding within
the minor groove.
Figure 85 Schematic representation of CMA binding in a ‘head to tail’ orientation within the self- 
complementary DNA duplex.
It was thought that this data would not be of sufficiently high quality to determine the structure 
o f the CMA-DNA adduct. As shown in Figure 85, only one aglycone is in the correct 
orientation to form a hydrogen bond with G9, i.e. the aglycone is facing the centre o f the DNA 
duplex. However, each CMA molecule has enough space to lay comfortably within the minor 
groove.
5.1.1.4 C ross-linking o f DNA by cyanom orpholinoadriam ycin
As previously described by Cullinane and Phillips (1991; 1992; 1994), the 5'GG site 
is thought to induce CMA-DNA intrastrand cross-links. Mazzini et al., (1998) examined the 
positions of the morpholino ring substituents o f 3-methoxymorpholinoadriamycin and 
morpholinoadriamycin, on formation of complexes with 5'd(C1G2A3T4C5G6)2 and 
5 d(C1G2T3A4C5G6)2 via NMR. In each case intercalation took place between 5 '-ClG2, with the 
aglycone hydroxyl within hydrogen-bonding distance o f G2N2. The daunosamine ring lay 
across G2 and T3 in the 5'-T3A4 adduct, while in the 5'-A3T4 sequence, daunosamine migrated 
closer to C11 and T 10 o f the opposite strand. The morpholino group exhibited NOEs to T4 of the 
5 AT complex and to A4 of the 5'TA CMA-DNA complex. Hence, the morpholino moiety of 
CMA would be expected to be adjacent to T7 in the CMA-5 'd(GTTCCATGGAAC) complex, 
when the aglycone intercalated between G8 and G9, with the tail projecting towards the centre o f 
the oligomer. Conversely, if  CMA was facing in the opposite direction, the morpholino group 
could be hypothesized to be located next to A11.
On cross-link formation, cyanide is lost from CMA to yield an iminium ion which can 
react with the nucleophilic centre of G-N2 (Westendorf et al. 1989). The cyanomorpholino
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substituent in the CMA-5'd(GTTCCATGGAAC) adduct is proposed to be adjacent to either an 
adenine (A11) or a thymine (T7), depending on the orientation of the drug, An inappropriate 
design o f this DNA duplex means there is no guanine in an adjacent position to the 
cyanomorpholino group. Therefore, no covalent bond can be formed between the 
cyanomorpholino moiety and G-N2 by the loss of cyanide.
CMA has bound to 5 'd(GTTCC ATGGAAC) via intercalation of the aglycone but the 
formation of a stabilizing hydrogen-bond from the 0 9  hydroxyl to G-N2 will depend on the 
orientation o f the CMA within the minor groove. It is also very unlikely that any covalent 
modification o f this DNA duplex has taken place. This is due to the lack o f a guanine 
nucleotide N2 within two flanking base pairs either side of the intercalation site. It is possibly 
the absence o f this guanine where a CMA-DNA covalent cross-link could have formed that is 
responsible for the inferior sequence-selectivity displayed by CMA on this DNA oligomer. 
Two base pairs 5'GG, are not enough to constitute a sequence selective binding site for the 
anthracycline, cyanomorpholinoadriamycin. Hence, on reaction of this drug with DNA, 
multiple species were formed.
5.1.2 The ID *H NMR spectrum of 5'd(GCTAGCTAICb
Analysis of the one-dimensional NMR spectrum (Fig. 86) of the DNA duplex 
5'd(G1C2T3A4G5C6T7A8I9C10)2 demonstrated that this was a pure sample. The spectrum was 
referenced to the D20  peak at 8 4-71ppm. The methyl and aromatic regions were examined in 
more detail, as previously described, to see if  the correct number of nucleotides were present. 
The palindromic nature o f the helix produced a single set o f resonances equivalent to one strand 
of the duplex.
Only two singlets at 8 1*5 and 8 l*6ppm were observed in the methyl region, 
corresponding to T3 and T7. Eleven peaks were present in the aromatic region, three o f which 
were doublets at 8 7-2, 8 7-3 and 8 7-4ppm which correspond to C2, C6 and C10H6. The two 
peaks at 8 7-25 and 8 7*7ppm were particularly tall and sharp and, therefore, were likely to be 
the inosine (I)H2 and adenine H2 resonances. The remaining peaks at 8 6*95 (x2 overlaid), 8
7-6, 8 7*8, 8 7-9, 8 7-1 and 8 7- 15ppm correlated with the TH6, GH8 and AH8 aromatic protons.
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5.1.2.1 The IP *H NMR spectrum of the CMA-5 WGCTAGCTAICV> complex
This DNA sequence was designed so that it contained a central 5'GC interstrand 
cross-linking site, as defined by Cullinane and Phillips (1992; 1993). It was proposed that CMA 
would intercalate between these base pairs and in doing so form an interstrand cross-link 
between the guanines. The terminal 5'GC sequences had an inosine incorporated into their 
complementary base pairs i.e. IC-3', so that no N2 was available for covalent modification by 
CMA, hence yielding a more unfavourable binding site.
Figure 87, shows the spectrum of the CMA/5'd(GCTAGCTAIC)2 DNA reaction 
mixture, after being stirred for 48h in the dark. All peaks are very broad and the sample is in 
need o f purification. However, even though this sample has produced a poorly resolved 
spectrum, the general topology of the peaks appears to be the same as in Figure 86. Purification 
of the mixture by Cig Sep Pak cartridges, followed by NMR, yielded the spectrum in Figure 88. 
Overlaying Figures 88 and 86 verified that this sample was in fact unmodified DNA duplex. 
All proton chemical shifts were identical in both spectra. The 5'd(GCTAGCTAIC)2 oligomer 
did not react with CMA to form an interstrand cross-link. CMA did not even intercalate at the 
central 5 'GC in a noncovalent mode.
5.1.2.2 CMA does not react with 5'dtGCTAGCTAICb
Cullinane and Phillips (1993) demonstrated that no cross-linking took place at 5'IC 
sites, which was why this pair of base pairs was chosen as the terminal of this DNA duplex. 
Interstrand cross-linking had been noted at 5 GC sequences (Cullinane and Phillips, 1991; 1992; 
1994). This single site was incorporated into this DNA duplex, in the hope that on reaction with 
CMA, one species of monoadduct only would be formed.
In hindsight, the 5 'GC combination of base pairs was the wrong choice o f sequence to 
target CMA in the hope o f forming an interstrand cross-link. Both Chaires et al., (1987) and 
Wang et al., (1995) described 5'(A/T)CG as the consensus sequence for binding of 
anthracyclines. The reversal of the 5'GC base pairs to 5'CG, puts the guanine N2 in a prime 
position for hydrogen bond formation with the CMA aglycone hydroxyl at C9 and the ether 
group at 07  (Wang et al., 1987; Odefey et al., 1992; Mazzini et al. 1998). Adriamycin and 
daunomycin morpholino analogues have been shown to intercalate between the terminal 5'CG 
sequences of 5'd(CGATCG)2 and 5'd(CGTACG)2 (Odefey et al., 1992; Mazzini et al., 1998). 
These oligomers are particularly short and may not truly represent the molecular movement of 
P-DNA adducts o f nuclear DNA. Terminal base pairs are not the site of choice to study the
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Figure 87 The ID *H NMR spectrum of the CMA-5 d(GCTAGCTAIC) 2  reaction mixture, prior to 
purification.
T1  •   r h  ■ i i r
1C 8 6
Figure 8 8  The ID 'HNMR spectrum post-purification of the CMA-5 d(GCTAGCTAIC) 2  reaction 
mixture.
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effect o f drug binding, because they are often subject to end-fray (base pair opening) and show 
stronger NOE connectivities than the bases in the centre of oligomers. This could confuse 
findings from NMR and molecular modelling studies. However, it would be interesting to see 
whether these analogues and, indeed, CMA would bind in a sequence-selective manner to the 
5'CGTA or 5 CGAT consensus sequences when they are incorporated into the centre o f a DNA 
duplex, or if they intercalate between 5'CG, projecting the morpholino ‘tail’ indiscriminately in 
both the 5'- and 3 '- directions. This would then explain the use of the extremely short DNA 
hexamers which trap the ligand within the DNA minor groove in one orientation only. A 
species where the daunosamine and morpholino group project outside the helix would be 
energetically unfavourable. If CMA was unable to bind to 5'ATCGTA or 5TACGAT for 
example, to form a single species owing to a lack of sequence specificity, this could also explain 
the multiple species obtained with the 5 GG containing duplex.
As with the design of the 5'd(GTTCCATGGAAC)2 sequence, the make-up o f the 
5 'd(GCTAGCTAIC ) 2  was also flawed. There was no guanine within the second flanking base 
pair, either in the 5' or 3 ' direction, adjacent to the GC base pairs o f the intercalation site. This 
would have presented an opportunity for covalent bond formation between the 
cyanomorpholino moiety o f CM A and the nucleophilic N2 of guanine. An additional two bases 
added to the consensus sequence described by Chaires et al., (1987) could possibly enhance the 
sequence selectivity o f this reaction. After consideration of previous research and these data, 
the evidence seems to suggest that the structures in Figure 89,
5" G 1 T2 A3 C4 G5 A6 C7 T8 A9 C 10
Intercalation of Hydrogen Alkylation of GI4 N2
aglycone head. bond by the morpholino moiety.
Intercalation of Hydrogen Alkylation of G7N2
aglycone head. bond by the morpholino moiety.
Figure 89 Possible DNA sequences producing CMA interstrand and intrastrand cross-links.
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are likely candidates for interstrand and intrastrand cross-linkers respectively. Both sequences 
would hopefully lead to CMA-DNA monoadducts, if  CMA does have a preferred binding 
sequence-orientation. The inability of such a potent minor groove binding agent as CMA to 
distinguish groove direction would be very unusual. This is because all other minor groove 
binding ligands (as discussed in Chapter 1) are extremely specific in their consensus sequence 
requirements, for enabling precise binding within the minor groove.
5.2 Intrastrand cross-linking in DNA by DSB-120
DSB-120 is a synthetic analogue of the naturally occurring pyrrolo [2,1- 
c\ [ 1,4]benzodiazepines (PBDs). This compound was allowed to react with the non-self- 
complementary DNA duplex 5 'd(GTGATGAG)-5 'd(CTC ATCAC), in the hope o f achieving an 
intrastrand cross-linked adduct.
5.2.1 The ID *H NMR spectrum of 5'd(GTGATGAGV5'd(CTCATCAC)
Owing to the non-palindromic nature of this sequence, each strand o f this duplex had 
to be synthesized separately. A one-dimensional proton NMR spectrum was collected on each 
strand, to check the purity of the sample and that the correct oligonucleotide had been 
synthesized.
Figure 90 shows the spectrum of the pure 5 'd(G1T2G3A4T5G6A7G8) octamer. Two 
methyl resonances were noted at 8 1-55 and 8 l-6ppm, which correlated with the two thymines 
(T3 and T5) present in this sequence. Examination o f the aromatic region between 8 7 and 8
8-5ppm showed four clear singlets at 8 7-1, 8 7-25, 8 8 0 and 8 8-2 ppm. The two peaks furthest 
upfield are likely to correspond to thymine (T3 and T5), owing to their weaker ring current 
effects yielding greater shielding than seen with purine aromatic protons. A4 and A7H8 are 
more deshielded so must correspond to the peaks furthest downfield at 8 8 0 and 8 8-2ppm. The 
peaks in the centre o f this region are quite overlaid but must incorporate G1, G3, G6 and G8H8 
protons, plus two aromatic AH2 protons.
Figure 91 displays the NMR spectrum of the oligomer
5'd(C9T10CuA 12T13C14A15C16). Inspection o f the methyl region shows two large singlets at 8 
T6 and 8 1 -8ppm, consistent with the presence of two methyls; T10 and T13. Analysis of the 
aromatic region shows a large number of well-resolved peaks. Protons with shifts of 
approximately 8 8-35, 8 8-3, 8 8 1 and 8 8*0 ppm are most likely to correspond to adenine H8 
and H2 protons o f A12 and A15. The peak at 8 7-3ppm is probably due to a thymine H6 (T10 or
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T13). The remaining peaks are more overlaid but it is possible to discern four sets of doublets at 
8 7-45, 5 7*5, 8 1-1 and 8 7*75ppm which will tally with cytosine C9, C12, C14 or C16H6s. The 
last peak at 8 7-6ppm should correspond to the remaining thymine (T10 or T13) H6.
These samples were then mixed together and annealed to form a (3-DNA duplex. 
Hydroxylapatite chromatography was used to separate the double-stranded DNA from any 
excess single-stranded DNA. The NMR spectrum of the 5 'd(GTGATGAG)-5 'd(CTCATCAC) 
duplex is given in Figure 92. Small changes in chemical shift were noted for many resonances 
on duplex formation. A total of four methyl signals at 8 1-3 (x2 overlaid), 8 1-4 and 8 l -6ppm 
were noted, relating to the methyl protons of nucleotides T3, T5, T9 and T13. The aromatic 
region is more crowded now that it harbours 4 x TH6, 4 x AH8, 4 x AH2, 4 x GH8 and 4 x CH6 
(doublets) proton resonances. This gives a total of 20 predicted peaks, 4 of which are split into 
doublets, which equals the peak count in this region o f the spectrum.
5.2.2 DSB-120 mav form an intrastrand cross-link in the DNA sequence 
5 'd(GTGATGAGV5 'd(C ACT ACTC
DSB-120 is a synthetic antitumour agent. Its structure consists of two C8-linked 
pyrrolo[2,1 -c] [ 1,4]benzodiazepine subunits, each o f which are capable of monofunctional 
alkylation of DNA via Cl la and the N2 of guanine (Hurley et al., 1977). The formation of a 
dimer results in bifunctional alkylation of the DNA, yielding interstrand cross-links. Jenkins et 
al., (1994) and Mountzouris et al., (1994) produced a refined molecular model, from NMR data, 
of the symmetric cross-link between G4 (one on each strand) of the self-complementary DNA 
duplex 5'd(CICG*ATCICG)2. DSB-120 was shown to span a total o f six base pairs at its 
preferred consensus sequence 5 '(Pu/Py)G*A TC(Py/Pu), where * and _(on  the opposite strand) 
represent sites o f covalent modification.
The 5 'd(GTGATGAG)*5 'd(CACTACTC) DNA duplex contained only the first three 
bases of the 5 'd(GATC) consensus sequence (Jenkins et al., 1994). This was because a guanine 
was required at position four instead of a cytosine, to provide an opportunity for the formation 
of an interstrand DNA-DNA cross-link via DSB-120.
Figure 93 displays the one-dimensional proton NMR spectrum of 
5 'd(GTGATGAG)-5 'd(CACTACTC) after it had been allowed to react with DSB-120 and 
purified using Cig Sep Pak cartridges. Although the sample is not very concentrated owing to 
some loss during purification, it is evident from the increased number o f peaks in this spectrum 
that some reaction has taken place. Examination of the methyl region (Appendix XX Fig. 178 
gives an expansion) shows there are approximately six peaks at 8 1-6, 8 1-55, 8 T4, 8 1-35, 8 1-3
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Figure 90 The ID ’H NMR spectrum of the single strand 5'd(GTGATGAG) DNA oligomer.
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Figure 91 The ID ’H NMR spectrum of the single strand 5 d(CTCATCAC) DNA oligomer.
Figure 92 The ID ‘H NMR spectrum of 5'd(GTGATGAG)*5'd(CTCATCAC) DNA duplex
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and 8 lT5ppm. Three peaks seem to represent unmodified DNA, duplex signalling that the 
reaction with DSB-120 is not at completion (perhaps only around 40% from the ratio o f peak 
heights). Further exposure of the DNA to DSB-120 did not change the topology o f the 
spectrum, indicating that equilibrium had been attained. Two new methyl peaks at 5 1*35 and 8 
T15ppm correspond to the DSB-120 modified DNA. The remaining two methyls o f the DNA 
which has reacted with DSB-120 seem to be overlaid with duplex resonances, perhaps 
indicating little change in chemical environment for these TCH3.
Analysis o f the aromatic region not only shows a large increase in the number o f 
peaks but, more interestingly, a broad hump has appeared at about 8 8-7ppm. Mountzouris et 
al., (1994) noted a similar peak in 90% D20  at 9Tppm in the DSB-120-5'd(CICGATCICG)2 
adduct. This was attributed to the NH proton of guanine N2 which is covalently bound to DSB- 
120 at C l l ,  via an aminal linkage. It was thought to be a result o f DSB-120-induced 
conformational stress within the minor groove, making it more accessible to the solvent. The 
fact that this peak is present in Figure 93 supports covalent modification o f 
5 'd(GTGATGAG)-5 'd(CACTACTC) by DSB-120. It is not possible to tell whether this ligand 
has only monoalkylated the DNA, probably at G3 which is incorporated in its preferred 
consensus sequence 5 (Pu/Py)G3A4, without additional two-dimensional 'H NMR NOESY, 
DQF-COSY and deuterium exchange data. It is also conceivable that an intrastrand cross-link 
may have been formed between G3 and G6, as hoped (Fig. 92).
S ' - G 1
C16 A 15 C14 T13 A12 C11 T10 C9-5'
Figure 92 The proposed structure of the intrastrand DNA-DNA cross-link formed by DSB-120.
However, the fact that this reaction did not proceed to completion indicates that there is either a 
problem with the target sequence o f the oligomer, or that intrastrand cross-linking has an 
incurred energy penalty, due to the deviation o f the propanediyldioxy linkage from its preferred
H-Bond




trans conformation, as seen in the interstrand cross-link. No further work was possible to 
investigate the exact nature o f the observed interaction between DSB-120 and this DNA 
sequence, owing to the degradation o f the PBD dimer.
Figure 93 The ID *H NMR spectrum of 5 'd(GTGATGAG)-5 'd(CACTACTC) after reaction with DSB- 
120.
5.3 The reaction of sibiromvcin with DNA
Sibiromycin is a pyrrolo[2,l-c][l,4]benzodiazepine (Gause et al. 1969). This drug 
was allowed to react with the palindromic DNA sequences 5 d(GAGATCTC) 2  and 
5 'd(GCAGAATTCTIC) 2  to try to produce a DNA adduct via alkylation of G-N2 (Hurley et al. 
1977).
5.3.1 ID *H NMR spectra of 5'd(GAGATCTCV> and 5'd(GCAGAATTCTIC
This NMR spectrum (Fig. 94) of 5 'd(GlA2G3A4T5C6T7C8)2 was analysed as previously 
described. The methyl region contained only one large singlet which integrated for six protons, 
corresponding to thymines T5 and T7 which were overlaid at 5 l-6ppm. The two upfield 
resonances in the aromatic region (8 7 05 and 8 7-2ppm) could be attributed to T5 and T7H6. In 
contrast, the two most deshielded protons were likely to be adenine A2 and A4H8s. The 
remaining peaks in this region were overlaid, owing to their integrals being twice the height o f
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the adenine and thymine singlets. This accounted for the remaining guanine and cytosine 
protons.
The 5'd(GlCJA3G4A5A6T7T8C9T T 1C l2}2 sequence produced the NMR spectrum 
shown in Figure 97. Three methyl resonances were noted at 5 1-15, 8 1-4 and 8 l-55ppm, which 
corresponded to thymines T7, T8 and T10. There appears to be the correct number o f aromatic 
H6 and H8 protons equal to: 2 x GH8, 3 x CH6, 3 x AH8, 1 x IH8 and 3 x TH6. Inosine and 
adenine H2 protons appear to be overlaid with the H6/H8 peaks.
Figure 94 The ID lH NMR spectrum of 5 d(GAGATCTC>2 .
Figure 95 The ID lH NMR spectrum following exposure of 5 d(GAGATCTC) to sibiromycin.
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5.3.2 The reaction of sibirom vcin w ith 5 d(GAGATCTC)? and 5 'd (G C A G A A T T C T IC b
The methyl region of the NMR spectra yielded from each oligonucleotide sequence would be 
expected to symbolize whether sibiromycin had indeed formed a drug-DNA adduct on mixing. 
Purification using Cig Sep Pak cartridges would have removed any unreacted drug from the 
sample. Additional methyl resonances observed in these spectra, therefore, would symbolize 
sibiromycin covalently bound to DNA. There are five methyl groups in the structure of 
sibiromycin (Fig. 96), whose expected chemical shifts would be approximately: CFh-C=C 





Figure 96 The molecular structure of sibiromycin.
Figure 95 shows that no modification o f the DNA self-complementary sequence 
5'd(GAGATCTC)2 has occurred, even after 2 x 48h exposures to sibiromycin. This ’H NMR 
spectrum is identical to that o f the duplex DNA in Figure 94. Sibiromycin does not bind to the 
synthetic oligomer 5 d(GAGATCTC)2.
Inspection of Figure 98, however, shows there is a marked increase in the complexity 
o f this *H NMR spectrum, symbolizing a possible reaction between 
5 'd(G1C2A3G4A5A6T7T8C9T 10I11C12)2 and sibiromycin. Comparison o f this spectrum with the 
one corresponding to the duplex (Figure 97), demonstrated that the reaction of this sequence 
with sibiromycin had not achieved completion yielding adduct only. The methyl resonances 
corresponding to T7, T8 and T10 were in analogous positions in both spectra, indicating duplex 
DNA persisted after two exposures to sibiromycin. Some new methyl peaks did appear in 
Figure 98, which corresponded to both sibiromycin methyls, as well as those of T7, T8 and T 10. 
The chemical environments o f these thymine methyls are likely to have changed on 
modification o f this sequence by sibiromycin, leading to upfield or downfield shifting o f these 
peaks to new positions. These new methyl peaks seem to be located at approximately 8 1-15(2 
x CH3 overlaid?), 8 1-35, 8 1-6, 8 1-65 and 5 l-75ppm. They are all only about two thirds o f the
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height of the remaining DNA duplex methyl peaks, some existing as shoulders only on these 
peaks. This suggests that sibiromycin has at best, only modified 40% of the DNA in this sample 
i.e. a ratio of 3:2 unreacted:reacted DNA. No further analysis of the nature of the sibiromycin- 
modified DNA was undertaken owing to the small size of the sample, which would have made 
2D *H NOESY assignments extremely difficult.
Figure 97 The ID *H NMR spectrum of 5'd(GCAGAATTCTIC)2.
Figure 98 The ID *H NMR spectrum following exposure of 5 d(GCAGAATTCTIC)2 to sibiromycin
Hurley et al., (1980) constructed CPK models to demonstrate how the concave surface 
(C9, N10, C l 1, C l la  and C l) o f PBDs such as sibiromycin bound isohelically within the minor 
groove. Mostad et al., (1978) described the stabilizing influence the sibirosamine sugar would 
have from within the minor groove via its interaction with the sugar phosphate backone. 
Sibiromycin can compete for the binding sites o f anthramycin and tomaymycin (Hurley et al.,
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1977). The most preferred binding sequence in DNA for the PBDs is 5'PuGPu (Hertzberg et 
al., 1986). Pierce et al., (1993) defined these purines as adenines in the case o f anthramycin and 
tomaymycin binding, yielding the consensus sequence 5'AGA. Considering sibiromycin can 
compete for both of these binding sites, it would be logical that 5'AGA would also be a 
consensus sequence for sibiromycin. Puwada et a l, (1997) established that in fact sibiromycin 
was a stronger inhibitor o f transcription by binding to plasmid DNA, than tomaymycin, 
anthramycin or neothramycin. Blockage of transcription took place at the 5' AGA sequence by 
sibiromycin.
Considering the preferred consensus sequence for sibiromycin binding has proved to 
be 5'AGA, the 5 d(GAGATCTC)2 and 5'd(GCAGAATTCTIC)2 DNA duplexes used in this 
study, would have been expected to produce sibiromycin-DNA adducts. The latter sequence did 
undergo some low level modification, perhaps due to the higher adenine content within the 
flanking sequences (Puwada et al., 1997). It is probable that the consensus sequence for 
sibiromycin is more complex than that described by a 5 'AGA trimer. The flanking sequence 
could induce some conformational effect on DNA which makes the binding o f sibiromycin 
more favourable. It would be interesting to see if  synthetic DNA oligomers consisting of base 
combinations such as 5'AAAGACA or 5'CAAGAAC, which were pinpointed as particularly 
reactive sequences in the transcription footprinting assays, were more successful in forming 
synthetic sibiromycin-DNA adducts.
It is also possible that some environmental factor may have inhibited sibiromycin 
binding to these synthetic oligomers. Gause et al., (1975) found that sodium dodecylsulphate 
completely blocks the interaction o f sibiromycin with DNA, but is unable to induce dissociation 
of the ligand from a preformed complex. Dimethylformamide has also been demonstrated to be 
unable to remove sibiromycin from a preformed drug-DNA adduct. However, 
dimethylformamide was added to the sibiromycin/NMR buffer/D20/DNA reaction mixture to 
increase the solubility and hence, availability o f sibiromycin for reaction. Dimethylformamide 
could be responsible for blocking sibiromycin-DNA adduct formation. Gause and Dudnik, 
(1972) described the inhibition o f the sibiromycin reaction with native DNA in the presence of 
Mg2+ ions. Some ion contamination in these samples may have produced the same effect. Use 
of a chelating agent such as EDTA to sequester ions, could solve a problem such as this.
It is not clear why sibiromycin did not react with these synthetic nucleotides 
containing the preferred 5'AGA consensus sequence. This is particularly perplexing when 
sibiromycin is known to be a potent alkylator of DNA.
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CHAPTER 6: CONCLUSION
The covalent modification o f two DNA sequences 5'-d(CGTAAGCGCTTA*CG)2 and 
5 '-d(CGAAAAA*CGG)-5 -d(CCG ITT'1'TCG) by adozelesin has been investigated by high- 
field NMR. A refined molecular model was generated o f each adozelesin-DNA adduct structure 
using distance-range restraints. The molecular models o f these DNA adducts which demonstrate 
the binding o f the pharmacologically active, monofunctional cyclopropapyrroloindole 
adozelesin are the first o f their kind.
Despite the differences in these DNA sequences, there were some fundamental 
similarities between the two adduct structures. Adozelesin covalently modified the N3 of 
adenine from within the minor groove, with the benzofuran ‘tail* extending in the 5 '-direction. 
In each case, the concave hydrophobic surface of the drug was directed deep into the minor 
groove, whilst the convex hydrophilic spine was directed out o f the groove in contact with the 
surrounding solvent. The sequence-specificity of adozelesin has been previously noted in 
sequencing studies (Weiland and Dooley, 1991), who described p(A) and 5'-(T/A)(TA)T- 
A*(C/G)G consensus sequences. The 5'-TTA*CG and 5-AAAAA* binding sites were 
incorporated into the DNA duplexes used in this study and, in both cases, adduct formation was 
sequence specific, yielding only one major adduct species.
Perhaps one o f the most interesting observations noted within the 5 '- 
d(CGTAAG6CGCTTA*CG)2-adozelesin adduct is the significant distortion noted around the 
central guanine (G6). This guanine is on the unmodified strand and is adjacent to the ureylene 
linker between the benzofuran and indole sub-units o f adozelesin. Previous studies with 
bizelesin (Thompson et al., 1995) have indicated the important role o f this linker in determining 
the sequence specificity o f this dimeric compound. A hydrogen-bond from the exocyclic amine 
of the central guanine in the consensus sequence to the carbonyl o f the linker distorted the 
duplex in such a manner that seven base-pairs (5 -TTAGTTA) were spanned to form the cross­
link instead o f six. This NMR and dynamics study indicates that a similar situation also exists 
within the monomeric CPI analogues, in that this linking function between the sub-units may 
have a significant effect in allowing the binding o f these ligands to DNA sequences which 
would not normally be favourable for binding. Whilst Weiland and Dooley (1991) restricted 
their consensus sequence to AT base pairs, Yoon and Lee (1998) have identified the 
incorporation of a GC base-pair at the first and second flanking base-pair positions. GC-rich 
minor grooves are generally wider, with the steric problem of the guanine-NH2 projecting into 
the minor groove and colliding with any ligand situated there. The hydrogen-bond between the 
amide of the linker and the carbonyl o f thymine possibly tethers the adozelesin to the modified 
strand, stabilizing the structure so that the benzofuran ‘tail’ does not ‘flail’ around within the
208
minor groove. The second, weak (or maybe even transient) bifurcating hydrogen-bond to the 
guanine-NH2 may encourage the observed distortion around this base.
However, a second strong explanation for the distortion around G6 is that it is a result 
of a distortional wave propagated from 6 bp upstream where a second adozelesin molecule is 
alkylating this duplex at A12 on the same strand. Similar proposals of this nature have been cited 
in the literature previously. Seaman et al., (1996) established that CPI-I bisalkylation o f 5'- 
T A A2 A A A1 proceeded in a ‘head to tail’ fashion as a result o f this phenomenon. Lin et al., (see 
review by Hurley and Draves, 1993) also observed a distortion around a cytosine (G7 = C18) 
adjacent to (+)CC-1065 on the non-covalently modified strand of the sequence 5 '-G7T8T9A10\  
This cytosine is in exactly the same position as G6 o f this study. A similar conformational 
change has also been noted in homeodomain binding specificity studies (Ades and Sauer, 1994). 
The results o f this study verify that cyclopropapyrroloindoles give rise to a distortion when 
binding to the minor groove. Without further investigation, one can only speculate whether it is 
upstream of the modification site or adjacent to the ureylene linker as a result of a bifurcating 
bond. The CPI-I ligand does not contain a ureylene linker owing to the lack of a third sub-unit. 
Therefore, the distortion noted within the CPI-I bisadduct cannot be attributed to the ureylene 
linker. This suggests the former explanation is more favourable i.e. it is the 
cyclopropapyrroloindole ‘headunit’ common to all of these structures which is responsible for 
the distortion. This could be examined by binding a CPI ‘headunit’ only to DNA duplex to 
form a monoadduct, using a duplex sequence such as 5 '-d(CGCGCGTTA*CGCGCG)2. This 
duplex contains a single alkylation site (due to its self-complementary nature) and eight flanking 
base-pairs in the 5 '-direction to detect any distortion. No evidence was available from the ‘A’ 
tract adduct to determine whether distortion was present, because the 6th flanking base-pair was 
a terminal. Extending the terminal ends by an extra set o f two base-pairs would provide an 
answer to this question.
Previous studies with (+)CC-1065 have also shown that the ethano bridges o f the B 
and C sub-units in the natural product are responsible for the observed delayed lethality and 
DNA over-winding (Sun and Hurley, 1992b; Warpehoski et al., 1988). Interestingly, in (+)CC- 
1065, the NH of the amide linker is part o f a ring system incorporating these ethano bridges and 
the amine is hence unable to interact with the DNA, as observed in this self-complementary 
adozelesin-DNA adduct. Obviously, the origins o f over-winding must originate from ligand- 
DNA interactions around the amide linker between the sub-units. A future direction o f this 
project could be to synthesize a closely related (+)CC-1065 and adozelesin duplex-adduct using 
the same DNA sequence, to try to establish the exact structural origins o f the DNA over­
winding in (+)CC-1065 adducts. The observation o f significant hydrogen-bonding within the 
adozelesin-self complementary DNA adduct would appear to indicate a significant difference in
209
the binding mechanism for these two closely structurally related compounds. It is likely that this 
difference holds the key to the inability o f adozelesin to over-wind DNA and cause the delayed 
lethality observed with (+)CC-1065.
The fact that the adozelesin-5 -d(CGTAAGCGCTTA*CG)2 adduct results in a 
symmetrical bisadduct with adozelesin orientated ‘tail to tail’ yields the possibility of 
synthesizing an adozelesin dimer. The bisalkylation o f 5'-T A A2 A A A1 by CPI-I (half of 
bizelesin dimer) proceeds unsymmetrically in a ‘head to tail’ orientation o f the ligands. This 
indicates a conformational change in the second binding site (6 bp upstream) after the first CPI-I 
binds, which leads to the second CPI-I binding more favourably in the reverse orientation. A 
distortion 6 bp to the 5 '-side of the first binding site to which bizelesin alkylates is likely to 
make the second alkylation less favourable, which is reflected in the rate of cross-link formation 
(Woynarowski et al., 1995). The adozelesin bisadduct does not encounter this problem; hence, 
it would follow that a synthesized adozelesin dimer, wherein the adozelesin molecules are 
linked ‘tail to tail’ via a linker similar to that o f bizelesin, would produce an extremely potent 
cross-linker with increased sequence selectivity, owing to the drug being able to span a longer 
consensus sequence o f 10 base-pairs. This is approaching the 15 base-pairs required for 
recognition of a single site on the human genome, for complete sequence selectivity.
It is clear from inspection o f the DNA ‘A’ tract-adozelesin adduct that binding of 
adozelesin within this sequence yields a complementary fit better than that observed in the self- 
complementary adduct. Within the ‘A’ tract, adozelesin lies ‘edge-on’ and centrally positioned 
along the length o f this deep, narrow minor groove. The facts that the sub-units of adozelesin do 
not show alternate close associations with the modified and unmodified strands or curving o f the 
drug demonstrates why adozelesin is able to span six rather than five base-pairs. The NMR data 
and the resulting refined molecular model both indicate that ‘A’ tract character has been 
maintained after formation o f the adduct. This is the first monofunctional cyclopropapyrrolo- 
indole-‘A’ tract DNA adduct to be characterized.
The maintenance o f propellor twisted ‘A’ tract character (Nelson et al., 1987) was 
detected after adduct formation by high-field NMR. The insertion o f an ‘A’ tract sequence (the 
length of a half-helical turn) between two general base sequences with no base-pair roll yields a 
macroscopically bent DNA structure (Nelson et al., 1987; Goodsell et al., 1994). Although 13- 
helical structure is conserved on adduct formation, it is obvious from the model that the DNA is 
macroscopically bent, with the flanking base pairs to the 3 '-side o f the alkylation site showing 
the most deviation from the helix axis. A slight compression o f the major groove is also 
observed. Adozelesin clearly favours the unique conformation o f this DNA sequence. The 
bending of the helix, beginning at the end o f the ‘A’ tract, facilitates the fit o f the CPI headunit,
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with the projecting methyl allowed more space to follow the floor o f the minor groove as the 
helix bends. This allows adozelesin to bind perfectly ‘edge-on’ and in a central position. The 
narrowness of the minor groove promotes many non-covalent interactions (van der Waals 
forces) from the close complementarity o f fit of adozelesin, which enhances the bias of the 
sequence selectivity o f the drug towards ‘A’ tract sequences. This agrees with the finding of 
Weiland and Dooley (1991), where p(A) was the most preferred consensus sequence, as indeed 
it is o f many minor groove binding agents for the same reasons. Unlike previous studies where 
the binding of bizelesin was able to trap out straight DNA after the formation of an interstrand 
cross-link across the ‘A’ tract impeded propellor twisting (Thompson and Hurley, 1995), 
monoalkylation does not affect ‘A’ tract character which is advantageous to binding.
Only multiple species of the cyanomorpholinoadriamycin-DNA adduct were obtained 
with the DNA sequences used in this study. Hence, no refined molecular model was obtainable. 
However, an adduct has been reported in the literature (Mazzini et al., 1998) where CM A is 
intercalated between the terminal base-pairs of the 5'-d(CGATCG)2. This was not thought to 
give a true representation of the adduct structure in an NMR study, owing to the effects of 
fraying of the terminal bases. It would be interesting to see whether CMA would bind in a 
sequence selective manner to the 5-CGTA or 5'-CGAT consensus sequences when they are 
incorporated into the centre o f a DNA duplex. The use of a terminal strand intercalation site 
may be a tactic to avoid CMA binding to the minor groove in either orientation. A sequence- 
selective minor groove binder which did not specify a particular binding orientation, i.e. the 
morpholino ‘tail’ directed to 5'- or 3'-, would be very unusual. The sequences 5'- 
d(GTACGACTAC) and 5'-d(GTACGAGTAC) could be a good starting point for producing 
interstrand and intrastrand cross-linking monoadducts, respectively.
The pyrrolo[2-l-c][l,4]benzodiazepines DSB-120 and sibiromycin were also 
investigated. An NMR study on the DSB-120-5'-d(GTG*ATG*AA) adduct suggested that an 
intrastrand cross-link may have formed in this sequence. This would be particularly interesting 
because DSB-120 is normally associated only with interstrand cross-links. Sibiromycin, 
however, could be persuaded to react with the 5'-d(GCAGAATTCTIC)2 duplex only partly, 
while it did not react at all with the 5 '-d(GAGATCTC)2 duplex. This was quite unexpected, 
considering that both sequences contain the 5 '-AGA site which is known to be the consensus 
sequence for sibiromycin (Hurley et al., 1977; Hertzberg et al., 1986). This suggests that the 
consensus sequence for sibiromycin is more complex than the 5 '-AGA trimer. It is possible that 
the flanking sequence, e.g. like the ‘A’ tract in the adozelesin adduct, induces some 
conformational change of DNA which makes the binding o f sibiromycin more favourable.
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It is clear from the varying degrees o f success in the production of drug-DNA adducts 
investigated in this project that the requirements of the make-up o f the DNA consensus 
sequence as defined by the drug are extremely stringent. These minor groove binding ligands 
will not be ‘fooled’ into binding to any base in DNA just because it can form a covalent bond to 
it. The complementarity of the fit between the ligand and the binding site and, more importantly, 
the abundance of non-covalent interactions to which it gives rise within the flanking sequence, 
dictates the sequence-specificity of these minor groove binding drugs.
The adozelesin-DNA self-complementary adduct in this study has provided a new and 
exciting starting point for rational drug design of an adozelesin dimer, a proposed antineoplastic 
agent with enhanced sequence-selectivity. Not only has the first CPI-‘A’ tract adduct structure 
been characterized where adozelesin is a perfect isohelical fit within the minor groove, but it has 
also been demonstrated how adozelesin achieves tolerance o f unfavourable GC-bases within its 
consensus sequence. These adozelesin-DNA adducts have proved to be an excellent model 
system to investigate the molecular basis for DNA sequence recognition and binding. An 
understanding of sequence-specificity is the key first step in the design o f new drugs which will 
react with their molecular target in a defined and predictable manner.
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APPENDIX I
PERKIN ELMER 62 STEP PROTOCOL FOR OLIGONUCLEOTIDE 
SYNTHESIS
































Function Name Step Time
#18 to waste 6




Tet to Waste 3
B+Tet to Column 100
Wait 30
#18 To Waste 10




Cap to Column 60
Reverse Flush 5
Cap to Column 50
Reverse Flush 5
Cap to Column 50
Wait 120
#18 To Waste 10
Block Flush 6
#15 To Waste 10
#15 To Column 180
Wait 30
#18 To Waste 10
Reverse Flush 80
Block Flush 5
#18 To Column 100
Reverse Flush 80

































9 #18 To Column 100
2 Reverse Flush 80
9 #18 To Column 100
2 Reverse Flush 80
1 Block Flush 6
33 Cycle Entry 1
10 #18 To Waste 7
9 #18 To Column 50
2 Reverse Flush 80
1 Block Flush 6
6 Waste Port 1
5 Advance FC 1
82 #14 To Waste 5
14 #14 To Column 80
2 Reverse Flush 5
14 #14 To Column 50
2 Reverse Flush 5
14 #14 To Column 50
2 Reverse Flush 5
14 #14 To Column 50
2 Reverse Flush 5
14 #14 To Column 50
2 Reverse Flush 5
14 #14 To Column 50
1 Block Flush 6
10 #18 To Waste 5
9 #18 To Column 160
2 Reverse Flush 80
1 Block Flush 6
7 Waste Bottle 1
34 Cycle End 1
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APPENDIX II
The four stages of oligonucleotide synthesis
A summary (Applied Biosystems manual) of the four stages of oligonucleotide synthesis, using 
automated solid-phase phosphotriester and phosphoramidite chemistry (Gait, 1984).
1) D etritvlation
The purpose o f this step is to remove the dimethoxytrityl protecting group from the 5 -OH 
of the nucleoside anchored to the column using TCA (Fig. 99).
Figure 99 Detritylation of the 5' end nucleoside.
5'DMTrI
O Base (C,G,A,T,I)
0 = P ~ O C H
Base (C or G)
CPG Support
from TCA O — ? OCH,




The 5' hydroxyl is then available for further reaction.
21 A ddition
Tetrazole is added to the column simultaeneously with the nucleoside derivative, so that it 
will protonate the nitrogen of the diisoprapyl group on the 3' phosphorus. This makes the 
phosphoramidite susceptible to nucleophilic attack, by the detritylated hydroxyl o f the 
growing DNA strand attached to the column. This results in a (5' to 3 ) intemucleotide 






























Figure 100 The coupling of a phosphoramidite to the nucleotide on the column.
3) Capping
Although the coupling reaction should have an efficiency of between 98-100%, a 
capping procedure is required to terminate any chains which did not undergo addition, thus 
limiting the lengths o f any impurities and facilitating post-synthetic purification. The 
deoxynucleotides which reacted with the phosphoramidite previously, are blocked with a 
dimethoxytntyl group, whereas the unreacted chains have a free 5 'OH that requires capping. 
This is achieved using an acetylating agent formed from equal volumes of equimolar acetic 
anhydride and dimethylaminopyridine (DMAP) (Fig. 101).
























Figure 101 Capping reaction to terminate unreacted chains.
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4) O xidation
The linkage formed in the coupling reaction is an unstable phosphite (trivalent phosphorus) 
triester one, which is susceptible to acid and base cleavage. Conversion to a more stable 
pentavalent phosphate triester is therefore performed immediately after the capping step, 
hence also avoiding the water from the oxidising solution causing acetic anhydride to form 
acetic acid around the oligonucleotides. Iodine is the oxidising agent and water the oxygen 
donor in a basic lutidine/tetrahydroturan (THF) solution. On delivery to the column, an 
iodine lutidine complex is formed with the rivalent phosphorus, where it then undergoes 
displacement by water to a pentavalent phosphorous, within 30 seconds (Fig. 102).














Figure 102 Oxidation of the intemucleotide linkage to a stable pentavalent phosphorous.
These four steps were repeated for each nucleoside addition to the DNA strand, resulting in 
an oligonucleotide attached to the CPG column at the 3 ' terminal and protected by a 
dimethoxytrityl group at the 5' terminal.
APPENDIX III
The 400 MHz NOESY *H NMR spectrum of the DNA duplex 5 - 
rC‘GzT ,A V G tC7GllC!,TluTllAlzC‘,Gl4) ~
Figure 103 The 400 MHz NOESY lH NMR spectrum of the DNA duplex 5 -
(C G2T3A4A5G6C7G8C9T10Tn A,2C13G,4>2
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Figure 104 The 400 MHz NOESY *H NMR spectrum of the DNA duplex 5 - 
(C1G2T3A4A5G6C7G8C9Tl0T11Al2C13G14)2 The H6/H8-*H3' region.
Figure 105 The 400 MHz NOESY ‘H NMR spectrum of the DNA duplex 5 -  
(C 1G2 T3 A4 A5 G6 C7 G8 C9 T 1 0T 1 1A1 2 C1 3G14)2. The H6 /H 8 -»H 6 /H 8  region.
T,,CHj
4C,JH2 ICTU'l
C'H 21 —  
P H 2 1
C*H2' 1— ■ T"Hil-2 
P*H2 1 2 -
C 'JH 2 2 —
C H 2'2  








A T O 2  
Al:f j2 ‘2
A W  2-
. I Dl| I l\\\\ .............................
- > - o ----- H-o->QoQ>_ n —i-cnrrt
5  3  ■? x x -f ^ 5 x
Figure 106 The 400 MHz NOESY !H NMR spectrum of the DNA duplex 5 -









Figure 107 The 400 MHz NOESY 'H NMR spectrum of the DNA duplex 5 -  
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Figure 108 The 400 MHz NOESY ‘H NMR spectrum of the DNA duplex 5 -
(C1G2T3A4A5G6C7G8C9T10T1iA12C13G14)2 The H17H3'->H47H5'1/H5'2 region.
223
APPENDIX IV
One-dimensional NMR spectrum of the DNA and adozelesin-DNA reaction 
mixture.
Figure 109 One-dimensional 'H NMR spectrum of the 5'-(C,G2T3A4A5G6C7G8C9T10T11A12C,3G14)2 DNA 
duplex and adozelesin-DNA adduct reaction mixture.
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APPENDIX V
The 400 MHz DQF-COSY spectrum of the adozelesin-5 
fC lG 2T3A4A5G>C7G!,C;,T l,)T A^'C'^G14^  DNA adduct.
Figure 110 The 400 MHz DQF-COSY NMR spectrum of the adozelesin-5 -
(C°G£r3A4A5G6C7G8C9T10TllA12*C13Gl4)2 DNA adduct.
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Figure 111 The 400 MHz DQF-COSY NMR spectrum of the adozeIesin-5-
(C1G2T3A4A5G6C7G8C9T10ThA12*C13G14)2 DNA adduct. The CH5->CH6 region.
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Figure 112 The 400 MHz DQF-COSY NMR spectrum of the adozelesin-5 '-





Figure 113 The 400 MHz DQF-COSY NMR spectrum of the adozelesin-5 -
( C 'G ^ a V g ^ G V t V V ^ C ^ G 14^  DNA adduct The H2'1->H2'2 region.
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Figure 114 The 400 MHz DQF-COSY NMR spectrum of the adozelesin-5 - 











Figure 115 The 400 MHz DQF-COSY NMR spectrum of the adozelesin-5 -
(C1G2T3A4A5G6C7G8C9T10T11A12*C13G14)2 DNA adduct. The aromatics-^aromatics region.
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APPENDIX VI
The 400 M ID NQESY^HNM R spectrum of the adozelesin-5 - 
(CIG2T3A4ASG6C7G?<C;,Tl0T 11A li Ci3G 14^  DNA a d d u c ~
Figure 116 The 400 MHz NOESY 'H NMR spectrum of the adozelesin-5
(C G 2T3A4A5G6C7G8C9T10T uA12*C13G14)2 DNA adduct.
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Figure 117 The 400 MHz NOESY !H NMR spectrum of the adozelesin-5 -
(C1G2! 0A4A5G*’C7G8C9TI0T 11 An 'C 1 3G i 4 >2 DNA adduct. The H1'->H2'1/H2'2 region
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Figure 118 The 400 MHz NOESY *H NMR spectrum of the adozelesin-5 
(C,G2T3 A4 A5G6 C7 G8C9 TioT,,A,2 *C,3 G , 4 ) 2  DNA adduct. The H2'1-»H2'2 region
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Figure 119 The 400 MHz NOESY *H NMR spectrum of the adozelesin-5











Figure 120 The 400 MHz NOESY NMR spectrum of the adozelesin-5'-
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Figure 121 The 400 MHz NOESY !H NMR spectrum of the adozelesin-5'-
( C ^ V a ^ V C ^ C V V V ^ C 13^  DNA adduct. The H3'->H47H5'1/H5'2 region.
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Figure 122 The 400 MHz NOESY *H NMR spectrum of the adozelesin-5 - 










Figure 123 The 400 MHz NOESY *H NMR spectrum of the adozelesin-5
(C1G2T3A4A5G6C7G8C9T10T,1A12'C 13G14>2 DNA adduct. Adozelesin NOEs from the CPI headunit.
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APPENDIX VII
The 600 MHz DQF-COSY lH NMR spectrum of the adozelesin-5 
DNA adduct"
CD <7> cn ro
oo
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Figure 124 The 600 MHz DQF-COSY *H NMR spectrum of the adozelesin-5
(C G2! 0A4A5G6C7G8C9TI0Tl 1 A12*C 13G14>2 DNA adduct.
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Figure 125 The 600 MHz DQF-COSY NMR spectrum of the adozelesin-5'-
(C1G2T3 A4 A5G6 C7 G8 C9 T 1 0T1 1A1 2*C1 3G 1 4 ) 2  DNA adduct. The aromatics-^aromatics region and the 
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Figure 126 The 600 MHz DQF-COSY NMR spectrum of the adozelesin-5'-
(C1G2T3A4A5G6C7G8C9T10T11Al2*C13G14)2 DNA adduct. The H2'1->H2'2
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Figure 127 The 600 MHz DQF-COSY *H NMR spectrum of the adozelesin-5-









N O  (*> Lnto m
—T“H5I
—  O H 5 I— CWl






—  C IO '
Figure 128 The 600 MHz DQF-COSY ]H NMR spectrum of the adozelesin-5-
(C1G2T V a 5G6C7G8C9T,0T1,A12*C13G14)2 DNA adduct. The H5'1->H5'2 region
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Appendix VIII
The 600 MHz NOESY^H NMR spectrum of the adozelesin-5 
( C ^ V A W ^ G V T ' T ^ ^ C ^ G 1^  DNA adduct.
Figure 129 The 600 MHz NOESY 'H NMR spectrum of the adozelesin-5-






Figure 130 The 600 MHz NOESY NMR spectrum of the adozelesin-5 - 






Figure 131 The 600 MHz NOESY ’H NMR spectrum of the adozelesin-5
(C,G2T3A4A5G6C7G8C9T10T,1A12*C13G14)2 DNA adduct. The aromatics-»aromatics region.
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Figure 132 The 600 MHz NOESY ]H NMR spectrum of the adozelesin-5-
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Figure 133 The 600 MHz NOESY ]H NMR spectrum of the adozelesin-5
(C1G2tV a 5G6C7G8C9T10T11A12*C,3G14)2 DNA adduct. The H I', H4\ H3', H5'l and H5'2 proton NOEs.
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Figure 134 The 600 MHz NOESY *H NMR spectrum of the adozelesin-5 - 
(C 1G2 T3 A4 A5 G6 C7G8 C9 T,0T 1IAI2 "C13G , 4 ) 2  DNA adduct The H I’, H3', H4’->H2’1/H2’ region.
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Figure 135 The 600 MHz NOESY 'H NMR spectrum of the adozelesin-5 
(C 1G2T3 A4 A5 G6 C7 G8 C9 T 1 0T 1 1A 1 2 *C1 3G 1 4 ) 2  DNA adduct. The H2 ' 1 -*H 2 ' 2  region.
APPENDIX IX
The 600 MHz TOCSY *H NMR spectrum of the adozelesin-5'- 
lC1G W A iGtC1GlC’Tl'T "A '1 C 'i G'<l, DNA adducT
.
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Figure 137 The 600 MHz TOCSY ’H NMR spectrum of the adozelesin-5 
(C1G2 T3 A4 A5 G6 C7 G8 C9 T1 0T1 1A1 2 *C1 3G 1 4 ) 2  DNA adduct Stacked plot.
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Figure 138 The 600 MHz TOCSY *H NMR spectrum of the adozelesin-5-






Figure 139 The 600 MHz TOCSY !H NMR spectrum of the adozelesin-5-





Figure 140 The 600 MHz TOCSY 'H NMR spectrum of the adozelesin-5- 







Figure 141 The 600 MHz TOCSY NMR spectrum of the adozelesin-5- 
(C1G2T3A4A5G6C7G8C9T10T11A12*C13G , 4 > 2  DNA adduct. The H17H3'->H2'1/H2'2 region.
Figure 142 The 600 MHz TOCSY *H NMR spectrum of the adozelesin-5 
(C G2T3A4A5G6C7G8C9T10T11A12*C13G1 4 > 2 DNA adduct. Deoxyribose proton NOEs.
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Appendix X
The 600 MHz ROESY 2D *H NMR spectrum of the adozelesin-5'- 
(C 1G 2r iA4A5GtC7G,lC*T1(lT11A i2 C u G14)7 DNA adduct
00
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Figure 143 The 600 MHz ROESY *H NMR spectrum of the adozelesin-5
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Figure 144 The 600 MHz ROESY *H NMR spectrum of the adozelesin-5




Figure 145 The 600 MHz ROESY *H NMR spectrum of the adozelesin-5'-
(C1G2T3A4A5G6C7G8C9T10Tn A12*C13G14) 2  DNA adduct. The aromatics->CH5 region.
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Figure 146 The 600 MHz ROESY ’H NMR spectrum of the adozelesin-5-
( C ^ W a W g W Y 1^ 13^  DNA adduct. The H2'1->H2'2 region.
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Figure 147 The 600 MHz ROESY *H NMR spectrum of the adozelesin-5'-
(C G2!0A4A5G6C7G8C9T10T11 A12*C13G14>2 DNA adduct. The deoxyribose protons cross-connectivities.
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Appendix XI
The Master Assignment Spreadsheet for the adozelesin self-complementary 
adduct
Table 6 The Master Assignment spreadsheet.
1: SHIFT
1: A/C1.H5’2 3.922
2: A/Cl .H5’1 3.547
3: A/C1 .H4’ 3.934
4: A/C1.H1’ 5.577
5: A/C1 .H2’2 1.803
6: A/C1 .H2’1 2.202
7: A/C1.H3’ 4.567
































































1: SHIFT 1: SHIFT
71: B/G8.H3’ 4.787 106: B/A12.H5’2 4.182
72: B/G8.H8 7.583 107: B/A12.H5’1 3.788
73: B/C9.H5’2 4.027 108: B/A12.H4’ 4.271
74: B/C9.H5’1 3.808 109: B/A12.H1’ 5.749
75: B/C9.H4’ 4.144 110: B/A12.H2’2 2.542
76: B/C9.H1’ 5.816 111: B/A12.H2’1 2.809
77: B/C9.H2’2 1.825 112: B/A12.H3’ 4.832
78: B/C9.H2’1 2.175 113: B/A12.H8 8.375
79: B/C9.H3’ 4.337 114: B/A12.H2 7.956
80: B/C9.H6 7.194 115: B/C13.H5’2 3.671
81: B/C9.H5 5.221 116: B/C13.H5’1 3.353
82: B/T10.H5’2 3.304 117: B/C13.H4’ 4.023
83: B/T10.H5’1 2.789 118: B/C13.H1’ 5.240
84: B/T10.H4’ 4.151 119: B/C13.H2’2 1.575
85: B/T10.H1’ 5.748 120: B/C13.H2’1 2.015
86: B/T10.H2’2 1.725 121: B/C13.H3’ 4.493
87: B/T10.H2’1 2.265 122: B/C13.H6 7.212
88: B/T10.H3’ 4.338 123: B/C13.H5 5.538
89: B/T10.H6 7.157 124: B/G14.H5’2 4.033
90: B/T10.H5M3 1.365 125: B/G14.H5’1 3.759
91: B/T10.H5M2 1.365 126: B/G14.H4’ 4.145
92: B/T10.H5M1 1.365 127: B/G14.H1’ 5.993
93: B/T10.Q5M ? 128: B/G14.H2’2 2.226
94: B/T11 .H5’2 3.708 129: B/G14.H2’1 2.527
95: B/T11.H5’1 3.555 130: B/G14.H3’ 4.596
96: B/T11.H4’ 3.988 131: B/G14.H8 7.797
97: B m i.H 1 ’ 5.095 132: A/OH1.H3 7.985
98: B/T11 .H2’2 1.526 133: A/OH1.H6 6.980
99: B/T11 .H2’1 1.623 134: A/OH1.M1 2.546
100: B7T11.H3’ 4.392 135: A/OH1.M2 2.546
101: B/T11.H6 7.062 136: A/OH1.M3 2.546
102: B/T11 .H5M3 1.453 137: A/OH1.H8A2 4.495
103: B/T11.H5M2 1.453 138: A/OH1.H8A 5.063
104: B/T11.H5M1 1.453 139: A/OH1.H8B 5.155




142: A/OH1 .H7’1 7.629
143: A/OH1.H6’1 8.243
144: A/0H1.H4’1 7.805
145: A/0H1 .H3’1 7.283
146: A/OH1.H4’2 7.932
147: A/0H1 .H5’2 7.497
148: A/0H1 .H6’2 7.373
149: A/0H1 .H7’2 7.736
150: A/OH1 .H3’2 7.651
APPENDIX XII
The Peak Pick Spreadsheet for the adozelesin-DNA self-complementary adduct.
Table 7 The Peak Pick Spreadsheet.
1: PCS1 2: POS2 3: INTEGRAL 4: ATOM_POS1 5: ATOM_POS2 6: LOWER 7: UPPER
1: P1 7.51 1.80 4.77e+06 A/C1.H6 A/C1.H2’2 1.58 3.00
2: P2 7.51 2.20 5.83e+06 A/C1.H6 A/C1.H2’1 1.58 3.00
3: P3 7.83 2.51 6.77e+06 A/G2.H8 A/G2.H2’1 1.58 3.00
4: P4 7.83 2.46 2.37e+06 A/G2.H8 A/G2.H2’2 1.58 3.00
5: P5 7.33 2.19 5.68e+06 A/T3.H6 A/T3.H2'2 1.58 3.00
6: P6 7.33 2.37 6.29e+06 A/T3.H6 A/T3.H2’1 1.58 3.00
7: P7 8.23 2.58 4.81 e+06 A/A4.H8 A/A4.H2'2 1.58 3.00
8: P8 8.23 2.77 2.69e+06 A/A4.H8 A/A4.H2’1 1.58 3.00
9: P9 7.65 2.09 3.5e+06 A/A5.H8 A/A5.H2'2 1.58 3.00
10: P10 7.65 2.48 2.94e+06 A/A5.H8 A/A5.H2'1 1.58 3.00
11: P11 6.82 1.60 6.62e+05 A/G6.H8 A/G6.H2’2 1.58 5.00
12: P12 6.82 1.68 4.2e+05 A/G6.H8 A/G6.H2’1 1.58 5.00
13: P13 6.73 1.20 8.41e+05 A/C7.H6 A/C7.H2'2 1.58 5.00
14: P14 6.73 1.72 7.44e+05 A/C7.H6 A/C7.H2’1 1.58 5.00
15: P15 7.59 2.41 2.46e+06 B/G8.H8 B/G8.H2'2 1.58 3.00
16: P16 7.59 2.65 1.19e+06 B/G8.H8 B/G8.H2’1 1.58 3.00
17: P17 7.19 2.17 2.13e+06 B/C9.H6 B/C9.H2’1 1.58 3.00
18: P18 7.19 1.82 3.9e+06 B/C9.H6 B/C9.H2’2 1.58 3.00
19: P19 ‘ 7.15 2.26 2.79e+06 B/T10.H6 B/T10.H2’1 1.58 3.00
20: P20 7.15 1.72 4.1 e+06 B/T10.H6 B/T10.H2’2 1.58 3.00
21: P21 7.06 1.52 1.13e+06 B/T11.H6 B/T11 .H2’2 1.58 3.00
22: P22 7.06 1.62 1,54e+06 B/T11.H6 B/T11 .H2'1 1.58 3.00
23: P23 8.37 2.54 3.73e+06 B/A12.H8 B/A12.H2’2 1.58 3.00
24: P24 8.37 2.81 3.99e+06 B/A12.H8 B/A12.H2’1 1.58 3.00
25: P25 7.21 1.57 5.99e+06 B/C13.H6 B/C13.H2’2 1.58 3.00
26: P26 7.21 2.01 5.41 e+06 B/C13.H6 B/C13.H2’1 1.58 3.00
27: P27 7.79 2.22 3.04e+06 B/G14.H8 B/G14.H2'2 1.58 3.00
28: P28 7.79 2.53 3.9e+06 B/G14.H8 B/G14.H2’1 1.58 3.00
29: P29 7.83 1.80 2.36e+06 A/G2.H8 A/C1 ,H2’2 1.58 3.00
30: P30 7.83 2.20 3.67e+06 A/G2.H8 A/C1.H2’1 1.58 3.00
31: P31 7.33 2.46 1,07e+06 A/T3.H6 A/G2.H2’2 1.58 3.00
32: P32 7.33 2.51 1.21 e+06 A/T3.H6 A/G2.H2'1 1.58 3.00
33: P33 8.22 2.19 7.76e+05 A/A4.H8 A/T3.H2’2 1.58 5.00
34: P34 8.23 2.37 2.5e+06 A/A4.H8 A/T3.H2'1 1.58 3.00
35: P35 7.65 2.77 2.77e+06 A/A5.H8 A/A4.H2’1 1.58 3.00
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36: P36 7.65 2.58 1,8©+06 A/A5.H8 A/A4.H2'2 1.58 3.00
37: P37 6.82 2.09 1.11e+06 A/G6.H8 A/A5.H2’2 1.58 3.00
38: P38 6.82 2.49 1.33e+06 A/G6.H8 A/A5.H2’1 1.58 3.00
39: P39 6.74 1.60 8.63e+05 A/C7.H6 A/G6.H2’2 1.58 5.00
40: P40 6.74 1.68 2.43e+05 A/C7.H6 A/G6.H2’1 1.58 5.00
41: P43 7.19 2.65 1,84e+06 8/C9.H6 B/G8.H2’1 1.58 3.00
42: P44 7.19 2.42 1,74e+06 B/C9.H6 B/G8.H2'2 1.58 3.00
43: P45 7.15 2.17 9.36e+05 B/T10.H6 B/C9.H2’1 1.58 5.00
44: P46 7.16 1.82 1,78e+06 B/T10.H6 B/C9.H2'2 1.58 3.00
45: P47 7.06 2.26 3.61 e+06 B/T11.H6 B m o.H 2’1 1.58 3.00
46: P48 7.06 1.73 2.44e+06 B/T11.H6 B/T10.H2’2 1.58 3.00
47: P49 8.37 1.53 8.52e+05 B/A12.H8 B/T11 ,H2'2 1.58 5.00
48: P50 8.37 1.62 5.14e+05 B/A12.H8 B/T11 ,H2’1 1.58 5.00
49: P51 7.21 2.81 8.28e+05 B/C13.H6 B/A12.H2'1 1.58 5.00
50: P52 7.21 2.54 4.06e+06 B/C13.H6 B/A12.H2’2 1.58 3.00
51: P53 7.79 1.58 2.97e+06 B/G14.H8 B/C13.H2'2 1.58 3.00
52: P54 7.79 2.01 2.16e+06 B/G14.H8 B/C13.H2’1 1.58 3.00
53: P55 7.51 5.57 2.4e+06 A/C1.H6 A/C1.H1' 1.58 3.00
54: P56 7.83 5.57 6.81e+05 A/G2.H8 A/C1.H1' 1.58 5.00
55: P57 7.83 5.71 7.01 e+05 A/G2.H8 A/G2.H1' 1.58 5.00
56: P58- 7.33 5.72 1.97e+06 A/J3.H6 A/G2.H1* 1.58 3.00
57: P59 7.33 5.13 2.32e+06 A/T3.H6 A/T3.H1' 1.58 3.00
58: P60 8.22 5.14 2.12e+06 A/A4.H8 A/T3.H1’ 1.58 3.00
59: P61 8.22 6.07 1.28e+06 A/A4.H8 A/A4.H1’ 1.58 3.00
60: P62 7.65 6.07 1,49e+06 A/A5.H8 A/A4.H1’ 1.58 3.00
61: P63 7.65 5.70 1.01 e+06 A/A5.H8 A/A5.H1' 1.58 3.00
62: P64 6.82 5.70 4.85e+05 A/G6.H8 A/A5.H1' 1.58 5.00
63: P65 6.73 5.11 3.95e+05 A/C7.H6 A/C7.H1' 1.58 5.00
64: P66 7.58 5.83 8.92e+05 B/G8.H8 B/G8.H1’ 1.58 5.00
65: P67 7.20 5.84 1,23e+06 B/C9.H6 B/G8.H1’ 1.58 3.00
66: P68 7.19 5.82 1,43e+06 B/C9.H6 B/C9.H1’ 1.58 3.00
67: P69 7.16 5.82 1.35e+06 B/T10.H6 B/C9.H1’ 1.58 3.00
68: P71 7.15 5.75 1,57e+06 B/T10.H6 B/T10.H1’ 1.58 3.00
69: P72 7.06 5.75 1.88e+06 B/T11.H6 B/T10.H1’ 1.58 3.00
70: P73 7.06 5.09 3.17e+05 B/T11.H6 B/T11.H1’ 1.58 5.00
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71: P74 8.37 5.75 4.78e+05 B/A12.H8 B/A12.H1’ 1.58 5.00
72: P75 7.20 5.75 1.22e+06 B/C13.H6 B/A12.H1’ 1.58 3.00
73: P76 7.20 5.24 3.19e+06 B/C13.H6 B/C13.H1’ 1.58 3.00
74: P77 7.79 5.24 8.78e+05 B/G14.H8 B/C13.H1’ 1.58 5.00
75: P78 7.79 5.99 1.79e+06 B/G14.H8 B/G14.H1’ 1.58 3.00
76: P79 7.51 7.82 2.56e+05 A/C1.H6 A/G2.H8 1.58 5.00
77: P80 7.83 7.31 7.28e+05 A/G2.H8 A/T3.H6 1.58 5.00
78: P81 8.22 7.31 5.55e+05 A/A4.H8 A/T3.H6 1.58 5.00
79: P82 8.22 7.65 2.21 e+06 A/A4.H8 A/A5.H8 1.58 3.00
80: P83 7.64 6.81 5.05e+05 A/A5.H8 A/G6.H8 1.58 5.00
81: P84 6.82 6.73 3.53e+05 A/G6.H8 A/C7.H6 1.58 5.00
82: P85 7.19 7.57 8.73e+05 B/C9.H6 B/G8.H8 1.58 5.00
83: P87 8.37 7.05 6.31 e+04 B/A12.H8 B/T11.H6 1.58 7.00
84: P88 7.21 8.36 5.66e+05 B/C13.H6 B/A12.H8 1.58 5.00
85: P89 7.79 7.21 6.06e+05 B/G14.H8 B/C13.H6 1,58 5.00
86: P90 7.51 4.57 2.88e+06 A/C1.H6 A/C1.H3’ 1.58 3.00
87: P91 7.83 4.57 5.41e+05 A/G2.H8 A/C1.H3' 1.58 5.00
88: P92 7.83 4.84 5.09e+05 A/G2.H8 A/G2.H3' 1.58 5.00
89: P93 7.33 4.83 6.2e+05 A/T3.H6 A/G2.H3' 1.58 5.00
90: P94 7.33 4.80 1.1 e+06 A/T3.H6 A/T3.H3’ 1.58 3.00
91: P95 7.19 4.79 6.03e+05 B/C9.H6 B/G8.H3' 1.58 5.00
92: P96 7.19 4.34 1,08e+06 B/C9.H6 B/C9.H3' 1.58 3.00
93: P97 7.16 4.34 1,26e+06 B/T10.H6 BfT10.H3’ 1.58 3.00
94: P98 7.06 4.34 7.65e+05 B7T11 ,H6 B/T10.H3' 1.58 5.00
95: P99 7.06 4.39 2.21 e+06 B/T11 ,H6 B/T11.H3* 1.58 3.00
96: P100 8.37 4.40 1,7e+05 B/A12.H8 B/T11 ,H3' 1.58 5.00
97: P101 8.37 4.83 1.39e+06 B/A12.H8 B/A12.H3' 1.58 3.00
98: P102 7.20 4.83 4.35e+05 B/C13.H6 B/A12.H3’ 1.58 5.00
99: P103 7.20 4.49 2.92e+06 B/C13.H6 B/C13.H3’ 1.58 3.00
100: P104 7.80 4.49 4.19e+05 B/G14.H8 B/C13.H3’ 1.58 5.00
101: P105 7.80 4.59 2.18e+06 B/G14.H8 B/G14.H3’ 1.58 3.00
102: P106 8.22 4.80 6.51 e+05 A/A4.H8 A/T3.H3’ 1.58 5.00
103: P107 8.22 4.91 1.66e+06 A/A4.H8 A/A4.H3’ 1.58 3.00
104: P108 7.65 4.91 9.83e+05 A/A5.H8 A/A4.H3’ 1.58 5.00
105: P109 7.65 4.45 1.52e+06 A/A5.H8 A/A5.H3’ 1.58 3.00
268
1: POS1 2: POS2 3: INTEGRAL 4: ATOM_POS1 5: ATOM_POS2 6: LOWER 7: UPPER
106: P110 6.82 4.45 1.76e+05 A/G6.H8 A/A5.H3’ 1.58 5.00
107: P111 6.82 4.46 1.39e+05 A/G6.H8 A/G6.H3' 1.58 5.00
108: P112 6.74 4.47 4.16e+05 A/C7.H6 A/G6.H3' 1.58 5.00
109: P113 6.74 4.50 6.66e+05 A/C7.H6 A/C7.H3’ 1.58 5.00
110: P133 7.79 4.03 5.24e+05 B/G14.H8 B/G14.H5'2 1.58 5.00
111: P135 7.64 3.67 2.18e+06 A/A5.H8 A/A5.H5’2 1.58 3.00
112: P136 7.65 3.03 4.09e+05 A/A5.H8 A/A5.H5’1 1.58 5.00
113: P137 5.59 1.80 3.92e+06 A/C1.H1’ A/C1.H2’2 1.58 3.00
114: P138 5.59 2.21 7.49e+06 A/C1.H1' A/C1.H2'1 1.58 3.00
115: P139 5.13 2.20 4.87e+06 A/T3.H1' A/T3.H2’2 1.58 3.00
116: P140 5.13 2.37 7.13e+06 A/T3.H1’ A/T3.H2’1 1.58 3.00
117: P141 6.09 2.57 4.61 e+06 A/A4.H1’ A/A4.H2’2 1.58 3.00
118: P142 6.09 2.76 2.56e+06 A/A4.H1’ A/A4.H2’1 1.58 3.00
119: P143 5.69 2.09 5.01e+06 A/A5.H1’ A/A5.H2’2 1.58 3.00
120: P145 5.12 1.20 3.31 e+06 A/C7.H1’ A/C7.H2'2 1.58 3.00
121: P146 5.12 1.71 6.42e+06 A/C7.H1’ A/C7.H2’1 1.58 3.00
122: P147 5.85 2.41 5.59e+06 B/G8.H1’ B/G8.H2'2 1.58 3.00
123: P148 5.84 2.65 5.67e+06 B/G8.H1’ B/G8.H2’1 1.58 3.00
124: P149 5.82 1.83 4.84e+06 B/C9.H1’ B/C9.H2’2 1.58 3.00
125: P150 5.81 2.16 7.38e+06 B/C9.H1’ B/C9.H2'1 1.58 3.00
126: P151 5.75 1.73 4.57e+06 B/T10.H1’ B/T10.H2’2 1.58 3.00
127: P152 5.75 2.27 4.43e+06 BAnO.HV B/T10.H2’1 1.58 3.00
128: P153 5.09 1.52 7.05e+06 B/T11.H1’ B/T11 ,H2’2 1.58 3.00
129: P154 5.10 1.62 1.96e+06 B/T11.H1’ B/T11.H2’1 1.58 3.00
130: P155 5.75 2.54 7.06e+06 B/A12.H1’ B/A12.H2’2 1.58 3.00
131: P157 5.72 2.50 2.09e+06 A/G2.H1' A/G2.H2’1 1.58 3.00
132: P158 5.72 2.45 2.14e+06 A/G2.H1’ A/G2.H2’2 1.58 3.00
133: P159 6.00 2.22 7.55e+06 B/G14.H1’ B/G14.H2'2 1.58 3.00
134: P160 6.00 2.53 5.97e+06 B/G14.H1’ B/G14.H2’1 1.58 3.00
135: P161 5.24 2.01 6.16e+06 B/C13.H1’ B/C13.H2’1 1.58 3.00
136: P162 5.24 1.58 2.96e+06 B/C13.H1’ B/C13.H2’2 1.58 3.00
137: P163 5.75 2.81 1.17e+06 B/A12.H1’ B/A12.H2’1 1.58 3.00
138: P164 5.69 2.48 9.54e+06 A/A5.H1’ A/A5.H2'1 1.58 3.00
139: P165 4.79 3.45 2.16e+06 B/G8.H3’ B/G8.H5’1 1.58 3.00
140: P166 4.79 3.79 3.99e+06 B/G8.H3’ B/G8.H5’2 1.58 3.00
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141: P167 4.83 3.79 5.54e+06 B/A12.H3’ B/A12.H5'1 1.58 3.00
142: P168 4.83 4.18 1.02e+07 B/A12.H3’ B/A12.H5'2 1.58 3.00
143: P169 4.59 3.76 6.09e+06 B/G14.H3’ B/G14.H5’1 1.58 3.00
144: P170 4.59 4.03 9.43e+06 B/G14.H3’ B/G14.H5’2 1.58 3.00
145: P171 4.57 3.55 7.16e+06 A/C1.H3’ A/C1 ,H5'1 1.58 3.00
146: P172 4.57 3.92 3.37e+06 A/C1.H3’ A/C1.H5’2 1.58 3.00
147: P173 4.50 3.80 5.81 e+06 A/C7.H3’ A/C7.H5'2 1.58 3.00
148: P174 4.50 3.46 5.01 e+06 A/C7.H3’ A/C7.H5’1 1.58 3.00
149: P175 4.49 3.35 5.57e+06 B/C13.H3’ B/C13.H5’1 1.58 3.00
150: P176 4.49 3.67 5.18e+06 B/C13.H3' B/C13.H5'2 1.58 3.00
151: P177 4.45 3.02 4.81 e+06 A/A5.H3’ A/A5.H5T 1.58 3.00
152: P178 4.34 3.30 6.l9e+06 B/T10.H3' B/T10.H5’2 1.58 3.00
153: P179 4.34 2.79 2.47e+06 B/T10.H3’ B/T10.H5T 1.58 3.00
154: P180 4.80 3.98 6.73e+06 A/T3.H3' A/T3.H5'1 1.58 3.00
155: Pi 81 4.80 4.02 2.31 e+06 A/T3.H3’ A/T3.H5’2 1.58 3.00
156: P182 4.40 3.55 3.56e+06 B/T11.H3’ B/T11.H5'1 1.58 3.00
157: P183 4.39 3.71 5.75e+06 B/T11.H3' B/T11.H5’2 1.58 3.00
158: P185 4.33 3.80 4.49e+06 B/C9.H3' B/C9.H5’1 1.58 3.00
159: P186 4.92 4.11 4.54e+06 A/A4.H3’ A/A4.H5’2 1.58 3.00
160: P187 4.92 4.06 5.22e+06 A/A4.H3’ A/A4.H5'1 1.58 3.00
161: P188 4.85 3.95 2.45e+06 A/G2.H3' A/G2.H5'2 1.58 3.00
162: P189 4.85 3.79 4.16e+06 A/G2.H3' A/G2.H5’1 1.58 3.00
163: P190 4.45 3.66 2.6e+06 A/A5.H3' A/A5.H5'2 1.58 3.00
164: P191 5.58 4.57 1.98e+06 A/C1.H1' A/C1.H3’ 1.58 3.00
165: P192 5.85 4.78 1.21e+06 B/G8.H1’ B/G8.H3’ 1.58 3.00
166: P193 6.00 4.59 1,8e+06 B/G14.H1' B/G14.H3’ 1.58 3.00
167: P194 5.13 4.80 1.91 e+06 A/T3.H1’ A/T3.H3' 1.58 3.00
168: P195 6.06 4.91 1.05e+06 A/A4.H1' A/A4.H3’ 1.58 3.00
169: P196 5.81 4.34 2.37e+06 B/C9.H1’ B/C9.H3' 1.58 3.00
170: P197 5.10 4.40 1.76e+06 B/T11.HV B/T11 ,H3' 1.58 3.00
171: P198 5.11 4.50 1,25e+06 A/C7.H1' A/C7.H3’ 1.58 3.00
172: P199 5.75 4.34 3.06e+06 B/T10.H1’ B/T10.H3’ 1.58 3.00
173: P200 5.69 4.45 1.09e+06 A/A5.H1’ A/A5.H3' 1.58 3.00
174: P201 5.24 4.49 3.82e+06 B/C13.H1’ B/C13.H3’ 1.58 3.00
175: P202 | 5.72 4.83 1,52e+06 A/G2.H1’ A/G2.H3' 1.58 3.00
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176: P203 5.75 4.83 2.68e+06 B/A12.H1’ B/A12.H3' 1.58 3.00
177: P204 5.78 4.46 1.62e+06 A/G6.H1’ A/G6.H3' 1.58 3.00
178: P205 5.59 3.94 3.4e+06 A/C1.H1’ A/C1.H4’ 1.58 3.00
179: P206 6.00 4.15 2.65e+06 B/G14.H1' B/G14.H4’ 1.58 3.00
180: P207 6.08 4.29 6.1e+05 A/A4.H1’ A/A4.H4’ 1.58 5.00
181: P208 5.14 4.15 1.93e+06 ^T3.H1’ A/T3.H4' 1.58 3.00
182: P209 5.82 4.14 1.85e+06 B/C9.H1’ B/C9.H4’ 1.58 3.00
183: P210 5.75 4.27 1.12e+06 B/A12.H1' B/A12.H4’ 1.58 3.00
184: P211 5.75 4.15 8.88e+05 BT10.H1’ B/T10.H4’ 1.58 5.00
185: P212 5.11 4.10 1.12e+06 A/C7.H1' A/C7.H4’ 1.58 3.00
186: P213 5.72 3.96 8.61e+05 A/G2.H1' A/G2.H4' 1.58 5.00
187: P214 5.85 4.08 1 64e+06 B/G8.H1’ B/G8.H4' 1.58 3.00
188: P215 4.57 1.80 7.16e+06 A/C1.H3’ A/C1.H2’2 1.58 3.00
189: P216 4.57 2.20 3.86e+06 A/C1.H3’ A/C1.H2'1 1.58 3.00
190: P217 4.80 2.19 4.81 e+06 A/T3.H3’ A/T3.H2'2 1.58 3.00
191: P218 4.80 2.37 7.56e+06 A/T3.H3’ A/T3.H2’1 1.58 3.00
192: P219 4.92 2.57 6.47e+06 A/A4.H3* A/A4.H2'2 1.58 3.00
193: P220 4.92 2.77 3.11 e+06 A/A4.H3’ A/A4.H2'1 1.58 3.00
194: P221 4.51 1.20 2.51e+06 A/C7.H3’ A/C7.H2’2 1.58 3.00
195: P222 4.51 1.72 2.42e+06 A/C7.H3’ A/C7.H2’1 1.58 3.00
196: P225 4.60 2.22 5.68e+06 B/G14.H3’ B/G14.H2'2 1.58 3.00
197: P226 4.60 2.53 4.58e+06 B/G14.H3’ B/G14.H2’1 1.58 3.00
198: P227 4.83 2.82 2.91e+06 B/A12.H3' B/A12.H2'1 1.58 3.00
199: P228 4.83 2.54 6.05e+06 B/A12.H3' B/A12.H2'2 1.58 3.00
200: P229 4.85 2.47 8.28e+06 A/G2.H3’ A/G2.H2’2 1.58 3.00
201: P230 4.85 2.51 7.09e+06 A/G2.H3’ A/G2.H2’1 1.58 3.00
202: P231 4.79 2.65 1,27e+06 B/G8.H3' B/G8.H2'1 1.58 3.00
203: P232 4.79 2.41 2e+06 B/G8.H3’ B/(j 8.H2’2 1.58 3.00
204: P233 4.49 1.58 3.96e+06 B/C13.H3’ B/C13.H2’2 1.58 3.00
205: P234 4.49 2.02 1.21e+07 B/C13.H3' B/C13.H2’1 1.58 3.00
206: P235 4.34 1.82 5.2e+06 B/C9.H3’ B/C9.H2’2 1.58 3.00
207: P236 4.34 2.17 4.25e+06 B/C9.H3' B/C9.H2’1 1.58 3.00
208: P238 4.39 1.53 5.71e+06 B/T11.H3’ B/T11.H2'2 1.58 3.00
209: P239 4.36 1.72 4.29e+06 B/T10.H3’ B7T10.H2’2 1.58 3.00
210: P240 4.36 2.27 1,58e+06 B/T10.H3’ B/T10.H2'1 1.58 3.00
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211: P241 4.45 2.09 4.43e+06 A/A5.H3' A/A5.H2’2 1.58 3.00
212: P242 4.45 2.48 5.54e+06 A/A5.H3' A/A5.H2’1 1.58 3.00
213: P244 2.02 1.58 4.21 e+06 B/C13.H2'1 B/C13.H2’2 1.58 3.00
214: P245 1.72 1.20 2.41 e+06 A/C7.H2’1 A/C7.H2'2 1.58 3.00
215: P246 2.53 2.23 2.21 e+07 B/G14.H2’1 B/G14.H2’2 1.58 3.00
216: P247 2.77 2.57 6.53e+06 A/A4.H2’1 A/A4.H2’2 1.58 3.00
217: P248 2.83 2.54 2.25e+06 B/A12.H2’1 B/A12.H2'2 1.58 3.00
218: P249 2.20 1.80 1,85e+07 A/C1.H2’1 A/C1.H2’2 1.58 3.00
219: P251 2.18 1.82 3.83e+06 B/C9.H2’1 B/C9.H2'2 1.58 3.00
220: P252 2.37 2.20 2.88e+06 A/T3.H2'1 A/T3.H2'2 1.58 3.00
221: P253 2.67 2.42 2.16e+06 B/G8.H2'1 B/G8.H2’2 1.58 3.00
222: P255 3.02 2.48 4.6e+06 A/A5.H5'1 A/A5.H2’1 1.58 3.00
223: P256 3.35 2.01 3.31 e+06 B/C13.H5'1 B/C13.H2’1 1.58 3.00
224: P257 3.30 2.78 2.05e+06 B/T10.H5’2 B/T10.H5’1 1.58 3.00
225: P258 4.31 2.09 1.61 e+06 A/A5.H4’ A/A5.H2’2 1.58 3.00
226: P259 4.31 2.48 4.84e+06 A/A5.H4’ A/A5.H2’1 1.58 3.00
227: P260 4.29 2.77 6.43e+05 A/A4.H4’ A/A4.H2’1 1.58 5.00
228: P261 4.29 2.56 4.08e+06 A/A4.H4' A/A4.H2’2 1.58 3.00
229: P262 4.27 2.81 7.63e+05 B/A12.H4' B/A12.H2'1 1.58 5.00
230: P265 3.93 2.20 5.47e+06 A/C1.H4' A/C1 .H2’1 1.58 3.00
231: P267 6.73 4.60 2.03e+06 A/C7.H6 A/C7.H5 1.58 3.00
232: P268 7.21 5.54 5.04e+06 B/C13.H6 B/C13.H5 1.58 3.00
233: P269 7.51 5.74 1.24e+07 A/C1.H6 A/C1.H5 1.58 3.00
234: P270 7.20 5.22 6.55e+06 B/C9.H6 B/C9.H5 1.58 3.00
235: P271 7.97 7.81 5.7e+05 B/A12.H2 A/A4.H2 1.58 5.00
236: P276 7.95 6.06 6.09e+05 B/A12.H2 A/A4.H1’ 1.58 5.00
237: P277 7.81 6.06 3.5e+05 A/A4.H2 A/A4.H1’ 1.58 5.00
238: P278 7.81 5.10 5.14e+05 A/A4.H2 B /rn .H i’ 1.58 5.00
239: P272 7.95 5.75 1.26e+06 B/A12.H2 B/A12.H1' 1.58 3.00
240: P274 7.95 5.13 1,95e+06 B/A12.H2 A/T3.H1’ 1.58 3.00
241: P275 7.86 5.75 2.42e+05 A/A5.H2 B/T10.H1’ 1.58 5.00
242: P279 7.81 5.75 1,25e+05 A/A4.H2 B/A12.H1’ 1.58 5.00
243: P280 7.06 1.45 2.44e+06 B m i.H 6 B/T11.C5M 1.58 3.00
244: P281 7.16 1.45 7.87e+05 B/T10.H6 B/T11 .C5M 1.58 5.00
245: P283 7.16 1.37 2.93e+06 B/T10.H6 B/T10.C5M 1.58 3.00
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246: P284 7.83 1.56 1,47e+06 A/G2.H8 A/T3.C5M 1.58 3.00
247: P285 7.33 1.56 2.34e+06 A/T3.H6 A/T3.C5M 1.58 3.00
248: P286 5.82 1.36 6.97e+05 B/C9.H1’ B/T10.C5M 1.58 5.00
249: P287 5.22 1.36 7.84e+05 B/C9.H5 B/T10.C5M 1.58 5.00
250: P288 5.75 1.45 7.97e+05 B/T10.H1’ B/T11 .C5M 1.58 5.00
251: P289 5.10 1.45 3.05e+05 B/T11.H1’ B/T11.C5M 1.58 5.00
252: P290 5.72 1.56 5.84e+05 A/G2.H1’ A/T3.C5M 1.58 5.00
253: P291 5.14 1.56 4.7e+05 A/T3.H1’ A/T3.C5M 1.58 5.00
254: P293 4.36 1.45 6.96e+05 B/T10.H3' B/T11.C5M 1.58 5.00
255: P294 4.85 1.56 5.4e+05 A/G2.H3’ A/T3.C5M 1.58 5.00
256: P295 2.18 1.37 1,03e+06 B/C9.H2'1 B/T10.C5M 1.58 3.00
257: P296 2.27 1.45 1.28e+06 B/T10.H2'1 B/T11.C5M 1.58 3.00
258: P297 1.84 1.37 1.25e+06 B/C9.H2’2 B/T10.C5M 1.58 3.00
259: P298 1.73 1.45 1.52e+06 B/T10.H2’2 B/T11.C5M 1.58 3.00
260: P299 2.51 1.56 2.18e+06 A/G2.H2’1 A/T3.C5M 1.58 3.00
261: P300 2.46 1.56 1,78e+06 A/G2.H2’2 A/T3.C5M 1.58 3.00
262: P301 7.74 7.37 5.56e+06 A/OH1 ,H7’2 A/OH1.H6'2 1.58 3.00
263: P302 7.50 7.37 5.5e+06 A/OH1 .H5'2 A/OH1 ,H6’2 1.58 3.00
264: P303 8.24 7.63 6.46e+06 A/OH1 .H6’1 A/OH1 ,H7'1 1.58 3.00
265: P304 7.94 7.49 4.96e+06 A/OH1 .H4'2 A/OH1 ,H5'2 1.58 3.00
266: P306 7.95 6.96 2.94e+06 B/A12.H2 A/OH1.H6 1.58 3.00
267: P307 7.28 7.63 7.13e+05 A/OH1 ,H3’1 A/OH1 ,H7’1 1.58 5.00
268: P308 7.81 7.26 8.14e+05 A/A4.H2 A/OH1 .H3’1 1.58 5.00
269: P310 7.93 7.37 6.62e+05 A/OH1 ,H4'2 A/OH1 ,H6’2 1.58 5.00
270: P313 7.81 7.28 4.09e+05 A/OH1 ,H4’1 A/OH1 ,H3’1 1.58 5.00
271: P314 7.28 7.86 1,43e+05 A/OH1 .H3’1 A/A5.H2 1.58 5.00
272: P315 7.74 7.48 7.65e+05 A/OH1 ,H7’2 A/OH1 .H5’2 1.58 5.00
273: P316 7.93 7.65 1.62e+05 A/OH1 ,H4’2 A/OH1 .H3'2 1.58 5.00
274: P317 7.80 7.62 2.77e+05 A/OH1 .H4’1 A/OH1.H7’1 1.58 5.00
275: P319 7.81 8.24 7.25e+05 A/OH1 .H4’1 A/OH1.H6’1 1.58 5.00
276: P322 8.36 5.53 9.34e+05 B/A12.H8 B/C13.H5 1.58 5.00
277: P323 7.50 5.82 3.19e+06 A/OH1 .H5’2 B/C9.H1’ 1.58 3.00
278: P324 7.58 5.21 4.85e+05 B/G8.H8 B/C9.H5 1.58 5.00
279: P325 7.99 5.16 2.28e+06 A/OH1.H3 A/OH1.H8B 1.58 3.00
280: P326 7.99 5.75 1.14e+06 A/OH1.H3 B/A12.H1' 1.58 3.00
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281: P327 7.93 5.82 2.51e+06 A/OH1 ,H4’2 B/C9.H1’ 1.58 3.00
282: P328 7.93 5.83 1.08e+06 A/OH1 .H4’2 B/G8.H1’ 1.58 3.00
283: P338 7.39 5.82 4.36e+05 A/OH1.H6’2 B/C9.H1' 1.58 5.00
284: P339 6.82 4.60 1.36e+05 A/G6.H8 A/C7.H5 1.58 5.00
285: P341 7.59 4.79 7e+05 B/G8.H8 B/G8.H3’ 1.58 5.00
286: P347 7.81 4.50 3.7e+05 A/A4.H2 A/OH1.H8A2 1.58 5.00
287: P350 8.24 4.10 2.95e+05 A/OH1 .H6’1 A/C7.H4’ 1.58 5.00
288: P353 7.50 4.03 2.31 e+05 A/OH1 .H5’2 B/C9.H5’2 1.58 5.00
289: P354 7.50 4.14 1.41 e+06 A/OH1 .H5’2 B/C9.H4' 1.58 3.00
290: P359 7.80 4.00 3.09e+05 A/OH1 .H4’1 B/T11 ,H4’ 1.58 5.00
291: P361 7.94 4.33 5.22e+05 A/OH1 .H4’2 B/C9.H3' 1.58 5.00
292: P363 8.24 3.80 1.35e+06 A/OH1 .H6'1 A/C7.H5’2 1.58 3.00
293: P364 8.24 3.46 1.34e+06 A/OH1 .H6'1 A/C7.H5T 1.58 3.00
294: P367 7.51 3.55 2.53e+06 A/C1.H6 A/C1.H5’1 1.58 3.00
295: P371 7.65 3.47 2.65e+05 A/OH1 .H3'2 A/C7.H5'1 1.58 5.00
296: P372 7.63 3.79 7.13e+05 A/OH1 .H7’1 B/A12.H5T 1.58 5.00
297: P374 7.50 3.31 1,09e+06 A/OH1 .H5’2 B/T10.H5'2 1.58 3.00
298: P376 7.93 3.32 7.1 e+05 A/OH1 .H4’2 B/T10.H5’2 1.58 5.00
299: P379 7.50 2.79 7.73e+05 A/OH1.H5'2 B/T10.H5T 1.58 5.00
300: P380 7.93 2.79 1.53e+06 A/OH.1 .H4’2 B/T10.H5T 1.58 3.00
301: P382 7.99 2.54 6.05e+05 A/OH1.H3 A/OH1.C34 1.58 5.00
302: P383 7.95 2.54 7.91 e+05 B/A12.H2 A/OH1.C34 1.58 5.00
303: P384 6.98 2.55 5.32e+05 A/OH1.H6 A/OH1.C34 1.58 5.00
304: P386 7.65 1.72 4.91 e+05 A/OH1.H3’2 B/T10.H2'2 1.58 5.00
305: P387 7.93 1.82 8.12e+05 A/OH1 .H4'2 B/C9.H2'2 1.58 5.00
306: P389 7.93 2.18 2.87e+06 A/OH1 .H4’2 B/C9.H2T 1.58 3.00
307: P390 5.25 2.55 5.06e+05 B/C13.H1’ A/OH1.C34 1.58 5.00
308: P391 5.16 2.55 2.17e+06 A/OH1.H8B A/OH1.C34 1.58 3.00
309: P392 5.23 2.41 8.39e+05 B/C9.H5 B/G8.H2’2 1.58 5.00
310: P393 5.23 2.66 1.05e+06 B/C9.H5 B/G8.H2'1 1.58 3.00
311: P395 5.55 1.57 1.01 e+06 B/C13.H5 B/C13.H2’2 1.58 3.00
312: P396 5.22 1.83 1.26e+06 B/C9.H5 B/C9.H2’2 1.58 3.00
313: P397 5.56 2.82 1,88e+06 B/C13.H5 B/A12.H2’1 1.58 3.00
314: P398 5.56 2.54 2.97e+06 B/C13.H5 B/A12.H2’2 1.58 3.00
315: P399 4.62 1.19 3.63e+05 A/C7.H5 A/C7.H2’2 1.58 5.00
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316: P402 6.98 5.06 9.77e+05 A/OH1.H6 A/OH1.H8A 1.58 5.00
317: P403 7.96 5.06 3.25e+06 B/A12.H2 A/OH1.H8A 1.58 3.00
318: P404 7.96 5.16 1,77e+06 B/A12.H2 A/OH1.H8B 1.58 3.00
319: P405 6.98 5.16 1.17e+06 A/OH1.H6 A/OH1.H8B 1.58 3.00
320: P406 5.16 4.50 3.01e+05 A/OH1.H8B A/OH1.H8A2 1.58 5.00
321: P407 4.83 4.27 6.98e+06 B/A12.H3’ B/A12.H4’ 1.58 3.00
322: P408 4.93 4.29 7.53e+06 A/A4.H3’ A/A4.H4’ 1.58 3.00
323: P409 4.60 4.15 6.45e+06 B/G14.H3' B/G14.H4’ 1.58 3.00
324: P410 4.80 4.15 4.85e+06 A/T3.H3’ A/T3.H4' 1.58 3.00
325: P411 4.79 4.08 2.46e+06 B/G8.H3' B/G8.H4' 1.58 3.00
326: P412 4.50 4.10 3.63e+05 A/C7.H3’ A/C7.H4’ 1.58 5.00
327: P413 4.83 3.97 2.27e+06 A/G2.H3' A/G2.H4’ 1.58 3.00
328: P414 4.49 4.02 1.61e+06 B/C13.H3’ B/C13.H4’ 1.58 3.00
329: P415 7.81 3.69 1.47e+05 A/A4.H2 A/OH1.H1A 1.58 5.00
330: P416 7.86 3.69 9.66e+05 A/A5.H2 A/OH1.H1A 1.58 5.00
331: P417 7.86 3.81 4.04e+05 A/A5.H2 A/OH1.H1B 1.58 5.00
332: P418 7.96 3.69 7.59e+05 B/A12.H2 A/OH1.H1A 1.58 5.00
333: P419 7.96 3.81 1.13e+06 B/A12.H2 A/OH1.H1B 1.58 3.00
334: P421 7.81 3.81 1.4e+06 A/A4.H2 A/OH1.H1B 1.58 3.00
335: P422 7.28 3.81 4.09e+05 A/OH1 .H3’1 A/OH1.H1B 1.58 5.00
336: P423 7.27 3.69 4.24e+05 A/OH1 ,H3'1 A/OH1.H1A 1.58 5.00
337: P424 4.50 3.81 5.89e+05 A/OH1.H8A2 A/OH1.H1B 1.58 5.00
338: P425 4.50 3.69 6.48e+05 A/OH1.H8A2 A/OH1.H1A 1.58 5.00
339: P426 5.26 3.67 6.94e+05 B/C13.H1' B/C13.H5’2 1.58 5.00
340: P427 5.59 3.55 1,08e+06 A/C1.H1’ A/C1 .H5'1 1.58 3.00
341: P436 3.80 3.45 1.74e+07 A/C7.H5’2 A/C7.H5'1 1.58 3.00
342: P437 3.92 3.55 1.11e+07 A/C1.H5’2 A/C1 ,H5’1 1.58 3.00
343: P438 4.10 3.45 1.69e+06 A/C7.H4' A/C7.H5’1 1.58 3.00
344: P439 4.39 3.99 1,25e+06 B/T11.H3' B/T11.H4' 1.58 3.00
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APPENDIX XIII
The 2D *H NOESY of the S'^C 'g V a W a V c V g 'V S'- 
(C11C12G 13T 14T15T 1>T I7T 1sC G2<>) PNA duplex.
Figure 148 The 2D 600 MHz *H NOESY of the 5,-(C1G2A3A4A5A6A7C8G9G,0)-5'-
(C C12G13T14T15T16T17T18C19G20) DNA duplex.
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Figure 149 The 2D 600 MHz ’H NOESY of the 5'-(C1G2A3A4AsA6A7C8G9G10)-5'-
(Cn C12G13T14TI5T16T17Tl8C19G20) DNA duplex. The aromatic->H37H47H5'l/H5'2 region.
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Figure 150 The 2D 600 MHz 'H NOESY of the 5'-(C'G2A 3A4A5A6A1C*G9G ic)-5'-
(Cn C12GI3T14T15TI6T17T18C19G20) DNA duplex. The aromatic->aromatic region.
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Figure 151 The 2D 600 MHz *H NOESY of the 5'-(C1G2A3A4A5A6A7C8G9GI0)-5'-















Figure 152 The 2D 600 MHz ’H NOESY of the S'-CC’g W a V a V cW G 10)^ '-
(CHc ^ g 13! 14! 15! 16! 17! 1^ 1^ 20) DNA duplex. The H1'-»H37H47H5'1/H5'2 NOE region.
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APPENDIX XIV
The 2D 600 MHz *H DQF-COSY of the adozelesin-5'-
(C1G2A3A4AsA6A7'C8G9G10)- 5^>-(cnC12G13T14T15T16T17T18C19G20) DNA adduct.
Dl
Figure 153 The 2D 600 MHz DQF-COSY of the a d o z e le s in -S '^ G W A W A ^ ’c V G 10)^ '-
(C C^G13! 14! 15! 16! 17! 1^ 1^ 20) DNA adduct.
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Figure 154 The 2D 600 MHz *H DQF-COSY of the adozelesin-5,-(C1G2 A3 A4 A5A6 A7 'C 8 G9 G 1 0)-5'- 
(Cn C1 2 G 1 3T 1 4T 1 5T 1 6T1 7 T 1 8C1 9G20) DNA adduct. The aromatics->aromatics/CH5 region.
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Figure 155 The 2D 600 MHz DQF-COSY of the a d o z e le s in -S X C 'G ^ A V A V c V G 10)^ '-








Figure 156 The 2D 600 MHz *H DQF-COSY of the adozelesin-S'^C'G’A’A V A V c 'G ’G10)^ '-













Figure 157 The 2D 600 MHz ]H DQF-COSY spectrum of the adozelesin-5'-




The 2D 600 MHz *H TOCSYspectrum of the adozeIesin-5'- 
(C1G2A3A4A5A6A7,C8G9G 10V5WC11C12G 13T 14T 15T 16T 17T18C19G20) DNA adduct.
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Figure 158 The 2D 600 MHz lH TOCSY spectrum of the ad o z e le s in -S X C ^ A V A W A ^ C ^ G 10)^ '-
(C C12G13T14T15T,6T17Ti8C19G20) DNA adduct.
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Figure 159 The 2 D 600 MHz 'H TOCSY spectrum of the adozelesin-5'-(C1G2 A3 A4 A5A6 A7 ’C*G9 G1 0)-5'- 
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Figure 160 The 2D 600 MHz ]H TOCSY spectrum of the adozelesin-SXC’G ^ A 'V A V ’c V G 10)^ '-
(C1^ 1^ 13! 14! 15! 16! 17! 1^ 1^ 20) DNA adduct. The aromatics -> aromatics region.
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Figure 161 The 2D 600 MHz ‘H TOCSY spectrum of the adozelesin-5'-(C,G2A3A4A5A6A7 C8G9G,0>5'-
(CuC12G13T14T15T16T17T18C19G20) DNA adduct. The aromatics->CH5 region.
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Figure 163 The 2D 600 MHz 'H TOCSY spectrum of the adozelesin-5'-(C1G2A3A4A5A6A7*C8G9G10)-5'-
(Cn C12G13T14T15T16T17T18C19G20) DNA adduct. The H2'1->H2'2 region.
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Figure 164 The 2D 600 MHz ]H TOCSY spectrum of the a d o z e le s in -S '- tC ^ A V A V A ^ G V 0)^'- 
(Cn C12G,3T14T15T16T,7T18C19G20) DNA adduct. COSY cross-peaks from the H3', H4', H5'l and H5'2 
protons.
APPENDIX XVI
The 2D 600 MHz !H NOESY spectrum of the adozelesin-5'- 
(C1G2A3A4AsA<A7"C8G9G 10y y -(C llC12G13T 14T lsT 16T17T18C 19G20) DNA adduct.
Figure 165 The 2D 600 MHz ]H NOESY spectrum of the a d o z e le s in -S X C ^ A W A ^ V ’C ^ G 10) ^ -
(C C12G13T14T15T16T17T18C19G20) DNA adduct.
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Figure 166 The 2D 600 MHz ’H NOESY spectrum of the ad o zelesin -S X C 'G ^A V A W ’c V G 10)^ '-  
(C C1 2G 1 3T 1 4T1 5T1 6T 1 7T18C 1 9G20) DNA adduct. The aromatics to aromatics NOE region.
Figure 167 The 2D 600 MHz !H NOESY spectrum of the adozelesin-SXC’G W A W A W G ’G10)^ '- 
(Cn C12G13T14T15Tl6T,7T18C19G20) DNA adduct The aromatics->H37H47H5'l/H5'2 region.
Figure 168 The 2D 600 MHz JH NOESY spectrum of the ad ozelesin -S X C 'G ^V A 'A V ’c V G 10)^ '-  
(Cn Cl2 G 1 3T 14T 1 5T 1 6Tl7 T 1 8C1 9G20) DNA adduct. The H1'->H2'1/H2'2 region.
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Figure 169 The 2D 600 MHz *H NOESY spectrum of the ad o ze lesin -S '-^G W A W A V ’c V G 10)^ '-  
(C1^ 1^ 13! 14! 15! 16! 17! 1^ 1^ 20) DNA adduct. The Hr->H37H47H5'1/H5'2 region.
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Figure 170 The 2D 600 MHz ‘H NOESY spectrum of the a d o z e le s in -S '-^ G ^ A V A V ’C ^ G 10)^ '-  
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Figure 171 The 2D 600 MHz ’H NOESY spectrum of the adozelesin-SXC’G W A V A V ’C ^ G 10)^ '-
(Cn C12G13T14T15T16T,7T18CI9G20) DNA adduct. The H2'1->H2'2 region.
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APPENDIX XVII
The 2D 600 MHz !H ROESY spectrum of the adozelesin-5'- 
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Figure 172 The 2D 600 MHz 'H ROESY spectrum of the adozelesin-5'-(C1G2A3A4A5A6A7*C8G9G,0)-5'-
(C C12G13T14T15T16T17T18C19G2<5 DNA adduct.
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Figure 173 The 2D 600 MHz ‘H ROESY spectrum of the a d o z e le s in -S '-^ G W A V A V c V G 10)^ '-
(C1,C,2G,3T,4T 15T16T17TI8C19G20) DNA adduct. The aromatics->aromatics/CH5 region.
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Figure 174 The 2D 600 MHz 'H ROESY spectrum of the adozelesin-S^C’G W A W A V ’C ^ G 10)^ '-
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Figure 145 The 600 MHz ROESY NMR spectrum of the adozelesin-5-
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Figure 176 The 2D 600 MHz !H ROESY spectrum of the ad ozelesin -S X C 'G ^V A 'A V ’c V G 10)^ '-
(Cn C12G,3T,4T15T16T,7T18C19G20) DNA adduct. The H2'1->H2'2 region.
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Figure 177 The 2D 600 MHz 'H ROESY spectrum of the ad o ze lesin -S '-^G W A V A W ’C ^ G 10)^ '-  




The Peak Pick Spreadsheet for the adozelesin-S'-fC'GWA'AWA7'c V g 'VS'- 
(C11CuGl3T14T1T ,ltT17TlsC1!>G ^  DNA addnct
Table 8 The peak pick spreadsheet.
1: P0S1 2: P0S2 3: INTEGRAL 4: AT0M_P0S1 5: AT0M_P0S2 6: LOWER 7: UPPER
1: P1 7.25 5.32 2.6e+08 A/C1.H6 A/C1.H1’ 1.49 5.00
2: P2 7.72 5.32 2.9e+08 A/G2.H8 A/C1.H1' 1.49 3.00
3: P3 7.72 5.14 3.5e+08 A/G2.H8 A/G2.H1’ 1.49 3.00
4: P4 7.94 5.14 2.7e+08 A/A3.H8 A/G2.H1’ 1.49 5.00
5: P5 7.94 5.75 4.7e+08 A/A3.H8 A/A3.H1' 1.49 3.00
6: P6 8.00 5.75 1.2e+08 A/A4.H8 A/A3.H1’ 1.49 7.00
7: P7 8.00 5.55 4.1e+07 A/A4.H8 A/A4.H1’ 1.49 7.00
8: P8 7.91 5.55 9.4e+07 A/A5.H8 A/A4.H1’ 1.49 7.00
9: P9 7.91 5.67 2.6e+08 A/A5.H8 A/A5.H1’ 1.49 5.00
10: P10 7.47 5.67 1.5e+08 A/A6.H8 A/A5.H1' 1.49 5.00
11: P11 7.47 5.07 1.2e+08 A/A6.H8 A/A6.H1’ 1.49 7.00
12: P12 8.27 5.07 1,4e+07 A/A7.H8 A/A6.H1’ 1.49 7.00
13: P13 8.27 5.08 1.2e+06 A/A7.H8 A/A7.H1' 1.49 7.00
14: P14 7.18 5.08 5.8e+07 A/C8.H6 A/A7.H1’ 1.49 7.00
15: P15 7.18 5.19 3.5e+07 A/C8.H6 A/C8.H1' 1.49 7.00
16: P16 7.58 5.20 9.9e+07 A/G9.H8 A/C8.H1’ 1.49 7.00
17: P17 7.58 5.92 3.1e+08 A/G9.H8 A/G9.H1' 1.49 3.00
18: P20 7.39 5.61 2.9e+08 B/C11.H6 B/C11.H1' 1.49 3.00
19: P21 7.34 5.61 2e+08 B/C12.H6 B/C11.H1’ 1.49 5.00
20: P24 7.77 5.73 2.4e+08 B/G13.H8 B/G13.H1' 1.49 5.00
21: P25 7.46 5.73 1,8e+08 B/T14.H6 B/G13.H1’ 1.49 5.00
22: P26 7.46 6.14 1,4e+08 B/T14.H6 B/T14.H1' 1.49 5.00
23: P27 7.41 6.14 8.9e+07 B/T15.H6 B/T14.H1' 1.49 7.00
24: P28 7.41 6.06 4.9e+07 B/T15.H6 B/T15.H1' 1.49 7.00
25: P29 7.18 6.06 4.9e+07 B/T16.H6 B/T15.H1’ 1.49 7.00
26: P30 7.18 5.71 3e+07 B/T16.H6 B/T16.H1' 1.49 7.00
27: P31 7.02 5.72 1.1e+08 B/T17.H6 BT16.H1' 1.49 7.00
28: P32 7.02 5.06 1.5e+08 B/T17.H6 BT17.H1’ 1.49 5.00
29: P33 6.95 5.06 9.7e+07 B/T18.H6 B/T17.H1’ 1.49 7.00
30: P34 6.95 5.44 6.8e+07 B/T18.H6 B/T18.H1’ 1.49 7.00
31: P35 7.03 5.16 1e+08 B/C19.H6 B/C19.H1’ 1.49 7.00
32: P36 7.66 5.16 2.4e+08 B/G20.H8 B/C19.H1' 1.49 5.00
33: P37 7.67 5.90 2.6e+08 B/G20.H8 B/G20.H1' 1.49 5.00
34: P38 7.26 1.31 3.7e+08 A/C1.H6 A/C1.H2T 1.49 3.00
35: P39 7.25 2.01 4.3e+08 A/C1.H6 A/C1.H2’2 1.49 3.00
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1: POS1 2: POS2 3: INTEGRAL 4: ATOM_POS1 5: ATOM_POS2 6: LOWER 7: UPPER
36: P40 7.72 1.31 2.2e+08 A/G2.H8 A/C1 .H2'1 1.49 5.00
37: P41 7.72 2.01 2.7e+08 A/G2.H8 A/C1 .H2'2 1.49 5.00
38: P42 7.72 2.50 2.7e+08 A/G2.H8 A/G2.H2’1 1.49 3.00
39: P43 7.72 2.56 3e+08 A/G2.H8 A/G2.H2’2 1.49 3.00
40: P44 7.94 2.50 1.5e+08 A/A3.H8 A/G2.H2’1 1.49 5.00
41: P45 7.94 2.56 1.6e+08 A/A3.H8 A/G2.H2’2 1.49 5.00
42: P46 7.94 2.73 4.8e+08 A/A3.H8 A/A3.H2’2 1.49 3.00
43: P47 7.94 2.52 8.3©+08 A/A3.H8 A/A3.H2’1 1.49 3.00
44: P48 8.00 2.73 8.8e+07 A/A4.H8 A/A3.H2'2 1.49 7.00
45: P49 8.00 2.45 2.3e+08 A/A4.H8 A/A4.H2’2 1.49 5.00
46: P50 8.00 2.52 1,6e+08 A/A4.H8 A/A3.H2’1 1.49 5.00
47: P51 8.00 2.43 2.3e+08 A/A4.H8 A/A4.H2’1 1.49 5.00
48: P52 7.90 2.54 1.9e+08 A/A5.H8 A/A5.H2’1 1.49 5.00
49: P53 7.90 2.90 1.8e+08 A/A5.H8 A/A5.H2’2 1.49 5.00
50: P54 7.90 2.43 1.6e+08 A/A5.H8 A/A4.H2’1 1.49 5.00
51: P55 7.90 2.45 1,7e+08 A/A5.H8 A/A4.H2'2 1.49 5.00
52: P56 7.47 2.90 4.5e+07 A/A6.H8 A/A5.H2'2 1.49 7.00
53: P57 7.47 2.54 1,9e+08 A/A6.H8 A/A5.H2’1 1.49 5.00
54: P58 7.47 1.47 2.3e+08 A/A6.H8 A/A6.H2’1 1.49 5.00
55: P59 7.47 1.81 1,4e+08 A/A6.H8 A/A6.H2'2 1.49 7.00
56: P60 8.26 2.56 4e+07 A/A7.H8 A/A7.H2'1 1.49 7.00
57: P61 8.26 2.57 4.4e+07 A/A7.H8 A/A7.H2'2 1.49 7.00
58: P62 • 7.18 2.56 1.5e+08 A/C8.H6 A/A7.H2'1 1.49 5.00
59: P63 7.18 2.57 1,7e+08 A/C8.H6 A/A7.H2’2 1.49 5.00
60: P64 7.58 2.21 1.8e+08 A/G9.H8 A/C8.H2'1 1.49 5.00
61: P65 7.18 2.21 5.4e+07 A/C8.H6 A/C8.H2'1 1.49 7.00
62: P66 7.18 2.46 2.9e+08 A/C8.H6 A/C8.H2'2 1.49 3.00
63: P67 7.25 2.21 1,8e+08 A/G10.H8 A/G9.H2’2 1.49 5.00
64: P68 7.58 2.39 3.2e+08 A/G9.H8 A/G9.H2’1 1.49 3.00
65: P69 7.58 2.46 2.4e+08 A/G9.H8 A/C8.H2’2 1.49 5.00
66: P70 7.58 2.21 1,8e+08 A/G9.H8 A/G9.H2’2 1.49 5.00
67: P71 7.25 2.39 2.2e+08 A/G10.H8 A/G9.H2’1 1.49 5.00
68: P74 7.39 2.21 2.3e+08 B/C11.H6 B/C11 ,H2’2 1.49 5.00
69: P75 7.39 1.62 3.2e+08 B/C11.H6 B/C'l 1 .H2’1 1.49 3.00
70: P76 7.35 1.62 4e+08 B/C12.H6 B/C11 .H2’1 1.49 3.00
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1: POS1 2: POS2 3: INTEGRAL 4: ATOM.POSI 5: ATOM_POS2 6: LOWER 7: UPPER
71: P77 7.35 2.21 3.5e+08 B/C12.H6 B/C11 .H2'2 1.49 3.00
72: P78 7.35 2.20 2.6e+08 B/C12.H6 B/C12.H2’1 1.49 5.00
73: P79 7.35 1.98 2.2e+08 B/C12.H6 B/C12.H2’2 1.49 5.00
74: P80 7.77 1.99 1,7e+08 B/G13.H8 B/C12.H2’2 1.49 5.00
75: P81 7.77 2.20 36+08 B/G13.H8 B/C12.H2'1 1.49 3.00
76: P82 7.77 2.40 3.4e+08 B/G13.H8 B/G13.H2’1 1.49 3.00
77: P83 7.77 2.55 5.4e+08 B/G13.H8 B/G13.H2'2 1.49 3.00
78: P84 7.45 2.40 2.1e+08 B m 4.H 6 B/G13.H2'1 1.49 5.00
79: P85 7.45 2.21 3.4e+08 B/T14.H6 B/T14.H2'1 1.49 3.00
80: P86 7.46 2.55 1,3e+08 B/T14.H6 B/T14.H2’2 1.49 7.00
81: P87 7.45 2.55 1.3e+08 B/T14.H6 B/G13.H2'2 1.49 7.00
82: P88 7.41 1.38 1.4e+08 B/T15.H6 B/T15.H2'1 1.49 5.00
83: P89 7.41 1.61 2.6e+08 B/T15.H6 B/T15.H2’2 1.49 5.00
84: P90 7.41 2.21 2.1e+08 B/T15.H6 B/T14.H2'1 1.49 5.00
85: P91 7.41 2.55 1.2e+08 B/T15.H6 B/T14.H2’2 1.49 7.00
86: P92 7.18 1.38 2.6e+08 B/T16.H6 B/T15.H2’1 1.49 5.00
87: P93 7.18 1.46 5.1e+08 B/T16.H6 B/T16.H2'2 1.49 3.00
88: P94 7.18 1.61 1,2e+08 Bm 6.H 6 B/T15.H2'2 1.49 7.00
89: P95 7.18 2.19 6.5e+07 B/T16.H6 B/T16.H2'1 1.49 7.00
90: P96 7.02 1.46 2.1e+08 B/T17.H6 B/T16.H2’2 1.49 5.00
91: P97 7.02 2.19 2.2e+08 B/T17.H6 B/T16.H2'1 1.49 5.00
92: P98 7.02 1.72 2.5e+08 B/T17.H6 B/T17.H2’1 1.49 5.00
93: P99 • 7.02 1.84 3.66+08 B/T17.H6 B/T17.H2'2 1.49 3.00
94: P100 6.95 1.84 9.7e+07 B/T18.H6 B/T17.H2’2 1.49 7.00
95: P101 6.95 1.73 5.6e+07 B/T18.H6 B/T17.H2’1 1.49 7.00
96: P102 6.95 1.80 1.9e+08 B/T18.H6 B/T18.H2’1 1.49 5.00
97: P104 7.03 1.92 2.7e+08 B/C19.H6 B/C19.H2'1 1.49 5.00
98: P105 7.03 1.49 5.4e+08 B/C19.H6 B/C19.H2’2 1.49 3.00
99: P107 7.03 1.80 1.2e+08 B/C19.H6 B/T18.H2'1 1.49 7.00
100: P108 7.66 1.49 2.4e+08 B/G20.H8 B/C19.H2’2 1.49 5.00
101: P109 7.66 1.93 2.5e+07 B/G20.H8 B/C19.H2’1 1.49 7.00
102: P 110 7.66 2.20 3.9e+08 B/G20.H8 B/G20.H2’2 1.49 3.00
103: P111 7.67 2.43 66+08 B/G20.H8 B/G20.H2’1 1.49 3.00
104: P112 7.39 4.40 2.5e+08 B/C11.H6 B/C11.H3’ 1.49 5.00
105: P113 7.34 4.40 2.5e+08 B/C12.H6 B/C11.H3’ 1.49 5.00
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1: POS1 2: POS2 3: INTEGRAL 4: ATOM_POS1 5: ATOM_POS2 6: LOWER 7: UPPER
106: P114 7.34 4.65 4.9e+08 B/C12.H6 B/C12.H3’ 1.49 3.00
107: P 115 7.76 4.65 1,4e+07 B/G13.H8 B/C12.H3' 1.49 7.00
108: P116 7.77 4.85 2.4e+08 B/G13.H8 B/G13.H3' 1.49 5.00
109: P117 7.46 4.85 7.4e+07 B/T14.H6 B/G13.H3' 1.49 7.00
110: P118 7.46 4.83 1,4e+08 B/T14.H6 B/T14.H3' 1.49 7.00
111: P119 7.42 4.82 9.6e+07 B/T15.H6 B/T14.H3’ 1.49 7.00
112: P120 7.18 4.30 1,6e+08 B/T16.H6 B/T15.H3' 1.49 5.00
113: P121 7.18 4.39 6e+07 B/T16.H6 B/T16.H3’ 1.49 7.00
114: P122 7.02 4.39 8.4e+07 B/T17.H6 B/T16.H3' 1.49 7.00
115: P123 6.95 4.40 7.2e+07 B/T18.H6 B/T18.H3' 1.49 7.00
116: P124 7.02 4.30 2.2e+08 B/T17.H6 B/T17.H3' 1.49 5.00
117: P125 6.95 4.30 7.2e+07 B/T18.H6 B/T17.H3’ 1.49 7.00
118: P126 7.03 4.40 6.9e+07 B/C19.H6 B/T18.H3’ 1.49 7.00
119: P127 7.03 4.54 1.3e+08 B/C19.H6 B/C19.H3' 1.49 7.00
120: P128 7.66 4.54 2.3e+08 B/G20.H8 B/C19.H3' 1.49 5.00
121: P129 7.25 4.39 2.4e+08 A/C1.H6 A/C1.H3' 1.49 5.00
122: P130 7.71 4.39 2.6e+08 A/G2.H8 A/C1.H3' 1.49 5.00
123: P131 7.72 4.81 2.2e+09 A/G2.H8 A/G2.H3' 1.49 3.00
124: P132 7.94 4.81 2.6e+08 A/A3.H8 A/G2.H3' 1.49 5.00
125: P133 7.94 4.89 4.3e+08 A/A3.H8 A/A3.H3’ 1.49 3.00
126: P134 8.00 4.89 6.4e+07 A/A4.H8 A/A3.H3’ 1.49 7.00
127: P135 8.00 4.50 1,3e+08 A/A4.H8 A/A4.H3’ 1.49 7.00
128: P136 7.90 4.50 1.7e+08 A/A5.H8 A/A4.H3’ 1.49 5.00
129: P137 7.90 4.30 1.1e+08 A/A5.H8 A/A5.H3’ 1.49 7.00
130: P138 7.47 4.30 2e+08 A/A6.H8 A/A5.H3’ 1.49 5.00
131:P139 7.47 4.40 1,2e+08 A/A6.H8 A/A6.H3’ 1.49 7.00
132: P140 7.19 4.30 1e+08 A/C8.H6 A/A7.H3’ 1.49 7.00
133: P141 7.18 4.80 8.5e+07 A/C8.H6 A/C8.H3' 1.49 7.00
134: P142 7.58 4.80 1,3e+08 A/G9.H8 A/C8.H3’ 1.49 7.00
135: P143 7.58 4.51 2.4e+08 A/G9.H8 A/G9.H3’ 1.49 5.00
136: P144 7.25 4.51 5.5e+07 A/G10.H8 A/G9.H3’ 1.49 7.00
137: P146 7.66 4.52 1,4e+08 B/G20.H8 B/G20.H3' 1.49 7.00
138: P147 7.26 3.83 1.86+08 A/C1.H6 A/C1.H4’ 1.49 5.00
139: P148 7.71 3.83 2.5e+08 A/G2.H8 A/C1.H4’ 1.49 5.00
140: P149 7.72 4.12 1,8e+08 A/G2.H8 A/G2.H4' 1.49 5.00
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141:Pi 50 7.94 4.31 2.6e+08 A/A3.H8 A/A3.H4' 1.49 5.00
142: P151 8.00 3.11 7.4e+07 A/A4.H8 A/A4.H4’ 1.49 7.00
143: P152 7.90 2.42 2e+08 A/A5.H8 A/A5.H4' 1.49 5.00
144: P153 7.47 3.23 3.9e+07 A/A6.H8 A/A6.H4’ 1.49 7.00
145: P154 7.18 4.18 2.1e+08 A/C8.H6 A/C8.H4’ 1.49 5.00
146: P155 7.58 4.11 1.7e+08 A/G9.H8 A/G9.H4’ 1.49 5.00
147: P157 7.38 3.91 3.9e+08 B/C11.H6 B/C11.H4' 1.49 3.00
148: P160 7.77 4.22 1,8e+08 B/G13.H8 B/G13.H4’ 1.49 5.00
149: P161 7.46 4.24 2.2e+08 B/T14.H6 B/T14.H4' 1.49 5.00
150: P162 7.41 2.57 1,2e+08 B/T15.H6 B/T15.H4' 1.49 7.00
151: P163 7.18 3.97 8.8e+07 B/T16.H6 B/T16.H4’ 1.49 7.00
152:P165 7.67 4.05 2e+08 B/G20.H8 B/G20.H4' 1.49 5.00
153: P164 7.03 2.16 2.1e+08 B/C19.H6 B/C19.H4' 1.49 5.00
154: P166 7.25 3.56 2e+08 A/C1.H6 A/C1 .H5'1 1.49 5.00
155: P167 7.25 3.48 2e+08 A/C1.H6 A/C1 .H5‘2 1.49 5.00
156: P168 7.72 3.74 1.8e+08 A/G2.H8 A/G2.H5'2 1.49 5.00
157: P169 7.72 3.82 2e+08 A/G2.H8 A/G2.H5'1 1.49 5.00
158: P170 7.94 4.06 2.6e+08 A/A3.H8 A/A3.H5’2 1.49 5.00
159: P171 7.94 4.12 2.6e+08 A/A3.H8 A/A3.H5’1 1.49 5.00
160: P172 8.00 3.46 8e+07 A/A4.H8 A/A4.H5’2 1.49 7.00
161: P173 8.00 3.73 1e+08 A/A4.H8 A/A4.H5'1 1.49 7.00
162: P174 7.91 3.11 5.3e+07 A/A5.H8 A/A5.H5'2 1.49 7.00
163: P175 7.91 3.72 1.7e+08 A/A5.H8 A/A5.H5’1 1.49 5.00
164: P176 7.47 3.72 9.2e+07 A/A6.H8 A/A6.H5'1 1.49 7.00
165: P179 7.18 3.55 1e+08 A/C8.H6 A/C8.H5'2 1.49 7.00
166: P180 7.58 3.95 2e+08 A/G9.H8 A/G9.H5'2 1.49 5.00
167: P181 7.58 4.04 1.5e+08 A/G9.H8 A/G9.H5’1 1.49 5.00
168: P183 7.19 3.96 1,3e+08 A/C8.H6 A/C8.H5'1 1.49 7.00
169: P185 7.38 3.46 1,6e+08 B/C11.H6 B/C11 ,H5'2 1.49 5.00
170: P186 7.39 3.52 2e+08 B/C11.H6 B/C11.H5’1 1.49 5.00
171: P187 7.34 3.76 1,6e+08 B/C12.H6 B/C12.H5’2 1.49 5.00
172: P188 7.34 3.84 1,8e+08 B/C12.H6 B/C12.H5’1 1.49 5.00
173: P189 7.77 3.94 1,5e+08 B/G13.H8 B/G13.H5'1 1.49 5.00
174: P191 7.45 4.01 2e+08 B/T14.H6 B/T14.H5’2 1.49 5.00
175: P192 7.45 4.09 2.3e+08 B/T14.H6 B/T14.H5’1 1.49 5.00
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176: P193 7.41 4.02 2.6e+07 B/T15.H6 B/T15.H5'2 1.49 7.00
177: P194 7.41 4.25 2.4e+08 B/T15.H6 B/T15.H5’1 1.49 5.00
178: P195 7.18 2.91 6.4e+07 B/T16.H6 B/T16.H5'2 1.49 7.00
179: P196 7.18 3.44 2.6e+07 B/T16.H6 B/T16.H5’1 1.49 7.00
180: P197 7.02 3.73 2.5e+08 B/T17.H6 B/T17.H5'1 1.49 5.00
181: P198 7.03 2.89 1,4e+08 B/C19.H6 B/C19.H5'2 1.49 7.00
182: P199 7.03 3.31 5.1e+07 B/C19.H6 B/C19.H5’1 1.49 7.00
183: P200 7.66 3.88 1,2e+08 B/G20.H8 B/G20.H5’2 1.49 7.00
184: P201 7.66 3.93 1.1e+08 B/G20.H8 B/G20.H5'1 1.49 7.00
185: P202 7.71 7.25 1,5e+08 A/G2.H8 A/C1.H6 1.49 5.00
186: P203 7.95 7.71 1.76+08 A/A3.H8 A/G2.H8 1.49 5.00
187: P204 8.00 7.92 2.7e+08 A/A4.H8 A/A5.H8 1.49 5.00
188: P205 7.91 7.47 1.1 e+08 A/A5.H8 A/A6.H8 1.49 7.00
189: P206 8.27 7.47 3.8e+06 A/A7.H8 A/A6.H8 1.49 7.00
190: P207 7.58 7.18 4.9e+06 A/G9.H8 A/C8.H6 1.49 7.00
191: P208 7.41 7.18 7.9e+07 B/T15.H6 B/T16.H6 1.49 7.00
192: P209 7.58 7.25 4.3e+07 A/G9.H8 A/G10.H8 1.49 7.00
193: P210 7.76 7.35 1.3e+08 B/G13.H8 B/C12.H6 1.49 7.00
194: P211 7.76 7.45 1.9e+08 B/G13.H8 B/T14.H6 1.49 5.00
195: P212 7.18 7.02 5.3e+07 B/T16.H6 B/T17.H6 1.49 7.00
196: P213 7.02 6.95 1.2e+08 B/T17.H6 B/T18.H6 1.49 7.00
197: P214 7.67 7.03 1e+08 B/G20.H8 B/C19.H6 1.49 7.00
198: P215 5.32 5.15 8.9e+07 A/C1.H1’ A/G2.HT 1.49 7.00
199: P216 5.75 5.15 5.5e+07 A/A3.H1' A/G2.H1’ 1.49 7.00
200: P217 5.67 5.07 3.3e+07 A/A5.H1’ A/A6.H1’ 1.49 7.00
201: P218 5.20 5.08 1e+08 A/C8.H1’ A/A7.H1' 1.49 7.00
202: P219 5.94 5.19 3.2e+07 A/G9.H1' A/C8.H1’ 1.49 7.00
203: P223 6.15 5.72 1,7e+07 B/T14.H1’ B/G13.H1’ 1.49 7.00
204: P224 5.71 5.05 6.6e+07 BT16.H1' B/T17.H1' 1.49 7.00
205: P225 5.44 5.07 8.8e+07 B/T18.H1’ BT17.H1' 1.49 7.00
206: P226 5.90 5.16 3.8e+07 B/G20.H1’ B/C19.H1’ 1.49 7.00
207: P227 5.44 5.16 1,9e+08 B/T18.H1’ B/C19.H1' 1.49 5.00
208: P228 5.32 4.39 3.4e+08 A/C1.H1’ A/C1.H3' 1.49 3.00
209: P229 5.14 4.81 2.5e+08 A/G2.H1’ A/G2.H3' 1.49 5.00
210: P230 5.76 4.91 2.8e+08 A/A3.H1’ A/A3.H3’ 1.49 3.00
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211: P231 5.56 4.50 1,7e+08 A/A4.H1’ A/A4.H3' 1.49 5.00
212: P232 5.68 4.30 2.5e+08 A/A5.H1’ A/A5.H3' 1.49 5.00
213: P233 5.07 4.40 1,6e+08 A/A6.H1' A/A6.H3’ 1.49 5.00
214: P234 5.08 4.30 1.5e+08 A/A7.H1’ A/A7.H3’ 1.49 5.00
215: P235 5.20 4.80 2.9e+08 A/C8.H1' A/C8.H3’ 1.49 3.00
216: P236 5.94 4.51 3.2e+08 A/G9.H1’ A/G9.H3’ 1.49 3.00
217: P238 5.61 4.40 2.1 e+08 B/C11.H1’ B/C11.H3’ 1.49 5.00
218: P240 5.72 4.84 4.6e+08 B/G13.H1' B/G13.H3’ 1.49 3.00
219: P241 6.15 4.82 1,2e+08 B/T14.H1’ B/T14.H3' 1.49 7.00
220: P242 6.08 4.30 8.2e+07 B/T15.H1’ B/T15.H3’ 1.49 7.00
221: P243 5.71 4.39 1e+08 Bn"16.Hr B/T16.H3’ 1.49 7.00
222: P244 5.06 4.30 1,6e+08 B/T17.HV B/T17.H3’ 1.49 5.00
223: P245 5.44 4.40 4.3e+08 B/T18.H1' B/T18.H3’ 1.49 3.00
224: P246 5.17 4.53 1,2e+08 B/C19.H1’ B/C19.H3’ 1.49 7.00
225: P247 5.90 4.52 4.1 e+08 B/G20.H1’ B/G20.H3* 1.49 3.00
226: P248 5.32 3.83 3.3e+08 A/C1.H1’ A/C1.H4’ 1.49 3.00
227: P249 5.14 4.13 2.4e+08 A/G2.H1’ A/G2.H4’ 1.49 5.00
228: P250 5.75 4.31 5.8e+08 A/A3.H1' A/A3.H4' 1.49 3.00
229: P251 5.56 3.11 2.7e+07 A/A4.H1’ A/A4.H4' 1.49 7.00
230: P252 5.68 2.42 4.4e+08 A/A5.H1' A/A5.H4’ 1.49 3.00
231: P253 5.07 3.23 3.5e+06 A/A6.H1' A/A6.H4’ 1.49 7.00
232: P254 5.08 2.45 1,8e+08 A/A7.H1' A/A7.H4' 1.49 5.00
233: P255 5.20 4.18 2.4e+08 A/C8.H1’ A/C8.H4' 1.49 5.00
234: P256 5.93 4.11 3.6e+08 A/G9.H1’ A/G9.H4' 1.49 3.00
235: P258 5.61 3.90 3.2e+08 B/C11.H1’ B/C11.H4’ 1.49 3.00
236: P260 5.73 4.22 2.3e+08 B/G13.H11 B/G13.H4' 1.49 5.00
237: P261 6.15 4.24 2.6e+08 B/T14.H1’ B/T14.H4’ 1.49 5.00
238: P262 6.07 2.57 2.5e+08 B/T15.H1’ B/T15.H4’ 1.49 5.00
239: P263 5.71 3.97 1,8e+08 B/T16.H1' B/T16.H4' 1.49 5.00
240: P264 5.44 3.91 3.6e+08 B/T18.H1’ B/T18.H4’ 1.49 3.00
241: P265 5.16 2.15 3.2e+08 B/C19.H1’ B/C19.H4' 1.49 3.00
242: P266 5.90 4.05 4.1 e+08 B/G20.H1’ B/G20.H4’ 1.49 3.00
243: P267 5.32 3.48 1.3e+08 A/C1.H1’ A/C1 .H5’2 1.49 7.00
244: P268 5.33 3.56 1,5e+08 A/C1.H1' A/C1.H5’1 1.49 5.00
245: P269 5.14 3.74 1.4e+08 A/G2.HT A/G2.H5’2 1.49 5.00
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246: P270 5.14 3.81 1.4e+08 A/G2.H1’ A/G2.H5'1 1.49 5.00
247: P271 5.75 4.06 2.1 e+08 A/A3.H1' A/A3.H5’2 1.49 5.00
248: P272 5.75 4.12 2.1 e+08 A/A3.HT A/A3.H5’1 1.49 5.00
249: P273 5.56 3.46 7.4e+07 A/A4.H1’ A/A4.H5’2 1.49 7.00
250: P274 5.56 3.73 9.5e+07 A/A4.H1’ A/A4.H5T 1.49 7.00
251: P275 5.68 3.11 1e+08 A/A5.H1’ A/A5.H5'2 1.49 7.00
252: P276 5.68 3.72 2.2e+08 A/A5.H1' A/A5.H5'1 1.49 5.00
253: P277 5.07 3.57 1.3e+08 A/A6.H1 ’ A/A6.H5'2 1.49 7.00
254: P278 5.07 3.72 1,4e+07 A/A6.H1' A/A6.H5T 1.49 7.00
255: P279 5.08 4.03 1.2e+08 A/A7.H1' A/A7.H5’2 1.49 7.00
256: P280 5.08 4.19 1e+08 A/A7.H1' A/A7.H5T 1.49 7.00
257: P281 5.20 3.55 1.3e+08 A/C8.H1’ A/C8.H5'2 1.49 7.00
258: P282 5.20 3.96 3.4e+08 A/C8.H1' A/C8.H5'1 1.49 3.00
259: P283 5.93 3.96 4.8e+08 A/G9.H1' A/G9.H5'2 1.49 3.00
260: P284 5.94 4.04 4.2e+08 A/G9.H1’ A/G9.H5'1 1.49 3.00
261: P287 5.61 3.47 1 4e+08 B/C11.H1’ B/C11 ,H5’2 1.49 7.00
262: P288 5.61 3.52 1.9e+08 B/C11.H1’ B/C11.H5T 1.49 5.00
263: P292 5.72 3.94 2.5e+08 B/G13.H1’ B/G13.H5'1 1.49 5.00
264: P293 6.15 4.01 2.3e+08 B/T14.H1' B/T14.H5'2 1.49 5.00
265: P294 6.15 4.09 1,6e+08 B/T14.H1’ B/T14.H5'1 1.49 5.00
266: P295 6.08 4.02 2.2e+08 B/T15.HV B/T15.H5’2 1.49 5.00
267: P296 6.08 4.25 5.9e+07 B/T15.H1' B/T15.H5T 1.49 7.00
268: P297 5.71 3.45 1e+08 B/T16.H1’ B/T16.H5T 1.49 7.00
269: P298 5.71 2.91 1,4e+08 B/T16.H1’ B/T16.H5’2 1.49 7.00
270: P299 5.06 3.44 5.8e+07 B/T17.H1’ B/T17.H5'2 1.49 7.00
271: P300 5.06 3.73 1.7e+08 B/T17.H1’ B/T17.H5'1 1.49 5.00
272: P301 5.44 3.61 6.7e+07 B/T18.H1’ B/T18.H5’1 1.49 7.00
273: P302 5.17 3.31 7.3e+07 B/C19.H1’ B/C19.H5'1 1.49 7.00
274: P303 5.17 2.89 1.4e+08 B/C19.H1’ B/C19.H5’2 1.49 7.00
275: P304 5.90 3.93 1,8e+08 B/G20.H1’ B/G20.H5’1 1.49 5.00
276: P305 5.90 3.90 2.4e+08 B/G20.H1' B/G20.H5'2 1.49 5.00
277: P306 5.32 1.31 4e+08 A/C1.H1’ A/C1 .H2’1 1.49 3.00
278: P307 5.32 2.01 5.9e+08 A/C1.H1’ A/C1.H2’2 1.49 3.00
279: P308 5.14 2.50 3.8e+08 A/G2.H1’ A/G2.H2’1 1.49 3.00
280: P309 5.14 2.55 3.5e+08 A/G2.H1’ A/G2.H2’2 1.49 3.00
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316: P350 4.80 3.96 4.4e+08 A/C8.H3’ A/C8.H5’1 1.49 3.00
317: P351 4.80 4.19 3.4e+08 A/C8.H3' A/C8.H4' 1.49 3.00
318: P352 4.66 3.91 3.4e+08 B/C12.H3' B/C12.H4’ 1.49 3.00
319: P353 4.66 3.77 1,8©+08 B/C12.H3’ B/C12.H5'2 1.49 5.00
320: P354 4.66 3.84 1.5e+07 B/C12.H3’ B/C12.H5’1 1.49 7.00
321: P355 4.30 3.12 6.1e+07 B/T17.H3' B/T17.H4' 1.49 7.00
322: P356 4.30 3.44 3.2e+08 B/T17.H3’ B/T17.H5'2 1.49 3.00
323: P357 4.30 3.73 1,5e+09 B/T17.H3' B/T17.H5’1 1.49 3.00
324: P358 4.30 3.10 6e+07 A/A5.H3' A/A5.H5’2 1.49 7.00
325: P359 4.30 3.72 1 5e+08 A/A5.H3’ A/A5.H5’1 1.49 5.00
326: P360 4.30 2.42 3.3e+08 A/A5.H3’ A/A5.H4’ 1.49 3.00
327: P361 4.49 3.11 2.3e+08 A/A4.H3’ A/A4.H4' 1.49 5.00
328: P362 4.49 3.46 4.4e+08 A/A4.H3' A/A4.H5’2 1.49 3.00
329: P363 4.40 3.23 1.6e+08 A/A6.H3' A/A6.H4’ 1.49 5.00
330: P364 4.40 3.72 2.5e+08 A/A6.H3’ A/A6.H5’1 1.49 5.00
331: P365 4.40 3.58 1.9e+08 A/A6.H3’ A/A6.H5'2 1.49 5.00
332: P366 4.52 2.89 2.1 e+08 B/C19.H3' B/C19.H5’2 1.49 5.00
333: P367 4.53 2.16 2e+08 B/C19.H3' B/C19.H4’ 1.49 5.00
334: P368 4.41 3.23 2.6e+08 B/T18.H3' B/T18.H5’2 1.49 5.00
335: P369 4.41 3.61 2e+08 Bm 8.H3' B/T18.H5’1 1.49 5.00
336: P370 4.41 3.91 3.5e+08 B/T18.H3’ B/T18.H4’ 1.49 3.00
337: P371 4.39 2.92 2.9e+08 B/T16.H3’ B/T16.H5'2 1.49 3.00
338: P372 4.39 3.44 5e+08 B/T16.H3’ B/T16.H5'1 1.49 3.00
339: P373 4.39 3.48 4.2e+08 A/C1.H3’ A/C1 .H5'2 1.49 3.00
340: P374 4.39 3.56 3.9e+08 A/C1.H3’ A/C1 ,H5'1 1.49 3.00
341: P375 4.39 3.83 9.1 e+08 A/C1.H3’ A/C1.H4’ 1.49 3.00
342: P376 4.51 4.11 3.1 e+08 A/G9.H3’ A/G9.H4’ 1.49 3.00
343: P377 4.51 4.04 3.3e+08 A/G9.H3’ A/G9.H5’1 1.49 3.00
344: P378 4.51 3.96 3.4e+08 A/G9.H3' A/G9.H5’2 1.49 3.00
345: P379 4.81 3.74 2.4e+08 A/G2.H3' A/G2.H5'2 1.49 5.00
346: P380 4.81 3.81 5.7e+08 A/G2.H3’ A/G2.H5’1 1.49 3.00
347: P381 4.81 4.13 4e+08 A/G2.H3' A/G2.H4’ 1.49 3.00
348: P383 4.83 4.24 3.3e+08 B/T14.H3’ B/T14.H4’ 1.49 3.00
349: P386 4.85 3.94 2.9e+08 B/G13.H3* B/G13.H5'1 1.49 3.00
350: P387 4.84 4.22 2.6e+08 B/G13.H3' B/G13.H4’ 1.49 5.00
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281: P310 5.76 2.73 3.7e+08 A/A3.H1' A/A3.H2'2 1.49 3.00
282: P311 5.76 2.52 3.3e+08 A/A3.H1’ A/A3.H2'1 1.49 3.00
283: P312 5.56 2.43 1,7e+08 A/A4.H1’ A/A4.H2'1 1.49 5.00
284: P313 5.56 2.45 1.7e+08 A/A4.H1' A/A4.H2’2 1.49 5.00
285: P314 5.68 2.54 3.8e+08 A/A5.H1' A/A5.H2’1 1.49 3.00
286: P315 5.68 2.90 1,9e+08 A/A5.H1’ A/A5.H2’2 1.49 5.00
287: P316 5.07 1.47 3.8e+08 A/A6.H1’ A/A6.H2'1 1.49 3.00
288: P317 5.07 1.82 2.7e+08 A/A6.H1’ A/A6.H2’2 1.49 3.00
289: P318 5.08 2.56 1,7e+08 A/A7.H1’ A/A7.H2’1 1.49 5.00
290: P319 5.08 2.57 2e+08 A/A7.H1' A/A7.H2’2 1.49 5.00
291: P320 5.20 2.21 3.2e+08 A/C8.H1' A/C8.H2’1 1.49 3.00
292: P321 5.20 2.46 4.2e+08 A/C8.H1’ A/C8.H2'2 1.49 3.00
293: P322 5.94 2.21 4.2e+08 A/G9.H1' A/G9.H2'2 1.49 3.00
294: P323 5.94 2.39 4.1 e+08 A/G9.H1' A/G9.H2’1 1.49 3.00
295: P326 5.61 1.63 4.1 e+08 B/C11.H1’ B/C11 ,H2'1 1.49 3.00
296: P327 5.61 2.21 6.7e+08 B/C11.H1’ B/C11 ,H2’2 1.49 3.00
297: P330 5.73 2.41 3e+08 B/G13.H1' B/G13.H2'1 1.49 3.00
298: P331 5.73 2.55 3.2e+08 B/G13.H1' B/G13.H2'2 1.49 3.00
299: P332 6.14 2.21 1.3e+08 B/T14.H1' B/T14.H2'1 1.49 7.00
300: P333 6.15 2.55 2.5e+08 Brr14.Hr B/T14.H2'2 1.49 5.00
301: P334 6.07 1.39 8.4e+07 B/T15.H1' B/T15.H2’1 1.49 7.00
302: P335 6.08 1.60 1,7e+08 B/T15.H1’ B/T15.H2’2 1.49 5.00
303: P336 5.71 1.46 3.2e+08 B/T16.H1' B/T16.H2’2 1.49 3.00
304: P337 5.71 2.19 3.8e+08 B/T16.H1’ B/T16.H2'1 1.49 3.00
305: P338 5.07 1.72 1e+08 B/T17.H1’ B/T17.H2’1 1.49 7.00
306: P339 5.06 1.84 2.7e+08 B/T17.H1’ B/T17.H2’2 1.49 5.00
307: P341 5.44 1.80 1,9e+08 B/T18.H1’ B/T18.H2'1 1.49 5.00
308: P342 5.17 1.49 2e+08 B/C19.H1' B/C19.H2’2 1.49 5.00
309: P343 5.17 1.92 3.9e+08 B/C19.H1’ B/C19.H2’1 1.49 3.00
310: P344 5.90 2.19 4.4e+08 B/G20.H1' B/G20.H2’2 1.49 3.00
311: P345 5.89 2.43 3.9e+08 B/G20.H1’ B/G20.H2’1 1.49 3.00
312: P346 4.92 4.31 2.9e+08 A/A3.H3' A/A3.H4' 1.49 3.00
313: P347 4.91 4.12 3.2e+08 A/A3.H3’ A/A3.H5'1 1.49 3.00
314: P348 4.92 4.06 3.4e+08 A/A3.H3’ A/A3.H5’2 1.49 3.00
315: P349 4.80 3.55 2.3e+08 A/C8.H3’ A/C8.H5’2 1.49 5.00
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351: P388 4.52 4.05 2.5e+08 B/G20.H3’ B/G20.H4’ 1.49 5.00
352: P389 4.52 3.93 1.1 e+08 B/G20.H3’ B/G20.H5’1 1.49 7.00
353: P3S0 4.52 3.89 9.2e+07 B/G20.H3’ B/G20.H5’2 1.49 7.00
354: P391 4.39 1.31 3.4e+08 A/C1.H3’ A/C1.H2'1 1.49 3.00
355: P392 4.39 2.01 2.5e+08 A/C1.H3' A/C1 H2'2 1.49 5.00
356: P395 4.83 2.21 2e+08 B/T14.H3’ B/T14.H2'1 1.49 5.00
357: P396 4.83 2.55 4.3e+08 Brri4.H3' B7T14.H2'2 1.49 3.00
358: P397 4.92 2.72 3.4e+08 A/A3.H3’ A/A3.H2'2 1.49 3.00
359: P398 4.92 2.52 4.5e+08 A/A3.H3' A/A3.H2'1 1.49 3.00
360: P399 4.66 1.99 1,4e+08 B/C12.H3' B/C12.H2’2 1.49 7.00
361: P400 4.66 2.20 2.6e+08 B/C12.H3’ B/C12.H2’1 1.49 5.00
362: P401 4.53 1.49 2.4e+08 B/C19.H3' B/C19.H2’2 1.49 5.00
363: P402 4.53 1.92 2.2e+08 B/C19.H3' B/C19.H2'1 1.49 5.00
364: P403 4.40 1.47 1.2e+08 A/A6.H3' A/A6.H2’1 1.49 7.00
365: P404 4.40 1.82 1,6e+08 A/A6.H3' A/A6.H2’2 1.49 5.00
366: P405 4.39 1.46 1,4e+08 B/T16.H3' B/T16.H2’2 1.49 7.00
367: P406 4.39 2.19 1,4e+08 B/T16.H3’ B/T16.H2’1 1.49 7.00
368: P409 4.81 2.50 3.8e+08 A/G2.H3' A/G2.H2’1 1.49 3.00
369: P410 4.81 2.56 1,7e+08 A/G2.H3' A/G2.H2’2 1.49 5.00
370: P411 4.85 2.55 7e+08 B/G13.H3’ B/G13.H2’2 1.49 3.00
371: P412 4.85 2.41 4e+08 B/G13.H3’ B/G13.H2T 1.49 3.00
372: P413 4.30 1.61 6e+07 B/T15.H3' ■ B/T15.H2’2 1.49 7.00
373: P414 4.30 1.38 6.5e+08 B/T15.H3' B/T15.H2'1 1.49 3.00
374: P415 4.40 1.62 8.8e+07 B/C11.H3’ B/C11.H2’1 1.49 7.00
375: P416 4.40 2.21 1,4e+08 B/C11.H3’ B/C11 .H2'2 1.49 5.00
376: P417 4.30 2.90 9.4e+07 A/A5.H3’ A/A5.H2’2 1.49 7.00
377: P418 4.30 2.54 1,9e+08 A/A5.H3’ A/A5.H2’1 1.49 5.00
378: P419 4.50 2.45 1e+08 A/A4.H3' A/A4.H2’2 1.49 7.00
379: P420 4.50 2.43 1.1 e+08 A/A4.H3’ A/A4.H2’1 1.49 7.00
380: P421 4.30 2.56 1.2e+07 A/A7.H3* A/A7.H2’1 1.49 7.00
381: P422 4.30 2.57 1.2e+08 A/A7.H3’ A/A7.H2'2 1.49 7.00
382: P423 4.52 2.20 1.9e+08 B/G20.H3’ B/G20.H2'2 1.49 5.00
383: P424 4.52 2.43 2.3e+08 B/G20.H3’ B/G20.H2’1 1.49 5.00
384: P425 4.51 2.21 2.4e+08 A/G9.H3’ A/G9.H2’2 1.49 5.00
385: P426 4.51 2.39 2.7e+08 A/G9.H3' A/G9.H2’1 1.49 5.00
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386: P427 4.80 2.21 2.2e+08 A/C8.H3’ A/C8.H2’1 1.49 5.00
387: P428 4.80 2.46 4e+08 A/C8.H3' A/C8.H2’2 1.49 3.00
388: P429 4.30 1.83 2.4e+08 B/T17.H3’ B/T17.H2'2 1.49 5.00
389: P430 4.30 1.73 7.9e+07 B/T17.H3' B/T17.H2’1 1.49 7.00
390: P432 4.41 1.80 1,7e+08 B/T18.H3' B/T18.H2’1 1.49 5.00
391: P433 3.57 1.32 1,7e+08 A/C1 ,H5'1 A/C1 ,H2’1 1.49 5.00
392: P434 3.49 1.31 1,6e+08 A/C1 .H5'2 A/C1.H2'1 1.49 5.00
393: P435 3.53 1.63 1.1 e+08 B/C11 ,H5'1 B/C11 ,H2’1 1.49 7.00
394: P436 3.46 1.63 1.2e+08 B/C11 .H5’2 B/C11 ,H2’1 1.49 7.00
395: P437 3.57 2.01 2.3e+08 A/C1.H5'1 A/C1.H2’2 1.49 5.00
396: P438 3.49 2.01 2.4e+08 A/C1 .H5'2 A/C1.H2'2 1.49 5.00
397: P439 3.52 2.21 3.5e+08 B/C11.H5'1 B/C11 .H2'2 1.49 3.00
398: P440 3.46 2.21 2.6e+08 B/C11 .H5’2 B/C11 .H2'2 1.49 5.00
399: P441 3.46 2.44 2.4e+08 A/A4.H5'2 A/A4.H2'1 1.49 5.00
400: P442 3.46 2.45 2.2e+07 A/A4.H5'2 A/A4.H2'2 1.49 7.00
401: P443 3.44 1.84 2.9e+08 B/T17.H5’2 B/T17.H2’2 1.49 3.00
402: P444 3.73 1.84 5e+08 B/TJ17.H5'1 B/T17.H2’2 1.49 3.00
403: P445 3.73 1.72 3.1 e+08 B/T17.H5'1 B/T17.H2’1 1.49 3.00
404: P446 3.73 1.47 4e+08 A/A6.H5'1 A/A6.H2’1 1.49 3.00
405: P447 3.72 1.82 2.7e+08 A/A6.H5'1 A/A6.H2'2 1.49 5.00
406: P448 2.91 1.46 1,7e+08 B/T16.H5’2 B/T16.H2’2 1.49 5.00
407: P449 3.11 2.42 3.7e+08 A/A5.H5’2 A/A5.H4’ 1.49 3.00
408: P451 2.57 1.39 3.6e+08 B/T15.H4’ B/T15.H2’1 1.49 3.00
409: P452 3.83 1.30 3.5e+08 A/C1.H4’ A/C1.H2'1 1.49 3.00
410: P453 3.83 2.01 6.6e+08 A/C1.H4’ A/C1 .H2’2 1.49 3.00
411: P457 3.97 1.46 1,8e+08 B/T16.H4' B/T16.H2’2 1.49 5.00
412: P458 4.11 2.21 3.7e+08 A/G9.H4' A/G9.H2’2 1.49 3.00
413: P459 3.31 2.89 6.1 e+08 B/C19.H5’1 B/C19.H5’2 1.49 3.00
414: P460 3.46 3.11 2.1 e+08 A/A4.H5’2 A/A4.H4' 1.49 5.00
415: P461 3.72 3.11 2.6e+08 A/A5.H5’1 A/A5.H5’2 1.49 5.00
416: P462 3.73 3.11 7.3e+07 A/A4.H5’1 A/A4.H4' 1.49 7.00
417: P463 3.72 2.90 2e+08 A/A5.H5'1 A/A5.H2’2 1.49 5.00
418: P464 4.19 3.55 3.6e+08 A/C8.H4’ A/C8.H5'2 1.49 3.00
419: P465 2.02 1.31 3.1 e+08 A/C1.H2’2 A/C1.H2'1 1.49 3.00
420: P467 2.19 1.46 6.5e+08 B/T16.H2’1 B/T16.H2’2 1.49 3.00
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421: P468 1.82 1.47 7.7e+08 A/A6.H2'2 A/A6.H2'1 1.49 3.00
422: P469 2.90 2.54 1,8e+08 A/A5.H2’2 A/A5.H2'1 1.49 5.00
423: P470 2.55 2.21 7.4e+08 B/T14.H2’2 B/T14.H2’1 1.49 3.00
424: P471 2.20 1.99 2.6e+08 B/C12.H2'1 B/C12.H2’2 1.49 5.00
425: P473 1.91 1.49 5.2e+08 B/C19.H2'1 B/C19.H2'2 1.49 3.00
426: P474 2.21 1.62 3.9e+08 B/C11 .H2'2 B/C11 .H2'1 1.49 3.00
427: P475 8.11 7.63 3.1 e+08 A/OH1 .H6'1 A/OH1 ,H7'1 1.49 3.00
428: P476 7.82 7.48 5.6e+08 A/OH1.H4'2 A/OH1 .H5’2 1.49 3.00
429: P477 7.47 7.33 9.2e+08 A/OH1.H5'2 A/OH1 ,H6’2 1.49 3.00
430: P478 8.00 7.32 3.6e+08 A/OH1 .H7’2 A/OH1.H6’2 1.49 3.00
431: P479 7.90 7.82 2e+08 A/OH1 .H3'2 A/OH1 .H4'2 1.49 5.00
432: P480 8.00 7.82 1.7e+08 A/OH1 .H7'2 A/OH1 ,H4’2 1.49 5.00
433: P482 8.00 7.47 1 6e+08 A/OH1 .H7’2 A/OH1 ,H5’2 1.49 5.00
434: P483 8.11 7.90 1,4e+07 A/OH1 .H6’1 A/OH1 ,H3'2 1.49 7.00
435: P484 7.76 7.44 3.6e+08 A/OH1 ,H4'1 A/OH1 ,H3'1 1.49 3.00
436: P485 7.76 8.11 3.2e+07 A/OH1.H4’1 A/OH1 ,H6'1 1.49 7.00
437: P487 7.90 7.47 1.1e+08 A/OH1 ,H3’2 A/OH1 .H5'2 1.49 7.00
438: P488 7.83 7.31 4e+08 A/OH1 .H4’2 A/OH1 .H6’2 1.49 3.00
439: P489 7.90 7.03 3.4e+07 A/OH1.H3 A/OH1.H6 1.49 7.00
440: P490 7.90 7.44 6.6e+07 A/OH1.H3 A/OH1 .H3’1 1.49 7.00
441: P491 7.90 5.15 1,4e+08 A/OH1.H3 A/OH1.H8B 1.49 7.00
442: P492 7.90 3.73 6.3e+07 A/OH1.H3 A/OH1.H8A 1.49 7.00
443: P493 7.45 4.81 6.4e+07 A/OH1.H3’1 A/OH1.H1B 1.49 7.00
444: P494 5.15 4.81 1,9e+08 A/OH1.H8B A/OH1.H1B 1.49 5.00
445: P495 5.15 4.30 3.2e+08 A/OH1.H8B A/OH1.H8A2 1.49 3.00
446: P496 5.15 3.73 1,8e+08 A/OH1.H8B A/OH1.H8A 1.49 5.00
447: P497 5.15 3.71 9.2e+07 A/OH1.H8B A/OH1.H1A 1.49 7.00
448: P498 4.81 4.30 4.1 e+08 A/OH1.H1B A/OH1.H8A2 1.49 3.00
449: P499 4.81 3.71 5.2e+08 A/OH1.H1B A/OH1.H1A 1.49 3.00
450: P500 4.81 3.73 2.4e+08 A/OH1.H1B A/OH1.H8A 1.49 5.00
451: P501 4.30 3.71 1.3e+08 A/OH1.H8A2 A/OH1.H1A 1.49 7.00
452: P502 4.30 3.73 9.1e+07 A/OH1.H8A2 A/OH1.H8A 1.49 7.00
453: P503 8.16 7.68 2.1e+07 A/A7.H2 A/A6.H2 1.49 7.00
454: P504 8.11 7.68 3.1e+07 A/A5.H2 A/A6.H2 1.49 7.00
455: P505 7.55 7.31 2.2e+08 A/A3.H2 A/A4.H2 1.49 5.00
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456: P506 7.31 7.02 3.1e+07 A/A4.H2 B/T17.H6 1.49 7.00
457: P507 7.53 7.03 2.5e+07 A/A3.H2 B/C19.H6 1.49 7.00
458: P508 7.68 7.47 4.3e+07 A/A6.H2 A/A6.H8 1.49 7.00
459: P509 8.16 5.44 3.5e+07 A/A7.H2 A/C8.H5 1.49 7.00
460: P510 8.12 5.06 5.1e+06 A/A5.H2 B/T17.H1’ 1.49 7.00
461: P511 8.11 5.68 2.8e+07 A/A5.H2 A/A5.H1' 1.49 7.00
462: P512 7.68 5.71 1.1 e+08 A/A6.H2 B/T16.H1' 1.49 7.00
463: P514 7.68 5.07 1.1 e+08 A/A6.H2 A/A6.H1’ 1.49 7.00
464: P515 7.55 5.90 1,6e+08 A/A3.H2 B/G20.H1’ 1.49 5.00
465: P516 7.54 5.44 8.7e+07 A/A3.H2 B/T18.H1’ 1.49 7.00
466: P517 7.31 5.44 3e+07 A/A4.H2 B/T18.H1’ 1.49 7.00
467: P518 7.31 5.06 5.2e+07 A/A4.H2 B/T17.H1’ 1.49 7.00
468: P524 7.68 3.12 1,3e+08 A/A6.H2 B/T17.H4' 1.49 7.00
469: P526 7.68 2.91 1.1 e+08 A/A6.H2 B/T16.H5’2 1.49 7.00
470: P527 7.68 3.43 1.7e+08 A/A6.H2 B/T17.H5’2 1.49 5.00
471: P529 7.55 2.89 3.4e+07 A/A3.H2 B/C19.H5’2 1.49 7.00
472: P530 7.31 3.46 1,3e+08 A/A4.H2 A/A4.H5'2 1.49 7.00
473: P531 7.31 3.31 6.2e+07 A/A4.H2 B/C19.H5T 1.49 7.00
474: P532 7.31 2.89 1,2e+08 A/A4.H2 B/C19.H5'2 1.49 7.00
475: P534 8.11 2.42 1.1e+07 A/A5.H2 A/A5.H4’ 1.49 7.00
476: P535 7.31 2.45 1e+08 A/A4.H2 A/A4.H2'2 1.49 7.00
477: P536 7.31 2.43 8.5e+07 A/A4.H2 A/A4.H2T 1.49 7.00
478: P537 7.68 1.81 1.4e+08 A/A6.H2 A/A6.H2'2 1.49 7.00
479: P538 7.68 1.47 6.9e+07 A/A6.H2 A/A6.H2’1 1.49 7.00
480: P539 7.68 1.38 9.6e+07 A/A6.H2 B/T15.H2’1 1.49 7.00
481: P540 8.11 1.72 9.7e+06 A/A5.H2 B/T17.H2’1 1.49 7.00
482: P541 8.12 1.83 2e+07 A/A5.H2 B/T17.H2’2 1.49 7.00
483: P542 7.55 1.92 9.4e+07 A/A3.H2 B/C19.H2’1 1.49 7.00
484: P543 7.03 5.36 4e+08 B/C19.H6 B/C19.H5 1.49 3.00
485: P544 6.95 5.36 6.7e+07 B/T18.H6 B/C19.H5 1.49 7.00
486: P545 7.39 5.52 1e+09 B/C11.H6 B/C11.H5 1.49 3.00
487: P546 7.26 5.43 8.9e+08 A/C1.H6 A/C1.H5 1.49 3.00
488: P547 7.18 5.44 6.6e+07 A/C8.H6 A/C8.H5 1.49 7.00
489: P548 7.34 5.44 6.8e+08 B/C12.H6 B/C12.H5 1.49 3.00
490: P549 7.39 5.44 2.2e+08 B/C11.H6 B/C12.H5 1.49 5.00
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491: P550 5.37 5.16 1.4e+08 B/C19.H5 B/C19.HT 1.49 5.00
492: P552 5.61 5.52 2.2e+08 B/C11.H1’ B/C11.H5 1.49 5.00
493: P553 5.44 5.32 1.4e+08 A/C1.H5 A/C1.H1' 1.49 7.00
494: P554 5.61 5.44 1,3e+08 B/C11.HT B/C12.H5 1.49 7.00
495: P555 5.44 5.08 1.6e+08 A/C8.H5 A/A7.H1’ 1.49 5.00
496: P557 5.44 5.21 4.3e+07 A/C8.H5 A/C8.H1’ 1.49 7.00
497: P558 5.44 3.47 1,6e+08 A/C1.H5 A/C1 .H5’2 1.49 5.00
498: P559 5.44 3.56 1.1 e+08 A/C1.H5 A/C1 ,H5’1 1.49 7.00
499: P560 5.52 3.46 1,2e+08 B/C11.H5 b /c h .h s^ 1.49 7.00
500: P561 5.52 3.53 1.6e+08 B/C11.H5 B/C11.H5'1 1.49 5.00
501: P562 5.52 3.91 1.7e+08 B/C11.H5 B/C11.H4’ 1.49 5.00
502: P563 5.52 4.40 1,8e+08 B/C11.H5 B/C11.H3’ 1.49 5.00
503: P564 5.44 4.39 2.3e+08 A/C1.H5 A/C1.H3’ 1.49 5.00
504: P565 5.44 3.83 2.5e+08 A/C1.H5 A/C1.H4' 1.49 5.00
505: P567 5.44 3.55 1.2e+08 A/C8.H5 A/C8.H5’2 1.49 7.00
506: P568 5.44 3.96 6e+07 A/C8.H5 A/C8.H5'1 1.49 7.00
507: P569 5.44 4.19 8.1e+07 A/C8.H5 A/C8.H4' 1.49 7.00
508: P570 5.44 4.80 2.1e+07 A/C8.H5 A/C8.H3' 1.49 7.00
509: P571 5.44 3.76 8.7e+07 B/C12.H5 B/C12.H5’2 1.49 7.00
510: P572 5.44 3.91 2.3e+08 B/C12.H5 B/C12.H4' 1.49 5.00
511: P573 5.44 4.65 2.3e+07 B/C12.H5 B/C12.H3’ 1.49 7.00
512: P574 5.37 4.52 1.2e+08 B/C19.H5 B/C19.H3' 1.49 7.00
513: P575 5.37 2.89 7.8e+07 B/C19.H5 B/C19.H5'2 1.49 7.00
514: P576 5.37 3.30 2.6e+07 B/C19.H5 B/C19.H5’1 1.49 7.00
515: P577 5.37 2.14 2.7e+08 B/C19.H5 B/C19.H4' 1.49 5.00
516: P578 5.52 1.62 3.1 e+08 B/C11.H5 B/C11 ,H2’1 1.49 3.00
517: P579 5.52 2.21 3e+08 B/C11.H5 B/C11 .H2'2 1.49 3.00
518: P580 5.44 2.01 1.5e+08 A/C1.H5 A/C1.H2’2 1.49 5.00
519: P581 5.44 1.31 1,3e+08 A/C1.H5 A/C1.H2’1 1.49 7.00
520: P582 5.38 1.49 2.1 e+08 B/C19.H5 B/C19.H2’2 1.49 5.00
521: P583 5.37 1.93 1.9e+08 B/C19.H5 B/C19.H2'1 1.49 5.00
522: P584 5.44 2.21 2e+08 A/C8.H5 A/C8.H2'1 1.49 5.00
523: P585 5.44 1.99 2e+08 B/C12.H5 B/C12.H2'2 1.49 5.00
524: P586 5.44 2.20 2.1 e+08 B/C12.H5 B/C12.H2’1 1.49 5.00
5 25:P587 5.44 2.46 2e+08 A/C8.H5 A/C8.H2’2 1.49 5.00
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526: P588 7.77 1.62 1.7e+08 B/G13.H8 B/T14.C5M 1.49 5.00
527: P589 7.45 1.62 6.8e+08 B/T14.H6 B/T14.C5M 1.49 3.00
528: P590 7.41 1.47 3.1 e+08 B/T15.H6 Bm5.C5M 1.49 3.00
529: P591 7.46 1.47 1.3e+08 B/T14.H6 B/T15.C5M 1.49 7.00
530: P592 7.18 1.60 2.4e+08 B/T16.H6 B/T16.C5M 1.49 5.00
531: P593 7.41 1.60 1.2e+08 B/T15.H6 B/T16.C5M 1.49 7.00
532: P594 7.18 1.37 1.3e+08 B m 6.H 6 B/T17.C5M 1.49 7.00
533: P595 7.01 1.37 1.4e+08 B/T17.H6 B/T17.C5M 1.49 7.00
534: P596 6.95 1.35 2.3e+08 Bm 8.H 6 B/T18.C5M 1.49 5.00
535: P597 7.02 1.35 1 8e+08 B/T17.H6 B/T18.C5M 1.49 5.00
536: P598 6.07 1.47 9.1e+07 B/T15.H1' B/T15.C5M 1.49 7.00
537: P599 6.15 1.47 1.3e+08 B/T14.H1' B/T15.C5M 1.49 7.00
538: P600 6.15 1.62 3.1 e+08 B/T14.H1' B/T14.C5M 1.49 3.00
539: P601 5.73 1.62 1 3e+08 B/G13.H1’ B/T14.C5M 1.49 7.00
540: P602 5.71 1.58 4.1 e+08 B/T16.H1’ B/T16.C5M 1.49 3.00
541: P603 6.07 1.58 1e+08 B/T15.H1’ B/T16.C5M 1.49 7.00
542: P604 5.71 1.38 1.2e+08 B/T16.H1' B/T17.C5M 1.49 7.00
543: P605 5.06 1.38 1.1 e+08 B/T17.H1’ B/T17.C5M 1.49 7.00
544: P606 5.44 1.35 1.2e+08 B/T18.H1' B/T18.C5M 1.49 7.00
545: P607 5.06 1.35 2.5e+08 B/T17.H1’ B/T18.C5M 1.49 5.00
546: P608 4.84 1.62 9.6e+07 B/G13.H3’ B/T14.C5M 1.49 7.00
547: P609 4.24 1.62 1e+08 B/T14.H4’ B/T14.C5M 1.49 7.00
548: P610 4.39 1.58 2.4e+08 B/T16.H3' B/T16.C5M 1.49 5.00
549: P611 4.41 1.34 9.7e+07 B/T18.H3' B/T18.C5M 1.49 7.00
550: P613 4.30 1.38 3.6e+07 B/T17.H3’ B/T17.C5M 1.49 7.00
551: P614 8.11 7.01 1,3e+07 A/A5.H2 B/T17.H6 1.49 7.00
552: P615 8.11 7.00 1.2e+07 A/OH1 .H6’1 B/T17.H6 1.49 7.00
553: P617 7.76 7.01 1,4e+07 A/OH1 .H4'1 B/T17.H6 1.49 7.00
554: P618 7.47 7.02 1.5e+07 A/OH1 .H5'2 B/T17.H6 1.49 7.00
555: P621 7.54 7.31 8.1e+07 A/A3.H2 A/OH1.H6’2 1.49 7.00
556: P622 7.67 7.45 4.1e+07 A/A6.H2 A/OH1.H3’1 1.49 7.00
557: P623 7.90 7.55 9e+07 A/OH1 .H3’2 A/A3.H2 1.49 7.00
558: P624 7.83 7.55 1.8e+08 A/OH1 .H4’2 A/A3.H2 1.49 5.00
559: P626 7.90 7.68 9.5e+07 A/OH1.H3 A/A6.H2 1.49 7.00
560: P627 7.68 7.75 1,7e+08 A/A6.H2 A/OH1 .H4'1 1.49 5.00
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561: P629 7.82 7.31 3.9e+08 A/OH1 .H4’2 A/A4.H2 1.49 3.00
562: P630 7.45 6.07 4.4e+07 A/OH1 .H3’1 B/T15.H1’ 1.49 7.00
563: P631 8.16 5.09 3.5e+07 A/A7.H2 A/A7.H1' 1.49 7.00
564: P632 8.00 5.67 1.1 e+08 A/OH1 ,H7’2 A/A5.H1' 1.49 7.00
565: P633 7.76 5.06 1.5e+08 A/OH1.H4'1 B/T17.H1' 1.49 5.00
566: P634 7.82 5.16 1.5e+08 A/OH1.H4’2 B/C19.H1’ 1.49 5.00
567: P635 8.00 5.16 1.9e+08 A/OH1.H7'2 B/C19.H1’ 1.49 5.00
568: P636 7.82 5.55 5.5e+07 A/OH1.H4’2 A/A4.H1' 1.49 7.00
569: P637 7.82 5.67 1,8e+08 A/OH1 ,H4'2 A/A5.H1' 1.49 5.00
570: P638 7.75 5.71 1,3e+08 A/OH1 .H4'1 B/T16.H1' 1.49 7.00
571: P639 7.62 5.06 1e+08 A/OH1.Hn B/T17.HT 1.49 7.00
572: P640 7.45 5.07 6.1e+07 A/OH1.H3'1 A/A6.H1’ 1.49 7.00
573: P641 7.47 5.16 1,2e+08 A/OH1 .H5'2 B/C19.H1' 1.49 7.00
574: P642 7.31 5.67 1,7e+08 A/OH1 ,H6'2 A/A5.H1’ 1.49 5.00
575: P644 7.31 5.16 8.5e+07 A/OH1 ,H6'2 B/C19.H1’ 1.49 7.00
576: P645 7.31 5.54 9.7e+07 A/OH1 .H6’2 A/A4.H1’ 1.49 7.00
577: P648 7.68 4.81 1,7e+08 A/A6.H2 A/OH1.H1B 1.49 5.00
578: P649 8.00 4.40 8.3e+07 A/OH1 ,H7'2 B/T18.H3' 1.49 7.00
579: P653 7.82 4.48 1.2e+08 A/OH1 ,H4'2 A/A4.H3’ 1.49 7.00
580: P654 7.82 4.30 7.2e+07 A/OH1 ,H4’2 A/A5.H3’ 1.49 7.00
581: P655 7.76 4.30 1,2e+08 A/OH1.H4’1 B/T17.H3’ 1.49 7.00
582: P656 7.68 4.30 1e+08 A/A6.H2 A/OH1.H8A2 1.49 7.00
583: P657 7.62 4.30 1.1 e+08 A/OH1.H7’1 B/T17.H3’ 1.49 7.00
584: P659 7.47 4.48 1,2e+08 A/OH1.H5’2 A/A4.H3’ 1.49 7.00
585: P660 7.03 4.51 8.6e+07 A/OH1.H6 A/G9.H3’ 1.49 7.00
586: P661 8.16 3.71 6.3e+07 A/A7.H2 A/OH1.H1 A 1.49 7.00
587: P662 8.16 3.73 7.2e+07 A/A7.H2 A/OH1.H8A 1.49 7.00
588: P658 8.11 3.73 1.4e+08 A/OH1.H6’1 B/T17.H5’1 1.49 7.00
589: P663 8.00 3.72 1.1 e+08 A/OH1.H7’2 A/A5.H5’1 1.49 7.00
590: P664 7.82 3.72 1.2e+08 A/OH1.H4'2 A/A5.H5'1 1.49 7.00
591: P666 7.76 3.73 9.7e+07 A/OH1 ,H4’1 B/T17.H5’1 1.49 7.00
592: P667 7.68 3.71 9.8e+07 A/A6.H2 A/OH1.H1 A 1.49 7.00
593: P668 7.68 3.73 9.9e+07 A/A6.H2 A/OH1.H8A 1.49 7.00
594: P669 7.47 3.72 9.5e+07 A/OH1 .H5’2 A/A5.H5'1 1.49 7.00
595: P671 7.62 3.73 2.6e+08 A/OH1 ,H7’1 B/T17.H5’1 1.49 5.00
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596: P670 8.11 3.12 3.3e+07 A/OH1 ,H6’1 B/T17.H4' 1.49 7.00
597: P673 8.00 2.89 1.7e+08 A/OH1 ,H7’2 B/C19.H5’2 1.49 5.00
598: P674 8.00 3.30 3.9e+07 A/OH1 ,H7’2 B/C19.H5’1 1.49 7.00
599: P675 7.90 2.90 1.6e+08 A/OH1.H3’2 A/A5.H2'2 1.49 5.00
600: P676 7.90 3.23 4.9e+07 A/OH1.H3’2 B/T18.H5’2 1.49 7.00
601: P678 7.90 3.61 7.8e+07 A/OH1 ,H3'2 B/T18.H5’1 1.49 7.00
602: P679 7.82 2.90 8.1e+07 A/OH1 ,H4'2 A/A5.H2’2 1.49 7.00
603: P680 7.82 2.88 7e+07 A/OH1 .H4'2 B/C19.H5’2 1.49 7.00
604: P681 7.82 3.11 5.3e+07 A/OH1 ,H4’2 A/A5.H5’2 1.49 7.00
605: P682 7.82 3.30 5.3e+07 A/OH1.H4'2 B/C19.H5'1 1.49 7.00
606: P683 7.82 3.46 1,2e+08 A/OH1 ,H4’2 A/A4.H5’2 1.49 7.00
607: P684 7.75 3.23 3.5e+07 A/OH1.H4’1 B/T18.H5’2 1.49 7.00
608: P685 7.75 3.44 1.2e+08 A/OH1.H4’1 B/T17.H5’2 1.49 7.00
609: P686 7.62 3.61 2e+08 A/OH1 ,H7’1 B/T18.H5'1 1.49 5.00
610: P687 7.62 3.12 2.1 e+08 A/OH1.Hn B/T17.H4’ 1.49 5.00
611: P688 7.63 3.44 1.6e+08 A/OH1.H7T B/T17.H5'2 1.49 5.00
612: P689 7.47 2.88 5.6e+07 A/OH1 ,H5’2 B/C19.H5’2 1.49 7.00
613: P690 7.47 2.90 4.3e+07 A/OH1 ,H5’2 A/A5.H2’2 1.49 7.00
614: P691 7.45 3.44 1.1 e+08 A/OH1.H3’1 B/T17.H5’2 1.49 7.00
615: P692 7.47 3.31 4e+07 A/OH1.H5’2 B/C19.H5'1 1.49 7.00
616: P693 7.45 3.12 1,9e+07 A/OHt.H3'1 B/T17.H4’ 1.49 7.00
617: P694 7.48 3.11 1,7e+07 A/OH1.H5’2 A/A5.H5’2 1.49 7.00
618: P695 7.31 2.89 1.9e+08 A/OH1 ,H6’2 B/C19.H5'2 1.49 5.00
619: P696 7.31 3.11 6.7e+07 A/OH1 .H6’2 A/A5.H5’2 1.49 7.00
620: P697 7.31 3.30 4.8e+07 A/OH1 .H6'2 B/C19.H5’1 1.49 7.00
621: P698 7.31 3.46 1.8e+08 A/OH1 .H6’2 A/A4.H5’2 1.49 5.00
622: P699 8.00 2.42 4.6e+06 A/OH1.H7’2 A/A5.H4’ 1.49 7.00
623: P700 7.82 2.45 1,2e+08 A/OH1 .H4’2 A/A4.H2’2 1.49 7.00
624: P701 7.82 2.44 1.2e+08 A/OH1 ,H4’2 A/A4.H2’1 1.49 7.00
625: P704 7.62 1.84 1,3e+08 A/OH1 ,H7’1 B/T17.H2'2 1.49 7.00
626: P705 7.45 1.38 5.7e+07 A/OH1.H3’1 B/T15.H2T 1.49 7.00
627: P709 8.00 1.92 6e+07 A/OH1 ,H7’2 B/C19.H2’1 1.49 7.00
628: P712 8.00 1.49 1,7e+07 A/OH1.H7’2 B/C19.H2'2 1.49 7.00
629: P713 5.72 2.90 1,2e+08 B/G13.H1’ A/OH1.C34 1.49 7.00
630: P714 5.19 2.90 2.1 e+08 A/C8.H1’ A/OH1.C34 1.49 5.00
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APPENDIX XVIV
The Master Spreadsheet for the adozelesin-5f-(C1G2A3A4A5A6A7 C8G9G10)-5'- 
(CnC12G13Ti4T15TI6T17T18C19Gz^  PNA adduct
Table 9 The master s p r e a d s h e e t . _______________
1: SHIFT 1: SHIFT
1: A/C1.H5’1 3.561 36: A/A4.H4’ 3.111
2: A/C1 .H5’2 3.481 37: A/A4.HT 5.551
3: A/C1.H4’ 3.833 38: A/A4.H2’1 2.435
4: A/C1.H1’ 5.319 39: A/A4.H2’2 2.451
5: A/C1.H2’1 1.308 40: A/A4.H3’ 4.498
6: A/C1 .H2’2 2.010 41: A/A4.H8 8.000
7: A/C1.H3’ 4.392 42: A/A4.H61 ?
8: A/C1.H6 7.257 43: A/A4.H62 ?
9: A/C1.H5 5.436 44: A/A4.H2 7.307
10: A/C1.H41 ? 45: A/A5.H5’1 3.718
11: A/C1.H42 ? 46: A/A5.H5’2 3.109
12: A/G2.H5’1 3.816 47: A/A5.H4’ 2.424
13: A/G2.H5’2 3.744 48: A/A5.H1’ 5.672
14: A/G2.H4’ 4.128 49: A/A5.H2’1 2.538
15: A/G2.H1’ 5.139 50: A/A5.H2’2 2.896
16: A/G2.H2’1 2.504 51: A/A5.H3’ 4.299
17: A/G2.H2’2 2.557 52: A/A5.H8 7.904
18: A/G2.H3’ 4.812 53: A/A5.H61 ?
19: A/G2.H8 7.715 54: A/A5.H62 ?
20: A/G2.H1 ? 55: A/A5.H2 8.111
21: A/G2.H21 ? 56: A/A6.H5’1 3.723
22: A/G2.H22 ? 57: A/A6.H5’2 3.577
23: A/A3.H5’1 4.119 58: A/A6.H4’ 3.226
24: A/A3.H5’2 4.055 59: A/A6.H1’ 5.072
25: A/A3.H4' 4.306 60: A/A6.H2’1 1.473
26: A/A3.H1’ 5.744 61: A/A6.H2’2 1.816
27: A/A3.H2’1 2.520 62: A/A6.H3’ 4.400
28: A/A3.H2’2 2.727 63: A/A6.H8 7.473
29: A/A3.H3’ 4.905 64: A/A6.H61 ?
30: A/A3.H8 7.945 65: A/A6.H62 ?
31: A/A3.H61 ? 66: A/A6.H2 7.679
32: A/A3.H62 ? 67: A/A7.H5’1 4.188
33: A/A3.H2 7.551 68: A/A7.H5’2 4.026
34: A/A4.H5’1 3.729 69: A/A7.H4’ 2.450













































































































































































235: A/OH1 .H7’1 7.623
236: A/OH1.H6’1 8.110
237: A/OH1 ,H4’1 7.755
238: A/OH1 ,H3’1 7.450
239: A/OH1.H4’2 7.822
240: A/OH1.H5’2 7.475
241: A/OH 1.H6’2 7.308
242: A/OH1.H7’2 8.000
243: A/OH1 .H3’2 7.903
APPENDIX XX
Figure 178 Expansion of the methyl region of the ID NMR spectrum of 5'-(GTGATGAG)-5'- 
(CACTACTC) DNA duplex after the resction with DSB-120.
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